

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**209627Orig1s000**

**MULTI-DISCIPLINE REVIEW**

**Summary Review**

**Office Director**

**Cross Discipline Team Leader Review**

**Clinical Review**

**Non-Clinical Review**

**Statistical Review**

**Clinical Pharmacology Review**

## Reviewers of Multi-Disciplinary Review and Evaluation

DISCIPLINE	REVIEWER	OFFICE/ DIVISION	SECTIONS AUTHORED/ ACKNOWLEDGED/ APPROVED
CMC Lead	Mark Seggel, Ph.D.	OPQ/ONDP/DNDP2	Authored: Section 4.2
	<b>Signature: Mark R. Seggel -S</b> <small>Digitally signed by Mark R. Seggel -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Seggel -S, 0.9.2342.19200300.100.1.1=1300071539  Date: 2018.08.08 16:29:15 -04'00'</small>		
Pharmacology/ Toxicology Reviewer	Frederic Moulin, DVM, PhD	OND/ODE3/DBRUP	Authored: Section 5
	<b>Signature: Frederic Moulin -S</b> <small>Digitally signed by Frederic Moulin -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S  Date: 2018.08.08 15:26:57 -04'00'</small>		
Pharmacology/ Toxicology Team Leader	Kimberly Hatfield, PhD	OND/ODE3/DBRUP	Approved: Section 5
	<b>Signature: Kimberly P. Hatfield -S</b> <small>Digitally signed by Kimberly P. Hatfield -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S  Date: 2018.08.08 14:56:10 -04'00'</small>		
Clinical Pharmacology Reviewer	Li Li, Ph.D.	OCP/DCP3	Authored: Sections 6 and 17.3
	<b>Signature: Li Li -S</b> <small>Digitally signed by Li Li -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Li Li -S, 0.9.2342.19200300.100.1.1=2000508577  Date: 2018.08.08 15:39:23 -04'00'</small>		
Clinical Pharmacology Team Leader	Doanh Tran, Ph.D.	OCP/DCP3	Approved: Sections 6 and 17.3
	<b>Signature: Doanh C. Tran -S</b> <small>Digitally signed by Doanh C. Tran -S  Date: 2018.08.08 14:49:57 -04'00'</small>		
Physiologically Based Pharmacokinetic (PBPK) Reviewer	Nan Zheng, Ph.D.	OTS/OCP/DPM	Authored: Sections 6 and 17.3
	<b>Signature: Nan Zheng -S</b> <small>Digitally signed by Nan Zheng -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Nan Zheng -S, 0.9.2342.19200300.100.1.1=2000649162  Date: 2018.08.09 11:36:42 -04'00'</small>		
PBPK Team Leader	Yuching Yang, Ph.D.	OTS/OCP/DPM	Approved Sections: 6 and 17.3
	<b>Signature: Yuching Yang -S</b> <small>Digitally signed by Yuching Yang -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Yuching Yang -S, 0.9.2342.19200300.100.1.1=2001554924  Date: 2018.08.08 15:16:40 -04'00'</small>		
Clinical Pharmacology Associate Director Office of Clinical Pharmacology	Gilbert J Burckart, Pharm.D.	OCP/DCP3	Approved: Section 6 and 17.3
	<b>Signature: Gilbert J. Burckart -S</b> <small>Digitally signed by Gilbert J. Burckart -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300382447, cn=Gilbert J. Burckart -S  Date: 2018.08.09 11:56:09 -04'00'</small>		
Biostatistics	Weiya Zhang, Ph.D.	OB/DB3	Authored: Sections 8 and 9
	<b>Signature: Weiya Zhang -S</b> <small>Digitally signed by Weiya Zhang -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Weiya Zhang -S, 0.9.2342.19200300.100.1.1=2001554924  Date: 2018.08.08 14:11:09 -04'00'</small>		
Biostatistics Team Leader (Acting)	Mahboob Sobhan, PhD	OB/DB3	Approved: Sections 8 and 9
	<b>Signature: Mahboob Sobhan -S</b> <small>Digitally signed by Mahboob Sobhan -S  DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mahboob Sobhan -S, 0.9.2342.19200300.100.1.1=1300084769  Date: 2018.08.08 16:36:32 -04'00'</small>		

Biostatistics Division Director (Acting)	Laura Lee Johnson, PhD	OB/DB3	Approved: Sections 8 and 9
	<b>Signature: Laura L. Johnson -S</b> <small>Digitally signed by Laura L. Johnson -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=0011413414, cn=Laura L. Johnson -S Date: 2018.08.08 19:21:14 -04'00'</small>		
Clinical	Abby Anderson, MD	OND/DBRUP	Authored: Sections 1, 2, 3, 7, 8, 9, 10
	<b>Signature: Abby Anderson -S</b> <small>Digitally signed by Abby Anderson -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Abby Anderson -S, 0.9.2342.19200300.100.1.1=2002091441 Date: 2018.08.08 14:08:57 -04'00'</small>		
CDTL	Michelle Carey, MD, MPH	OND/DBRUP	Authored: Sections 1, 4, 11, 12, 13, 14, 15, 16
	<b>Signature:</b> see DARRTS signature page		
DBRUP	Audrey Gassman, M.D.	OND/DBRUP	Approved: All Sections
	<b>Signature:</b> see DARRTS signature page		
ODE 3	Victor Crentsil, MD	OND/ODE3	Approved: All Sections
	<b>Signature:</b> see DARRTS signature page		

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

**NDA/BLA Multi-disciplinary Review and Evaluation**

<b>Application Type</b>	NDA
<b>Application Number(s)</b>	209627
<b>Priority or Standard</b>	Standard
<b>Submit Date(s)</b>	August 17, 2017
<b>Received Date(s)</b>	August 17, 2017
<b>PDUFA Goal Date</b>	August 17, 2018
<b>Division/Office</b>	Division of Bone Reproductive and Urologic Products (DBRUP)/Office of Drug Evaluation III (ODE III)
<b>Review Completion Date</b>	August 8, 2018
<b>Established Name</b>	Segesterone acetate and ethinyl estradiol vaginal system
<b>(Proposed) Trade Name</b>	Annovera
<b>Pharmacologic Class</b>	Combined hormonal contraceptive (CHC) (progestin + estrogen)
<b>Applicant</b>	Population Council
<b>Formulation(s)</b>	Segesterone acetate 150 µg/ethinyl estradiol 13 µg
<b>Dose Form</b>	Vaginal system (ring)
<b>Dosing Regimen</b>	Vaginal for 21 days per 28-day cycle
<b>Applicant Proposed Indication(s)/Population(s)</b>	Prevention of pregnancy in females of reproductive potential
<b>Recommendation on Regulatory Action</b>	Approval
<b>Recommended Indication(s)/Population(s) (if applicable)</b>	Same as above

**Table of Contents**

Reviewers of Multi-Disciplinary Review and Evaluation ..... 10

Additional Reviewers of Application..... 10

1. Executive Summary ..... 12

    1.1. Product Introduction ..... 12

    1.2. Conclusions on the Substantial Evidence of Effectiveness ..... 13

    1.3. Benefit-Risk Assessment ..... 14

    1.4. Patient Experience Data ..... 19

2. Therapeutic Context ..... 20

    2.1. Analysis of Condition ..... 20

    2.2. Analysis of Current Treatment Options ..... 20

3. Regulatory Background ..... 22

    3.1. U.S. Regulatory Actions and Marketing History ..... 22

    3.2. Summary of Presubmission/Submission Regulatory Activity ..... 22

    3.3. Foreign Regulatory Actions and Marketing History ..... 27

4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ..... 27

    4.1. Office of Scientific Investigations (OSI) ..... 27

    4.2. Product Quality ..... 28

    4.3. Clinical Microbiology ..... 31

    4.4. Devices and Companion Diagnostic Issues ..... 31

5. Nonclinical Pharmacology/Toxicology ..... 32

    5.1. Executive Summary ..... 32

    5.2. Referenced NDAs, BLAs, DMFs ..... 37

    5.3. Pharmacology ..... 37

        5.3.1. Primary Pharmacology of Segesterone Acetate ..... 37

        5.3.2. Secondary Pharmacology of Segesterone Acetate ..... 38

        5.3.3. Safety Pharmacology of Segesterone Acetate ..... 40

        5.3.4. Pharmacology of Ethinyl Estradiol ..... 41

    5.4. ADME/PK ..... 41

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

5.4.1. Pharmacokinetics of Segesterone Acetate .....	41
5.4.2. Pharmacokinetics of Ethinyl Estradiol .....	51
5.5. Toxicology.....	51
5.5.1. General Toxicology of Segesterone Acetate.....	51
5.5.2. Genetic Toxicology of Segesterone Acetate .....	55
5.5.3. Carcinogenicity of Segesterone Acetate.....	55
5.5.4. Reproductive and Developmental Toxicology of Segesterone Acetate .....	57
5.5.5. Other Toxicology Studies of Segesterone Acetate .....	60
5.5.6. Summary of Toxicity for Ethinyl Estradiol.....	60
6. Clinical Pharmacology.....	62
6.1. Executive Summary .....	62
6.1.1. Recommendations .....	62
6.2. Summary of Clinical Pharmacology Assessment.....	62
6.2.1. Pharmacology and Clinical Pharmacokinetics Mechanism of action and pharmacodynamics (PD).....	63
6.2.2. General Dosing and Therapeutic Individualization.....	65
6.3. Comprehensive Clinical Pharmacology Review General Pharmacology and Pharmacokinetic Characteristics.....	66
6.3.1. Clinical Pharmacology Questions.....	67
7. Sources of Clinical Data and Review Strategy .....	77
7.1. Table of Clinical Studies.....	77
7.2. Review Strategy.....	78
8. Statistical and Clinical Evaluation of Efficacy.....	79
8.1. Study 300A : A Multicenter, Open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 mcg of Nesterone <sup>®*</sup> and 15 mcg of ethinyl estradiol (*Nesterone = segesterone acetate).....	81
8.1.1. Study Design.....	81
8.1.2. Study Results.....	87
8.2. Study 300B: A Multicenter, open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 mcg of Nesterone <sup>®*</sup> and 15 mcg of ethinyl estradiol (*segesterone acetate).....	100
8.2.1. Study Design.....	100
8.2.2. Study Results.....	102

8.3.	Integrated Summary of Effectiveness (ISE).....	115
9.	Integrated Review of Effectiveness.....	118
9.1.	Assessment of Efficacy Across Trials.....	118
9.1.1.	Primary Endpoints.....	118
9.1.2.	Secondary Endpoints .....	120
9.1.3.	Subpopulations .....	122
9.1.4.	Considerations on Benefit in the Postmarket Setting .....	124
9.1.5.	Other Relevant Benefits.....	124
9.2.	Statistical Issues .....	124
9.3.	Integrated Assessment of Effectiveness .....	125
10.	Review of Safety .....	126
10.1.	Safety Review Approach.....	126
10.2.	Review of the Safety Database.....	129
10.2.1.	Overall Exposure.....	129
10.2.2.	Relevant characteristics of the safety population:.....	130
10.2.3.	Adequacy of the safety database:.....	132
10.3.	Adequacy of Applicant’s Clinical Safety Assessments.....	132
10.3.1.	Issues Regarding Data Integrity and Submission Quality.....	132
10.3.2.	Categorization of Adverse Events.....	133
10.3.3.	Routine Clinical Tests.....	134
10.3.4.	ISS Disposition.....	134
10.4.	Safety Results.....	136
10.4.1.	Deaths.....	136
10.4.2.	Serious Adverse Events.....	136
10.4.3.	Dropouts and/or Discontinuations Due to Adverse Effects .....	141
10.4.4.	Significant Adverse Events.....	144
10.4.5.	Adverse Events and Treatment Emergent Adverse Events and Adverse Reactions	144
10.4.6.	Laboratory Findings .....	148
10.4.7.	Vital Signs/Physical Examination .....	150
10.4.8.	Electrocardiograms (ECGs) .....	153
10.4.9.	QT.....	154

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

10.4.10.	Immunogenicity.....	154
10.4.11.	Pregnancy Outcomes.....	154
10.4.12.	Return to Fertility .....	154
10.4.13	CVS Expulsions/Issues .....	155
10.5.	Analysis of Submission-Specific Safety Issues .....	156
10.5.1.	Venous Thromboembolism (VTE).....	156
10.5.2.	Angioedema/Drug Allergy .....	162
10.6.	Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability .....	163
10.7.	Safety Analyses by Demographic Subgroups .....	163
10.8.	Specific Safety Studies/Clinical Trials .....	164
10.8.1.	Microbiology sub-study .....	164
10.8.2.	Endometrial Safety Sub-Study.....	167
10.8.3.	Hepatic Factors Sub-Study.....	169
10.8.4.	Colposcopy.....	172
10.8.5.	Lactation Studies .....	172
10.9.	Additional Safety Explorations .....	173
10.9.1.	Human Carcinogenicity or Tumor Development.....	173
10.9.2.	Human Reproduction and Pregnancy .....	173
10.9.3.	Pediatrics and Assessment of Effects on Growth.....	173
10.9.4.	Overdose, Drug Abuse Potential, Withdrawal, and Rebound.....	174
10.10.	Safety in the Postmarket Setting.....	174
10.10.1.	Expectations on Safety in the Postmarket Setting Based on the safety profile from subjects in the CVS trials, it appears that safety is expected to be similar to other approved CHC products. See Section 16.....	175
10.11.	Integrated Assessment of Safety.....	175
10.12.	SUMMARY AND CONCLUSIONS.....	178
11.	Conclusions and Recommendations .....	178
12.	Advisory Committee Meeting and Other External Consultations.....	178
13.	Pediatrics .....	179
14.	Labeling Recommendations .....	179
14.1.	Prescription Drug Labeling .....	179

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

15. Risk Evaluation and Mitigation Strategies (REMS) .....	181
16. Postmarketing Requirements and Commitment .....	181
17. Appendices .....	182
17.1. Financial Disclosure .....	182
17.2. Nonclinical Pharmacology/Toxicology.....	183
17.3. OCP Appendices (Technical documents supporting OCP recommendations) .....	183
17.4. Additional Clinical Outcome Assessment Analyses.....	184
17.5. Clinical Appendices.....	184
17.5.1. Pregnancies.....	184
17.5.2. Microbiology Sub-study.....	188

### Table of Tables

Table 1 Patient Experience Data Relevant to this Application (check all that apply).....	19
Table 2. Selected CHCs.....	21
Table 3. Safety multiples of the therapeutic dose of SA* based on nonclinical studies.....	36
Table 4. Comparisons of SA and EE PK Parameters after administration of SA/EE CVS Alone or with Miconazole Vaginal Suppository or Cream.....	75
Table 5. Table of Clinical Trials.....	77
Table 6. Investigators with Financial Disclosure.....	79
Table 7. Study Flow Chart 300A.....	82
Table 8. Disposition of Study 300A Subjects.....	88
Table 9. Demographics 300A.....	90
Table 10. Contraceptive Use Within 6 Months of Enrollment (Study 300A).....	92
Table 11. Selected Active Medical History of Subjects (Study 300A).....	92
Table 12. Concomitant Medication Use in Subjects (Study 300A).....	93
Table 13. Adjudicated Pregnancies (300A).....	95
Table 14. Study 300 A: Pearl Index for subjects $\leq$ 35 years old using pregnancies from evaluable cycles within 7 days from CVS removal.....	96
Table 15. Study 300 A: Pearl Index for subjects $\leq$ 35 years old using pregnancies from evaluable cycles within 14 days from CVS removal.....	97
Table 16. Study 300A: Kaplan-Meier Analysis of Pregnancy Among Subjects $\leq$ 35 Years Old Using All Cycles.....	97
Table 17. Scheduled and Unscheduled Bleeding and Spotting (Study 300A).....	98
Table 18. Scheduled Bleeding and Spotting (Study 300A).....	98
Table 19. Unscheduled Bleeding and Spotting (300A).....	99
Table 20. Disposition of Study 300B Subjects.....	103
Table 21. Demographics 300B.....	105
Table 22. Contraceptive Use Within 6 Month of Enrollment (Study 300B).....	106
Table 23. Selected Active Medical History of Subjects (Study 300B).....	107
Table 24. Concomitant Medication Use in Subjects (Study 300B).....	107
Table 25. Adjudicated Pregnancies (Study 300B).....	108
Table 26. Study 300 B: Pearl Index for subjects $\leq$ 35 years old using pregnancies from evaluable cycles within 7 days from CVS removal.....	111
Table 27. Study 300B: Pearl Index for subjects $\leq$ 35 years old using pregnancies from evaluable cycles within 14 days from CVS removal.....	112
Table 28. Study 300B: Kaplan-Meier Analysis of Pregnancy Among Subjects $\leq$ 35 Years Old Using All Cycles.....	112
Table 29. Scheduled and Unscheduled Bleeding and Spotting (Study 300B).....	113
Table 30. Scheduled Bleeding and/or Spotting (Study 300B).....	114
Table 31. Unscheduled Bleeding and/or Spotting (Study 300B).....	114
Table 32. Pooled ISE Analysis Sets.....	115
Table 33. Selected Demographics for Three ISE Analysis Sets.....	116
Table 34. Subject Disposition, Pooled Studies 300A and 300B.....	117

Table 35. Studies 300A and 300B: Pearl Index for subjects ≤ 35 years old using pregnancies from evaluable cycles within 7 days from CVS removal.....	118
Table 36. Studies 300A and 300B: Pearl Index for subjects ≤ 35 years old using pregnancies from evaluable cycles within 14 days from CVS removal.....	119
Table 37. Kaplan-Meier Analysis of Pregnancy Among Subjects ≤ 35 Years Old Using All Cycles .....	119
Table 38. Pivotal Cycle Control, Scheduled Bleeding and/or Spotting.....	120
Table 39. Pivotal Cycle Control, Unscheduled Bleeding and/or Spotting.....	121
Table 40. US/Non-US Subjects and Cycles Used for PI .....	122
Table 41. Pearl Index for subjects ≤ 35 years old by subgroup .....	123
Table 42. Pearl Index by Age of CVS at Insertion.....	124
Table 43. Primary Efficacy of CVS (Primary ISE).....	125
Table 44. PI (95% CI) for Selected CHCs.....	125
Table 45. Studies Contributing Safety Data and Pooled Analysis Sets in the ISS .....	127
Table 46. ISS Subject Totals and Cycles of Therapy by Pooled Safety Analysis Set .....	129
Table 47 Demographics and Baseline Characteristics of the Primary ISS with BMI Subgroups.	131
Table 48. Disposition of Subjects in Primary ISS.....	134
Table 49. Disposition of Subjects in Secondary ISSs.....	135
Table 50. SAEs in Pivotal Trials and Primary ISS .....	136
Table 51. TEAEs Leading to >1% Subject Early Discontinuation by SOC.....	141
Table 52. AEs Leading to Early Discontinuation Occuring in >2 Subjects.....	142
Table 53. AEs by SOC Occuring in >10% of Subjects.....	144
Table 54. AEs by PT Occuring in >2% of Subjects .....	145
Table 55. Medical Officer's Analysis of ISS Combining Related Preferred Terms .....	147
Table 56. Discontinued Subjects due to Elevated Cholesterol/Triglyceride Laboratory Values	148
Table 57. Subjects with ALT/AST >2 Times Upper Limit of Normal.....	149
Table 58. CVS Complete Expulsions occurring in the Primary ISS .....	155
Table 59. Summary of VTE risk by Analysis Sets and BMI .....	160
Table 60. Disposition of Microbiology Population.....	165
Table 61 Results of Microbiology Quantitative Tests .....	166
Table 62. Disposition of Safety Population in the Endometrial Sub-Study .....	167
Table 63. Summary of Endometrial Biopsies in Endometrial Safety Sub-Study by Cycle Window and Prior Use of CHC.....	168
Table 64. Disposition of Safety Population in the Hepatic Factors Sub-Study .....	170
Table 65. Hepatic Factors Results by Cycle and Change from Baseline .....	171
Table 68. AEs Experienced by Subjects in Primary ISS.....	176
Table 69. Covered Clinical Study (Name and/or Number): 300B, 300PK, 330, 331, 323, 427, 571, 648, 300A (CCN006).....	182
Table 93. Table of Pregnancies .....	184

**Table of Figures**

Figure 1 SA/EE CVS\* ..... 12

Figure 2 Mean SA and EE Serum Concentrations-Time Profiles Delivered by SA/EE CVS (Study 300-PK)..... 64

Figure 3. P Serum Concentrations for Cycle 1 (N=39), Cycle 3 (N=35), and Cycle 13 (N=27)..... 69

Figure 4. Box-plot Comparison of SA and EE Systemic Exposure Grouped by BMI (Study 300PK) ..... 72

Figure 5 Arithmetic Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with a Single-Dose of Miconazole Nitrate Suppository (Treatment B1) in Healthy Female Subjects in Study 571..... 74

Figure 6 Arithmetic Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with Three-Day Regimen of Miconazole Nitrate Suppository (Treatment B2) in Healthy Female Subjects in Study 571 ..... 74

Figure 7 Arithmetic Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with Three-Day Regimen of Miconazole Nitrate Cream (Treatment B3) in Healthy Female Subjects in Study 571 ..... 75

## Reviewers of Multi-Disciplinary Review and Evaluation

<b>Regulatory Project Manager</b>	Charlene Williamson
<b>Nonclinical Reviewer</b>	Frederic Moulin, PhD
<b>Nonclinical Team Leader</b>	Kimberly Hatfield, PhD
<b>Office of Clinical Pharmacology Reviewer(s)</b>	Li Li, PhD; Nan Zheng, PhD
<b>Office of Clinical Pharmacology Team Leader(s)</b>	Doanh Tran, PhD; Yuching Yang, PhD
<b>Clinical Reviewer</b>	Abby Anderson, MD
<b>Clinical Team Leader</b>	Catherine Sewell, MD, MPH/ Michelle Carey, MD, MPH
<b>Statistical Reviewer</b>	Weiya Zhang, PhD
<b>Statistical Team Leader</b>	Mahboob Sobhan, PhD
<b>Cross-Disciplinary Team Leader</b>	Catherine Sewell, MD, MPH; Michelle Carey, MD, MPH
<b>Deputy Division Director (DBRUP)</b>	Audrey Gassman, MD
<b>Office Director (or designated signatory authority)</b>	Victor Crentsil, MD, MHS, FCP

## Additional Reviewers of Application

<b>OPQ</b>	Hong Cai, Suneet Shukla,
<b>Microbiology</b>	Marla Stevens-Riley, Avital Shimanovich
<b>OPDP</b>	Lynn Panholzer
<b>DMPP</b>	Karen Dowdy
<b>OSI</b>	Cara Alfaro
<b>OSE/DEPI</b>	Jie Li, David Moeny
<b>OSE/DMEPA</b>	Denise Baugh
<b>OSE/DRISK</b>	Courtney Cunningham
<b>CDRH</b>	Veronica Price

OPQ=Office of Pharmaceutical Quality  
 OPDP=Office of Prescription Drug Promotion  
 DMPP=Division of Medical Policy Programs  
 OSI=Office of Scientific Investigations  
 OSE= Office of Surveillance and Epidemiology  
 DEPI= Division of Epidemiology  
 DMEPA=Division of Medication Error Prevention and Analysis  
 DRISK=Division of Risk Management

## Glossary

ADME	absorption, distribution, metabolism, excretion
AE	adverse event
BLA	biologics license application
BRF	Benefit Risk Framework
CDER	Center for Drug Evaluation and Research
CDRH	Center for Devices and Radiological Health
CFR	Code of Federal Regulations
CHC	combined hormonal contraceptive
CMC	chemistry, manufacturing, and controls
COC	combined oral contraceptive
CRF	case report form
CRT	clinical review template
CSR	clinical study report
CVS	contraceptive vaginal system
ECG	electrocardiogram
EE	ethinyl estradiol
FDA	Food and Drug Administration
GCP	good clinical practice
ICH	International Conference on Harmonization
IND	Investigational New Drug
ISE	integrated summary of effectiveness
ISS	integrated summary of safety
MedDRA	Medical Dictionary for Regulatory Activities
NDA	new drug application
NME	new molecular entity
OCS	Office of Computational Science
ODE	Office of Drug Evaluation
OPQ	Office of Pharmaceutical Quality
OSE	Office of Surveillance and Epidemiology
OSI	Office of Scientific Investigation
PD	pharmacodynamics
PI	Pearl Index
PK	pharmacokinetics
PMC	postmarketing commitment
PMR	postmarketing requirement
PPI	patient package insert
PRO	patient reported outcome
REMS	risk evaluation and mitigation strategy
SA	segesterone acetate
SAE	serious adverse event
SAP	statistical analysis plan
SOC	standard of care
TEAE	treatment emergent adverse event
VTE	venous thromboembolism

## 1. Executive Summary

---

### 1.1. Product Introduction

ANNOVERA, a segesterone acetate/ethinyl estradiol contraceptive vaginal system (SA/EE CVS or CVS) is a combined hormone contraceptive (CHC) for the prevention of pregnancy in females of reproductive potential. The CVS is a non-biodegradable, flexible, contraceptive vaginal ring that contains two hormones, a progestin, SA, and an estrogen, EE, providing daily release rates of 150 µg and 13 µg respectively.

The CVS is used for thirteen 28-day cycles (one year). The CVS is inserted into the vagina for 21 days and then removed for 7 days. The CVS is washed and stored in a provided compact case for the 7 days per cycle that it is not in use.

SA is the progestin component and is a new molecular entity (NME). This derivative of 19-norprogesterone is not orally active. The SA/EE CVS has never been marketed. (b) (4)

#### Figure 1 SA/EE CVS\*



Source: NDA 209627, Module 2.2, CTD Introduction p 2/5

\*Nesterone=SA

The (b) (4) shaped silicone elastomer ring has two channels that contain cores: one with SA only, and the other with SA and EE. (b) (4)

The applicant notes the benefits of the CVS provide user-controlled contraception that does not require daily administration or special storage conditions. Only one CVS is needed for a full year of reversible contraception.

## **1.2. Conclusions on the Substantial Evidence of Effectiveness**

ANNOVERA is proposed for the prevention of pregnancy in females of reproductive potential. The applicant's evidence of clinical effectiveness derives from two one-year, multicenter Phase 3 trials that enrolled 2,265 females age 18-40 years who were healthy and sexually active, with regular menstrual cycles. The trials did not include control groups. Pooled data from the two trials was used to evaluate efficacy. Overall, there were 2,111 females  $\leq 35$  years old who completed 17,427 evaluable 28-day cycles (evaluable cycles for efficacy were those during which no back-up contraception was used). Efficacy was evaluated by calculation of the Pearl Index (PI). The PI for the evaluable cycles from the pooled Phase 3 trials was 2.98 (95% Confidence Interval {CI} [2.13, 4.06]) pregnancies per 100 woman-years of ANNOVERA. This PI is comparable to that of other recently approved products for the same indication. Based on the above information, we conclude that the applicant has provided substantial evidence of effectiveness of ANNOVERA for the proposed indication.

### 1.3. Benefit-Risk Assessment

#### Benefit-Risk Integrated Assessment

Unintended pregnancy affects millions of women in the United States each year, and has vast consequent public health effects including adverse maternal and child health outcomes as well as significant socioeconomic costs. Safe and effective contraception is, therefore, crucial to women's health. Although many contraceptive options are available—including oral tablets, intravaginal rings, implants, a transdermal patch, and depot injections—development of contraceptives with lower doses, more convenient dosing schedules, and optimal efficacy and safety profiles remains a priority. Considering that 95% of unintended pregnancies occur in women who use contraceptives inconsistently or incorrectly or women who do not use contraception at all during the year, a vaginal system with demonstrated efficacy and safety, that can be used for up to one year without the need for refrigeration prior to dispensing, would add to the armamentarium of available contraceptive products.

Segesterone acetate/ethinyl estradiol contraceptive vaginal system (SA/EE CVS), tradename ANNOVERA, is a new combined progestin-estrogen contraceptive for the prevention of pregnancy in females of reproductive potential. SA is the progestin component and is a new molecular entity; this derivative of 19-norprogesterone is not orally active. EE is a steroid hormone commonly used in contraceptive products. The SA/EE CVS has never been marketed. The CVS is inserted into the vagina for 21 days and then removed for 7 days; one CVS can be used for up to thirteen 28-day cycles (i.e. one year). It is washed and stored in a provided compact case for the 7 days per cycle that it is not in use.

Substantial evidence of effectiveness was demonstrated in two large, multicenter, uncontrolled Phase 3 trials. The Agency uses uncontrolled trials to assess the benefit risk profile of contraceptive products because decades of historical data are available to evaluate the new product in the context of the current armamentarium of approved contraceptives. Adequate efficacy was demonstrated based on the evaluable cycles from the Phase 3 trial data that enrolled a total of 2,265 females age 18-40 years who were healthy and sexually active with regular menstrual cycles. Study 300A had a PI of 3.10 (95% CI 1.87, 4.84) pregnancies per 100 woman-years. Study 300B had a PI of 2.89 (95% CI 1.79, 4.41) pregnancies per 100 woman-years. The pooled efficacy data from both Phase 3 studies demonstrated a PI of 2.98 (95% CI 2.13, 4.06). This PI is comparable to that of other recently approved products for the same indication and was sufficient to establish efficacy of the product. Other benefits of the product include the convenience of the dosing regimen: the ring is inserted for 21 days and removed for 7 days each cycle; the same ring can be used for up to 13 cycles (one year) without the need to obtain a replacement. In addition, pharmacokinetic data showed that

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

plasma EE exposure from the CVS is comparable or less than that of a low dose oral CHC. The CVS provides daily SA and EE release rates of 150 µg and 13 µg respectively; the product’s route of administration bypasses the first-pass metabolism of the drug substances.

The safety profile of the SA/EE CVS was evaluated using a safety database of 2,308 subjects exposed to the to-be-marketed SA/EE formulation, contributing 21,590 cycles. The safety profile of EE is well-characterized. SA is an NME and the applicant provided an adequate safety database to evaluate the risks with use of this product. Known risks of CHC use include venous thromboembolism (VTE), bleeding irregularities, headache, liver enzyme elevation and depression. The clinical development program for the SA/EE CVS identified an increased risk of VTE compared to other CHCs: the VTE rate for this product is 24.1 per 10,000 woman-years (95% CI 6.6, 61.7), whereas FDA labeling reports the likelihood of developing a VTE for CHC users is 3-12 per 10,000 woman-years. Although the VTE rate estimate appears higher than other products, it is important to recognize that the estimate is associated with considerable uncertainty as evidenced by the wide confidence interval, which has a lower limit that is less than 12 per 10,000 woman-years. Also, the Phase 3 clinical trials were not powered to evaluate an uncommon event such as VTE. To address this safety concern, a post-marketing study will be required to evaluate the risk of VTE in the general population of users of ANNOVERA. Of note, two VTEs occurred in individuals with a body mass index (BMI) greater than 29 kg/m<sup>2</sup>, prompting the applicant to stop enrollment of women in the BMI range >29 kg/m<sup>2</sup>. (b) (4)

(b) (4) other safety findings in the ANNOVERA clinical trials were comparable to those observed with use of other approved CHCs. Additional post-marketing requirements (PMRs) will be a clinical drug-drug interaction study and an (b) (4) study evaluating the effects of tampon use on the (b) (4) of SA and EE. The applicant has also agreed to a postmarketing commitment to conduct a study to characterize the in vivo release rate of ANNOVERA.

Based on the above considerations, we conclude that the benefits of ANNOVERA, when used according to labeling, outweigh its risks for the prevention of pregnancy in females of reproductive potential.

Dimension	Evidence and Uncertainties	Conclusions and Reasons
<a href="#">Analysis of Condition</a>	<ul style="list-style-type: none"> <li>Unintended pregnancy affects millions of women in the United States each year with vast consequent public health effects including adverse maternal and child health outcomes as well as social and economic costs at the family and state level.</li> </ul>	Safe and effective contraception is crucial to women’s health and as many options as possible should be available to women. Development of contraceptives with lower doses, more convenient dosing schedules, and

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

Dimension	Evidence and Uncertainties	Conclusions and Reasons
	<ul style="list-style-type: none"> <li>• In 2011, 45% (or 2.8 million) of the 6.1 million pregnancies in the United States were unintended.<sup>1</sup></li> </ul> <p>Of women at risk for unintended pregnancy:</p> <ul style="list-style-type: none"> <li>○ Those who use contraception consistently and correctly during any given year (68%) account for only 5% of all unintended pregnancies.</li> <li>○ Those who use contraceptives inconsistently or incorrectly (18%) account for 41% of all unintended pregnancies</li> <li>○ Those who do not use contraception at all or who have gaps of a month or more during the year (14%) account for 54% of all unintended pregnancies.</li> </ul>	<p>optimal efficacy and safety profiles is a priority. A contraceptive vaginal system (vaginal ring) with demonstrated efficacy and safety, that can be used for up to one year without the need to obtain a replacement product, would add to the armamentarium of available contraceptive products.</p>
<p><a href="#">Current Treatment Options</a></p>	<ul style="list-style-type: none"> <li>• A wide range of contraceptive products are currently available in the U.S. market, including oral tablets, intravaginal rings, implants, a transdermal patch, and depot injections.</li> <li>• There is one other approved intravaginal ring, Nuvaring. Nuvaring is used for three weeks and then removed for a one-week break, during which a withdrawal bleed usually occurs, after which a new ring must be inserted. Nuvaring requires refrigerated storage at 2-8°C until it is dispensed to the user, and can then be stored at 25°C for up to four months.</li> </ul>	<p>Despite the wide range of contraceptive options, convenience of dosing is a major limiting factor to their consistent use. Daily, weekly or monthly dosing regimens may be difficult for women to consistently adhere to, or may be associated with limiting side effects (e.g. irregular bleeding and spotting). Given that only about two thirds of women at risk for unintended pregnancy use contraceptives consistently and correctly throughout any given year, an additional vaginal ring that does not require replacement for one year, and does not require refrigeration prior to dispensing, offers a convenient and desirable option.</p>

<sup>1</sup> [https://www.guttmacher.org/sites/default/files/factsheet/fb-unintended-pregnancy-us\\_0.pdf](https://www.guttmacher.org/sites/default/files/factsheet/fb-unintended-pregnancy-us_0.pdf)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Dimension	Evidence and Uncertainties	Conclusions and Reasons
<a href="#">Benefit</a>	<ul style="list-style-type: none"> <li>• The drug substance EE is commonly used in contraceptive products and is well-characterized.</li> <li>• The progestin component of the CVS, SA, is an NME and the sponsor has provided adequate exposure in their Phase 3 program to evaluate efficacy and safety of the product.</li> <li>• Convenience of dosing regimen: The ring is inserted for 21 days and removed for 7 days each cycle. The same ring can be used for up to 13 cycles (one year) without the need to obtain a replacement.</li> <li>• First pass metabolism is bypassed, increasing the amount of parent drug(s) available systemically to produce a therapeutic response.</li> <li>• Pharmacokinetic data shows the plasma EE exposure with 21 days of use of the CVS is comparable (based on maximum plasma concentration) or less than (based on area under the curve) than a low-dose oral CHC.</li> <li>• Adequate efficacy was demonstrated based on the evaluable cycles from the Phase 3 trial data. Study 300A had a PI of 3.10 (95% CI 1.87, 4.84) pregnancies per 100 woman-years. Study 300B had a PI of 2.89 (95% CI 1.79, 4.41) pregnancies per 100 woman-years. The pooled efficacy data from both Phase 3 studies demonstrated a PI of 2.98 (95% CI 2.13, 4.06).</li> </ul>	<p>An additional vaginal ring providing safe and effective contraception, and that does not require patients to obtain a new ring for up to one year, provides a beneficial option to women. This option would be of particular benefit to women with limited access to healthcare providers.</p>
<a href="#">Risk and Risk Management</a>	<ul style="list-style-type: none"> <li>• Previously identified risks of CHC use include venous thromboembolic events (VTEs), bleeding irregularities, headache, liver enzyme elevation and depression.</li> <li>• The safety profile was evaluated using 2,308 subjects exposed to the to-be-marketed SA/EE formulation, contributing 21,590 cycles.</li> <li>• There were no deaths among subjects who used ANNOVERA during the development program.</li> <li>• There were four VTEs during the clinical development program. The</li> </ul>	<p>The risk of VTE will be evaluated in a post-marketing trial (PMR). The study will be a long-term cohort study comprising new users of ANNOVERA and new users of other forms of contraception, and will be powered to rule out a 1.5 to 2-fold risk of VTE for ANNOVERA compared to other products. Two other PMRs will be conducted: (1) a clinical drug-drug</p>

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

Dimension	Evidence and Uncertainties	Conclusions and Reasons
	<p>applicant noted that two of these VTEs occurred in subject with a BMI &gt;29 kg/m<sup>2</sup> and stopped enrolling subjects in this BMI range after their (b) (4) identified this finding.</p> <ul style="list-style-type: none"> <li>○ The VTE rate estimate for this product is 24.1 per 10,000 woman-years (95% CI 6.6, 61.7), which is higher than the reported rate in trials for other approved CHC products (3-12 per 10,000 woman-years). The VTE rate estimate for ANNOVERA has considerable uncertainty evidenced by the wide 95% CI. Of note is that the lower limit of the 95% CI is &lt;12 per 10,000 woman-years.</li> <li>○ Since the clinical trials were not powered to evaluate uncommon events such as VTE, a post-marketing study will be required to evaluate the risk of VTE in the general population of users of ANNOVERA.</li> </ul> <ul style="list-style-type: none"> <li>● All other safety findings in the ANNOVERA clinical trials were comparable to those observed with use of other approved CHCs.</li> </ul>	<p>interaction study to evaluate the effects of strong CYP3A induction and inhibition on the pharmacokinetics of SA and EE and (2) an (b) (4) study to evaluate the effects of tampons on the (b) (4) of SA and EE. Given that other safety findings observed in the clinical development program for ANNOVERA were comparable to that of other CHC products, we conclude that the benefits of ANNOVERA outweigh the risks.</p>

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

**1.4. Patient Experience Data**

**Table 1 Patient Experience Data Relevant to this Application (check all that apply)**

X	The patient experience data that was submitted as part of the application, include:	Section where discussed, if applicable
	<input type="checkbox"/> Clinical outcome assessment (COA) data, such as	
	<input type="checkbox"/> Patient reported outcome (PRO)	
	<input type="checkbox"/> Observer reported outcome (ObsRO)	
	<input type="checkbox"/> Clinician reported outcome (ClinRO)	
	<input type="checkbox"/> Performance outcome (PerFO)	
	<input type="checkbox"/> Qualitative studies (e.g., individual patient/caregiver interviews, focus group interviews, expert interviews, Delphi Panel, etc.)	
	<input type="checkbox"/> Patient-focused drug development or other stakeholder meeting summary reports	
	<input type="checkbox"/> Observational survey studies designed to capture patient experience data	
	<input type="checkbox"/> Natural history studies	
	<input checked="" type="checkbox"/> Patient preference studies (e.g., submitted studies or scientific publications)	<b>Section 8.2.2</b>
	<input type="checkbox"/> Patient experience data that was not submitted in the application, but were considered in this review.	
	<input type="checkbox"/> Input informed from participation in meetings with patient stakeholders	
	<input type="checkbox"/> Patient-focused drug development or other stakeholder meeting summary reports	
	<input type="checkbox"/> Observational survey studies designed to capture patient experience data	
	<input type="checkbox"/> Patient experience data was not submitted as part of this application.	

## 2. Therapeutic Context

---

### 2.1. Analysis of Condition

In 2011, 45% of all pregnancies in the US were unintended<sup>2</sup>, representing 2.8 million pregnancies<sup>3</sup>. The highest rates of unintended pregnancy were among women age 18-24 and women with low incomes. Among teens, 15-19 years of age, 75% of pregnancies were unintended<sup>1</sup>.

Unintended pregnancies can place undue financial burdens on women and can result in negative health consequences for women and children. Women with unintended pregnancies are more likely than those with intended pregnancies to receive later or no prenatal care, to smoke and consume alcohol, to be depressed and/or anxious, and to experience domestic violence during pregnancy<sup>4</sup>. For infants, there are greater risks of birth defects, low birth weight, and poor mental and physical functioning in early childhood<sup>5</sup>. Unintended pregnancy ends in abortion in about 40% of cases<sup>2</sup>.

Contraception is used to prevent pregnancy. In the most recent evaluation of unintended pregnancy in the US, Finer and Zolna<sup>2</sup> note a decrease in unintended pregnancy occurred at the same time the use of highly effective long-acting methods of contraception increased among women using contraception. Therefore, efforts to reduce unintended pregnancy include increasing access to contraception, particularly more effective, longer-acting reversible forms of contraception and increasing correct and consistent use of contraceptive methods<sup>1</sup>.

### 2.2. Analysis of Current Treatment Options

Reversible hormonal contraception includes progestin-containing IUSs, progestin implants, progestin injections, progestin-only pills, combined hormonal pills, combined hormonal patch, and combined hormonal vaginal ring. There is one CHC patch and one CHC vaginal ring and numerous combined oral contraceptives (COC)s. COCs vary based on type and dose of progestin, type and dose of estrogen, monophasic vs multiphasic, number of day regimen (21, 24, 26 days in a 28-day cycle) or extended (84 days).

---

<sup>2</sup> <https://www.cdc.gov/reproductivehealth/contraception/unintendedpregnancy/index.htm> accessed 4/20/2018. Accessed April 20, 2018

<sup>3</sup> Finer, L and Zolna M. Declines in Unintended Pregnancy in the United States, 2008-2011. N Engl J Med 2016; 374:843-852.

<sup>4</sup> Institute of Medicine. Clinical preventive services for women: Closing the gaps. Washington, DC: The National Academies Press; 2011:102-10

<sup>5</sup> ACOG Committee Opinion. Reproductive Life Planning to Reduce Unintended Pregnancy. Number 654, February 2016

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

Table 2 lists the currently marketed non-oral CHCs and four selected COCs, two recently approved (Quartette, Lo Loestrin FE), one with a 3<sup>rd</sup> generation progestin (Yasmin), and one with numerous generic products (Alesse).

**Table 2. Selected CHCs**

Product Name NDA #	Approval Year	Route/frequency Dose	Efficacy based on Pearl Index (PI) (upper limit of 95% CI)	Excluded sub-population
NuvaRing 21187	2001	vaginal ring/ 3wk each month  0.12mg etonogestrel/ 15µg EE	PI 1.28 (1.9)  PI US 2.02 (3.4)	no women >41 yo  no women with bmi ≥ 30
OrthoEvra 21180	2001	transdermal patch/weekly for 3 wk each month  0.15mg norelgestromin/ 35µg EE	PI 1.07 (1.76)	limitation of use: less effective in women ≥ 198 lbs
Quartette 204061	2013	po/daily  0.15mg levonorgestrel (LNG)/ 20,25,30,10 µg EE	PI 3.19 (4.03)	no women >40 y/o
Lo Loestrin FE 22501	2010	po/daily  1 <sup>(b)(4)</sup> mg norethindrone acetate (NETA)/10 µg EE	PI 2.92 (4.21)	no women with BMI >35 kg/m2
Yasmin 21098	2001	po/daily  3mg drospirenone/ 30 µg EE	Pregnancy rates less than 1 per 100 w-y*	no women >40 y/o
Alesse 020683	1997	po/daily  0.1mg LNG/20µg EE	Pregnancy rate less than 1 per 100 w-y*	

\*w-y=women-years

Source: <https://www.accessdata.fda.gov/scripts/cder/daf/>

More recently, contraceptive trials have calculated the PI instead of a pregnancy rate. The PI is now calculated based on actual use (rather than perfect use) and cycles where back up contraception was used are excluded. In addition, when possible, cycles where heterosexual intercourse did not occur (not at-risk cycles) are excluded. This, in addition to better detection of pregnancy may partially explain the increasing PIs in the more recently approved contraceptives.

CHCs as a general class have several safety issues that have been well-recognized since their introduction in the United States in the 1960s. The following adverse events represent the major concerns described in contraceptive labeling:

- Vascular events, which may be fatal, including:
  - Deep venous thrombosis, pulmonary embolism, other venous thromboses
  - Myocardial infarction (especially in women >35 years who smoke)
- Liver disease
- Hypertension
- Gallbladder disease
- Headaches
- Irregular uterine bleeding, amenorrhea, oligomenorrhea
- Adverse carbohydrate and lipid metabolic effects
- Depression
- Hereditary angioedema

### 3. Regulatory Background

---

#### 3.1. U.S. Regulatory Actions and Marketing History

SA is an NME and is not currently marketed in the U.S. This application is for a CVS with SA and EE. (b) (4)

[Redacted]

#### 3.2. Summary of Presubmission/Submission Regulatory Activity

The application for this CVS was opened in July 13, 1997 under IND 049980.

A pre-clinical guidance meeting occurred on January 12, 1999 for the development of SA contraceptive products including rings, (b) (4). Pre-clinical toxicology and pharmacology, pharmacokinetics, and CMC (now Office of Product Quality (OPQ)) provided comments and advise on the development program.

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

The applicant submitted questions for a pre-phase 3 meeting. On August 20, 2002, the Division provided written responses to the submission. Key advice included:

- General comments for contraceptive trials:
  - For contraceptive efficacy 18-35 y/o with at least 10,000 cycles of use, 200 must complete 1-year treatment
  - For NME requirements of a minimum of 100 subjects for one year of treatment, with a total treatment of 1500 subjects
  - PI >2.0 will be a review issue
  - The Division noted the Phase 3 protocol excluded women with BMI $\geq$ 31 and requested the reason for this exclusion
  - Trial design should collect data on expected menstrual bleeding
- Comments regarding product quality:
  - (b) (4) EE will not be considered a risk if it does not exceed those occurring with comparator 30  $\mu$ g EE COC that has been FDA approved.
  - Request that the applicant address concerns of bacterial contamination with the ring and how ring is stored.
  - Encourage development of a validated *in vitro* and *in vivo* (IVIVC) to support changes in the phase 3 trial formulation and the to be marketed (TBM) formulation or any formulation changes
  - Phase 4 studies for oil-based vaginal products and different tampons on the PK/PD, efficacy and safety of the CVS may be required

On June 27, 2005, the applicant submitted their protocols for two phase 3 trials for SA/EE CVS. Written comments and recommendations were provided to the applicant on December 28, 2005 and included:

- For an NME, the Division was now requesting that the NDA include safety and efficacy data from at least 20,000 cycles of exposure and at least 400 women completing 13 cycles of use. The Division acknowledged this advice was different from the advice given in the August 20, 2002 letter.
- Large and adequately powered Phase 4 comparative safety study to define the risk of serious thrombotic and thromboembolic adverse events (AEs) (PE, stroke, MI, death) associated with use of the new product will be requested for applicants with hormonal contraceptive products that contain an NME.
- Label will reflect the patient population studied in the clinical trials particularly in regards to (b) (4) subjects use of enzyme inducers, (b) (4)

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

- Collection of data on ring expulsion and problems with (b) (4) should be recorded on diary card.

A Type C teleconference to answer the applicant's questions concerning the Division's comments and recommendation occurred on April 3, 2006. The following were agreed to:

- Advise on collection of laboratory data:
  - Laboratory parameters for 300A sites (US sites) to include full lipid panel in addition to CBC and chemistry laboratories at baseline, 6 months and termination.
  - Coagulation parameters (Factor VIII, fibrinogen, protein S activity, SHBG) to be evaluated in 100 subjects at baseline, 6 months, and termination
  - Urine pregnancy testing (UPT) at each visit
  - Endometrial safety data obtained in a subset of subjects (at least 50 who have completed one year treatment) with baseline and post treatment endometrial biopsies.
- Advice on data analysis:
  - PI and Kaplan-Meier life table analyses be submitted for all subjects and all subjects ≤35 years.
  - PI on all cycles and on all cycles for which back-up contraception was not used, as these represent the true at-risk cycles
  - Above analyses to be submitted with data from each trial; pooled data may also be submitted
  - Provide analyses of the safety and efficacy data by geographic area (US and non-US), weight, parity, and age
  - The proportion of women over 35 years old to be included in the trial is not fixed but a sample that includes 15-20% of its subjects in this age group is acceptable

A protocol for special protocol agreement (SPA) was submitted July 11, 2006 with no agreement. In a September 18, 2006 meeting to discuss the Division's August 25, 2006 response letter to the SPA, discussions included:

- Retention of population exclusions of smokers over 35 y/o, women with family history of venous thromboembolism (VTE) (b) (4) and use of enzyme inducing medications. The Division stated these were acceptable with the understanding that any approved labeling would reflect the population studied.
- Comments regarding the diary recommending that investigators should enter data gained during a clinic visit on a separate form and not complete the diary for the subject, and noted that incomplete data would be a review issue

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

- Reiteration that the primary efficacy endpoint is the PI for women  $\leq 35$  years of age using only cycles for which back up contraception was not used. All other subgroup analyses would be considered supportive. 95% CI for PI and life table estimates should also be presented. Each study should be analyzed separately and each should independently demonstrate efficacy.

In October 19, 2010, a Type C Teleconference was held to discuss:

- How to conduct different metabolism studies due to difficulties performing mass balance study.
- The need to conduct a thorough QT (TQT) study
- The need for DDI of CVS with concomitant use of other vaginal products

The applicant changed the manufacturer of the drug substance and manufacturing processes testing part way through development. Therefore, in September 10, 2012, February 28, 2013 and September 30, 2013, we held meetings to discuss bridging from the phase 3 CVS to the TBM CVS, focusing on the in vitro release test method and proposed protocol for discriminatory ability of the in vitro release method. This bridging was also necessary for evaluation of data from the PK/PD, DDI, and QT/QTc studies.

On November 30, 2015, a Type C guidance meeting was held. Major issues included:

- The number of evaluable cycles was 15,647 (excluding women  $>35$  at entry and women with BMI  $\geq 29$ , and excluding cycles in which back up or emergency contraception (EC) was used), which fell short of the required number of cycles for efficacy. However, there were 19,726 cycles evaluable for safety based on all women treated in the two pivotal phase 3 trials and 21,590 cycles evaluable for safety based on all women who used the TBM CVS in phase 3. Upon reviewing the data on cycles, in post meeting comments, the Division concurred that the number of cycles of exposure is sufficient to support NDA filing because the number of cycles evaluable for safety was acceptable. In agreeing, the Division noted, "Although the intended target population is exclusive of women with BMI  $\geq 29$  kg/m<sup>2</sup>, the Division agrees that safety data that includes a subset of women in this higher BMI range is acceptable, because it appears that there may be a more concerning safety profile in this subset of women. Thus, inclusion of this subset of women would not result in a safety profile that is likely to be more favorable than that in the target population". The Division also requested that the applicant enumerate the number of women and number of cycles excluded from the pooled efficacy population and provide an explanation as to why the number of efficacy evaluable cycles was so much lower than the number in the safety population.
- The Division requested an efficacy analysis that includes women of all ages.
- Increased initial release rates of SA and EE depend on duration of storage time prior to use as well as the storage temperature. The Division asked the applicant to address the

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

impact of using aged CVS and provide a justification that the data will generalize to likely actual use situations. Phase 3 safety and efficacy data should be stratified by age of the CVS at time of first use.

- The FDA was unable to concur with the proposed bridging plan for the manufacturing process used in phase 3 to the TBM process and drug product without additional clinical data for NDA filing/review. In vitro release procedure advise was given.
- CDRH requirements for the device components of the CVS were given
- Outstanding clinical pharmacology issues for an NME were listed
- DMEPA guidance was given regarding need for risk analysis to determine whether a Human Factors study would be required.

A Type C meeting on June 2, 2016 between the FDA and the applicant discussed bridging the TBM product to the phase 3 batches, studies needed for biocompatibility and mechanical testing, and implementation of an accelerated in vitro release quality control method.

The preNDA meeting (Type B) was held January 24, 2017 with the applicant seeking FDA's concurrence on the data and format requirements. All responses depended on an appropriate bridging strategy (through CMC data) to link the phase 3 CVS formulation to the TBM formulation being performed. The Division found the studies and analyses adequate to support filing and review of the NDA and requested:

- A sensitivity analysis including as "on-treatment" any pregnancies conceived within 14 days after CVS removal
- Number of cycles in US women for each study and in the pooled data
- Subgroup analysis by region (US vs. Non-US) and race/ethnicity
- That the submission address the generalizability of trial results to the full population of CVS users, which likely will include premenopausal women over 40 years of age.

The Division agreed:

- To review studies that the applicant had conducted to assess the in vivo delivery of SA and EE using the TBM CVS and an FDA-approved EE containing oral product and assess the in vivo release of SA and EE from the TBM product to determine if the bioavailability requirements have been met.
- That a risk management plan should be described in the NDA and anticipates that if approved, the applicant would have a PMR for a large safety study to characterize the risk of VTE in CVS users regardless of weight/BMI.

The Division requested that the applicant address DDIs.

The marketing application will be a 505(b)(2) application using the FDA's finding of safety for EE exposure in the CVS (through comparative BA bridging study with a listed drug COC) and published literature.

### 3.3. Foreign Regulatory Actions and Marketing History

There is no marketing history for the combined SA/EE CVS.

(b) (4)

(b) (4)

## 4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety

---

### 4.1. Office of Scientific Investigations (OSI)

The Office of Scientific Investigations was consulted for this NDA. Two clinical sites in Study 300A and three clinical sites in Study 300B were selected for inspection. The rationale for site selection was based on high subject enrollment, adverse events of special interest (i.e. VTE), numbers of pregnancies occurring at the site, and prior inspectional history. The applicant, Population Council, was also inspected as part of a data audit inspection and a complaint related to the protocols under review for this NDA submission. In the OSI review dated May 31, 2018, the overall assessment of findings was that the investigations at these sites appear to have been conducted adequately and the data generated by these sites appear acceptable in support of the indication.

- **Site 12, Kevin Barnhart, MD; Philadelphia, PA (Study 300A):** This site was found to have excluded a concomitant medication (clonazepam) for one subject and to have failed to

---

<sup>6</sup> NDA 209627, Sequence 0018, submitted 4.26.2018, Response to IR, Module 1.11.4 p 10/11

<sup>7</sup> Email communication from Cherice Holloway CDER/OSE/OCT through Miriam Chehab OMPT/CDER/OSE/OPE/DPVII May 4, 2018

review screening labs before enrollment for three subjects. In addition, three subjects were not properly re-consented for the study using an updated informed consent form (ICF). This site was classified as deviation(s) from regulations (VAI) and the clinical investigator provided a corrective action plan to OSI. The OSI reviewer's conclusion was that "the regulatory compliance violations identified are unlikely to significantly impact data reliability."

- **Site 21, Michael Thomas, MD; Cincinatti, OH (Study 300A):** This site was selected due to VTE occurrence. Two subjects at this site had VTEs. This site was classified as no deviation from regulation (NAI).
- **Site 9, Melissa Gilman, MD; Chicago, IL (Study 300B):** One subject at this site had a VTE. There were protocol deviations involving incorrect reporting of 10 subjects' heights at this site. This site was classified as no deviation from regulation (NAI).
- **Site 23, Philip Darney, MD; San Francisco, CA (Study 300B):** This site was classified as deviation(s) from regulations (VAI) due to the clinical investigator obtaining informed consent for nine subjects using an amended version of the informed consent form not yet approved by the IRB. The clinical investigator stated that this occurred due to an oversight and outlined a corrective action plan to reduce ICF version issues. The OSI reviewer's conclusion was that "the regulatory compliance violations identified are unlikely to significantly impact data reliability."
- **Site 3, Vivian Brache, Santo Domingo, DR (Study 300B):** There were a higher number of pregnancies at this site compared to other sites. The OSI investigator noted that storage conditions may have contributed to product failure due to higher-than-acceptable temperature and humidity recordings at the site, and the fact that the air conditioning was turned off overnight at this site. The Medical Director of Population Council posited that there was more user error at this site compared with other sites, but the OSI investigator did not find any documentation of rates of user error higher than that at other sites. This site was classified as no deviation from regulation (NAI).
- **Applicant, Population Council:** The inspection covered practices related to both Study 300A and 300B and addressed a complaint made by a former Population Council employee who alleged that changes in the baseline BMI definition (which was used to analyze VTE risk) were made after the safety database was locked. Specifically, the complainant alleged that the definition of baseline BMI was changed to allow use of both screening and immediate pretreatment BMI (instead of just screening BMI) to link incidence of VTE to BMI >29 kg/m<sup>2</sup>. Baseline BMI was also used to analyze VTE risk, instead of BMI at time-of-event. After a detailed review of records, the OSI investigator did not find evidence that baseline BMI definition was changed after safety database locking. The OSI reviewer also noted that the applicant was regularly in contact with the DSMB for the studies and responsive to all DSMB documentation requests.

## 4.2. Product Quality

SA is a progestin chemically known as 19-norpregn-4-ene-3,20-dione, 17-hydroxy-16-methylene acetate, and as 17-hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione acetate ester. The

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Chemistry Manufacturing and Controls (CMC) of segesterone acetate, an NME, is adequately documented in (b) (4) Type II Device Master File (DMF) # (b) (4). EE has a long history and is a widely used component of CHCs. The CMC for EE is adequately documented in (b) (4) Type II DMF # (b) (4).

ANNOVERA Vaginal System differs from the three FDA-approved vaginal rings, NuvaRing, Estring and Femring, in several important ways. First, it is designed to be used for thirteen (b) (4) day cycles. It is removed and stored for 7-days between each (b) (4) cycle. Secondly, (b) (4)

(b) (4)

In addition to SA and EE, ANNOVERA consists of several types of silicone elastomers (b) (4) (b) (4) ) and titanium dioxide, which gives the ring a uniform opaque appearance. The silicone elastomer components are manufactured by (b) (4) as described in several DMFs (b) (4). These materials were previously (b) (4) (b) (4) silicone elastomers. (b) (4)

There are no safety concerns with these materials at the levels present.

There are three essential components of the ANNOVERA vaginal system: a ring body with an overall outside diameter of 56 mm and a cross-sectional diameter of 8.4 mm, and two drug-containing rod-shaped cores. Each ring weighs a total of (b) (4) grams. The ring body has two channels approximately 3.0 mm in diameter and 27 mm in length. Two drug-loaded cores are inserted and sealed in each channel with a silicone medical adhesive. Cores are 3 mm in diameter. One of the cores is 18 mm in length (b) (4). The other core is 11 mm in length (b) (4).

The silicone elastomer ring bodies are manufactured (b) (4)

(b) (4)

Despite the complexity, the current manufacturing process and in-process controls are adequate to ensure product with the requisite quality and performance.

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesteronone acetate and ethinyl estradiol vaginal system)

The essential performance characteristic of the vaginal system is the slow, controlled release of drug from the polymeric matrix. A fast release rate may result in safety concerns. Conversely, a slow release rate may result in delivery of levels of drug too low to support efficacy. To ensure the appropriate batch-to-batch performance characteristics of the product, two in vitro release tests were developed. The first, an accelerated method, was found inadequate for use. The second method measures the in vitro release of drugs over a 30-day period. The biopharmaceutics review team performed extensive analyses to establish clinically relevant acceptance criteria. To ensure that the in vitro release criteria are met throughout the shelf-life as required by the regulatory specification, acceptance criteria for in vitro release testing for batch release was also established.

The Applicant's proposed in vitro in vivo correlation (IVIVC) was found unsuitable for use in providing a bridge to support formulation and manufacturing process changes. The in vivo release rate of the active ingredients was determined by measuring residual drug levels in the rings after use for thirteen cycles. While this gives an idea of the average rate of in vivo release, it does not adequately capture the decrease in release rate over time. The Applicant has agreed to further characterize the in vivo release rate (b) (4) as a post-marketing commitment.

In addition to in vitro release testing, the product specification includes tests for identity, dimensions, mass, (b) (4) hardness (b) (4), EE assay, SA assay, content uniformity, and related substances. Although vaginal rings are not manufactured as sterile products, they must meet requirements for microbial quality, and must be free of several specific microorganisms (e.g., E. coli). To minimize microbial contamination during the 7-day storage, the removed rings should be washed with mild soap and water and rinsed and patted dry.

The reviewer from the Center for Devices and Radiological Health (CDRH) determined that the mechanical properties (e.g., (b) (4) hardness, elongation at break, compression strength) and biocompatibility of the finished combination were adequately characterized and documented, and that the vaginal ring was suitable for the intended use.

The stability of Anovera at 25°C for 18 months has been adequately demonstrated; an 18-month expiration dating period is therefore granted. (b) (4)

(b) (4) Storage at elevated temperatures for long periods of time can adversely impact product performance. This applies to product before first use and when stored between (b) (4) cycles.

The drug substance manufacturing facilities have acceptable CGMP status. The product manufacturer, QPharma AB, Malmo, Sweden, was satisfactorily inspected for drug and medical device GMP compliance in December 2017. All ancillary facilities have acceptable CGMP status. An Overall Inspection Recommendation of Approve was issued by the Office of Process and Facilities (OPF) Division of Inspectional Assessment on April 5, 2018. The OPF review team

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

recommends a post-approval inspection due to the complexity of the product and the likelihood of manufacturing scale-up.

The applicant submitted a claim for a categorical exclusion from the requirement to prepare an environmental assessment (EA) for ethinyl estradiol (EE), pursuant to 21CFR25.31(a) (i.e., use will not increase) and for segesterone, per 21 CFR 25.31(b) (i.e., use will increase but the expected introduction concentration (EIC) will be <1 parts per billion), for this application. A statement regarding the applicant's knowledge of extraordinary circumstances was submitted, as required per 21 CFR 25.15(a). Based on a review of the information provided by the applicant, and additional information obtained by FDA, the claims for categorical exclusions from EAs are acceptable. FDA also noted that because approval will result in expected concentrations of segesterone acetate that could approach environmental benchmarks, and because of the potential for cumulative effects from other drugs and xenobiotics with similar mechanisms of action, FDA recommends a prudent use of label language that provides guidance regarding environmentally protective disposal practices.

The Applicant also proposed a Comparability Protocol covering minor changes (b) (4) and documentation via a CBE-30 supplement, which was acceptable to the CMC review team.

#### **4.3. Clinical Microbiology**

Clinical Microbiology review was not necessary for this application.

#### **4.4. Devices and Companion Diagnostic Issues**

CDRH was consulted for this NDA. Contraceptive vaginal systems (referred to as “contraceptive vaginal rings” or CVR in the CDRH review) are combination products for which CDER is the lead center, with CDRH providing consultation on the ring itself. In the CDRH review dated March 8, 2018, the CDRH consultant concluded that “the information provided in the NDA including the associated responses to Informational requests is sufficient to demonstrate the adequacy of the mechanical design of the CVR to function as an intravaginal ring which may be inserted and removed monthly for a time frame of 13 months. It is also sufficient to demonstrate that its mechanical function will not be adversely affected by a shelf life of (b) (4) months.” The CDRH review also provided labeling recommendations to address that the CVR is compatible for use with male condoms, but not oil-based personal lubricants. These recommendations will be incorporated into the final label for the product.

## 5. Nonclinical Pharmacology/Toxicology

---

### 5.1. Executive Summary

SA/EE CVS is an intravaginal ring system designed for continuous release of a synthetic progestin (SA, 150 µg/day) and a synthetic estrogen (EE, 13 µg/day) for a maximum of 13 menstrual cycles of 28 days each. The CVS is inserted at the beginning of each menstrual cycle and remains in place continuously for three weeks (21 days) followed by a one-week (7 day) ring-free interval. A single device can provide reversible contraception for one year (13 cycles).

The progestin component of this product, SA, is a new molecular entity and the estrogen component, EE, is an approved product already marketed in the U.S. The applicant is seeking approval via the 505(b)(2) pathway to rely on published literature for the nonclinical safety evaluation of EE and to inform Sections 8 and 13 of the prescription labeling. Nonclinical studies were only conducted for SA.

Segesterone acetate is a high affinity ligand of the progesterone receptor, producing a dose-dependent increase in uterus weight with significant myometrium and endometrium proliferation. Doses  $\geq 2.8$  µg/kg/day block fertilization in female rabbits, and in female rats doses  $\geq 67$  µg/kg/day completely block spontaneous ovulation and estrus cycling. SA is not an agonist of the androgen receptor in rats, but subcutaneous (SC) doses  $\geq 33$  mg/kg/day are slightly anti-androgenic. SA is a very weak agonist of the glucocorticoid receptor and has no effect on either the estrogen or mineralocorticoid receptors in rats.

Orally administered segesterone is rapidly absorbed from the gastrointestinal (GI) tract, and the rise in portal concentration is followed by an equally rapid decrease in the systemic concentration with metabolites appearing in the bile. In all nonclinical species, SA is subject to extensive first-pass metabolism by hepatic cytochrome P450 (CYP 3A4) and carbonyl reductase enzymes, producing numerous Phase I and II metabolites that can be detected in plasma, urine and feces. At free concentrations of 1 µM and above, segesterone causes metabolism-dependent inhibition of CYP3A4 *in vitro*, suggesting the formation of reactive intermediates. Hepatocyte studies indicate that liver metabolism is somewhat slower in humans than in rats, and that segesterone does not induce its own metabolism.

After subcutaneous injections or implantation of sustained release delivery systems, SA distributes to a wide variety of tissues with the highest concentrations found in the gastrointestinal tract, adrenals, liver, ovaries, uterus, reproductive tract fat, and pancreas. The fraction of segesterone bound to serum proteins is approximately 95% in humans, rats and mice. The main route of excretion following systemic administration is fecal, with approximately 50% of the dose recovered in feces within 24 hours.

In patch-clamp studies, SA inhibited the ionic current of the human ether-à-go-go-related gene (hERG) potassium channel by 24% at 10  $\mu$ M free drug concentration. It also inhibited the L-type calcium channel (hCav1.2) and the hyperpolarization-activated potassium channel (hHCN4) currents by 13.5% and 14.4%, respectively at 1  $\mu$ M. In telemetrized freely moving cynomolgus monkeys, subcutaneous injections of SA at a dose of 2.5 mg/kg produced no change in blood pressure, heart rate, action potential duration or QT intervals. In rats, SA did not produce any mortality, clinical signs, respiratory or neurobehavioral effects after a single dose of 10 mg/kg SC, approximately 130 times the human exposure reported in Cycle 1 of clinical study 300PK.

Segesterone acetate was investigated in mice, rats, rabbits and monkeys. None of the anticipated endocrine effects were observed following oral administration, confirming the rapid and extensive first pass metabolism across nonclinical species. Hence, the toxicological properties of SA could only be evaluated using parenteral routes of administration.

CD1<sup>®</sup> female mice administered SA as a vaginal gel of 1, 3 and 9% SA (10, 30, and 90 mg/kg/day) for 28 days only showed alteration of the vaginal morphology consistent with the pharmacology of a progestin. Similarly, the administration of SA for three months to Sprague-Dawley rats at an average daily dose of 86  $\mu$ g/day (approximately 175  $\mu$ g/kg/day in males and 286  $\mu$ g/kg/day in females) by subdermal implant blocked the estrus cycle, inhibiting ovulation and stimulating mammary growth and milk secretion. In males, SA treatment produced a reduction in testes, epididymis, prostate and seminal vesicle weights and an increase in adrenal weights. Female CD<sup>®</sup> rats administered SA for a year by subdermal implants with release rates of 11, 15 and 48  $\mu$ g/day (approximately 75, 100 and 320  $\mu$ g/kg/day) presented with a combination of effects on the primary and secondary sex organs, including enlarged mammary and pituitary glands and a reduced uterus weight. Histologically, the ovaries were devoid of corpora lutea, the uterus and vagina were arrested in diestrus and the mammary glands showed little ductal or lobuloalveolar development. The no-observable adverse-effect-level (NOAEL) after a year of dosing was 48  $\mu$ g/day (320  $\mu$ g/kg/day) as the effects of SA were primarily pharmacological. The mean SA serum concentration at the NOAEL was 71-fold the average steady-state serum concentration ( $C_{ave}$ ) in cycle 1 of clinical study 300PK (515 pmol/L).

Female New Zealand White rabbits implanted with Silastic rods continuously releasing SA at daily rates of 25, 130 or 550  $\mu$ g/day (approximately 14, 72 and 306  $\mu$ g/kg/day) for three months showed a decrease in uterine weight and an increase in liver weight at all doses, and a decrease in adrenal and thyroid gland weights at the highest dose. All the effects reported in this study were consequences of the pharmacology of SA and the NOAEL for three months of dosing was 550  $\mu$ g/day, corresponding to 16-fold of the  $C_{ave}$  in cycle 1 of clinical study 300PK.

Segesterone acetate was administered for 1 year to female cynomolgus monkeys using subdermal Silastic implants with release rates of 30, 87 and 395  $\mu$ g/day (approximately 10, 30 and 130  $\mu$ g/kg/day) without indication of systemic toxicity. The menstrual cycle of all treated animals stopped within 10 days of test article implantation and a dose-related enlargement of the uterus was observed, which correlated histologically with myometrial hypertrophy,

endometrial decidualization and inhibition of endometrial gland growth. Hormonally-induced changes were also seen in the cervix and vagina. SA inhibited ovulation and the development of corpora lutea but allowed follicular growth up to the intermediate stage. All the observed effects were consequences of the pharmacology of SA and the NOAEL for 1 year of dosing in monkeys was 395 µg/day, corresponding to 18-fold of the  $C_{ave}$  in cycle 1 of clinical study 300PK.

Vaginal rings releasing SA at a rate of approximately 100 µg/day (approximately 33 µg/kg/day) were inserted in the vagina of female cynomolgus monkeys and remained in situ for 4 weeks without sign of systemic or local toxicity. The animals receiving SA exhibited morphologic differences in the vagina, the cervix and the uterus related to its pharmacology. The NOAEL in this study was 100 µg/day, corresponding to a serum concentration 4.4-fold greater than the average steady-state segesterone concentration in cycle one of clinical study 300PK.

Segesterone acetate was not mutagenic in bacterial mutation assays and did not cause chromosome aberrations in human peripheral blood lymphocyte cultures or in the bone marrow of mice. In a mouse carcinogenicity study, the daily administration of SA intravaginally for two years using gels of 0.3%, 1% and 3% SA, providing doses of 3, 10 or 30 mg/kg/day produced subchronic or chronic inflammation of the vaginal mucosa and at the highest dose per day, an increased incidence of adenocarcinoma and lobular hyperplasia in the breast. Based on the results of this 2-year study, 30 mg/kg/day SA is considered carcinogenic in female mice. A 2-year carcinogenicity study was also conducted in female rats using segesterone subdermal Silastic implants with release rates of 0, 40, 100, 200 µg/day (approximately 267, 667 and 1333 µg/kg/day). The high dose of 200 µg/day decreased the incidence of pituitary and mammary neoplasms in the rats compared to controls. The average serum concentration of SA at the end of the two-year period in female rats receiving 200 µg/day was approximately 35 times greater than the steady-state patient concentration in cycle 1 of clinical study 300PK, and 86 times the daily dose of SA based on body surface area. Exposure was not measured in the mouse carcinogenicity study, but relevant systemic exposure was measured in the 4-week dose-selection study in mice. The carcinogenic dose of 30 mg/kg/day is 10-fold greater than the AUC of SA in cycle one of clinical study 300PK, and the non-carcinogenic dose of 10 mg/kg/day is approximately 3-fold greater than the AUC of SA in cycle one of clinical study 300PK. Patients will be exposed to less than the lifetime non-carcinogenic dose in nonclinical species, and the use of ANNOVERA is, therefore, not expected to pose a significant cancer risk.

During reproductive toxicity studies, the subdermal administration of SA to female CD<sup>®</sup> rats for 90 days did not impair the return to fertility when the implants were removed. More females from the SA treatment group became pregnant after implant removal than in the vehicle control group, and prior treatment had no effect on the number of corpora lutea or the number of implantations recorded in the animals. The subcutaneous administration of SA to pregnant rats at doses up to 250 µg/kg/day during gestation days 6-15 did not cause maternal toxicity, embryotoxicity or teratogenicity. However, daily subcutaneous injections of SA at doses of 10, 50 and 250 µg/kg/day from gestational day 15 through gestational day 25 or postpartum resulted in prolonged gestation and delivery complications leading to the death of mothers

and/or pups at all three doses. In addition, feminization of male pups, as indicated by an increase of the anogenital distance, was evident in the 10 and 50 µg/kg/day dosage groups after delivery. This effect had disappeared by day 21 postpartum. A no-observable-effect-level (NOEL) for either maternal toxicity or viability and growth in the offspring could not be identified. In rabbit, daily subcutaneous injections of SA at 10, 50 and 250 µg/kg from gestational day 6 through gestational day 18 increased embryo death and litter resorptions at the highest dose, without adverse effects on the surviving fetuses. The developmental NOAEL for SA in rabbit was 50 µg/kg/day, corresponding approximately on day 18 to an exposure 1.8-fold greater than the average exposure (AUC<sub>0-24</sub>) in cycle one of clinical study 300PK.

The safety of EE is well-established and documented in the published literature following many years of clinical use. Ethinyl estradiol was first approved in 1943 and has been a component in various combined hormonal contraceptives either as a pro-drug or as the drug substance since 1960. There are several approved products that contain EE as the active pharmaceutical ingredient at the same or similar doses, and for the same or similar indication as the SA/EE 150/15 CVS (e.g. Nuvaring). The applicant has shown that the patient serum concentrations of EE following administration of the vaginal ring system were very similar to those recorded with an approved oral contraceptive product (Nordette 21; Wyeth Laboratories). This NDA however is not relying on any of the previous findings of safety for Nuvaring or Nordette 21 to support the safety of use of EE as a component of the drug product and has no right of reference to either NDA.

No toxicology studies were specifically conducted to evaluate the combination of SA and EE in a vaginal ring system, though biocompatibility studies of extracts of the SA/EE to-be-marketed device have been conducted to evaluate the potential for local toxicity. The chronic safety of EE alone has already been documented in the published literature and through extensive previous approved use through vaginal application, and the 12-month monkey study using subcutaneous implants provided evidence of the long-term safety of SA. The local tolerance of a vaginal ring system releasing SA alone was evaluated in a 4-week monkey intravaginal toxicity study, with only pharmacodynamic effects observed. There were no device-related toxicities observed. In addition, clinical studies informed the pharmacokinetics of the SA/EE vaginal ring system, eliminating the need for a nonclinical study of chronic duration with the combination. To assess the biocompatibility of the drug/device combination, nonclinical studies were completed using extracts from the proposed SA/EE vaginal ring system, and reviewed by CDRH. These studies were deemed sufficient to evaluate the local toxicity of the combined drug/device product.

The safety multiples of the therapeutic dose achieved in nonclinical studies are summarized in Table 3.

**Table 3. Safety multiples of the therapeutic dose of SA\* based on nonclinical studies**

Nonclinical Studies	Daily Doses	Exposure and BSA-corrected Dose		Multiples of	
		AUC <sub>0-24h</sub> (ng·hr/mL)	Human Equivalent Dose (mg/kg)	Cycle 1 Human AUC <sub>0-24h</sub>	Human Daily Dose (BSA)
<b>General Toxicology</b>					
4-Week Intravaginal Toxicity Study in Female Mice (Study 1571-001)	9% Gel 90 mg/kg NOAEL	1990	7.32	132	2926
3-month Subdermal Implant Toxicity Study in Rats (Study 01-ST-TOX-0682)	0.175 mg/kg (m) 0.286 mg/kg (f) NOAEL	ND	0.03 (m) 0.05 (f)	-	11 19
3-month Subdermal Implant Toxicity Study in Rabbits (Study PC-ST-05-KS/89)	0.07 mg/kg NOAEL	ND	0.02	-	9
12-month Subdermal Implant Toxicity Study in Rats (Study PC-ST-03-KS/89)	0.075 mg/kg LOAEL	ND	0.01	-	5
12-month Subdermal Implant Toxicity Study in Cynomolgus Monkeys (Study PC-ST-06-KS/90)	0.13 mg/kg NOAEL	ND	0.04	-	17
4-Week Local Toxicity Study of Vaginal Rings in Cynomolgus Monkeys (Study 6884-102)	0.04 mg/day NOAEL	ND	0.01	-	5
<b>Carcinogenicity</b>					
2-Year Intravaginal Carcinogenicity Study in Mice (Study 1571-002, GLP)	1% Gel 10 mg/kg NOAEL	39	0.81	3	325
2-Year Subdermal Implant Carcinogenicity Study in Rats (Study 6884-103)	1.33 mg/kg NOAEL	ND	0.21	-	86
<b>Reproductive Toxicology</b>					
Embryo-Fetal Toxicity and Teratogenicity Study in Pregnant Rats (Study PC-ST-07-KS/91)	0.25 mg/kg Maternal NOAEL	ND	0.04	-	16
	0.25 mg/kg Fetal NOAEL	ND	0.04	-	16
Embryo-Fetal Toxicity and Teratogenicity Study in Pregnant New Zealand White Rabbits (Study PC-ST-08-KS/91)	0.25 mg/kg Maternal NOAEL	111	0.08	7.4	32
	0.05 mg/kg Fetal NOAEL	28	0.02	1.9	6
Perinatal and Postnatal Reproduction Toxicity Study in Pregnant Rats (Study PC-ST-09-KS/92)	0.002 mg/kg Maternal LOAEL	ND	0.0003	-	0.13
	0.002 mg/kg Fetal LOAEL	ND	0.0003	-	0.13

\* Daily dose of SA = 150 µg/day; 0.0025 mg/kg/day; AUC = 14.99 ng\*hr/mL

## 5.2. Referenced NDAs, BLAs, DMFs

Reference was made to DMF

(b) (4)

## 5.3. Pharmacology

### 5.3.1. Primary Pharmacology of Segesterone Acetate

Primary pharmacology studies were only conducted for SA, a novel progestin. The applicant focused on investigating two possible mechanisms explaining the contraceptive effects of SA, both linked to its binding to the progesterone receptors.

#### **Agonist Activity of Segesterone Acetate on the Progesterone Receptor (Study *General Pharmacology 1, General Pharmacology 8 and General Pharmacology 3, non-GLP*)**

In rat tissues, segesterone demonstrated a high binding affinity for the progesterone receptor ( $EC_{50} = 10.3$  nM), but did not bind to either the estrogen or androgen receptor or the sex-hormone binding globulin (SHBG).

In human receptor studies, SA was a progesterone receptor full agonist with an  $EC_{50} = 23.7$  pM. In the same assay, the endogenous ligand, progesterone, activated the receptor with an  $EC_{50} = 650$  pM. Segesterone acetate was approximately 200-fold less potent as an agonist of the glucocorticoid receptor ( $EC_{50} = 4.68$  nM) and had no agonist activity on the mineralocorticoid receptor. Segesterone was an androgen receptor antagonist at relatively high concentrations ( $EC_{50} = 500$  nM). Several segesterone metabolites were also weak human progesterone receptor agonists, with the most potent being 5-dihydro-segesterone ( $EC_{50} = 0.41$  nM).

The ability of SA to activate the progesterone receptor *in vivo* was measured by its ability to promote the transformation of the endometrium from a proliferative to a secretory stage in immature female rabbits primed with  $17\beta$ -estradiol. This transformation was graded histologically using the McPhail index. Female immature New Zealand White rabbits were injected subcutaneously for six days with  $2.8$   $\mu$ g/kg/day of estradiol before receiving subcutaneous daily doses of segesterone at  $0.5$  and  $5$   $\mu$ g/kg/day for five additional days. A dose-dependent increase in uterine weight was observed with significant myometrial hypertrophy, endometrial stromal cell proliferation, and branching of endometrial glands. When administered orally, SA was 100-fold less potent in promoting the pseudo gestation changes in the uterus.

#### **Segesterone Acetate Blockage of Ovulation (Study *General Pharmacology 2, non-GLP*)**

In female rats, progestins cause a decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a negative feedback mechanism on the hypothalamus. The surge in LH and FSH is required for ovulation and blocking their secretion

inhibits spontaneous ovulation. Mature female Sprague Dawley rats were injected subcutaneously with increasing concentrations of progesterone, levonorgestrel and segesterone on the day of diestrus and the number of ova present in the oviduct was counted two days later. Spontaneous ovulation was completely blocked by doses of 67, 133, and 6000 µg/kg of segesterone, levonorgestrel, and progesterone, respectively.

Gonadotropin-releasing hormone (GnRH) causes ovulation in female rats by stimulating the release of gonadotropins from the pituitary. Hence, the ability of exogenous GnRH to override segesterone-induced suppression of ovulation would indicate that the pituitary gland is involved. Mature female Sprague Dawley rats were treated with progesterone, levonorgestrel or segesterone as described above, and received a subcutaneous injection of 2 µg GnRH 24 hours later. The number of ova present in the oviduct was counted on day 3. GnRH fully restored ovulation in animals treated with 66 µg/kg of segesterone, partially (57%) restored ovulation blocked by 15 µg of segesterone and was unable to overcome the blockage by doses of 133 µg/kg and above. At doses equal or greater than 353 µg/kg, segesterone also completely abolished estrus cycling in female rats.

#### **Segesterone Acetate Prevention of Pregnancy (Study *General Pharmacology 2*, non-GLP)**

Although progesterone is required for the maintenance of pregnancy, exogenous progestins administered post-coitally to pregnant rats during the transit of the fertilized egg through the oviduct (day 1 - day 7) prevent pregnancy or delay implantation. In this assay, pregnant Sprague Dawley female rats received daily subcutaneous injections of segesterone (0.01, 0.03, 0.1, 0.3, 1, 3, 5, 10, 15, 30 or 50 mg/day) from day 1 through 7 of pregnancy. On day 8, the number of implantation sites were counted in each horn. Doses ≤100 mg/kg/day were ineffective in preventing implantation. At 200 and 333 mg/kg/day, 33% of the animals showed no implantation sites or embryos at the time of autopsy. By comparison, levonorgestrel, at a dose of 333 mg/kg/day, prevented pregnancy in all animals.

The ability of SA to block fertilization was also investigated in rabbits. Segesterone acetate (0.3 to 30 µg/day) and Levonorgestrel (5 to 300 µg/day) were administered subcutaneously to adult female rabbits for 8 days. On the eighth day, FSH and human chorionic gonadotropin (hCG) were administered to induce ovulation and the animals were mated. The next day the oviducts were examined for the presence of dividing ova and the number of corpora lutea in each ovary was used as an index of ova released. Doses ≥0.55 µg/kg/day SA produced a significant reduction in the number of dividing ova found in the oviducts and doses ≥2.8 µg/kg/day completely blocked fertilization. In this assay, SA was 60 to 100 times more potent than levonorgestrel.

#### **5.3.2. Secondary Pharmacology of Segesterone Acetate**

In the secondary pharmacology studies, the applicant focused on characterizing the activity of SA on other steroid nuclear receptors.

**Agonist/Antagonist Activity of Segesterone Acetate on the Androgen Receptor (Study *General Pharmacology 4, non-GLP*)**

The androgenic effects of SA were evaluated in immature castrated male rats. Starting one day after castration, the rats received daily subcutaneous injections of SA (1 or 4 mg/day) or testosterone (0.2 or 0.8 mg/day) for 10 days. One day after the last injection, the ventral prostate, seminal vesicles and the levator ani muscles were removed. The weights of the prostate and seminal vesicles were used as markers of androgenic activity while the weight of levator ani muscle provided a measure of the anabolic activity. Segesterone acetate at doses up to 27 mg/kg/day did not increase the weight of any of the three tissues, showing that it is not an agonist of the rat androgen receptor. In addition, coadministration of 8.7 mg/kg/day testosterone and 27 mg/kg/day SA restored the weight of the tissues back to non-castrated values, showing that SA is not an antagonist of the rat androgen receptor either. In a similar study comparing its activity to nomegestrol and medroxyprogesterone acetates, SA at 33 mg/kg/day subcutaneously was slightly antiandrogenic.

**Agonist/Antagonist Activity of Segesterone Acetate on the Estrogen Receptor (Study *General Pharmacology 5, non-GLP*)**

The estrogenic/antiestrogenic activity of SA was investigated in ovariectomized immature female Sprague Dawley rats in which estrogens stimulate uterine growth. Animals were treated with segesterone (6.7 or 33 mg/day), estradiol (0.33 µg/kg/day) or a combination of both subcutaneously for 5 days, before the uterus was removed and weighed. Estradiol (0.33 µg/kg/day) increased the weight of the uterus, but segesterone (33 mg/kg/day) did not. However, the combination of 33 mg/kg/day segesterone and 0.33 µg/kg/day estradiol did not prevent the estradiol-induced uterus weight gain, showing that segesterone is neither an agonist nor an antagonist of the rat estrogen receptor.

**Agonist/Antagonist Activity of Segesterone Acetate on the Glucocorticoid Receptor (Study *R1201, non-GLP*)**

The *in vitro* binding affinity of SA for the glucocorticoid receptor is approximately five times weaker than for the progesterone receptor. The potential *in vivo* activity of SA on the glucocorticoid receptor was investigated by measure of the thymus weight in surgically-sterilized immature rats, and measure of liver glycogen and tyrosine transaminase (TAT) activity in adrenalectomized female rats. Subcutaneous injections of segesterone (33 mg/kg/day) for five days caused significant thymic involution in ovariectomized females and castrated males. However, SA at 27 mg/kg/day SC for 3 days did not increase hepatic glycogen content or TAT activity and when coadministered with dexamethasone, did not prevent the glucocorticoid-induced increase in hepatic glycogen content and TAT activity. Thus, SA has agonist activity at the glucocorticoid receptor.

**Agonist/Antagonist Activity of Segesterone Acetate on the Mineralocorticoid Receptor (Study *1571-023, non-GLP*)**

The activity of SA at the mineralocorticoid receptor was investigated by measure of sodium and potassium urinary excretion in adrenalectomized animals. Female Sprague Dawley rats with

both adrenal glands surgically removed received a single subcutaneous injection of aldosterone (0.2 µg), SA (50 or 250 µg) or the combination of both, followed approximately 30 minutes later by an intraperitoneal administration of sodium and potassium chloride. Urine was subsequently collected for three hours and the excretion rates of sodium and potassium were compared to evaluate the mineralocorticoid-mediated reabsorption of sodium. Segesterone had no effect on the excretion rates for sodium or potassium in the presence or absence of aldosterone.

### 5.3.3. Safety Pharmacology of Segesterone Acetate

#### **Effects of Segesterone Acetate on Cardiac Ion Channel (Studies 091105.QPD, 100308.QPD, non-GLP)**

The effect of segesterone on the human ether-à-go-go-related gene (hERG) potassium channel current was investigated in human embryonic kidney (HEK293) cells stably transfected with hERG using the patch-clamp technique. Segesterone acetate inhibits the potassium current by 1.6% at 1 µM, 8% at 3 µM, 24% at 10 µM and 47% at 30 µM free concentration. Under these conditions, the positive control terfenadine inhibited the hERG current by 73% at 60 nM. By comparison, SA activates the human progesterone receptor in cell cultures with an EC<sub>50</sub> = 23.7 pM.

The effects of SA on 11 other ion channels accounting for all the major ionic current in the cardiac action potential (Ca, K, Na hyperpolarization-activated, inward or outward rectifying, ATP-sensitive, ultra-rapid, delayed and slow rectifier) were investigated using automated patch clamp instrumentation. At a free drug concentration of 1 µM, the highest inhibitions recorded were 13.5% and 14.4% for the L-type calcium channel (hCav1.2) and the hyperpolarization-activated potassium channel (hHCN4).

The ability of SA to prolong the QT interval of the cardiac action potential was evaluated in wedge preparations of dog left ventricle. The isolated ventricular tissues were perfused with increasing concentrations of SA (4, 16, 64 and 256 nM) and transmembrane action potentials were recorded from epicardial and sub endocardial regions concurrently with a transmural pseudo-ECG. Segesterone acetate produced no significant change in either repolarization time or dispersion at any of the concentrations tested and caused neither spontaneous nor induced arrhythmic activity. When the wedges were pretreated with a toxin delaying sodium channels inactivation, SA increased repolarization time and transmural dispersion of repolarization in a dose-dependent manner, leading to the development of arrhythmias at or above 100 nM free drug.

#### **Cardiovascular Effects of Segesterone Acetate in Cynomolgus Monkeys (Study 1571-003, GLP)**

The *in vivo* cardiovascular effects of SA were investigated in freely moving telemetrized cynomolgus monkeys. The animals received subcutaneous injections of SA at doses of 0.1, 0.5 and 2.5 mg/kg once each with a washout period of seven days between doses. Under these conditions, SA produced no change in blood pressure, heart rate or any of the ECG parameters measured (QRS duration and the RR, PR, and QT intervals) at any concentration during the

twenty hours of continuous monitoring post dose. No mortality, morbidity or clinical signs were observed in the study.

#### **CNS Safety Pharmacology (Study 1571-014, GLP)**

The neurobehavioral effects of SA were investigated in rats using the Functional Observational Battery (FOB). Female Sprague Dawley rats received a single subcutaneous injection of 0.5, 2.5, or 10 mg/kg SA and FOB evaluations were conducted predose and at approximately 2 and 24 hours postdose. Segesterone acetate did not produce any neurobehavioral effects at doses up to and including 10 mg/kg.

#### **Pulmonary Safety Pharmacology (Study 1571-013, GLP)**

The effects of SA on respiratory functions were investigated in female rats receiving a single subcutaneous injection of 0.5, 2.5 or 10 mg/kg. Pulmonary functions (respiratory rate, tidal volume, and minute volume) were monitored using plethysmograph chambers for at least 1 hour prior to dosing followed by 4 hours postdose. A separate set of animals was used to determine exposure during the study. Segesterone acetate did not produce any effects on mortality, clinical observations, or any of the respiratory parameters measured at any dose. Test article concentrations in the serum following the 10 mg/kg subcutaneous dose produced mean  $AUC_{last}$  and  $C_{max}$  of 1939 ng·hr/mL and 745 ng/mL, respectively.

### **5.3.4. Pharmacology of Ethinyl Estradiol**

Ethinyl estradiol mimics the endocrine properties of its natural hormone counterpart estradiol. Following entry in cells, EE binds to the intracellular estrogen receptors and initiates translocation from the cytosol to the nucleus. In the nucleus, the activated estrogen receptors regulate gene expression to promote the proliferation and growth of the vaginal, uterine and mammary epithelium. In animals, the sensitivity of the various reproductive tissues to an estrogenic signal varies between species, with the monkey considered the best animal model for the prediction of human response to synthetic hormones.

## **5.4. ADME/PK**

### **5.4.1. Pharmacokinetics of Segesterone Acetate**

Orally administered segesterone is rapidly absorbed from the gastrointestinal (GI) tract in monkeys, rabbits, and rats. Intestinal absorption is followed by rapid disappearance of the parent from the systemic circulation with metabolites appearing in the bile, indicating extensive hepatic biotransformation.

After subcutaneous injections or implantation of sustained release delivery systems (subdermal implants or intravaginal ring), segesterone distributes to a wide variety of tissues with the highest mean concentrations found in the gastrointestinal tract, adrenals, liver, ovaries, uterus, reproductive fat, and pancreas. By contrast, the concentrations in the brain and kidneys are low. The fraction of segesterone bound to serum proteins is approximately 95% in humans, rats

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

and mice. The main route of excretion in rats following subcutaneous administration is fecal, with approximately 50% of the dose recovered in feces within 24 hours and 95% of the dose recovered in feces by 120 hours post-dose.

Segesterone is completely metabolized *in vitro* after a 60-minute incubation in rat hepatocyte suspensions, producing 5 metabolites from Phase I and II metabolic reactions. *In vivo*, the major metabolite is 4,5-dihydro-17 $\alpha$ -deacetyl-segesterone, that can be found in plasma, urine and feces.

In monkeys, the biotransformation of segesterone produces 66 different metabolites, including numerous Phase I metabolites, detected in serum and urine, and some Phase II metabolites (glucuronides), detected only in the urine.

Human hepatocytes did not fully metabolize segesterone after 240 minutes, suggesting a slower rate of liver biotransformation than in rats. Eight Phase I metabolites were produced but no subsequent Phase II reactions could be observed. The intestinal metabolism of segesterone is significantly less than the hepatic metabolism.

Cytochrome P450 (CYP 3A4) and carbonyl reductase enzymes are responsible for the hepatic biotransformation of segesterone. Segesterone did not induce any of the most common drug-metabolizing cytochromes (CYP 1A2, 2B6, 2C8, 2C9, 2C19 and 3A4/5) in cultures of human hepatocytes at concentrations up to 1000 nM. At concentrations of 1  $\mu$ M and above, segesterone caused metabolism-dependent inhibition of CYP3A4/5, highlighting the possibility of a reactive intermediate causing metabolism-mediated inactivation of the enzyme. However, the therapeutic concentrations of free segesterone in human plasma are orders of magnitude smaller than the concentration causing enzyme inhibition *in vitro*.

Type of Study	Major Findings
<b>Absorption</b>	
<i>Single Dose Intravenous and Oral Administration of <sup>3</sup>H-Segesterone Acetate in Male and Female Wistar Rats (Study 17247-16-220485, non-GLP)</i>	Following a single intravenous dose of 44.5-55.7 $\mu$ g/kg, the concentration of segesterone in plasma decreased in three distinctive phases: a rapid drop during the first two hours followed by near-constant level from 2 to 8 hours post dose, and finally a slow decrease for up to 32 hours. After a single oral dose of 38.5-50.0 $\mu$ g/kg, the C <sub>max</sub> was reached within 1 hour post-dose and the bioavailability was approximately 95%. There was no sex-related difference in the pharmacokinetics parameters.
<i>ADME of <sup>3</sup>H- Segesterone Acetate Following a Single Subcutaneous Injection of 50 <math>\mu</math>g/kg to Female</i>	<u>Rat (Females, Sprague Dawley)</u> T <sub>max</sub> (SC): 1 h C <sub>max</sub> (SC): 31.3 ng equivalents/g AUC <sub>inf</sub> (SC): 240 ng equivalents•h/g

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)


Type of Study	Major Findings																	
<i>Sprague Dawley Rats. (Study 6884-120, GLP)</i>																		
<i>Pharmacokinetics, ADME of <sup>3</sup>H-Segesterone Acetate Following Administration of a Single Subcutaneous Dose of 500 µg/kg to Female Sprague Dawley Rats (Study 6884-121, GLP)</i>	<p><u>Rat (Females, Sprague Dawley)</u>  <math>T_{max}</math> (SC): 2 h  <math>C_{max}</math>(SC): 95.4 ng equivalents/g  <math>AUC_{inf}</math>(SC): 1135 ng equivalents•h/g</p>																	
<i>Pharmacokinetic Analysis of Segesterone Acetate in Female Cynomolgus Monkeys Following a Single Subcutaneous Dose of 10 mg/kg (Study 1571-008, GLP)</i>	<p><u>Monkey (Females, Cynomolgus)</u>  <math>T_{max}</math> (SC): 2 h  <math>T_{1/2}</math>: 6.24 h  <math>C_{max}</math>(SC): 895 ng/mL  <math>AUC_{inf}</math>(SC): 6050 ng•h/mL</p>																	
<i>Bioavailability of Segesterone Acetate in Immature Rabbits: Comparison of Progestational Activity of Segesterone after Oral vs. Subcutaneous Administration in Immature Rabbits (Study ADME-1)</i>	<p><u>Rabbit (Immature female)</u>  Doses: 2.8 µg/kg/day, SC and 28 µg/kg/day, PO for 5 days.  <math>C_{1h}</math> SC: 895 ± 116 pmol/L  <math>C_{1h}</math> PO: 148 ± 16 pmol/L</p>																	
<b>Distribution</b>																		
<i>Determination of free Segesterone Acetate concentration in Female Rat, Mouse and Human sera by ultrafiltration after incubation with <sup>3</sup>H-Segesterone (Study ADME2)</i>	<p><u>Percentage of Free Segesterone at 37°C</u>  Human: 4.42 % ± 0.368  Rat: 4.73 % ± 0.282  Mouse: 5.45 % ± 0.158</p>																	
<i>Relative binding affinity of Segesterone Acetate to steroid hormone receptors and sex hormone binding globulin (SHBG) (Study General Pharmacology 1)</i>	<table border="1" data-bbox="638 1381 1187 1619"> <thead> <tr> <th rowspan="2">Test Article</th> <th colspan="2">Relative Binding Affinity* (nM)</th> </tr> <tr> <th>PR</th> <th>AR</th> </tr> </thead> <tbody> <tr> <td>Progesterone</td> <td>20</td> <td>NB</td> </tr> <tr> <td>Testosterone</td> <td>NB</td> <td>100</td> </tr> <tr> <td>Levonorgestrel</td> <td>100</td> <td>70</td> </tr> <tr> <td>Segesterone</td> <td>110</td> <td>0.2</td> </tr> </tbody> </table> <p>* Concentration of steroid competitors that reduced binding by 50%  PR=progesterone receptor; AR=androgen receptor</p> <ul style="list-style-type: none"> <li>The binding of SA to SHBG was negligible.</li> </ul>	Test Article	Relative Binding Affinity* (nM)		PR	AR	Progesterone	20	NB	Testosterone	NB	100	Levonorgestrel	100	70	Segesterone	110	0.2
Test Article	Relative Binding Affinity* (nM)																	
	PR	AR																
Progesterone	20	NB																
Testosterone	NB	100																
Levonorgestrel	100	70																
Segesterone	110	0.2																

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)




























Type of Study	Major Findings																																											
<p><i>Determination of free Segesterone Acetate concentration in Rats, Mouse and Human sera by ultrafiltration after incubation with <sup>3</sup>H-Segesterone (Study ADME2)</i></p>	<table border="1" data-bbox="638 346 1255 447"> <thead> <tr> <th colspan="3" data-bbox="638 346 1255 380">% of Free Segesterone</th> </tr> <tr> <th data-bbox="638 380 837 413">Human</th> <th data-bbox="837 380 1076 413">Rat</th> <th data-bbox="1076 380 1255 413">Mouse</th> </tr> </thead> <tbody> <tr> <td data-bbox="638 413 837 447">4.42 ± 0.36</td> <td data-bbox="837 413 1076 447">4.73 ± 0.28</td> <td data-bbox="1076 413 1255 447">5.45 ± 0.15</td> </tr> </tbody> </table>	% of Free Segesterone			Human	Rat	Mouse	4.42 ± 0.36	4.73 ± 0.28	5.45 ± 0.15																																		
% of Free Segesterone																																												
Human	Rat	Mouse																																										
4.42 ± 0.36	4.73 ± 0.28	5.45 ± 0.15																																										
<p><i>Pharmacokinetics, Absorption, Metabolism, Distribution and Excretion Study with <sup>3</sup>H-Segesterone Acetate by single subcutaneous administration in female rats (Study 6884-121)</i></p>	<table border="1" data-bbox="638 531 1255 1031"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">% of administered dose after single SC administration of 500 µg/kg</th> </tr> <tr> <th>2h</th> <th>24h</th> <th>72h</th> </tr> </thead> <tbody> <tr> <td><b>Adrenals</b></td> <td>0.03</td> <td>0.00</td> <td>0.00</td> </tr> <tr> <td><b>Brain</b></td> <td>0.12</td> <td>0.02</td> <td>0.00</td> </tr> <tr> <td><b>Kidney</b></td> <td>0.21</td> <td>0.06</td> <td>0.01</td> </tr> <tr> <td><b>Large Intestine Tissues/Content</b></td> <td>0.3/0.22</td> <td>0.68/11</td> <td>0.07/1.15</td> </tr> <tr> <td><b>Liver</b></td> <td>3.56</td> <td>1.31</td> <td>0.17</td> </tr> <tr> <td><b>Ovaries</b></td> <td>0.03</td> <td>0.00</td> <td>0.00</td> </tr> <tr> <td><b>Pancreas</b></td> <td>0.17</td> <td>0.03</td> <td>0.01</td> </tr> <tr> <td><b>Small Intestine Tissues/content</b></td> <td>3.74/20.1</td> <td>0.72/9.17</td> <td>0.33/2.13</td> </tr> <tr> <td><b>Uterus</b></td> <td>0.04</td> <td>0.01</td> <td>0.00</td> </tr> </tbody> </table>		% of administered dose after single SC administration of 500 µg/kg			2h	24h	72h	<b>Adrenals</b>	0.03	0.00	0.00	<b>Brain</b>	0.12	0.02	0.00	<b>Kidney</b>	0.21	0.06	0.01	<b>Large Intestine Tissues/Content</b>	0.3/0.22	0.68/11	0.07/1.15	<b>Liver</b>	3.56	1.31	0.17	<b>Ovaries</b>	0.03	0.00	0.00	<b>Pancreas</b>	0.17	0.03	0.01	<b>Small Intestine Tissues/content</b>	3.74/20.1	0.72/9.17	0.33/2.13	<b>Uterus</b>	0.04	0.01	0.00
	% of administered dose after single SC administration of 500 µg/kg																																											
	2h	24h	72h																																									
<b>Adrenals</b>	0.03	0.00	0.00																																									
<b>Brain</b>	0.12	0.02	0.00																																									
<b>Kidney</b>	0.21	0.06	0.01																																									
<b>Large Intestine Tissues/Content</b>	0.3/0.22	0.68/11	0.07/1.15																																									
<b>Liver</b>	3.56	1.31	0.17																																									
<b>Ovaries</b>	0.03	0.00	0.00																																									
<b>Pancreas</b>	0.17	0.03	0.01																																									
<b>Small Intestine Tissues/content</b>	3.74/20.1	0.72/9.17	0.33/2.13																																									
<b>Uterus</b>	0.04	0.01	0.00																																									
<p><b>Metabolism</b></p>																																												

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)





Type of Study	Major Findings																																																										
<p><i>In Vitro Metabolism of Segesterone Acetate by Female Rat Hepatocytes (Study 6884-113) and Hepatic Microsomes (Study 6884-119)</i></p>	<table border="1"> <thead> <tr> <th data-bbox="643 317 792 369">Metabolite<sup>a</sup></th> <th data-bbox="797 317 878 369">[M + H]<sup>+</sup></th> <th data-bbox="883 317 1057 369">Metabolite Structure from LC/MS/MS</th> <th data-bbox="1062 317 1143 369">Present in Hepatocyte Incubations</th> <th data-bbox="1148 317 1252 369">Present in Microsomal Incubations</th> </tr> </thead> <tbody> <tr> <td data-bbox="704 407 732 422">R1</td> <td data-bbox="818 407 846 422">567</td> <td data-bbox="883 375 1040 464"></td> <td data-bbox="1089 407 1117 422">Yes</td> <td data-bbox="1192 407 1219 422">No</td> </tr> <tr> <td data-bbox="704 499 732 514">R2</td> <td data-bbox="818 499 846 514">455</td> <td data-bbox="883 468 1040 556"></td> <td data-bbox="1089 499 1117 514">Yes</td> <td data-bbox="1192 499 1219 514">No</td> </tr> <tr> <td data-bbox="704 592 732 606">R3</td> <td data-bbox="818 592 846 606">551</td> <td data-bbox="883 560 1040 648"></td> <td data-bbox="1089 592 1117 606">Yes</td> <td data-bbox="1192 592 1219 606">No</td> </tr> <tr> <td data-bbox="704 684 732 699">R4</td> <td data-bbox="818 684 846 699">391</td> <td data-bbox="883 653 1040 741"></td> <td data-bbox="1089 684 1117 699">Yes</td> <td data-bbox="1192 684 1219 699">No</td> </tr> <tr> <td data-bbox="704 777 732 791">R5</td> <td data-bbox="818 777 846 791">375</td> <td data-bbox="883 745 1040 833"></td> <td data-bbox="1089 777 1117 791">Yes</td> <td data-bbox="1192 777 1219 791">No</td> </tr> <tr> <td data-bbox="704 919 743 934">R6<sup>b</sup></td> <td data-bbox="818 919 846 934">373</td> <td data-bbox="883 840 1040 1024"></td> <td data-bbox="1089 919 1117 934">No</td> <td data-bbox="1192 919 1219 934">Yes</td> </tr> </tbody> </table>					Metabolite <sup>a</sup>	[M + H] <sup>+</sup>	Metabolite Structure from LC/MS/MS	Present in Hepatocyte Incubations	Present in Microsomal Incubations	R1	567		Yes	No	R2	455		Yes	No	R3	551		Yes	No	R4	391		Yes	No	R5	375		Yes	No	R6 <sup>b</sup>	373		No	Yes																			
Metabolite <sup>a</sup>	[M + H] <sup>+</sup>	Metabolite Structure from LC/MS/MS	Present in Hepatocyte Incubations	Present in Microsomal Incubations																																																							
R1	567		Yes	No																																																							
R2	455		Yes	No																																																							
R3	551		Yes	No																																																							
R4	391		Yes	No																																																							
R5	375		Yes	No																																																							
R6 <sup>b</sup>	373		No	Yes																																																							
<p><i>Metabolic Stability and Metabolite Profiling of Segesterone Acetate in Human, Rat, and Mouse Liver S9 Fractions (Study 8POPUP1)</i></p>	<table border="1"> <thead> <tr> <th data-bbox="643 1087 792 1119" rowspan="2">Time (min)</th> <th colspan="3" data-bbox="906 1087 1166 1119">% of Parent Remaining</th> </tr> <tr> <th data-bbox="829 1125 943 1157">Human</th> <th data-bbox="1008 1125 1057 1157">Rat</th> <th data-bbox="1154 1125 1235 1157">Mouse</th> </tr> </thead> <tbody> <tr> <td data-bbox="643 1157 670 1171">0</td> <td data-bbox="846 1157 911 1171">99.8</td> <td data-bbox="1008 1157 1073 1171">86.3</td> <td data-bbox="1170 1157 1235 1171">87.7</td> </tr> <tr> <td data-bbox="643 1188 670 1203">60</td> <td data-bbox="846 1188 894 1203">0.0</td> <td data-bbox="1008 1188 1057 1203">0.0</td> <td data-bbox="1170 1188 1219 1203">0.0</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th data-bbox="643 1262 748 1314" rowspan="2">Metabolite Code (previous codes)<sup>a</sup></th> <th data-bbox="764 1262 829 1314" rowspan="2">[M + H]<sup>+</sup></th> <th data-bbox="846 1262 1024 1314" rowspan="2">Metabolite Structure from LC/MS/MS</th> <th colspan="3" data-bbox="1073 1262 1219 1283">Percent at 60 minutes</th> </tr> <tr> <th data-bbox="1049 1289 1122 1314">Human</th> <th data-bbox="1138 1289 1203 1314">Mouse</th> <th data-bbox="1211 1289 1252 1314">Rat</th> </tr> </thead> <tbody> <tr> <td data-bbox="643 1409 732 1430">M1<sup>b</sup> (H9, R6)</td> <td data-bbox="764 1409 797 1423">373</td> <td data-bbox="846 1325 1008 1444"></td> <td data-bbox="1057 1409 1089 1423">8.0</td> <td data-bbox="1138 1409 1170 1423">0.03</td> <td data-bbox="1211 1409 1243 1423">ND</td> </tr> <tr> <td data-bbox="643 1549 732 1570">M2 (H4A, H4B)</td> <td data-bbox="764 1549 797 1564">387</td> <td data-bbox="846 1430 1008 1549"></td> <td data-bbox="1057 1549 1089 1564">7.7</td> <td data-bbox="1138 1549 1170 1564">2.4</td> <td data-bbox="1211 1549 1243 1564">2.9</td> </tr> <tr> <td data-bbox="643 1654 699 1669">M3 (H3)</td> <td data-bbox="764 1654 797 1669">403</td> <td data-bbox="846 1549 1008 1703"></td> <td data-bbox="1057 1654 1097 1669">14.4</td> <td data-bbox="1138 1654 1179 1669">8.2</td> <td data-bbox="1211 1654 1252 1669">25.2</td> </tr> <tr> <td data-bbox="643 1717 683 1732">M4i</td> <td data-bbox="764 1717 797 1732">405</td> <td data-bbox="846 1717 1008 1732">Parent -2O +2 H</td> <td data-bbox="1057 1717 1089 1732">1.8</td> <td data-bbox="1138 1717 1170 1732">5.4</td> <td data-bbox="1211 1717 1243 1732">4.6</td> </tr> <tr> <td data-bbox="643 1749 683 1764">M5i</td> <td data-bbox="764 1749 797 1764">421</td> <td data-bbox="846 1749 1008 1764">Parent -3O +2 H</td> <td data-bbox="1057 1749 1089 1764">0.7</td> <td data-bbox="1138 1749 1170 1764">3.6</td> <td data-bbox="1211 1749 1243 1764">1.7</td> </tr> </tbody> </table>					Time (min)	% of Parent Remaining			Human	Rat	Mouse	0	99.8	86.3	87.7	60	0.0	0.0	0.0	Metabolite Code (previous codes) <sup>a</sup>	[M + H] <sup>+</sup>	Metabolite Structure from LC/MS/MS	Percent at 60 minutes			Human	Mouse	Rat	M1 <sup>b</sup> (H9, R6)	373		8.0	0.03	ND	M2 (H4A, H4B)	387		7.7	2.4	2.9	M3 (H3)	403		14.4	8.2	25.2	M4i	405	Parent -2O +2 H	1.8	5.4	4.6	M5i	421	Parent -3O +2 H	0.7	3.6	1.7
Time (min)	% of Parent Remaining																																																										
	Human	Rat	Mouse																																																								
0	99.8	86.3	87.7																																																								
60	0.0	0.0	0.0																																																								
Metabolite Code (previous codes) <sup>a</sup>	[M + H] <sup>+</sup>	Metabolite Structure from LC/MS/MS	Percent at 60 minutes																																																								
			Human	Mouse	Rat																																																						
M1 <sup>b</sup> (H9, R6)	373		8.0	0.03	ND																																																						
M2 (H4A, H4B)	387		7.7	2.4	2.9																																																						
M3 (H3)	403		14.4	8.2	25.2																																																						
M4i	405	Parent -2O +2 H	1.8	5.4	4.6																																																						
M5i	421	Parent -3O +2 H	0.7	3.6	1.7																																																						

Type of Study	Major Findings																								
<p><i>Detection, Structure Elucidation, and Relative Quantification of Segesterone Acetate and its Metabolites in Serum and Urine Samples of Female Cynomolgus Monkeys after a single SC dose of 10 mg/kg (Study 9POPUP4R1)</i></p>	<p>The metabolism of segesterone in monkeys produces a complex metabolite pattern, comprised of numerous Phase I metabolites, detected in serum and urine, and Phase II metabolites (glucuronides), detected in the urine matrix only.</p> 																								
<p><i>In Vitro Evaluation of Segesterone Acetate as an Inhibitor of Cytochrome P450 (CYP) Enzymes in Human Liver Microsomes (Study XT105121).</i></p>	<p>The study was performed to evaluate the ability of segesterone to inhibit the metabolism of concomitantly administered probe substrates for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in pooled human liver microsomes. Segesterone may have the potential to cause metabolism-dependent inhibition of CYP3A4 as an increase in inhibition (26%) was observed upon preincubation in the presence of NADPH at a concentration of 1 μM.</p>																								
<p><i>In Vitro Evaluation of Segesterone Acetate as an Inducer of Cytochrome P450 Expression in Cultured Human Hepatocytes (Study XT103116)</i></p>	<p>Treatment of cultured human hepatocytes from 3 separate donors with prototypical CYP inducers resulted in the anticipated increases in CYP activity. Treatment of the hepatocytes with up to 1000 nM segesterone, caused little or no change in CYP1A2, 2B6, 2C8, 2C9, 2C19 and 3A4 activity.</p> <table border="1" data-bbox="638 1606 1286 1806"> <thead> <tr> <th rowspan="2">Segesterone Concentration (nM)</th> <th colspan="4">% Control Activity of the P450 Enzyme</th> </tr> <tr> <th>CYP2C9</th> <th>CYP2C19</th> <th>CYP2B6</th> <th>CYP3A4</th> </tr> </thead> <tbody> <tr> <td>10</td> <td>105±28</td> <td>104±58</td> <td>101±22</td> <td>105±66</td> </tr> <tr> <td>100</td> <td>99±30</td> <td>104±62</td> <td>103±24</td> <td>106±65</td> </tr> <tr> <td>1000</td> <td>96±32</td> <td>101±55</td> <td>115±38</td> <td>99±58</td> </tr> </tbody> </table>	Segesterone Concentration (nM)	% Control Activity of the P450 Enzyme				CYP2C9	CYP2C19	CYP2B6	CYP3A4	10	105±28	104±58	101±22	105±66	100	99±30	104±62	103±24	106±65	1000	96±32	101±55	115±38	99±58
Segesterone Concentration (nM)	% Control Activity of the P450 Enzyme																								
	CYP2C9	CYP2C19	CYP2B6	CYP3A4																					
10	105±28	104±58	101±22	105±66																					
100	99±30	104±62	103±24	106±65																					
1000	96±32	101±55	115±38	99±58																					

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Type of Study	Major Findings																																													
<p><i>An Investigation of the Potential for Segesterone Acetate to Induce Cytochrome P450 Metabolism in Cultured Human Hepatocytes (Study M1999-056)</i></p>	<p>In primary cultures of human hepatocytes from a single donor, SA did not induce CYP1A2, 2A6, 2C9, 2D6 and 3A4 at up to 100 <math>\mu</math>M. It was an inducer of CYP2C19 at 100 <math>\mu</math>M and an inhibitor of CYP3A4 above 10 <math>\mu</math>M.</p> <table border="1" data-bbox="638 449 1287 648"> <thead> <tr> <th rowspan="2">Segesterone Concentration (<math>\mu</math>M)</th> <th colspan="4">% Control Activity of the P450 Enzyme</th> </tr> <tr> <th>CYP2C9</th> <th>CYP2C19</th> <th>CYP2D6</th> <th>CYP3A4</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>114<math>\pm</math>4</td> <td>95<math>\pm</math>24</td> <td>100<math>\pm</math>9</td> <td>97<math>\pm</math>3</td> </tr> <tr> <td>10</td> <td>107<math>\pm</math>7</td> <td>97<math>\pm</math>54</td> <td>111<math>\pm</math>5</td> <td>33<math>\pm</math>17</td> </tr> <tr> <td>100</td> <td>55<math>\pm</math>18</td> <td>238<math>\pm</math>52</td> <td>78<math>\pm</math>15</td> <td>9<math>\pm</math>10</td> </tr> </tbody> </table>	Segesterone Concentration ( $\mu$ M)	% Control Activity of the P450 Enzyme				CYP2C9	CYP2C19	CYP2D6	CYP3A4	1	114 $\pm$ 4	95 $\pm$ 24	100 $\pm$ 9	97 $\pm$ 3	10	107 $\pm$ 7	97 $\pm$ 54	111 $\pm$ 5	33 $\pm$ 17	100	55 $\pm$ 18	238 $\pm$ 52	78 $\pm$ 15	9 $\pm$ 10																					
Segesterone Concentration ( $\mu$ M)	% Control Activity of the P450 Enzyme																																													
	CYP2C9	CYP2C19	CYP2D6	CYP3A4																																										
1	114 $\pm$ 4	95 $\pm$ 24	100 $\pm$ 9	97 $\pm$ 3																																										
10	107 $\pm$ 7	97 $\pm$ 54	111 $\pm$ 5	33 $\pm$ 17																																										
100	55 $\pm$ 18	238 $\pm$ 52	78 $\pm$ 15	9 $\pm$ 10																																										
<p><i>In Vitro Metabolism of Segesterone Acetate by Female Human Hepatocytes (Study 6884-113) and Hepatic Microsomes (Study 6884-119)</i></p>	<table border="1" data-bbox="638 688 1261 1709"> <thead> <tr> <th>Metabolite*</th> <th>[M + H]<sup>+</sup></th> <th>Metabolite Structure from LC/MS/MS</th> <th>Present in Hepatocyte Incubations</th> <th>Present in Microsomal Incubations</th> </tr> </thead> <tbody> <tr> <td>H1</td> <td>361</td> <td></td> <td>Yes</td> <td>No</td> </tr> <tr> <td>H2</td> <td>345</td> <td></td> <td>Yes</td> <td>No</td> </tr> <tr> <td>H3</td> <td>403</td> <td></td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>H4A, H4B</td> <td>387</td> <td></td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>H5<sup>h</sup></td> <td>385</td> <td> or </td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>H6<sup>h</sup></td> <td>343</td> <td> or </td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>H7</td> <td>387</td> <td></td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>H8</td> <td>387</td> <td></td> <td>Yes</td> <td>Yes</td> </tr> </tbody> </table>	Metabolite*	[M + H] <sup>+</sup>	Metabolite Structure from LC/MS/MS	Present in Hepatocyte Incubations	Present in Microsomal Incubations	H1	361		Yes	No	H2	345		Yes	No	H3	403		Yes	Yes	H4A, H4B	387		Yes	Yes	H5 <sup>h</sup>	385	 or 	Yes	Yes	H6 <sup>h</sup>	343	 or 	Yes	Yes	H7	387		Yes	Yes	H8	387		Yes	Yes
Metabolite*	[M + H] <sup>+</sup>	Metabolite Structure from LC/MS/MS	Present in Hepatocyte Incubations	Present in Microsomal Incubations																																										
H1	361		Yes	No																																										
H2	345		Yes	No																																										
H3	403		Yes	Yes																																										
H4A, H4B	387		Yes	Yes																																										
H5 <sup>h</sup>	385	 or 	Yes	Yes																																										
H6 <sup>h</sup>	343	 or 	Yes	Yes																																										
H7	387		Yes	Yes																																										
H8	387		Yes	Yes																																										

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Type of Study	Major Findings																																																													
	<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> <p>H9<sup>b</sup>      373</p>  </div> <div style="text-align: center;"> <p>or</p>  </div> <div style="text-align: center;"> <p>No      Yes</p> </div> </div> <div style="display: flex; justify-content: space-between; align-items: center; margin-top: 20px;"> <div style="text-align: center;"> <p>H10      387</p>  </div> <div style="text-align: center;"> <p>No      Yes</p> </div> </div> <div style="display: flex; justify-content: space-between; align-items: center; margin-top: 20px;"> <div style="text-align: center;"> <p>H11      387</p>  </div> <div style="text-align: center;"> <p>No      Yes</p> </div> </div>																																																													
<b>Excretion</b>																																																														
<p><i>Pharmacokinetics of Segesterone Acetate –Studies on Animals; Rats, Guinea Pigs, Rabbits (Study 17247-16-220485)</i></p>	<p>Excretion into bile was studied in rats by both IV and oral administration. By both routes, about 50% of the radioactivity in the dose was excreted in bile within 6–7 hours.</p> <table border="1" data-bbox="638 972 1287 1171" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th rowspan="2">Time (hr)</th> <th colspan="2">Cumulative % of Radioactive Dose in Bile</th> </tr> <tr> <th>50 µg/kg IV</th> <th>50 µg/kg PO</th> </tr> </thead> <tbody> <tr> <td>2</td> <td>41</td> <td>-</td> </tr> <tr> <td>3</td> <td>-</td> <td>21-38</td> </tr> <tr> <td>6</td> <td>50</td> <td>-</td> </tr> <tr> <td>7</td> <td>-</td> <td>40-48</td> </tr> </tbody> </table>	Time (hr)	Cumulative % of Radioactive Dose in Bile		50 µg/kg IV	50 µg/kg PO	2	41	-	3	-	21-38	6	50	-	7	-	40-48																																												
Time (hr)	Cumulative % of Radioactive Dose in Bile																																																													
	50 µg/kg IV	50 µg/kg PO																																																												
2	41	-																																																												
3	-	21-38																																																												
6	50	-																																																												
7	-	40-48																																																												
<p><i>Pharmacokinetics of Segesterone Acetate –Studies on Animals; Rats, Guinea Pigs, Rabbits (Study 17247-16-220485)</i></p> <p><i>Absorption, Metabolism, and Excretion of <sup>3</sup>H-segesterone Acetate Following Subcutaneous Administration to Rats (Study 6884-120)</i></p>	<p>The overall recovery of radioactivity after a single intravenous, oral or subcutaneous administration of segesterone to female rats was 70-80% within 120 hours postdose. Feces was the main route of excretion. Less than 10% of the dose was found in urine.</p> <table border="1" data-bbox="638 1377 1414 1682" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th rowspan="3">Time (hr)</th> <th colspan="6">Cumulative % of Radioactive Dose</th> </tr> <tr> <th colspan="2">50 µg/kg IV</th> <th colspan="2">50 µg/kg PO</th> <th colspan="2">50 µg/kg SC</th> </tr> <tr> <th>Urine</th> <th>Feces</th> <th>Urine</th> <th>Feces</th> <th>Urine</th> <th>Feces</th> </tr> </thead> <tbody> <tr> <td>8</td> <td>1.2±0.5</td> <td>0.0±0</td> <td>3.1±2.1</td> <td>0.1±0.2</td> <td>3±0.8</td> <td>ND</td> </tr> <tr> <td>24</td> <td>3.6±0.8</td> <td>39.1±9.6</td> <td>6.4±1.8</td> <td>58.8±10</td> <td>5.2±0.8</td> <td>46.3±4.1</td> </tr> <tr> <td>48</td> <td>4.6±0.8</td> <td>61.8±3.1</td> <td>7.7±1.7</td> <td>72±3.6</td> <td>6.3±0.8</td> <td>80.7±2.6</td> </tr> <tr> <td>72</td> <td>5.1±0.9</td> <td>64.6±2.6</td> <td>8.1±1.7</td> <td>74.2±4.2</td> <td>6.7±0.7</td> <td>90.9±0.6</td> </tr> <tr> <td>96</td> <td>5.6±0.9</td> <td>66.1±3.5</td> <td>8.2±1.7</td> <td>74.8±4.4</td> <td>6.8±0.7</td> <td>93.8±1.2</td> </tr> <tr> <td>120</td> <td>5.7±0.9</td> <td>67±4.2</td> <td>8.4±1.8</td> <td>75.6±4.4</td> <td>6.9±0.7</td> <td>94.6±1.3</td> </tr> </tbody> </table>	Time (hr)	Cumulative % of Radioactive Dose						50 µg/kg IV		50 µg/kg PO		50 µg/kg SC		Urine	Feces	Urine	Feces	Urine	Feces	8	1.2±0.5	0.0±0	3.1±2.1	0.1±0.2	3±0.8	ND	24	3.6±0.8	39.1±9.6	6.4±1.8	58.8±10	5.2±0.8	46.3±4.1	48	4.6±0.8	61.8±3.1	7.7±1.7	72±3.6	6.3±0.8	80.7±2.6	72	5.1±0.9	64.6±2.6	8.1±1.7	74.2±4.2	6.7±0.7	90.9±0.6	96	5.6±0.9	66.1±3.5	8.2±1.7	74.8±4.4	6.8±0.7	93.8±1.2	120	5.7±0.9	67±4.2	8.4±1.8	75.6±4.4	6.9±0.7	94.6±1.3
Time (hr)	Cumulative % of Radioactive Dose																																																													
	50 µg/kg IV		50 µg/kg PO		50 µg/kg SC																																																									
	Urine	Feces	Urine	Feces	Urine	Feces																																																								
8	1.2±0.5	0.0±0	3.1±2.1	0.1±0.2	3±0.8	ND																																																								
24	3.6±0.8	39.1±9.6	6.4±1.8	58.8±10	5.2±0.8	46.3±4.1																																																								
48	4.6±0.8	61.8±3.1	7.7±1.7	72±3.6	6.3±0.8	80.7±2.6																																																								
72	5.1±0.9	64.6±2.6	8.1±1.7	74.2±4.2	6.7±0.7	90.9±0.6																																																								
96	5.6±0.9	66.1±3.5	8.2±1.7	74.8±4.4	6.8±0.7	93.8±1.2																																																								
120	5.7±0.9	67±4.2	8.4±1.8	75.6±4.4	6.9±0.7	94.6±1.3																																																								
<p><i>Pharmacokinetics of Segesterone Acetate –Studies on Animals; Rats, Guinea Pigs, Rabbits (Study 17247-16-220485)</i></p>	<p>In rabbit, the urinary route of excretion was slightly more important than the biliary route, accounting for approximately 50% of the dose as compared to 30% in the feces.</p>																																																													

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Type of Study	Major Findings																																											
	<table border="1"> <thead> <tr> <th rowspan="3">Time (hr)</th> <th colspan="4">Cumulative % of Radioactive Dose</th> </tr> <tr> <th colspan="2">50 µg/kg IV</th> <th colspan="2">50 µg/kg PO</th> </tr> <tr> <th>Urine</th> <th>Feces</th> <th>Urine</th> <th>Feces</th> </tr> </thead> <tbody> <tr> <td>8</td> <td>5.1±6</td> <td>1.8±2.1</td> <td>4.7±4.2</td> <td>3.9±1.8</td> </tr> <tr> <td>24</td> <td>34.3±2.8</td> <td>13±1</td> <td>30.6±3.2</td> <td>18.9±2</td> </tr> <tr> <td>48</td> <td>41.4±2.3</td> <td>20.4±2.5</td> <td>39.7±1.3</td> <td>26.4±1.2</td> </tr> <tr> <td>72</td> <td>42.9±2.7</td> <td>23.8±2.9</td> <td>41.7±1.9</td> <td>28.4±1.8</td> </tr> <tr> <td>96</td> <td>44±2.6</td> <td>24.5±3.1</td> <td>42.8±2.4</td> <td>29.3±2.2</td> </tr> <tr> <td>120</td> <td>44.4±2.6</td> <td>25.5±3</td> <td>43.2±2.4</td> <td>30.3±2.1</td> </tr> </tbody> </table>	Time (hr)	Cumulative % of Radioactive Dose				50 µg/kg IV		50 µg/kg PO		Urine	Feces	Urine	Feces	8	5.1±6	1.8±2.1	4.7±4.2	3.9±1.8	24	34.3±2.8	13±1	30.6±3.2	18.9±2	48	41.4±2.3	20.4±2.5	39.7±1.3	26.4±1.2	72	42.9±2.7	23.8±2.9	41.7±1.9	28.4±1.8	96	44±2.6	24.5±3.1	42.8±2.4	29.3±2.2	120	44.4±2.6	25.5±3	43.2±2.4	30.3±2.1
Time (hr)	Cumulative % of Radioactive Dose																																											
	50 µg/kg IV		50 µg/kg PO																																									
	Urine	Feces	Urine	Feces																																								
8	5.1±6	1.8±2.1	4.7±4.2	3.9±1.8																																								
24	34.3±2.8	13±1	30.6±3.2	18.9±2																																								
48	41.4±2.3	20.4±2.5	39.7±1.3	26.4±1.2																																								
72	42.9±2.7	23.8±2.9	41.7±1.9	28.4±1.8																																								
96	44±2.6	24.5±3.1	42.8±2.4	29.3±2.2																																								
120	44.4±2.6	25.5±3	43.2±2.4	30.3±2.1																																								
<p><i>Pharmacokinetics of Segesterone Acetate –Studies on Animals; Beagles and Rhesus Monkey (Study 17247-17-220485)</i></p>	<p>In Rhesus monkeys, an approximately equal percentage of the dose was excreted in urine and feces following a single oral or IV administration of segesterone.</p> <table border="1"> <thead> <tr> <th rowspan="3">Time (hr)</th> <th colspan="4">Cumulative % of Radioactive Dose</th> </tr> <tr> <th colspan="2">50 µg/kg IV</th> <th colspan="2">50 µg/kg PO</th> </tr> <tr> <th>Urine</th> <th>Feces</th> <th>Urine</th> <th>Feces</th> </tr> </thead> <tbody> <tr> <td>8</td> <td>15-26</td> <td>0-10</td> <td>1-11</td> <td>0-0.2</td> </tr> <tr> <td>24</td> <td>23-31</td> <td>6-14</td> <td>14-24</td> <td>1-4</td> </tr> <tr> <td>48</td> <td>27-35</td> <td>22-31</td> <td>17-29</td> <td>16-22</td> </tr> <tr> <td>72</td> <td>31-36</td> <td>25-38</td> <td>20-31</td> <td>23-29</td> </tr> <tr> <td>96</td> <td>31-37</td> <td>25-41</td> <td>21-32</td> <td>24-31</td> </tr> </tbody> </table>	Time (hr)	Cumulative % of Radioactive Dose				50 µg/kg IV		50 µg/kg PO		Urine	Feces	Urine	Feces	8	15-26	0-10	1-11	0-0.2	24	23-31	6-14	14-24	1-4	48	27-35	22-31	17-29	16-22	72	31-36	25-38	20-31	23-29	96	31-37	25-41	21-32	24-31					
Time (hr)	Cumulative % of Radioactive Dose																																											
	50 µg/kg IV		50 µg/kg PO																																									
	Urine	Feces	Urine	Feces																																								
8	15-26	0-10	1-11	0-0.2																																								
24	23-31	6-14	14-24	1-4																																								
48	27-35	22-31	17-29	16-22																																								
72	31-36	25-38	20-31	23-29																																								
96	31-37	25-41	21-32	24-31																																								
<p>Heikinehimo O, Rana S, Moo-Young A, Lahteenmaki P, Gordon K. Parenteral administration of progestin Nestorone® to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation? <i>Human Reproduction</i>. 1999, 14 (8): 1993-1997.</p>	<p><b>Monkey (Females, Cynomolgus)</b>  <b>Dose:</b> SC implants releasing 40 µg/day  <b>Maternal Serum Concentration:</b> 125 ± 33 pg/mL  <b>Maternal Milk Concentration:</b> 217 ± 112 pg/mL  <b>Milk/Serum Ratio:</b> 1.68 ± 0.12  <b>Infant Serum Concentration:</b> Below LLQ (&lt;5 pg/mL)</p>																																											
<p><b>TK data from Safety Pharmacology and Toxicology Studies</b></p>																																												
<p><i>Pulmonary Evaluation of Subcutaneously Administered Segesterone Acetate at a Dose of 10 mg/kg in Female Sprague Dawley Rats (Study 1571-013, GLP)</i></p>	<p><b>Rat (Females, Sprague Dawley)</b>  <b>T<sub>max</sub> (SC):</b> 1 h  <b>T<sub>½</sub>:</b> 1.1 h  <b>C<sub>max</sub>(SC):</b> 745 ng/mL  <b>AUC<sub>inf</sub>(SC):</b> 1952 ng•h/mL</p>																																											
<p><i>4-Week Intravaginal Toxicity Study of Segesterone Acetate Gel in Female Mice (Study 1571-001)</i></p>	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="6">Dose (µg/day)</th> </tr> <tr> <th colspan="2">200 (1%)</th> <th colspan="2">600 (3%)</th> <th colspan="2">1800 (9%)</th> </tr> </thead> <tbody> <tr> <td><b>Day</b></td> <td><b>1</b></td> <td><b>28</b></td> <td><b>1</b></td> <td><b>28</b></td> <td><b>1</b></td> <td><b>28</b></td> </tr> <tr> <td><b>T<sub>max</sub> (hr)</b></td> <td>1</td> <td>1</td> <td>1</td> <td>2</td> <td>4</td> <td>2</td> </tr> <tr> <td><b>C<sub>max</sub> (ng/mL)</b></td> <td>14</td> <td>26</td> <td>91</td> <td>35</td> <td>99</td> <td>718</td> </tr> </tbody> </table>		Dose (µg/day)						200 (1%)		600 (3%)		1800 (9%)		<b>Day</b>	<b>1</b>	<b>28</b>	<b>1</b>	<b>28</b>	<b>1</b>	<b>28</b>	<b>T<sub>max</sub> (hr)</b>	1	1	1	2	4	2	<b>C<sub>max</sub> (ng/mL)</b>	14	26	91	35	99	718									
	Dose (µg/day)																																											
	200 (1%)		600 (3%)		1800 (9%)																																							
<b>Day</b>	<b>1</b>	<b>28</b>	<b>1</b>	<b>28</b>	<b>1</b>	<b>28</b>																																						
<b>T<sub>max</sub> (hr)</b>	1	1	1	2	4	2																																						
<b>C<sub>max</sub> (ng/mL)</b>	14	26	91	35	99	718																																						

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Type of Study	Major Findings																																																
	<table border="1"> <tr> <td><b>AUC<sub>0-24</sub></b> <b>(ng•h/L)</b></td> <td>39</td> <td>106</td> <td>155</td> <td>101</td> <td>519</td> <td>1991</td> </tr> </table>	<b>AUC<sub>0-24</sub></b> <b>(ng•h/L)</b>	39	106	155	101	519	1991																																									
<b>AUC<sub>0-24</sub></b> <b>(ng•h/L)</b>	39	106	155	101	519	1991																																											
<i>3-month Subdermal Implant Toxicity Study of Segesterone Acetate in Rats (Study 01-ST-TOX-0682)</i>	<p><b>Rat (Both sexes, Sprague Dawley)</b>  <b>Dose:</b> 86 µg/day  <b>C<sub>max</sub>(Males):</b> 2.5 ng/mL  <b>C<sub>max</sub>(Females):</b> 3.3 ng/mL</p>																																																
<i>3-month Subdermal Implant Toxicity Study of Segesterone Acetate in Female Rabbits (Study PC-ST-05-KS/89)</i>	<table border="1"> <tr> <td></td> <th colspan="3">Dose (µg/day)</th> </tr> <tr> <td></td> <th>24.6</th> <th>128.9</th> <th>551.4</th> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 4w</b></td> <td>0.1</td> <td>0.7</td> <td>2.6</td> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 8w</b></td> <td>0.1</td> <td>0.7</td> <td>2.4</td> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 12w</b></td> <td>0.1</td> <td>0.7</td> <td>3.1</td> </tr> </table> <p><small>4w 4 weeks, 8w 8 weeks, 12w 12 weeks</small></p>		Dose (µg/day)				24.6	128.9	551.4	<b>C<sub>serum</sub> (ng/mL) 4w</b>	0.1	0.7	2.6	<b>C<sub>serum</sub> (ng/mL) 8w</b>	0.1	0.7	2.4	<b>C<sub>serum</sub> (ng/mL) 12w</b>	0.1	0.7	3.1																												
	Dose (µg/day)																																																
	24.6	128.9	551.4																																														
<b>C<sub>serum</sub> (ng/mL) 4w</b>	0.1	0.7	2.6																																														
<b>C<sub>serum</sub> (ng/mL) 8w</b>	0.1	0.7	2.4																																														
<b>C<sub>serum</sub> (ng/mL) 12w</b>	0.1	0.7	3.1																																														
<i>12-month Subdermal Implant Toxicity Study of Segesterone Acetate in Female Rats (Study PC-ST-03-KS/89)</i>	<table border="1"> <tr> <td></td> <th colspan="3">Dose (µg/day)</th> </tr> <tr> <td></td> <th>11.4</th> <th>15.1</th> <th>47.8</th> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 1y</b></td> <td>1.0</td> <td>2.5</td> <td>13.6</td> </tr> </table> <p><small>1y 1 year</small></p>		Dose (µg/day)				11.4	15.1	47.8	<b>C<sub>serum</sub> (ng/mL) 1y</b>	1.0	2.5	13.6																																				
	Dose (µg/day)																																																
	11.4	15.1	47.8																																														
<b>C<sub>serum</sub> (ng/mL) 1y</b>	1.0	2.5	13.6																																														
<i>12-month Subdermal Implant Toxicity Study of Segesterone Acetate in Female Cynomolgus Monkeys (Study PC-ST-06-KS/90)</i>	<table border="1"> <tr> <td></td> <th colspan="3">Dose (µg/day)</th> </tr> <tr> <td></td> <th>30</th> <th>87</th> <th>395</th> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 1m</b></td> <td>0.19</td> <td>0.82</td> <td>4.22</td> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 7m</b></td> <td>0.30</td> <td>1.33</td> <td>6.08</td> </tr> <tr> <td><b>C<sub>serum</sub> (ng/mL) 12m</b></td> <td>0.26</td> <td>0.85</td> <td>3.45</td> </tr> </table> <p><small>1m 1 month, 2m 2 months, 3m 3 months</small></p>		Dose (µg/day)				30	87	395	<b>C<sub>serum</sub> (ng/mL) 1m</b>	0.19	0.82	4.22	<b>C<sub>serum</sub> (ng/mL) 7m</b>	0.30	1.33	6.08	<b>C<sub>serum</sub> (ng/mL) 12m</b>	0.26	0.85	3.45																												
	Dose (µg/day)																																																
	30	87	395																																														
<b>C<sub>serum</sub> (ng/mL) 1m</b>	0.19	0.82	4.22																																														
<b>C<sub>serum</sub> (ng/mL) 7m</b>	0.30	1.33	6.08																																														
<b>C<sub>serum</sub> (ng/mL) 12m</b>	0.26	0.85	3.45																																														
<i>A Toxicokinetic Evaluation of Segesterone Acetate in Pregnant Rabbits (Study 1571-020, GLP)</i>	<p><b>Rabbit (Females, New Zealand White)</b>  <b>Dose:</b> 60 µg/kg/day, SC  <b>C<sub>max</sub>(GD6):</b> 2.69 ng/mL  <b>AUC<sub>24h</sub> (GD6):</b> 21.7 ng•h/mL  <b>C<sub>max</sub>(GD18):</b> 3.26 ng/mL  <b>AUC<sub>24h</sub> (GD18):</b> 28.8 ng•h/mL</p> <p><b>Rabbit (Females, New Zealand White)</b>  <b>Dose:</b> 250 µg/kg/day, SC  <b>C<sub>max</sub>(GD6):</b> 17.4 ng/mL  <b>AUC<sub>24h</sub> (GD6):</b> 92.2 ng•h/mL  <b>C<sub>max</sub>(GD18):</b> 24.4 ng/mL  <b>AUC<sub>24h</sub> (GD18):</b> 111 ng•h/mL</p>																																																
<i>2-Year Subdermal Implant Carcinogenicity Study of Segesterone Acetate in Rats (Study 6884-103)</i>	<table border="1"> <tr> <td></td> <th colspan="6">Serum Concentrations (ng/mL)</th> </tr> <tr> <td rowspan="2">Weeks</td> <th colspan="2">40 µg/day</th> <th colspan="2">100 µg/day</th> <th colspan="2">200 µg/day</th> </tr> <tr> <th>Males</th> <th>Females</th> <th>Males</th> <th>Females</th> <th>Males</th> <th>Females</th> </tr> <tr> <td><b>4</b></td> <td>2.67</td> <td>3.85</td> <td>6.08</td> <td>10.08</td> <td>16.08</td> <td>20.04</td> </tr> <tr> <td><b>26</b></td> <td>1.78</td> <td>2.63</td> <td>4.26</td> <td>6.63</td> <td>10.71</td> <td>13.67</td> </tr> <tr> <td><b>79</b></td> <td>1.67</td> <td>2.41</td> <td>3.04</td> <td>5.41</td> <td>6.08</td> <td>12.93</td> </tr> <tr> <td><b>104</b></td> <td>0.78</td> <td>1.52</td> <td>2.22</td> <td>3.93</td> <td>3.41</td> <td>6.74</td> </tr> </table>		Serum Concentrations (ng/mL)						Weeks	40 µg/day		100 µg/day		200 µg/day		Males	Females	Males	Females	Males	Females	<b>4</b>	2.67	3.85	6.08	10.08	16.08	20.04	<b>26</b>	1.78	2.63	4.26	6.63	10.71	13.67	<b>79</b>	1.67	2.41	3.04	5.41	6.08	12.93	<b>104</b>	0.78	1.52	2.22	3.93	3.41	6.74
	Serum Concentrations (ng/mL)																																																
Weeks	40 µg/day		100 µg/day		200 µg/day																																												
	Males	Females	Males	Females	Males	Females																																											
<b>4</b>	2.67	3.85	6.08	10.08	16.08	20.04																																											
<b>26</b>	1.78	2.63	4.26	6.63	10.71	13.67																																											
<b>79</b>	1.67	2.41	3.04	5.41	6.08	12.93																																											
<b>104</b>	0.78	1.52	2.22	3.93	3.41	6.74																																											

Type of Study	Major Findings
<i>4-Week Local Toxicity Study of Segesterone Acetate Contraceptive Vaginal Rings in Cynomolgus Monkeys (Study 6884-102)</i>	<b>Monkey (Female, Cynomolgus)</b> <b>Dose:</b> 80-100 µg/day <b>C<sub>serum</sub> (Day 4):</b> 666 ± 69 pg/mL <b>C<sub>serum</sub> (Day 15):</b> 805 ± 75 pg/mL <b>C<sub>serum</sub> (Day 29):</b> 799 ± 21 pg/mL

#### 5.4.2. Pharmacokinetics of Ethinyl Estradiol

The bioavailability of EE from the 150/15 CVS was compared to an approved oral contraceptive product delivering doses of levonorgestrel (150 µg/day) and EE (30 µg/day) in each of the active tablets (Nordette 21; Wyeth Laboratories) for 21 days. The serum concentration of EE peaked shortly after insertion of the ring on Day 1. After 21 days, the EE plasma exposure of patients was less with the vaginal ring than with the approved oral contraceptive product. Overall, the bioavailability of EE was very similar by the oral or vaginal routes of administration.

Type of Study	Major Findings
<i>Phase 1 Cross-over Study to Evaluate the Kinetics of Ethinyl Estradiol and Segesterone Acetate Delivered Vaginally from a Silicone Rubber Ring as Compared with Oral Administration of Ethinyl Estradiol and Levonorgestrel in an Oral Contraceptive Pill (Nordette 21®). Study 330</i>	<div style="background-color: #cccccc; height: 150px; width: 100%;"></div> <div style="text-align: right; font-size: small;">(b) (4)</div>

### 5.5. Toxicology

#### 5.5.1. General Toxicology of Segesterone Acetate

The toxicology of SA (segesterone) was investigated in mice, rats, rabbits and monkeys. None of the endocrinological effects were observed following oral administration, highlighting the rapid and extensive first pass metabolism of SA across nonclinical species. For this reason, oral studies provided very limited information regarding the toxicological properties of the parent molecule, and their usefulness was limited to the evaluation of the toxicity of segesterone’s metabolites. The relevant toxicology studies for SA are therefore limited to parenteral routes of administration.

#### **Single-Dose Subcutaneous Toxicity Study in Female Rats and Mice (Study PC-ST-01-KS/89 and PC-ST-02-KS/89, GLP)**

Single subcutaneous injections of segesterone at 10 mg/kg in rats and 8.85 mg/kg in mice were well tolerated. All animals survived the 14-day observation period and exhibited no change in behavior, respiration or gross appearance. No changes were seen at necropsy and the organ weights were not different from the vehicle controls.

#### **4-Week Intravaginal Toxicity Study in Female Mice (Study 1571-001, GLP)**

A 4 week GLP intravaginal study was conducted in CD1® female mice, with SA administered intravaginally each day in 0.02 mL of propylparaben gel containing 1, 3 and 9% segesterone (10, 30, and 90 mg/kg/day) for 28 days.

Plasma concentrations of SA appeared to be similar on Days 1 and 28.  $AUC_{0-24}$  and  $C_{max}$  increased with the percentage of segesterone in the administered gel in a less than proportional ratio.

All animals survived to their scheduled terminal necropsy. No effect of treatment was seen in clinical findings, food consumption, hematology, clinical chemistry, macroscopic pathology examinations or organ weights. A slight test article related increase in mean body weight gain was observed in females treated with 3% and 9% SA but was not considered to be adverse. A segesterone-related alteration of the reproductive cycle in female mice was observed during microscopic examination. All animals treated with 3% and 9% gels had vaginal morphology consistent with diestrus. These changes are typical of those seen in female mice treated with progestins, are related to the pharmacology of segesterone, and not considered adverse. The NOAEL was determined to be 90 mg/kg/day in this study.

#### **3-month Subdermal Implant Toxicity Study in Rats (Study 01-ST-TOX-0682, non-GLP)**

In a non-GLP 3-month subdermal implant toxicity study, Sprague-Dawley rats were administered SA in Silastic capsules at the average daily dose of 86 µg/day (175 µg/kg/day for males and 286 µg/kg/day for females, on a live weight basis, respectively). Serum concentrations of segesterone treated males and females on Day 90 were 2.50 ng/mL and 3.32 ng/mL, respectively.

No unscheduled death occurred in the study. The administration of SA disrupted the normal estrus cycles in females, inhibiting ovulation and stimulating mammary growth and milk secretion. Segesterone treatment produced a significant increase in female body weights (21%) as compared to controls but had no effect on the body weights of the males.

Minor changes in eosinophils and neutrophils counts, BUN/creatinine ratio, triglyceride values, calcium and albumin levels, and total bilirubin were also observed. None of these changes were deemed physiologically significant or adverse.

Mean serum testosterone in male was 4.29 ng/mL for controls, and 1.85 ng/mL for treated animals. Luteinizing hormone levels were 46.0 ng/mL for controls and 29.4 ng/mL for treated male rats.

In the male, segesterone treatment resulted in decreases in heart, kidney, liver, testes, epididymis, prostate and seminal vesicle weights, and an increase in adrenal weights. Although the smaller testes, epididymis, prostate and seminal vesicles were likely secondary to reductions in serum levels of testosterone and LH, these changes were not associated with microscopic observations. In the female, segesterone treatment resulted in an increase in heart and liver weights and a significant decrease in pituitary, ovarian and uterine weights. Histological evaluation of tissues from segesterone treated rats only revealed a segesterone-dependent effect on the primary and secondary sex organs of female rats, with no evidence of any other organ toxicity. The ovaries were anovulatory and without corpora lutea. The endometrial and vaginal mucosae were in diestrus and the mammary glands had mild to moderate acinar development with some evidences of secretory activity. These changes in male and female reproductive tissues are typical of those seen in rats treated with progestins, and are consequences of the pharmacology of SA. The changes in liver weight (19% decrease in males and 18% increase in females) or heart weight (9% decrease in males and 13% increase in females) were not associated with histologic evidences of cellular injury or hypertrophy and were not considered adverse. The NOAEL in this study was 175 µg/kg/day for males and 286 µg/kg/day for females.

### **3-month Subdermal Implant Toxicity Study in Rabbits (Study PC-ST-05-KS/89, GLP)**

In a 3-month subdermal implant toxicity study, female New Zealand White rabbits were administered silastic implants releasing doses of 0, 24.6, 128.9 or 551.4 µg/day, corresponding approximately to doses of 0, 15, 70 and 300 µg/kg/day).

There were no drug-related deaths in the study. Compared to controls, MCHC, MCV and the percentages of neutrophils, eosinophils and basophils were elevated in segesterone-treated groups. The serum levels of glucose, total proteins, albumin, globulin, cholesterol and triglycerides were also elevated in response to segesterone treatment, but all hematology and clinical chemistry parameters remained within the range of normality.

Segesterone treatment produced a decrease in uterine weight and an increase in liver weight at all doses, and a decrease in adrenal and thyroid weights in the high dose group. These effects were associated with adrenocortical atrophy in the mid- and high-dose groups. Hepatocytes in the high-dose group were enlarged with a swollen cytoplasm and excess glycogen content. The mammary glands of all treated animals and the uterine glands of high-dose animals were mildly dilated. Segesterone acetate displayed both a progestin activity on the reproductive organs and a glucocorticoid-type activity on the liver and the adrenal glands. The NOAEL in this study was 70 µg/kg/day.

### **12-month Subdermal Implant Toxicity Study in Rats (Study PC-ST-03-KS/89, GLP)**

In a GLP 12-month subdermal toxicity study, female CD<sup>®</sup> rats were administered SA using subdermal silastic implants. The release rates were 0, 11.4, 15.1 and 47.8 µg/day, corresponding approximately to doses of 0, 75, 100 and 320 µg/kg/day.

A dose related increase in mean SA serum concentration was observed between the treatment groups, with the average serum concentration for the high dose (48 µg/day) reaching 36809 pmol/L at study termination.

Seven unscheduled deaths were reported in the study, one in the control group and three each in the low and high dose groups, occurring all between study day 292 and study day 359. All unscheduled deaths presented with a combination of enlarged mammary and pituitary glands. In addition, several rats across all dose groups were found at study termination with either mammary or pituitary masses. However, the incidence of mammary or pituitary lesions in the segesterone treatment groups was not significantly different from control. Uterine weights were significantly lower in segesterone treated rats as compared to vehicle controls.

Histologically, segesterone effects were evident in the uterus, ovaries, vagina and mammary glands. Corpora lutea were absent from the ovaries of high dose animals suggesting a complete inhibition of ovulation. The uterus and vagina from high dose rats were characteristic of diestrus while those of the untreated and vehicle controls were primarily in proestrus. The mammary gland of high dose rats was unstimulated with little ductal or lobuloalveolar development whereas those from vehicle controls displayed varying degrees of secretory activity. Segesterone treatment also caused an increase in body weight gain and serum glucose as compared to vehicle, and a decrease in cholesterol, total proteins and globulin serum levels. These changes remained within the range of normality for untreated rats.

Segesterone is a progestin and its inhibition of gonadotropins secretion from the pituitary gland suppresses ovarian functions. All the observed effects in this study can therefore be related to excessive pharmacology of the drug. Due to the unscheduled deaths in the low dose group, no NOAEL could be established in this study.

### **12-month Subdermal Implant Toxicity Study in Cynomolgus Monkeys (Study PC-ST-06-KS/90, GLP)**

In a GLP 12-month toxicity study, female cynomolgus monkeys were administered segesterone via subdermal silastic implants. The release rates of segesterone were 0, 30, 87 and 395 µg/day, corresponding approximately to doses of 0, 10, 30 and 130 µg/kg/day.

There were no drug-related clinical observations or unscheduled deaths in the study. The menstrual cycle of all treated animals essentially stopped within 10 days of test article implantation and a dose-related enlargement of the uterus was reported during physical examination. At necropsy, the only treatment related change was an enlarged uterus in many of the treated animals, which correlated histologically with myometrial hypertrophy, endometrial decidualization and inhibition of endometrial gland growth.

Hormonally induced changes were also seen at all treatment levels in the ovaries, cervix and vagina. Segesterone inhibited ovulation and the development of corpora lutea but allowed follicular growth up to the intermediate follicle stage. The cervical gland of all treated animals was markedly branched and contained copious amounts of thick mucous secretions. The vaginal mucosa of all treated animals was lined by very thin, non-cornified epithelium indicating minimal to non-existent endogenous estrogen stimulation.

All the effects reported in this study were consequences of the pharmacology of segesterone, and the no-observable adverse-effect-level for a year of dosing was 130 µg/kg/day. Because of the sustained-release of SA, the classical parameters of pharmacokinetics ( $C_{max}$  and AUC) could not be determined, but a dose of 395 µg/day maintained plasma concentrations between 9.3±3.2 and 18.3±4 nM over the course of 12 months.

### 5.5.2. Genetic Toxicology of Segesterone Acetate

#### **Bacterial Reverse Mutation Assay (Study PC-ST-14-KS/99, GLP)**

The mutagenic potential of segesterone was evaluated in the bacterial reverse mutation assay using *Salmonella Typhimurium* strains TA98, TA100, TA1535 and TA1537 and *E. coli* strain WP2 uvrA, in the presence and absence of Aroclor-induced rat liver S9 fraction. The study was considered valid and SA was not mutagenic when tested up to a dose level of 5000 µg/plate, with or without a metabolic activation.

#### **Chromosome Aberrations in Human Peripheral Blood Lymphocytes (Study PC-ST-11-KS/94 and PC-ST-15-KS/99, GLP)**

Segesterone acetate was tested in human peripheral blood lymphocytes for the ability to induce chromosomal aberrations in the absence or presence of Aroclor-induced S9 fraction. In two separate valid assays, SA did not cause chromosome aberrations in human lymphocytes at concentrations up to 100 µg/mL, with or without metabolic activation.

#### **Micronucleus Cytogenic Assay in Mice (Study PC-ST-10-KS/94 and PC-ST-16-KS/99, GLP)**

The ability of SA to increase the incidence of micronucleated polychromatic erythrocytes in the bone marrow was investigated in male and female mice. In the first assay, the animals received intraperitoneal injections of 2.5–10 mg/kg SA on two consecutive days with the two administrations separated by about 24 hours. In the second assay, mice were given single intraperitoneal injections of 500–2000 mg/kg SA. Segesterone acetate did not significantly increase the incidence of micronucleated polychromatic erythrocytes in bone marrow slides at any dose, and is not considered clastogenic in mice at doses up to 2000 mg/kg.

### 5.5.3. Carcinogenicity of Segesterone Acetate

#### **2-Year Intravaginal Carcinogenicity Study in Mice (Study 1571-002, GLP)**

In a 2-year carcinogenicity study in female CD1 mice, segesterone was administered intravaginally each day in gels of 0, 0.3%, 1% and 3% segesterone, providing doses of 0, 3, 10 or 30 mg/kg/day.

There was no test-article related difference in mortality between control, sham and segesterone-treated animals. Segesterone at 10 and 30 mg/kg/day produced modest but statistically significant increases in food consumption and mean body weights. No treatment-related changes in hematology, clinical chemistry or urinalysis were observed at any dose. The highest dose of segesterone (30 mg/kg/day) was found to produce an increased incidence of adenocarcinoma and lobular hyperplasia in the breast. In addition, the incidence of vaginal subchronic or chronic inflammation was increased in all segesterone gel dose groups when compared to vehicle and sham controls.

Based on the results of this 2-year carcinogenicity study, 30 mg/kg/day is considered carcinogenic in female mice. Segesterone, at all concentrations, was an irritant when administered intravaginally in a gel, producing inflammation of the proximal, mid- and distal vaginal mucosa. Exposure was not measured in the mouse carcinogenicity study, but relevant systemic exposure values were obtained in the 4-week intravaginal dose-selection study in mice (Study 1571-001). In that study, the AUC<sub>0-24h</sub> on day 1 following administration of 1% gel was 39.1 ng·h/mL and 155 ng·h/mL following the administration of 3% gel. Assuming similar exposures, the carcinogenic dose of 30 mg/kg/day is 10-fold greater than the AUC of SA in cycle one of clinical study 300PK, and the non-carcinogenic dose of 10 mg/kg/day is approximately 3-fold greater than the AUC of SA in cycle one of clinical study 300PK.

### **2-Year Subdermal Implant Carcinogenicity Study in Rats (Study 6884-103, GLP)**

In a 2-year carcinogenicity study, segesterone was administered to 5 groups of in Sprague Dawley rats by subdermal Silastic implants. The release rates of segesterone were 0, 40, 100 or 200 µg per day (267, 667, 1333 µg/kg/day) and a sham control was included in the design. Serum samples on weeks 4, 13, 36, 53, 79, 93 and 104 showed continuous segesterone exposure throughout the study but with a decrease in circulating concentrations over time. Exposures increased with increasing dose in both sexes but the plasma levels of segesterone were higher in females than in males.

There were no treatment-related effects on survival or clinical signs in either males or females. Although all animals were provided a controlled quantity of diet daily, segesterone administration produced significant body weight increases at all doses in the females. This effect was not observed in the males. No treatment-related changes in hematology, clinical chemistry or urinalysis were observed at any dose in both sexes.

Unlike the mice, the high dose of 200 µg/day decreased the incidence of pituitary and mammary neoplasms in the rats. Non-neoplastic treatment-related findings consisted of a decreased incidence of tubular hyperplasia normally observed in aged rat ovaries, an increased incidence of endometrial glands dilation/secretion in the uterus and an increased incidence of activated/secretory mammary gland tissues. These effects have been shown in previous rat studies and are a consequence of the pharmacology of segesterone.

The results of this 2-year carcinogenicity study in rats did not provide evidence of tumorigenic effect associated with the presence of SA implants at doses up to 1333 µg/kg/day.

#### **5.5.4. Reproductive and Developmental Toxicology of Segesterone Acetate**

##### **Fertility and Early Embryonic Development**

###### **Return to Fertility after 3-Month Subdermal Implant Administration in Rats (Study PC-ST-03-KS/89, GLP)**

Satellite groups within the 12-month toxicity study of subdermal implants in female CD® rats were used to assess the return to fertility after exposure to a SA dose of 59 µg/day for 90 days (393 µg/kg/day).

Following three months of treatment, the implants were removed and the animals allowed to recover for seven weeks. Daily vaginal lavages established the return to estrus cyclicity. Cycling females were housed with adult male rats for 5 consecutive days and the presence of sperm in the vagina and copulatory plug(s) was checked daily. The females were euthanized 10 to 14 days after confirmation of mating and the number of implantation sites and corpora lutea were recorded from each female.

Segesterone acetate administration for 90 days did not impair the return to fertility in female CD® rats. More females became pregnant after segesterone treatment than in the vehicle control group, and segesterone had no effect on the number of corpora lutea or the number of implantations recorded in the animals.

##### **Embryo-Fetal Development**

###### **Embryo-Fetal Toxicity and Teratogenic Potential Study of segesterone Administered Subcutaneously to Presumed Pregnant Female Rats (Study PC-ST-07-KS/91, GLP)**

Four groups of CrI:CD® BR VAF/plus® pregnant female rats received daily subcutaneous injections of segesterone in solution between gestational day 6 and 15. Dose levels were 0, 10, 50 and 250 µg/kg/day respectively. On day 20 of presumed gestation, all rats were sacrificed and all uteri were examined to record the number of implantations, early and late resorptions, live and dead fetuses and the presence of corpora lutea. Fetus weight and sex were determined and all live fetuses were prepared for histology.

There were no treatment-related effects on survival or clinical signs in the dams. The litter averages for corpora lutea, implantations, litter size, live fetuses, early and late resorptions, fetal sex ratios and number of dams with resorptions or live fetuses were comparable in all four groups.

The fetal alterations observed during gross external, soft tissue or skeletal examination occurred in the groups treated with segesterone at frequencies that were either not

significantly different from the controls or significantly reduced rather than increased. No segesterone-treated group exhibited any unique type of fetal malformation.

The subcutaneous administration of SGT to pregnant rats at doses up to 250 µg/kg/day during gestation days 6-15 did not cause maternal toxicity, embryotoxicity or teratogenicity.

**Embryo-Fetal Toxicity and Teratogenic Potential Study of segesterone Administered Subcutaneously to Presumed Pregnant Female New Zealand White Rabbits (Study PC-ST-08-KS/91, GLP)**

Four groups of artificially inseminated female New Zealand White rabbits received subcutaneous injections of segesterone from gestational day 6 through gestational day 18. The animals were administered a daily dose of 0, 10, 50 and 250 µg/kg in an aqueous solution of Molecusol™ (hydroxypropyl-β-cyclodextrin). On day 29 of presumed gestation, all surviving rabbits were sacrificed and necropsied. The number and distribution of implantations, early and late resorptions, live and dead fetuses and the number of corpora lutea in each ovary were recorded. Each fetus was weighed and examined for external alterations, visceral alterations and sex and stained for skeletal deformities.

The pharmacokinetic parameters of segesterone administered by subcutaneous injection to pregnant female New Zealand White rabbits were investigated in a supporting separate study (Study 1571-020). The systemic exposure (AUC<sub>24h</sub>) increased in a generally proportional manner and the C<sub>max</sub> values increased in a greater than dose proportional manner. No accumulation of segesterone was observed following repeated administration from G6 to G18.

There were no treatment-related effects on survival, food consumption or body weight gain of the does. One animal in the 10 µg/kg/day dose group aborted on day 20 and one 250 µg/kg/day dosage group rabbit showed signs of genital bleeding on days 22 and 24 of gestation, followed by resorption of the entire litter. The high dose of 250 µg/kg/day increased embryo death and the litter average number of resorptions, the fraction of resorbed conceptuses and the number of does with any resorptions.

All other indicators of fetal health, i.e. litter averages for corpora lutea, implantations, fetal body weights and sex ratios were comparable among control and segesterone groups. The incidence of interrelated malformations of the vertebrae and/or ribs was increased in the high dose group. These included cervical hemivertebrae, unilateral, fused or misaligned vertebrae or ribs and thoracic vertebrae with small arches. Several soft tissue malformations were also recorded but considered unrelated to treatment since these were single events and their incidences remained within the historical control ranges.

The maternal no-observable-adverse-effect-level (NOAEL) for segesterone was 250 µg/kg/day corresponding on day 18 to an AUC<sub>24h</sub> of 111 ng\*hr/mL. The developmental NOAEL for segesterone was 50 µg/kg/day, corresponding approximately on day 18 to an AUC<sub>24h</sub> of 28 ng\*hr/mL.

## **Prenatal and Postnatal Development**

### **Perinatal and Postnatal Reproduction Toxicity Study of segesterone Administered Subcutaneously to Presumed Pregnant Female Rats (Study PC-ST-09-KS/92, GLP)**

Four groups of Crl:CD®Br Vaf/Plus® presumed pregnant female rats received daily subcutaneous injections of segesterone in solution from gestational day 15 through either gestational day 25, or through day 21 of lactation. Dose levels were 0, 10, 50 and 250 µg/kg/day respectively in Phase I of the study, and 0 and 2 µg/kg/day in Phase 2.

The observations of individual births were discontinued prior to completion of all births during Phase I of the study because of prolonged gestation and parturition in all groups. Rats that did not deliver or complete delivery of a litter by day 25 of (presumed) gestation were sacrificed, and examined for gross lesions. The uteri of apparently nonpregnant rats were excised and examined. Fetuses found in rats that had partially delivered were all dead. Delivered pups were either found dead or stillborn.

Two, one and five rats in the 0 (Vehicle), 50 and 250 µg/kg/day dosage group respectively, were found dead or sacrificed for humane reasons. All segesterone-related unscheduled death were the consequence of prolonged gestation and delivery complications. Body weight gains, feed consumption and body weights were comparable among the dosage groups during gestation. The 50 µg/kg/day dosage group had significantly reduced body weight on day 1 of lactation, possibly related to the stress of prolonged gestation and parturition.

The high dose (250 µg/kg/day) of segesterone significantly increased the numbers of rats with apparent vaginal bleeding and observations related to dystocia and morbidity (red, black or brown perivaginal substance, pale appearance, coldness to touch and labored breathing). Increases in the duration of gestation were noted in the 2 µg/kg/day and higher dosages of segesterone. The duration of parturition was increased in the 10, 50 and 250 µg/kg/day dosage groups, and the cause of the increased perinatal pup deaths. Only two out of 25 high dosage group rats delivered liveborn pups. In groups given 50 and 250 µg/kg/day, a significant maternal mortality during parturition was also recorded.

Feminization of male pups, as marked by an increase of the anogenital distances was evident in the 10 and 50 µg/kg/day dosage groups on day 1 postpartum. This effect had disappeared on day 21 postpartum. No clinical or pathological observations in the pups were attributable to segesterone.

The maternal and reproductive no-observable-effect-level (NOEL) for segesterone is less than 2 µg/kg/day, as demonstrated by the weight loss on days 1 to 4 of lactation and slight increase in the duration of gestation recorded at that dose. The NOEL for viability and growth in the offspring is also less than 2 µg/kg/day since dosages of 2 µg/kg/day and higher caused perinatal mortality.

#### 5.5.5. Other Toxicology Studies of Segesterone Acetate

##### 4-Week Local Toxicity Study of Segesterone Contraceptive Vaginal Rings in Cynomolgus Monkeys (Study 6884-102, GLP)

Segesterone-containing vaginal rings were inserted in the vagina of five female cynomolgus monkeys and remained *in situ* for 4 weeks. The ring system released SA at a rate of approximately 80 to 100 µg/day. A control group of five animals received a placebo ring containing no SA.

The serum levels of SA in treated monkeys increased to  $2.244 \pm 0.219$  nM by Day 8 and remained in this range through the remainder of the treatment period (Day 29). All monkeys survived until the scheduled sacrifice. There were no treatment-related clinical observations, body weight changes, or macroscopic findings.

Monkeys treated with SA had an increased mean uterus weight and uterus-to-body weight ratio which corresponded microscopically to a secretory (progravid) endometrium and a thickened myometrium. By contrast, the endometrium from all control monkeys was in a follicular (proliferative) phase of growth. Morphologic differences were also noted in the mucosal epithelium of the vagina and cervix between the control and SA-treated monkeys; these changes were attributed to the pharmacologic effects of SA on the reproductive tract. There were no local toxic effects of SA when delivered to monkeys via vaginal rings for 4 weeks. The NOAEL in this study was 40 µg/kg/day, corresponding to a SA serum concentration 4.4-fold greater than the Cycle 1 average concentration in clinical studies.

#### 5.5.6. Summary of Toxicity for Ethinyl Estradiol

The safety of EE is supported by a significant amount of information available in the literature, public databases and within the FDA at the proposed dose and route of administration. The information in this review was summarized from NIH Publications 10-5888 and 10-5889, the National Toxicology Program (NTP) technical report on the toxicology and carcinogenesis of EE, the EE monograph from the International Agency for Research on Cancer (IARC), the EE review conducted by the International Program on Chemical Safety (IPCS, monograph 221) and the review by Maier *et al.* in *Regulatory Toxicology and Pharmacology*, 2001, 34; 56-61. In brief, the acute toxic dose for EE in rodents ranges from 0.5 to 5 g/kg, with the death of the animals attributed to liver and kidney injuries. Repeat dose toxicity studies have highlighted the exaggerated pharmacology effects of EE on the reproductive organs such as hypertrophy of the uterus, vaginal keratinization, the development of mammary glands and testicular atrophy in males. At supra-physiological doses, the toxicity of EE is mainly observed in the liver and the hematopoietic tissues. In rodents, EE at doses above 1 mg/kg/day inhibits bile production and excretion, leading to cholestasis and subsequent hepatic injury. The NOEL for cholestasis in rats is approximately 0.25 mg/kg, with some strain variations. Dogs appear less sensitive to the cholestatic effects and doses above 1 mg/kg/day EE lead instead to progressive thrombocytopenia and depressed hematopoiesis.

Ethinyl estradiol is not mutagenic in bacterial genotoxicity assays, but can induce chromosomal aberrations in some mammalian cell systems. In mice given a single IP injection of 1 or 10 mg/kg, the incidence of bone marrow micronuclei was increased. EE can act as a tumor promoter following initiation by a DNA-reactive compound. In rats, EE at doses of 0.3 to 4 mg/kg/day for two years did not increase the overall incidence of tumors or the probability of tumor development, but altered the incidence of tumor types, favoring hepatocellular adenomas, uterine polyps, pituitary adenomas and mammary gland tumors. In dogs, the chronic administration of estrogen/progestin combination elicited alopecia, pyometra and hematotoxicity. However, in five-year toxicity studies, EE in combination with Norethindrone Acetate (NA) (1:50 ratio) at doses up to 25 mg/kg/day failed to produce an increase in mammary tumors in beagle dogs. Similarly, female rhesus monkeys treated for 10 years with Norlestrin (EE/NA 1:50) up to 2.55 mg/kg/day showed no systemic toxicity or increased incidence of tumors.

Ethinyl estradiol, through its pharmacological action, can alone or in combination with progestins, prevent reproduction. The mechanism of this contraceptive effect is complex and involves impairment of the fertilized egg transport in the fallopian tubes and an alteration of the uterus lining that prevents implantation. In reproductive toxicity studies, EE was embryo lethal but not teratogenic in mice, rats or rabbits. Pregnant rhesus monkeys given doses of 5 to 25 mg/kg Norlestrin (EE/NA 1:50) during early or late gestation as well as throughout the organogenesis period had an increased incidence of fetal mortality, but the surviving offspring were devoid of teratogenic or histologic findings and did not exhibit abnormalities in neurological functions during the first year of life.

## 6. Clinical Pharmacology

### 6.1. Executive Summary

Segesterone Acetate/Ethinyl Estradiol (SA/EE) contraceptive vaginal system (CVS) is a progestin/estrogen combination hormonal contraceptive (CHC). Segesterone is a synthetic progestin and is considered as a new molecular entity (NME) in the US. SA/EE CVS contains 103 mg SA and 17.4 mg EE, which releases on average 150 µg/day of SA and 13 µg/day of EE. The applicant conducted 2 Phase III studies to support safety and efficacy of SA/EE CVS.

#### 6.1.1. Recommendations

The Office of Clinical Pharmacology, Divisions of Clinical Pharmacology-3 and Pharmacometrics have reviewed the information contained in NDA 209627 and recommend approval of this NDA. The key review issues with specific recommendations/comments are summarized in the table below:

Review Issue	Recommendations and Comments
<b>Supportive evidence of effectiveness</b>	<ul style="list-style-type: none"> <li>Two pivotal Phase III studies (Study 300A and 300 B) demonstrated the safety and efficacy of SA/EE CVS for the proposed indication of prevention of pregnancy.</li> <li>Dose-dependent suppression of ovulation provides supportive evidence of efficacy.</li> </ul>
<b>General dosing instructions</b>	<ul style="list-style-type: none"> <li>One SA/EE CVS is inserted in the vagina. The ring should remain in place continuously for three weeks, followed by a one-week ring-free interval. SA/EE CVS is designed to be used for up to 13 cycles (1 year).</li> </ul>
<b>Dosing in patient subgroups (intrinsic and extrinsic factors)</b>	<ul style="list-style-type: none"> <li>Do not use SA/EE CVS in women with liver disease such as acute viral hepatitis or severe (decompensated) cirrhosis of the liver.</li> <li>Do not use SA/EE CVS in women with renal impairment.</li> <li>Use a back-up or alternative method of contraception when enzyme inducers are used with SA/EE CVS</li> <li>Do not use oil-based vaginal products with SA/EE CVS</li> </ul>
<b>Labeling</b>	Refer to Section 14 for the review team's recommendations.
<b>Bridge between the to-be-marketed (TBM) and clinical trial formulations</b>	There were minor (b) (4) manufacturing process changes between clinical trial and TBM products, which were bridged by in vitro dissolution studies (see Biopharmaceutics review).
<b>Other (specify)</b>	None.

### 6.2. Summary of Clinical Pharmacology Assessment

### 6.2.1. Pharmacology and Clinical Pharmacokinetics Mechanism of action and pharmacodynamics (PD)

SA/EE CVS is a fixed-dose CHC, which prevents pregnancy primarily by suppressing ovulation.

#### Pharmacokinetics (PK) of SA and EE from SA/EE CVS

##### Absorption

Median  $T_{max}$  of SA and EE following vaginal administration of SA/EE CVS was around 2 hours in Cycle 1, Cycle 3, and Cycle 13. Concentrations of both components declined after  $T_{max}$  and became more constant after 96 hours post-dose. The <sup>(b) (4)</sup> release of SA and EE as indicated by  $C_{max}$  values was most significant upon initial use of the vaginal ring and became less prominent in subsequent cycles (Figure 2).

##### *In vivo Release Rate:*

Based on residual amounts of SA and EE in SA/EE CVS after 13 cycles of use, average daily release rates were 150  $\mu\text{g}/\text{day}$  for SA and 13  $\mu\text{g}/\text{day}$  for EE. (See Biopharmaceutics Review).

*Note: Although the determined actual in vivo release rates of SA and EE from Annovera<sup>TM</sup> are 150  $\mu\text{g}/\text{day}$  and 13  $\mu\text{g}/\text{day}$ , respectively, the remaining review denotes Annovera<sup>TM</sup> as SA/EE 150/15 CVS. This is to be consistent with other SA/EE dose combinations (i.e., SA/EE 200/15 CVS and SA/EE 150/20 CVS) studied under this NDA.*

##### Distribution

The volume of distribution of SA was 19.6 L/kg (Study POP-648). SA is approximately 95% bound to human serum proteins and has negligible binding affinity for sex hormone-binding globulin (SHBG). EE is highly (98.5%) but not specifically bound to serum albumin.


##### Metabolism

In vitro data shows that both SA and EE are metabolized by cytochrome P450 (CYP) 3A4. In human serum, two oxidative metabolites (5 $\alpha$ -dihydro- and 17 $\alpha$ -hydroxy-5 $\alpha$ -dihydro metabolites) constitute 50% of exposure relative to SA. Both metabolites are not considered as active metabolites with 10-fold higher  $EC_{50}$  to progesterone receptor than that of SA. EE is primarily metabolized by aromatic hydroxylation, but a wide variety of hydroxylated and methylated metabolites are formed. These are present as free metabolites and as sulfate and glucuronide conjugates. The hydroxylated EE metabolites have weak estrogenic activity.

##### Excretion

Mass balance study of SA was not conducted. The median apparent terminal elimination half-life ( $T_{1/2}$ ) of SA is approximately 3.7 hours. EE is known to be excreted in the urine and feces as glucuronide and sulfate conjugates, and it undergoes enterohepatic recirculation. The median half-life ( $T_{1/2}$ ) for EE from SA/EE CVS is 16.5 hours.

Figure 2 Mean SA and EE Serum Concentrations-Time Profiles Delivered by SA/EE CVS (Study 300-PK)



## 6.2.2. General Dosing and Therapeutic Individualization

### General Dosing

One SA/EE CVS is inserted in the vagina. The ring must remain in place continuously for three weeks, followed by a one-week ring-free interval. SA/EE CVS is designed to be used for up to 13 cycles (1 year).

### Therapeutic Individualization

#### Hepatic Impairment

The effect of hepatic impairment on the PK of SA/EE CVS has not been studied. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal and CHC causation has been excluded.

#### Renal Impairment

The effect of renal impairment on the PK of SA/EE CVS has not been studied. Given the lack of mass balance study and renal impairment study, it is not known whether renal excretion plays a significant role in the clearance of SA and/or metabolites. Therefore, SA/EE CVS is not recommended in patients with renal impairment.

#### Drug-Drug Interaction (DDI)

- DDI with other vaginal products: Clinical DDI Study (Study 571) showed that a single-dose vaginal administration of an oil-based 1200 mg miconazole suppository increased the systemic exposure of EE and SA by 67% and 19%, respectively. Following multiple-doses of 200 mg miconazole vaginal suppository, the systemic exposure of EE and SA increased by 42% and 27%, respectively. Water-based vaginal miconazole cream had no effect on SA/EE CVS. Therefore, concurrent use of oil-based vaginal products should not occur with SA/EE CVS use due to acute and potential long-term effect on the ring. If there is a need to treat a vaginal condition, water-based vaginal cream or oral therapy may be used concurrently with the ring.
- CYP-mediated DDI: No clinical DDI studies have been conducted to assess the effects of strong CYP3A induction and inhibition on the PK of SA and EE from SA/EE CVS. Considering similar metabolic pathway of progestins (i.e., via CYP3A4) and EE as a commonly used estrogen component in CHCs, CHC class labeling is applied to describe the general trend of PK changes of SA/EE CVS in the presence of CYP3A modulating drugs and support the management strategy for CYP-based DDI with SA/EE CVS. Particularly, decreased exposure of the estrogen and/or progestin component of CHCs may potentially diminish the effectiveness of CHCs and may lead to contraceptive failure or an increase in breakthrough bleeding. An alternative method of contraception or a backup method should be used when enzyme inducers are used with CHCs.

**Obesity**

SA and EE concentrations decreased with increased body weight. There was limited information on the safety and efficacy of SA/EE CVS in females of reproductive potential with BMI >29.0 kg/m<sup>2</sup> due to insufficient number of obese subjects in the Phase III studies.

**Outstanding Issues**

None.

**6.3. Comprehensive Clinical Pharmacology Review General Pharmacology and Pharmacokinetic Characteristics**

Pharmacology	
<b>Mechanism of Action</b>	CHC lowers the risk of becoming pregnant primarily by suppressing ovulation.
<b>Active Moieties</b>	SA and EE
<b>QT Prolongation</b>	No QT interval prolongation of clinical concern was observed at a single i.v. bolus dose of 200 µg SA.
General Information	
<b>Bioanalysis</b>	SA and EE concentrations in serum were measured using validated GC-MS/MS methods. A summary of the method validation reports is included in Section 22.1.1.
<b>Healthy vs. Patients</b>	The target population of SA/EE CVS are healthy pre-menopausal women
<b>Drug exposure at steady state (Mean ± SD)</b>	SA/EE CVS is to be used under a 21/7-day in/out regimen in each cycle with a total of 13 cycles. SA AUC <sub>0-504h</sub> for Cycles 1 and 13 were 96243 ± 16881 and 47162 ± 10148 pg•h/mL, respectively. EE AUC <sub>0-504h</sub> for Cycles 1 and 13 were 22158 ± 9795 and 9568 ± 4059 pg•h/mL, respectively.
<b>Minimal effective dose or exposure</b>	Phase III studies assessed the efficacy (Pearl Index) of SA/EE CVS at one dose level, i.e., 150 µg/day SA combined with 15 µg/day EE <sup>1</sup> . See Pharmacodynamics section below
<b>Maximally tolerated dose or exposure</b>	Maximally tolerated dose has not been established. SA/EE 200 µg/15µg CVS and SA/EE 150 µg/20 µg CVS were studied in healthy women for 1 year.
<b>Pharmacodynamics</b>	Data showed when SA/EE CVS was used as directed, luteal activity, as measured by progesterone and E2 levels, remained adequately suppressed
<b>Dose Proportionality</b>	Slightly less than dose proportional in the dose range of 50-150 µg/day SA
<b>Accumulation</b>	SA and EE concentrations decrease to zero during 7-day ring-free period. No residual concentrations are accumulated to the subsequent cycle.

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

<b>Variability</b>	SA CV% for C <sub>max</sub> : 27~39% and AUC <sub>0-21days</sub> : 17~22% EE CV% for C <sub>max</sub> : 30~53 % and AUC <sub>0-21days</sub> : 32~42%
<b>Absorption</b>	
<b>Bioavailability</b>	The absolute bioavailability in humans has not been established.
<b>T<sub>max</sub> (Median)</b>	SA: 2.0 hours; EE: 2.0 hours
<b>Food effect</b>	N/A
<b>Distribution</b>	
<b>Volume of Distribution</b>	SA: 19.6 L/kg
<b>Plasma Protein Binding</b>	Fraction unbound of SA in human plasma is 5%. SA has negligible binding affinity for SHBG.
<b>Elimination</b>	
<b>Terminal Elimination half-life (Mean ± SD)</b>	SA: 4.5±3.4 hours; EE: 15.1 ± 7.5 hours from SA/EE CVS
<b>Metabolism</b>	
<b>Primary metabolic pathway(s)</b>	In vitro data shows that SA is primarily metabolized by CYP 3A4. In human serum, two oxidative metabolites (5α-dihydro- and 17α-hydroxy-5α-dihydro metabolites) constitute 50% of exposure relative to SA. Both metabolites are not considered as active metabolites with EC <sub>50</sub> to progesterone receptor 10- fold higher than that of SA. EE is primarily metabolized by aromatic hydroxylation, but a wide variety of hydroxylated and methylated metabolites are formed. These are present as free metabolites and as sulfate and glucuronide conjugates. The hydroxylated EE metabolites have weak estrogenic activity <sup>2</sup> .
<b>Excretion</b>	
<b>Primary excretion pathways (% dose) ±SD</b>	Unknown due to lack of mass balance study
<b><i>In vitro</i> interaction liability (Drug as perpetrator)</b>	
<b>Inhibition/Induction of metabolism</b>	SA is unlikely to inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 or induce CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 at clinically relevant dose.
Notes: <sup>1</sup> Although the determined actual in vivo release rates of SA and EE from Annovera™ are 150 µg/day and 13 µg/day, respectively, the remaining review denotes Annovera™ as SA/EE 150/15 CVS. <sup>2</sup> Information on metabolism of EE comes from approved EE- containing product label.	

### 6.3.1. Clinical Pharmacology Questions

**To what extent does the available clinical pharmacology information provide pivotal or supportive evidence of effectiveness?**

Two open labelled Phase III studies (Studies 300A and 300B) provided the pivotal evidence to support efficacy for SA/EE 150/15 CVS. In the pooled database, the pregnancy rate (Pearl Index) in the subgroup of women ≤35 years of age using pregnancies from evaluable cycles within 14 days from CVS removal (the Primary Subgroup; n= 2111) was 3.36 (95% CI [2.45, 4.49]) per 100


Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

woman-years of CVS use (See clinical review). The clinical pharmacology information which provides supportive evidence of effectiveness is presented below.

As a CHC, SA/EE CVS lowers the risk of pregnancy primarily by suppressing ovulation. PD data in Study 300PK suggested that when SA/EE CVS was used as directed, luteal activity remained adequately suppressed.

Study 300PK assessed the effect of SA/EE CVS on ovulation suppression in 39 subjects by measuring serum estradiol (E2) and progesterone (P) levels twice a week during Cycles 1, 3 and 13 of SA/EE CVS use. No study subjects had luteal activity, defined as two consecutive P measurements of more than 10 nmol/L. One subjects had 1 serum P concentration > 10 nmol/L in Cycles 13. Serum E2 concentrations were also suppressed during the 21-day period of the cycle when the CVS was in place (Figure 3).

**Figure 3. P Serum Concentrations for Cycle 1 (N=39), Cycle 3 (N=35), and Cycle 13 (N=27)<sup>8</sup>**




**Is the proposed dosing regimen appropriate for the general patient population for which the indication is being sought?**

Yes. The following can be considered regarding the selection of the (b) (4) dosing regimen of 21-day continuous use followed by 7-day ring-free interval.

- Earlier clinical studies (Study 124, Study 174 and some literature reports) evaluated the effects of continuous use of SA alone on luteal activity. The data showed an exposure-response in ovulation suppression and a SA serum concentration  $\geq 100$  pmol/L (37 pg/mL) was demonstrated to inhibit ovulation in most cycles.

<sup>8</sup> In Cycle 13, three study subjects were excluded from analysis due to compliance issue as evidenced by undetectable segesteron concentrations.

-  (b) (4)
- Study 181 compared the efficacy of SA/EE CVS in preventing ovulation between two different dosing regimens: 21 days in/7 days out versus 26 days in/4 days out. This 6-month study showed comparable luteal suppression, bleeding control and safety profiles between the two regimens. Therefore, the 21/7-day regimen, was selected based on lower SA and EE exposure.

#### SA Concentrations Associated with Ovulation Inhibition

 (b) (4)  
cut-off value should not be applied to SA/EE 150/15 CVS due to the following concerns:

-  (b) (4)  
the product in the current submission is a fixed-dose combination of SA and EE administered under a 21/7-day in/out regimen.  (b) (4)
- Different bioanalytical techniques (i.e., RIA vs. GC-MS/MS) were used to determine SA serum concentrations and the values from one assay may not be interchangeable with another assay.

#### VTE Risks Associated with EE Exposure

It is known that higher EE exposure associates with increased VTE risks. The applicant compared EE systemic exposure from SA/EE 150/15 CVS to an approved oral contraceptive (OC) containing 30 µg EE to support the safety of SA/EE CVS on VTE risk (Study 330). However, the result of study is not considered valuable, as the CVS formulation used in this study is different from the TBM formulation and no adequate bridge has been made between the two formulations. A post-marketing safety requirement to assess the VTE risks of SA/EE CVS is recommended by the review team.

#### QTc Assessment

The effect of SA on QT interval prolongation was evaluated in healthy premenopausal women and no significant QTc prolongation effect was detected following a single i.v. bolus dose of 200

µg SA. The supra-therapeutic SA dose (200 µg) produced a mean SA  $C_{max}$  value ( $5150.2 \pm 3333.2$  pg/mL) of ~4.5-fold the mean  $C_{max}$  ( $1147.1 \pm 315.3$  pg/mL) at the therapeutic dose of SA/EE CVS.

**Is an alternative dosing regimen and/or management strategy required for subpopulations based on intrinsic factors?**

Yes. Comments for each specific population are provided below.

Renal Impairment

The effect of renal impairment on the PK of SA/EE CVS has not been studied. Given the lack of mass balance study and renal impairment study, it is not known whether renal excretion plays a significant role in the clearance of SA and/or metabolites. Therefore, the review team agrees with the applicant and recommends SA/EE CVS not to be used in patients with renal impairment.

Hepatic Impairment

The effect of hepatic impairment on the PK of SA/EE CVS has not been studied. Steroid hormones such as SA and EE may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of SA/EE CVS use until markers of liver function return to normal.


Age

SA/EE CVS is only indicated for use in females of reproductive potential. No PK study has been done in post-pubertal adolescents under the age of 18. Nonetheless, PK of SA/EE CVS is expected to be the same for post-pubertal adolescents under the age of 18 as for users 18 years and older. Use of SA/EE CVS before menarche is not indicated. SA/EE CVS has not been studied in women who have reached menopause and is not indicated in this population.

Body Weight and Body Mass Index (BMI)

The applicant did not conduct population PK analysis to assess the effect of body weight on the PK of SA and EE. Based on the PK data from individual PK studies, decreased systemic exposures of SA and EE were observed with increased body weight of the study subjects. Study 300PK evaluated PK of SA and EE in Cycle 1, Cycle 3 and Cycle 13 of SA/EE CVS use. Of 39 subjects who completed the study, 18 women had BMI < 25 (range: 16.89 - 24.34) kg/m<sup>2</sup> and 21 women had BMI > 25 (range: 25.15 - 37.46) kg/m<sup>2</sup>. As shown in Figure 4, SA  $AUC_{0-504h}$  was 7% -16% lower in subjects with BMI > 25 kg/m<sup>2</sup> compared to subjects with BMI < 25 kg/m<sup>2</sup> in the tested cycles.  $AUC_{0-504h}$  of EE was 26% - 33% lower in subjects with BMI > 25 kg/m<sup>2</sup> compared to subjects with BMI < 25 kg/m<sup>2</sup>. There was limited information on the safety and efficacy of SA/EE CVS in females of reproductive potential with BMI >29.0 kg/m<sup>2</sup> due to insufficient number of obese subjects in the Phase III studies. The clinical relevance of the observed lower SA and EE exposure in subjects with higher BMI is not known.

**Figure 4. Box-plot Comparison of SA and EE Systemic Exposure Grouped by BMI (Study 300PK)**



**Are there clinically relevant food-drug or drug-drug interactions and what is the appropriate management strategy?**

Yes, the applicant conducted one clinical DDI study, one physiologically-based PK (PBPK) model and several in vitro studies to assess the DDI potential of SA/EE CVS.

Effect of other drugs or vaginal products on the PK of SA/EE CVS

- CYP-based DDI

In vitro data showed that CYP3A contributes at least 30% of hepatic clearance of SA (Study XT174098). The applicant used physiology-based PK (PBPK) model to predict the impact of CYP3A inhibition and induction on the systemic exposure of SA following parenteral administration.

(b) (4)

Upon detailed review, the review team concluded that the PBPK model

performance was not adequately qualified, and thus the model is not adequate to support waiver of clinical DDI studies between SA/EE CVS and CYP3A modulating drugs (See Appendix 17.4).


This issue will be addressed through a postmarketing requirement. Particularly, the review team recommends the applicant conduct a clinical DDI study to assess the effects of strong CYP3A induction and inhibition on the PK of SA and EE from SA/EE CVS (See Section 16). Given similar metabolic pathway of SA compared to other progestins and EE as commonly used estrogen component in CHCs, CHC class labeling is used to describe the general trend of PK changes of SA/EE CVS in the presence of CYP3A modulating drugs and support the general management strategy for CYP-based DDI with SA/EE CVS.

- DDI with other vaginal products


The applicant conducted a randomized, cross-over DDI study (Study 571) to evaluate the effects of vaginal antimycotic medication (miconazole nitrate) on the PK of SA and EE in 29 women using SA/EE CVS. The results showed that 1) vaginal administration of a single-dose of 1200 mg miconazole suppository on Day 8 of CVS use increased the systemic exposure of EE ( $AUC_{Day8-21}$ ) by approximately 67%. Similar trend was observed with SA with  $AUC_{Day8-9}$ ,  $AUC_{Day8-10}$  and  $AUC_{Day8-21}$  increasing by approximately 30%, 32% and 19%, respectively (Figure 5 and Table 4); 2) When 200 mg miconazole vaginal suppository were administered on Day 8, Day 9 and Day 10 of CVS use, EE  $AUC_{Day8-11}$  and  $AUC_{Day8-21}$  were increased by 9% and 42%, respectively. SA  $AUC_{Day8-11}$  and  $AUC_{Day8-21}$  were increased by 28% and 27%, respectively (Figure 6 and Table 4); 3) EE and SA exposure ( $AUC_{Day10}$ ,  $AUC_{Day8-11}$  and  $AUC_{Day8-21}$ ) was bioequivalent with or without 3-Day (Day 8 - Day 10) treatment of vaginal miconazole cream, indicating no PK interaction between SA/EE vaginal ring and miconazole vaginal cream (Figure 7 and Table 4).

These findings suggest that the active ingredient, miconazole, does not affect the PK of SA and EE from the CVS; but the lipophilic nature of suppository formulation may enhance release and/or absorption of the lipophilic steroids contained in the CVS. The increase in exposure to EE extended beyond the duration of concomitant administration with the suppositories suggesting a potential alteration in the release characteristic of the CVS. Given the potential long-term effect on the ring's performance, the review team recommends the following in the label: concurrent use of oil-based vaginal suppositories should not occur with SA/EE CVS use. If there is a need to treat a vaginal condition, water-based vaginal cream or oral therapy may be used concurrently with the ring. No further evaluation or studies are necessary based on this data.


**Figure 5 Arithmetic Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with a Single-Dose of Miconazole Nitrate Suppository (Treatment B1) in Healthy Female Subjects in Study 571**



**Figure 6 Arithmetic Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with Three-Day Regimen of Miconazole Nitrate Suppository (Treatment B2) in Healthy Female Subjects in Study 571**



**Figure 7 Arithmetic Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with Three-Day Regimen of Miconazole Nitrate Cream (Treatment B3) in Healthy Female Subjects in Study 571**



**Table 4. Comparisons of SA and EE PK Parameters after administration of SA/EE CVS Alone or with Miconazole Vaginal Suppository or Cream**

Geometric mean (90% CI) of Test to Reference Ratio			
Treatments	PK Parameters	SA	EE
Concomitant use of a single dose of miconazole vaginal suppository with CVS (test) vs CVS alone (Reference)	AUC <sub>Day8-9</sub>	1.30 (1.19, 1.41)	1.04 (0.91, 1.19)
	AUC <sub>Day 8-10</sub>	1.32 (1.19, 1.47)	1.18 (1.04, 1.35)
	AUC <sub>Day 8-21</sub>	1.19 (1.04, 1.36)	1.67 (1.51, 1.86)
3-Day concomitant use of miconazole vaginal suppository with CVS (test) vs CVS alone (Reference)	AUC <sub>Day8-11</sub>	1.28 (1.03, 1.58)	1.09 (0.84, 1.40)
	AUC <sub>Day 8-15</sub>	1.26 (1.10, 1.43)	1.28 (1.08, 1.53)
	AUC <sub>Day 8-21</sub>	1.27 (1.15, 1.40)	1.42 (1.21, 1.66)
3-Day concomitant use of miconazole vaginal cream with CVS (test) vs CVS alone (Reference)	AUC <sub>Day8-11</sub>	1.19 (1.15, 1.22)	0.98 (0.81, 1.11)
	AUC <sub>Day 8-15</sub>	1.11 (1.09, 1.14)	1.12 (1.01, 1.25)
	AUC <sub>Day 8-21</sub>	1.09 (1.04, 1.14)	1.14 (1.07, 1.21)

The applicant also assessed the effects of various water- and oil-based lubricants on SA/EE CVS. The results showed the oil silicone based lubricants significantly increased the size of the ring and led to much higher in vitro release rates of SA and EE from the ring. The applicant proposed to avoid the concurrent use of SA/EE CVS with vaginal lubricants containing silicone (See CDRH review for details).

Effect of SA/EE CVS on Other Drugs

In vitro data showed that SA did not inhibit or induce the liver enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP2E at concentrations up to 1 µM. At concentrations of 1 µM and above, SA may have the potential to cause metabolism-dependent inhibition of CYP3A4. As the observed mean SA C<sub>max</sub> of 1147 ng/mL (3 nM) following the vaginal administration of SA/EE CVS is about 333-fold lower than SA concentrations with DDI potential,

the *in vitro* studies suggest that SA/EE CVS is unlikely to inhibit or induce CYP enzymes at the therapeutic dose.

**Is the to-be-marketed formulation the same as the clinical trial formulation, and if not, are there bioequivalence data to support the to-be-marketed formulation?**

No, compared to the Phase III clinical trial formulation, which was also used in the pivotal PK study 300PK, the to-be-marketed (TBM) formulation had some minor changes in (b) (4) manufacturing process. Nonetheless, these changes are considered as minor and were bridged by *in vitro* dissolution studies (see Biopharmaceutics review). There were 2 prior formulations that are not adequately bridged to the TBM formulation. A brief summary of formulations is provided below.

During the drug development program, three formulations have been used for SA/EE CVS, i.e., Phase 1 Formulation and Phase 2 Formulation manufactured by Population Council, and Phase 3 Formulation manufactured by QPharma.

- Phase 1 Formulation by Population Council: used in Clinical Study 64 and 97.
- Phase 2 Formulation by Population Council: used in several clinical studies including Study 180, Study 181 and Study 330. The applicant attempted to use (b) (4) *in vitro/in vivo* correlation (IVIVC) to demonstrate the similarity of the QPharma-manufactured Phase 3 batch to an earlier Phase 2 batch manufactured by the Population Council. However, this IVIVC method is not considered as reliable per Biopharmaceutics reviewer. Therefore, there is no adequate bridge between Phase 2 Formulation and Phase 3 Formulation.
- Phase 3 Formulation by QPharma: used in two pivotal Phase III studies (Study 300A and 300B) and a PK study (Study 300PK)
- TBM Formulation: used in a clinical DDI study (Study 571)

## 7. Sources of Clinical Data and Review Strategy

### 7.1. Table of Clinical Studies

The following are the studies conducted to support the efficacy and safety of SA/EE CVS.

**Table 5. Table of Clinical Trials**

Study Phase Dates Duration NCT number	Trial Design Country Number of sites	Study Population Dose regimen	Endpoints	Number of subjects analyzed
300A Phase 3  Dec 2006- Oct 2009  up to 13 cycles  NCT00455156	Open-label, single arm, prospective US 15 sites	Healthy, sexually active women with regular menses 18-40.0 yo*  150 µg SA/15 µg EE CVS Vaginal, 21/7 days in/out for up to 13 cycles	Pearl Index Life Table analysis Cycle control Safety	1129
Endometrial	sub-study	same as 300A	Histology of endometrium	159
Hepatic	sub-study		Hepatic proteins	129
Microbiology	sub-study		Presence of vaginal microbes	120
300B Phase 3  Nov 2006 – July 2009  up to 13 cycles  NCT00263342	Open-label, single arm, prospective 8 countries 12 sites 5 US 3 Latin America 3 Europe 1 Australia	Healthy, sexually active women with regular menses 18-40.8 yo*  150 µg SA/15 µg EE CVS Vaginal, 21/7 days in/out for up to 13 cycles	Pearl Index Life Table analysis Cycle control Safety	1135
300PK Phase 1  Dec 2005- Jun 2007  up to 13 cycles	Open-label, non-randomized PK/PD study 3 countries/sites Chile Dominican Republic US	Healthy, sexually active women 18-38 yo 150 µg SA/15 µg EE CVS Vaginal, 21/7 days in/out for up to 13 cycles	Estradiol and Progesterone levels Luteal activity (based on consecutive progesterone levels)	39

			SA and EE serum concentrations: Cmax, AUC, steady-state	
180 Phase 2  May 1996- Jul 1998  up to 13 cycles	Randomized, parallel-group, dose finding study 4 countries 5 sites Dominican Republic Finland Chile US – 2 sites	Healthy, sexually active women with regular menses, 18-38 yo 150 µg SA/15 µg EE 150 µg SA/20 µg EE 200µg SA/15 µg EE  CVS, Vaginal, 21/7 days in/out for up to 13 cycles	SA and EE serum levels Luteal activity (based on progesterone levels) Vaginal effects Adverse effects Bleeding patterns	150
181 Phase 2  Feb 1997- Dec 1998  6 cycles	Randomized parallel-group open-label 4 countries/sites Dominican Republic Finland Australia US	Healthy, sexually active women with regular cycles, 18-35 y/o 150 µg SA/15 µg EE CVS, vaginal, 21/7 OR 26/4 days in/out for 6 cycles	SA and EE serum levels Luteal activity including ultrasound Bleeding patterns	101
204OL Phase 2  Dec 1999- Aug 2001  6 cycles	Single group, open-label 5 countries/sites Dominican Republic Australia Chile US Finland	Healthy, sexually active women with regular menses, 18-38 y/o ≤80 kg 150 µg SA/15 µg EE CVS, vaginal, remove with bleeding for 4 days followed by insertion into vagina for at least 2 weeks	Ovulation inhibition (based on progesterone levels) Menstrual patterns SA and EE serum levels	76

Source: NDA 209627, Module 2.5, Clinical Overview, Table 1 p 11/68

\*weight exclusion >29 kg/m<sup>2</sup> after September 25 and October 4, 2007

## 7.2. Review Strategy

Studies 300A and 300B provide the efficacy data and most of the safety data. Details for these two studies are provided in section 8 of this review. Pooled data from Studies 300A and 300B were used to evaluate the primary efficacy endpoint. We used this review strategy because neither trial provided the 10,000 evaluable menstrual cycles that the Agency generally requires for contraceptive trials; because the trials were of similar design, pooling was possible to derive the required number of evaluable cycles to establish efficacy of the product. The evaluation and

conclusions in Section 8 represents the combined evaluation of the clinical and statistical teams.

Additional safety data are derived from two phase 1 trials (Studies 300 PK and 330—not listed in the table above) and four phase 2 trials (Studies 180, 181, 2040L and 323—not listed in the table above). Because SA is an NME, the Division requested safety data for other formulations of the SA CVS, which included an SA/EE CVS with lower doses (204R) and CVS with only SA (174, 175). See 10.2 Review of the Safety Database for more detailed information on the safety analysis sets.

## 8. Statistical and Clinical Evaluation of Efficacy

### Financial Disclosure

The applicant provided financial disclosure (FD) for all clinical investigators involved in all studies in one Form 3454 and one Form 3455. The FD information is provided here rather than presenting the information twice under each of the pivotal studies.

There were no funds furnished to clinical investigators or other individuals or groups working on the sponsored studies. Funds provided were to be used for the sponsored studies. Population Council is a non-profit organization and there are no stocks or possibility of full or partial ownership. Population Council did not believe FD requirements (21CFR Part 54), effective February 2, 1999, applied to their organization due to its non-profit status. In April 2011, an outside auditor inquired about the FD requirements for Population Council. FDA advised retrospective compliance with FD regulations with post-hoc collection of FD forms being acceptable for inclusion in the NDA. For investigators who could not be located, the reviewer concluded that the Applicant made appropriate due diligence efforts to document all financial information.

**Table 6. Investigators with Financial Disclosure**

Protocol	Investigator	Compensation	Amount	Minimized Bias
331	(b) (6)	ICCR* membership annual stipend	\$17,500 @ year 1999-2014	Endpoints are results of laboratory studies, therefore, unlikely to be subject to bias. PK/PD study involving safety measures of EE on vaginal vs oral administration.
		attendance 3 day meeting	\$6,000 @ year	
300B, 300PK (b) (6)	(b) (6)	ICCR membership annual stipend	\$10,000 @ year 1999-2004 \$17,500 @ year 2005-2014	Site PI higher, therefore, unlikely investigator biased tests to have higher PI

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteronone acetate and ethinyl estradiol vaginal system)

		attendance 3 day meeting	\$6,000 @ year	
300B, 300PK (b) (6)	(b) (6)	ICCR membership annual stipend	\$17,500 @ year 1992-2008	Site PI was lower than FD site PI but not statistically significant, therefore bias did not occur
300B (b) (6)	(b) (6)	ICCR membership annual stipend	\$17,500 @ year 1992-2014	Site PI higher, therefore, unlikely investigator biased tests to have higher PI
300B (b) (6)	(b) (6)	ICCR membership annual stipend	\$17,500 @ year 2007-2014	Site PI higher, therefore, unlikely investigator biased tests to have higher PI
		3 day meeting	\$6,000	
300A (b) (6)	(b) (6)	ICCR membership	\$17,500 @ year 2009-2015	Site had no pregnancies and unable to perform statistical analysis
300B, 300PK (b) (6)	(b) (6)	ICCR membership	17,500 @ year 1999-2014	Site PI higher, therefore, unlikely investigator biased tests to have higher PI
300B (b) (6)	(b) (6)	Spouse receives salary from Population Council		Investigator never involved in subject selection, subject assessments, or recording of any data. Bias unlikely given the lack of participation in critical study procedures

\* Population Council's International Committee for Contraception Research (ICCR)

Source: NDA 209627, Module 1.3.4 Financial Certificate and Disclosure Form 3455

Despite due diligence there were eight clinical investigators from whom FD information could not be obtained: (b) (6)

(b) (6) None of these investigators was a principal investigator and each site had four or more investigators. Together, the sites where these eight investigators participated contributed a total of 402 (17.4%) subjects to both 300A and 300B (2308 subjects).

The applicant has disclosed key financial interests/arrangements with the clinical investigators and disclosures from all major investigative sites. No concerns were raised by the clinical review team regarding the overall integrity of the data.

The Financial Disclosure table is provided in 17.1 Appendices.

**8.1. Study 300A : A Multicenter, Open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 mcg of Nesterone<sup>®\*</sup> and 15 mcg of ethinyl estradiol (\*Nesterone = segesterone acetate)**

**8.1.1. Study Design**

**Overview and Objective**

The primary objective of Study 300A was to evaluate the contraceptive efficacy and safety of the CVS as a new drug delivery system for contraception. The secondary objectives were to evaluate cycle control and side effects of the 21-day continuous use regimen, followed by one week off per 28-day cycle. There were three sub-studies nested in Study 300A, with each evaluating a separate aspect of CVS use. The three sub-studies' objectives were to evaluate the CVS effect on hepatic factors, endometrial safety, and vaginal microbiology, and these results are discussed in Section 10.8 10.8 Specific Safety Studies/Clinical Trials.

**Trial Design**

Study 300A was designed as a phase 3, multicenter, open-label, uncontrolled clinical trial in US sites. The drug regimen was 21 days of CVS use followed by seven days without CVS use (during which the vaginal ring was removed). One CVS was used for up to thirteen 28-day cycles (i.e. up to a full year).

The study consisted of a screening period of up to 90 days, a treatment period of up to 12 months (thirteen 28-day cycles), and an optional recovery (post-treatment) period of up to six months to assess return to fertility. Enrollment began in November 2006 and continued through June 2008. All subjects had to finish active treatment by December 31, 2008 when the CVS expired; therefore, not all subjects were eligible to complete all 13 cycles. The study ended when the last subject completed the recovery period.

The study plan called for enrollment of 1200 healthy heterosexually active women aged 18 to <40 years at risk of becoming pregnant. The pregnancy rate was assessed by the PI and life table methods. All pregnancies with an estimated date of conception within 7 days after the last study treatment were to be counted as "on treatment" pregnancies.

Removal of subjects was allowed due to an AE, violation of inclusion or exclusion criteria, non-compliance, withdrawal of consent by the subject, pregnancy, and safety and administrative reasons.

Key inclusion criteria:

1. Sexually active females at risk for pregnancy
2. Age 18 to <40 years at time of enrollment
3. Able to complete study procedures including required diaries and visits
4. Must have a history of regular menstrual cycles (21-35 days in length)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

5. Be willing to discontinue current contraceptive method

Key exclusion criteria:

1. Conditions (history or presence of) which are contraindications to use of CHC, including thromboembolic disorders, cerebrovascular or coronary artery disease or myocardial infarction; diabetes mellitus; migraine headaches with focal, neurological symptoms; chronic renal disease; diastolic blood pressure (BP) > 85 mmHg and or systolic BP > 135 mmHg; cholestatic jaundice; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; impaired liver function; hepatic adenomas or carcinomas; retinal vascular lesions; family history of thromboembolic disorders
2. History of infertility or sterilization in either partner
3. History of toxic shock syndrome or history of PID since last pregnancy
4. Vaginal discharge, lesions or abnormalities
5. Papanicolaou (pap) smear with high-grade precancerous lesions
6. Cystoceles or rectoceles or anatomical abnormality that would preclude use of CVS
7. Known hypersensitivity to estrogens, progestins, or silicone rubber
8. Smoking in women >35 years and women <35 years who smoke 15 cigarettes or more need evaluation by PI for inclusion based on risk factors
9. Known or suspected pregnancy, breast feeding
10. Severe depression
11. Severe constipation
12. Known or suspected alcoholism or drug abuse
13. Use of injectable or implanted hormonal contraceptives
14. Known HIV or women at high risk of contracting HIV
15. Use of liver enzyme inducers on a regular basis
16. Body mass index (BMI) > 29 (Amendment 1.1)
17. Exclusionary concomitant medication taken chronically included isotretinoin, any sex steroid hormonal treatments, anticonvulsant therapies (except valproic acid), rifampicin, Griseofulvin, retinoic acid, ketoconazole, St. John's Wort. Use of vaginal lubricant containing mineral oil or any other oil-based vaginal products.

Study visits and procedure schedule are shown in Table 7.

**Table 7. Study Flow Chart 300A**

Cycle #	Pre-Study Screening	Baseline	1	3	4	6	7	9	10	11	13 <sup>a</sup> Final	14	Follow Up
Visit (V) No. or Telephone Call (T)	V0	V1	T1	V2	T2	V3	T3 <sup>b</sup>	V4 <sup>b</sup>	T4 <sup>b</sup>	T5 <sup>b</sup>	V5 or Early Term	V6 or Final Visit <sup>+1c</sup>	V7.1-7.3

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Treatment Cycle Day		1	22 - 29	1-7d	22 - 29	1-7d	22 - 29	1-7d	22 - 29	22 - 29	21-27	+1-2 wks	+ mos. 1-6
Informed consent signed	X												
Complete medical & gynecologic history	X												
Complete physical & gynecologic examination	X					X					X		
Sitting blood pressure & pulse	X	X		X		X		X			X	X	
Weight/BMI	X	X		X		X		X			X	X	
Height	X												
Pap smears	X										X		
Hematology	X										X		
Chlamydia and gonorrhea	X										X		
Clinical chemistry	X										X		
Urinalysis	X												
Pregnancy test (urine)	X	X		X		X		X			X	X	
Pregnancy determination			X		X		X		X	X			X <sub>e</sub>
Telephone contact			X <sub>f</sub>		X <sub>f</sub>		X <sub>f</sub>		X <sub>f</sub>	X <sub>f</sub>			X <sub>e</sub>
AE recording			X	X	X	X	X	X	X	X	X	X	X
SAE reporting			X	X	X	X	X	X	X	X	X	X	X
Concomitant medications		X	X	X	X	X	X	X	X	X	X	X	X
CVSs													
Dispensed		X											
Returned											X		
Diary card													
Dispensed		X		X		X		X			X		
Reviewed/Returned				X		X		X			X	X	
<b>Sub-studies<sup>h</sup></b>													
Hepatic Factors Sub-study	X					X					X		
Endometrial Safety Sub-study	X					X					X		
Microbiology Sub-study	X					X					X		
Visit (V) No. or Telephone Call (T)	V0	V1	T1	V2	T2	V3	T3 <sup>b</sup>	V4 <sup>b</sup>	T4 <sup>b</sup>	T5 <sup>b</sup>	V5 or Early Term	V6 or Final Visit +1 <sub>c</sub>	V7.1-7.3
Treatment Cycle Day		1	22 - 29	1-7d	22 - 29	1-7d	22 - 29	1-7d	22 - 29	22 - 29	21-27	+1-2 wks	+ mos. 1-6

<sup>a</sup>For subjects scheduled to complete < 13 cycles, the Visit 5 assessments were performed at their last scheduled cycle visit (Final Cycle Visit).

## Multi-disciplinary Review and Evaluation NDA209627 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

If the last scheduled cycle was a cycle for which a telephone visit would have been scheduled (Cycles 4, 7, 10, or 11), the subjects returned to the site for Visit 5 assessments instead. All subjects were to complete Visit 6 assessment as their Final Cycle +1 visit.

• Completed as needed, based on subject's contraceptive vaginal ring (CVS) start date.

• Subjects returned to the clinic within 1 to 2 weeks of CVS removal for pregnancy determination via urine human chorionic gonadotropin (hCG) and diary review.

• Scheduled within 1 week following CVS insertion.

• Follow-up phone calls occurred for applicable subjects once every 2 months for a maximum of 6 months. If a subject could not be reached by telephone then office visits were scheduled every 2 months. If a subject suspected pregnancy a visit was scheduled to confirm status.

• Subjects were contacted during the last week of the cycle.

• Details of procedures for the sub-studies are provided in individual sub-study reports included in the appendices.

Source: NDA 209627, Module 5.3.5.2 Study Report 300A, Table 1 p 44/1147

All women in the active treatment phase of the study had up to seven clinic visits. Prior to subject enrollment (V1), the investigator reviewed the results of laboratory tests obtained from the pre-study visit (V0). The V1 visit occurred on day 2 to 5 of the woman's menstrual cycle, when use of the CVS started. Clinic visits occurred at 3, 6, and 9 months during days 1-7 of each menstrual cycle. The exit visit (V5) occurred at the end of cycle 13 and the CVS was collected at the study site. One to two weeks after the exit visit a final visit occurred (V6). If early discontinuation of the study occurred, the exit and final visit were completed together. Subjects who enrolled in the return to fertility phase of the study had an additional visit between one to 6 months post-treatment. Telephone contact between clinic visits to enhance compliance occurred during cycles 1, 4, 7, 10, and 11.

Complete physical and gynecologic examinations were performed at Visit 0, 3, and 5 (or at early termination). Urine pregnancy tests (UPT) were done at each clinic visit. Blood samples for complete blood count (CBC) and chemistry (glucose, SGOT, SGPT, creatinine, total bilirubin, GGT, potassium, sodium, BUN, cholesterol, HDL, LDL, triglycerides, albumin, calcium) were obtained at Visit 0 and 5 (or early discontinuation). Pap smears and tests for chlamydia and gonorrhea were performed at the site in accordance with local standards. Safety assessments were done at each clinic visit and all AEs and concomitant medications were recorded on CRFs.

All subjects were to complete a paper diary and record days the CVS was in and out of the vagina, the number of hours the CVS was out if > 2 hours, days when bleeding or spotting occurred, whether vaginal intercourse occurred during each 2-week interval, dates of condom or other contraception use, any complete or partial expulsions, any CVS problems or medical problems, and any concomitant medication. Bleeding and spotting were defined per Mishell<sup>9</sup>. Subjects were to choose between no bleeding, spotting, normal bleeding, or heavy bleeding in their diary. Diary entries were used to determine treatment compliance.

Post-treatment follow-up for women no longer using hormonal contraception documented the timing of the first spontaneous menstrual cycle; for women wishing to become pregnant, follow

---

<sup>9</sup> Mishell, DR, Jr. et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. *Contraception* 2007; 75(1):11-5.

up continued until pregnancy or six months had elapsed, whichever occurred first.

### Study Endpoints

The primary efficacy analysis was based on the PI in women 18-35 years of age at time of entry into study. Included cycles were those in which the subjects used the CVS for at least 1 day as the only method of contraception. Cycles excluded from the PI were those in which a subject became pregnant, cycles in which adjunctive (back-up) contraception was used, and cycles beyond one year from the date of first CVS insertion.

The endpoint was “on treatment” pregnancy defined as the estimated date of conception within seven (7) days of last CVS use. The estimated date of conception was derived from the gestational age and the date gestational age was determined, the estimated date of delivery, and the date of last menses. The estimated date of conception was compared with the last CVS use to determine if pregnancy conception occurred within seven days of CVS use.

***Comment:** The endpoint of pregnancy conception within seven days of CVS use was requested by the Division, and is consistent with the NuvaRing efficacy endpoint. In COC trials, “on treatment” pregnancy has been defined as any pregnancy occurring within 14 days after the last dose of the study drug, which may include placebo pills. Therefore, the number of days without hormones in defining “on treatment” pregnancy varies depending on the combined hormonal contraceptive being evaluated. In this submission, the above endpoint allows for exclusion of pregnancies that would have been included in other contraceptive studies (i.e. pregnancies that occur between day 8-14). The Division requested the applicant to calculate PI for pregnancies through day 14 as a sensitivity analysis.*

*The Division also requested removal of cycles when heterosexual intercourse did not occur from the “at-risk” cycles when calculating the PI, as this information was collected on the subject diary cards. However, at the Late Cycle Meeting the applicant noted that data on occurrence of intercourse was not reliable, i.e. this data was not confirmed at clinic visits. Further, the applicant stated that two pregnancies occurred during cycles where the diary noted no intercourse had occurred. In addition, the SAP for this Phase 3 study specified that only cycles during which backup contraception was used would be excluded from the primary efficacy analysis. Exclusion of cycles during which no intercourse occurred was not prespecified for calculation of the primary efficacy endpoint. Therefore, the Division determined that the primary efficacy endpoint presented in labeling would be the PI, calculated by excluding only cycles during which backup contraception was used, consistent with the prespecified SAP and considering the unreliable intercourse diary data.*

Supportive efficacy variables were life table analyses using all cycles for all women and for subjects 35 years or younger, and PIs (with 95% CI) of all users with and without adjunctive contraception.

Secondary endpoints were cycle control characteristics and vaginal bleeding patterns. For data to be included in these analyses, 15 days of bleeding entries during weeks 1-3 and at least three days of bleeding entries during week 4 were required.

Cycle control summarized the number of unscheduled and scheduled bleeding or spotting days and number of all bleeding and spotting days. Week 4 was classified as scheduled bleeding even if the subject used the CVS during that week. Scheduled bleeding was bleeding during ring free intervals and the first 4 days of CVS use each cycle.

Vaginal bleeding information was derived from subject diary entries describing bleeding as none, spotting, normal or heavy bleeding. Spotting did not require protection and bleeding required a tampon or pad. The normal and heavy bleeding categories were combined for the bleeding variable.

Safety analysis included assessment of SAEs, AEs, use of concomitant medications, clinical laboratory and urinalysis evaluations, physical and gynecological examinations, and vital signs.

### **Statistical Analysis Plan**

The primary endpoint was the Pearl Index for women  $\leq 35$  years of age (at enrollment) derived from all cycles from which no back-up contraception was used. The statistical methodologies and rationale for this endpoint were described above in the Study Endpoints section.

The applicant followed the Agency's recommendations for a phase 3 trial of a new contraceptive containing a new molecular entity, which stipulate that participants be exposed to the drug for approximately 20,000 cycles, with at least 400 women completing one year of use.

Considering the premature drop-outs during the study, about 1200 subjects were planned for enrollment in Study 300A. Another 1200 subjects were planned for enrollment in Study 300B.

The following subject populations were used for analysis of the study:

- Enrolled: all subjects who were enrolled into the study.
- Evaluable for Safety: all enrolled subjects that inserted the ring.
- Evaluable for Efficacy: all subjects Evaluable for Safety who used study drug for at least one day, provided diary card data, and were not pregnant at the start of Cycle 1. If no diary data was available, then the enrolled subject needed to have the date of last ring use recorded in their CRFs, along with the other criteria to be included this population.

Eight subjects were enrolled who were not included in the Evaluable for Efficacy population, because they fell into the following categories:

- Enrollment with overlapping dates at 2 study sites (five subjects)
- Second enrollment in the same study with non-overlapping dates (three subjects)

For the first category, the applicant excluded all data from these five subjects from the Evaluable for Efficacy population, with the possible exception of any pregnancies that may have occurred. For the second category, the applicant excluded all data from these three subjects' second study enrollment from the Evaluable for Efficacy population, while data from these three subjects' first study enrollment were included.

### **Protocol Amendments**

The applicant submitted Amendment 1.1 on October 4, 2007, with the following protocol changes:

- Exclusion criteria:
  - Change in exclusion of subjects with weight >95 kg or >209 pounds to exclusion of subjects with BMI >29 kg/m<sup>2</sup>, based on the study's DSMB recommendations after review of VTEs. See Section 10.5.1 (Analysis of VTEs) for detailed discussion.
  - Diastolic BP >85 mmHg and/or systolic BP >135 mmHg after 5-10 minute rest
- Analysis of Efficacy: the applicant added the Safety and Efficacy Review committee (SERC) to meet quarterly to review efficacy data
- Bleeding Pattern: further defined that menstrual diaries will be examined to determine the number of days of scheduled bleeding (bleeding/spotting when the ring is out according to the prescribed ring schedule) and unscheduled bleeding (any other bleeding)

The applicant submitted Amendment 2 on December 3, 2007, with the following protocol changes:

- Amended the 1-year duration of CVS use to less than 1 year if subject enrolled in the study after January 2008
- Specified that all subjects must be discontinued from the trial by December 31, 2008 because the batches of rings were expiring, and modified visits depending on subject date of study entry
- Changed exclusion criterion for abnormal Pap smear as follows: subjects with CIN 1 lesions that did not require treatment were allowed to participate in the study
- Further defined primary objective for CVS "when used for up to 13 consecutive cycles", and secondary objective to define cycle control/bleeding patterns of a 21-day continuous use regimen followed by 1 week off per cycle

### **8.1.2. Study Results**

#### **Compliance with Good Clinical Practices**

The study report states that Study 300A was conducted according to the guidelines of Good Clinical Practices (GCP) and the International Conference on Harmonization (ICH) in compliance with the regulations of the Declaration of Helsinki regarding the ethical use of human subjects in clinical trials. Institutional Review Boards (IRB) for each study site reviewed and approved the study protocol and subsequent amendments. In addition, an autonomous DSMB was

established and conducted regular reviews of pregnancies and safety data. Population Council SERC convened quarterly to review data in relation to study objectives.

### Data Quality and Integrity

Each site underwent a study initiation visit to review study conduct and procedures. During the study, regular monitoring visits were made to each site to assess compliance. Data management review was conducted on Case Report Form (CRF) data and queries were sent to the sites to address any discrepancies or missing data.

During review of this study, issues that were of concern for data quality and integrity included:

- Subject exclusion
  - 5 subjects were excluded from the efficacy analysis because of concomitant enrollment at two sites. The applicant stated that by excluding these subjects no pregnancies were excluded. However, at the time of adjudication of pregnancies, one of the subjects did have an on-treatment pregnancy.
  - 3 additional subjects enrolled at two sites sequentially, and only the data from the first site was included in the safety analysis. The data from the second site was excluded.
  - All eight of the above subjects were enrolled at the same two sites.
- Inconsistent data
  - There were instances in which subject-entered diary data did not agree with clinic-entered data on the CRF. Examples of these inconsistencies included information regarding last menstrual period (LMP) and date of last CVS use. In these instances, the applicant provided additional information (i.e. phone call records) to corroborate the clinic-entered data.

**Comment:** After review of the data, it was determined that the clinic-entered data, as opposed to the diary data, was of sufficient quality for review, and the noted inconsistencies did not affect the adequacy of the overall dataset to complete the clinical review.

### Patient Disposition

There were 1,806 subjects screened of which 1,135 were randomized (62.8%). The Efficacy and Safety populations included 1,129 unique subjects. Six (6) subjects were excluded from both analyses: five of these were concurrently enrolled at two sites and one subject never inserted the CVS. Subject disposition information is shown in Table 8.

**Table 8. Disposition of Study 300A Subjects**

	<b>Study 300A</b>
--	-------------------

<b>Disposition</b>	<b>(N=1129) n (%)</b>
Completed the Study	582 (51.6)
Discontinued Study	547 (48.4)
Reason for Discontinuation	
Lost to follow-up	138 (12.2)
Adverse Event	130 (11.5)
Withdrew consent	129 (11.4)
Eligibility BMI>29 kg/m <sup>2</sup>	88 (7.8)
Compliance	26 (2.3)
Pregnancy	24 (2.1)
Expulsions	9 (0.8)
Eligibility other	2 (0.2)
Other	1 (0.1)

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, p 67/1147

Two hundred and twelve subjects (212) or 18.8% of the population enrolled in the 6-month follow-up for return to fertility data.

The overall subject discontinuation rate was 48% which is comparable with discontinuation rates in other Phase 3 trials for similar products (i.e. 41% and 40% discontinuation rates in the NuvaRing and Quartette trials, respectively). In this US study, approximately 12% of subjects were lost to follow up. Discontinuations due to AEs and withdrawal of consent occurred in approximately 11% of subjects each. Withdrawal of consent included subjects who were no longer sexually active, reported personal problems, relocated, were planning pregnancy, as well as four subjects with reasons suggestive of AEs: two with medical problems, one with mood change, and one with pelvic problems. These proportions are comparable to other contraceptive trials in North America where AEs accounted for 11-13% of discontinuations, withdrawal of consent accounted for 6-9%, and loss-to-follow up accounted for 13-14%. Overall, the disposition of subjects in 300A is within the expected range for contraceptive trials.

### **Protocol Violations/Deviations**

There were 56 eligibility criteria violations. Of these, 33 violations encompassed abnormal serum chemistry values, 10 violations were due to subjects' not having a history of regular menses, and 9 violations were due to abnormal Pap smears suggestive of HGSIL.

There were 3,004 other deviations: 1,203 related to visits outside of the protocol time window, 358 where CVS was not returned, 354 due to noncompliance with CVS, and 264 where visits were not completed.

In addition, there were 86 exclusion criteria violations noted by study monitors, involving deviation in laboratory tests or blood pressure, errors in signatures and dates on screening visit

test results. All subjects signed an informed consent form (ICF) but there were 72 cases where subjects were not re-consented to protocol amendments and 29 violations where subjects did not initial all pages of ICF.

A total of 1,143 CVS were distributed to the 15 sites. Eighty percent (80%) or 908 of the CVSs were returned.

**Comments:** *The majority of protocol violations/deviations involved visits outside the protocol time window with only a small number of visits not completed. Thus, the protocol violations and deviations are unlikely to have significantly altered our overall conclusion regarding the product's efficacy.*

### Demographic Characteristics

The Safety and Efficacy populations are the same. The applicant's table of summary demographics and baseline characteristics is shown below.

**Table 9. Demographics 300A**

<b>Characteristic</b>	<b>Study 300A (N=1129) n (%)</b>
<b>Race (Multiple Races Allowed per Subject)</b>	
Asian	67 (5.9)
Black or African American	261 (23.1)
American Indian or Native Alaskan	12 (1.1)
Native Hawaiian or Pacific Islander	10 (0.9)
White	748 (66.3)
Other/Unknown	76 (6.7)
<b>Ethnicity</b>	
Hispanic or Latina	148 (13.1)
Not Hispanic or Latina	981 (86.9)
<b>Marital Status</b>	
Never married	808 (71.6)
Married	232 (20.5)
Divorced	62 (5.5)
Separated	26 (2.3)
Widowed	1 (0.1)
<b>Age (y)</b>	
18 – 19	56 (5.0)
20 – 24	436 (38.6)
25 – 29	376 (33.3)
30 – 35	186 (16.5)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

<b>Characteristic</b>	<b>Study 300A (N=1129) n (%)</b>
36 +	75 (6.6)
<b>Education: Highest Level Attained</b>	
College degree or higher	537 (47.6)
Some college	452 (40.0)
High school diploma/equivalent	115 (10.2)
Less than high school	25 (2.2)
<b>Subject Desires to Have Children After the Study</b>	
Yes	596 (52.8)
No	302 (26.7)
Unsure	231 (20.5)
<b>Body Mass Index (kg/m<sup>2</sup>)</b>	
value < 20	131 (11.6)
20 ≤ value < 25	588 (52.1)
25 ≤ value < 27	162 (14.3)
27 ≤ value ≤ 29	128 (11.3)
29 > value	120 (10.6)
<b>Smoking</b>	
Never smoked	764 (67.7)
Former smoker	209 (18.5)
Current smoker	155 (13.7)
Unknown	1 (0.1)
<b>Alcohol Use History</b>	
Never drank	190 (16.8)
Former drinker	87 (7.7)
Current drinker	852 (75.5)

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 5 p 72/1147

The mean age was 26.6 ± 5.0 years and the mean BMI was 24.1 ± 3.9 kg/m<sup>2</sup>.

Menstrual characteristics showed 67.6% of subjects had moderate menstrual flow and 98.3% of subjects had menstrual flow ≤ 7 days. Over 50% of subjects reported mood changes, cramps, and bloating associated with menstruation.

The majority of subjects used condoms or hormonal contraception in the 6 months prior to enrollment into the study. The breakdown of contraceptive use is shown in the table below.

**Table 10. Contraceptive Use Within 6 Months of Enrollment (Study 300A)**

Type of contraceptive	Study 300A (N=1129) n (%)
Condoms	520 (46.1)
Withdrawal	117 (10.4)
Hormonal contraceptives	515 (45.6)
Vaginal rings	265 (23.3)
COC	225 (19.9)
Transdermal patch	22 (1.9)

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, p 380/1147

Twenty-three percent (23%) of subjects used hormonal contraception within 30 days prior to CVS: 210 (18.5%) of subjects used the vaginal ring and 61 (5.4%) used other CHCs.

***Comment:** Almost a quarter of the subjects could be considered continuous contraceptive users (within 4 weeks of enrollment) and over 45% were prior users. Overall, 64.6% of enrolled subjects had used non-hormonal contraceptives within 6 months of enrollment which is expected in U.S. populations recruited for contraceptive trials.*

Table 11 lists selected active medical history in the study population by preferred term.

**Table 11. Selected Active Medical History of Subjects (Study 300A)**

Preferred Term	Study 300A (N=1129) n (%)
Headache	311 (27.5)
Drug Hypersensitivity	154 (13.6)
Acne	152 (13.5)
Dysmenorrhea	145 (12.8)
Premenstrual Syndrome	101 (8.9)
Depression	72 (6.4)
Migraine	61 (5.4)
UTI	43 (3.8)

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.1.7 p360/1147

**Concomitant Medications and Treatment Compliance**

1,035 (91.7%) of subjects used concomitant medication. A table of the most common concomitant medication (excluding cough, cold, and nasal preparations and vitamin/mineral supplementation) is shown below.

**Table 12. Concomitant Medication Use in Subjects (Study 300A)**

Level 2 Therapeutic Class	Study 300A (N=1129) n (%)
Anti-inflammatory (including NSAIDs*)	723 (64.0)
Analgesics (majority acetaminophen)	679 (60.1)
Antihistamines for systemic use	389 (34.5)
Antibacterial for system use	337 (29.8)
Psychoanaleptics (including SSRIs**)	138 (12.2)
Antidiarrheal	134 (11.9)
Antimycotic for systemic use***	105 (9.3)

\*nonsteroidal anti-inflammatory drugs

\*\*selective serotonin reuptake inhibitor

\*\*\* includes 104 fluconazole users but does not include gynecological anti-infective and antiseptics (miconazole, terconazole, clotrimazole = 68 subjects).

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.1.9.3 p 389/1147

**Comment:** *A reasonable assumption is that fluconazole was used for vaginal candidiasis in this study population (as opposed to oropharyngeal/esophageal candidiasis and cryptococcal meningitis). Therefore, vaginal antimycotic use can be estimated by use of fluconazole and gynecological antimycotics, i.e. 172 subjects or 15.2% of the study population. Vaginal candidiasis is common in females of reproductive age, and although it is uncomfortable, it is rarely a serious adverse event. The applicant’s microbiology substudy also did not raise concern for elevated risk of vaginal infections with this product. Vaginal infections, including candidiasis, will be labeled among adverse events observed in the CVS clinical trials.*

Compliance was determined by the subjects’ diary cards. Only subjects who provided diary cards that confirmed insertion of CVS on day 1 for the given cycle were included in the compliance data. A subject was considered in compliance if the CVS was inserted on day 1 and had continuous use for the first 21 days of the cycle, with no more than 2 hours’ interruption per day, followed by 7 days of nonuse. Using this definition, perfect compliance for subjects was >81%.

### **Efficacy Results – Primary Endpoint**

Efficacy was based on the PI using “on-treatment” pregnancies. On-treatment pregnancies were defined as those pregnancies for which conception occurred on or after the date of the first insertion of CVS and extended through seven days following removal of CVS. The PI was derived from women ages 18-35 years at time of entry. All 28-day cycles where additional back-up methods of birth control occurred were excluded.

The applicant identified 17 on-treatment pregnancies. Upon detailed review, two additional pregnancies were adjudicated as on-treatment for a total of 19 on-treatment pregnancies for Study 300A. The details of the two additional on-treatment pregnancies are as follows:

**Subject** (b) (6) enrolled in April 2008 at age 22 years. At her (b) (6) clinic visit a UPT was performed due to late withdrawal bleed. The UPT was negative but due to the subject's symptoms, a  $\beta$ hCG was obtained and reported as 70 mIU/mL. On (b) (6) the subject removed the CVS and a repeat  $\beta$ hCG was reported as 20 mIU/mL. An ultrasound on (b) (6) showed no evidence of pregnancy. The narrative states the subject subsequently had return to menses but the date is not given. The applicant justified excluding this pregnancy from the efficacy population stating it was a non-pregnancy and due to heterophilic antibodies, i.e. a false  $\beta$ hCG test result.

***Comment:** The narrative is most consistent with an early missed abortion/blighted ovum; thus, should be counted as an on-treatment pregnancy, despite the outcome of early pregnancy failure.*

**Subject** (b) (6) enrolled on (b) (6) at age 20 years. She removed her CVS for 13 days, from (b) (6) through (b) (6), and then reinserted the CVS. On (b) (6), her  $\beta$ hCG level was 388 mIU/mL. An ultrasound performed on (b) (6) determined the gestational age (GA) of the pregnancy to be 5 weeks and 5 days, with an estimated date of conception of (b) (6). The applicant dated this pregnancy as occurring 8-14 days after CVS use because the subject did not use the CVS correctly.

***Comment:** We include compliant and non-compliant patients in the PI calculation as this more accurately reflects real-world use of contraceptives. Because the subject reinserted her CVS, this pregnancy is considered on-treatment.*

In addition, there were two subjects ((b) (6) and (b) (6)) that were considered to have on-treatment pregnancies based on diary entries, and one subject ((b) (6)) considered to have an on-treatment pregnancy based on a dating ultrasound. In response to an information request (IR) sent on December 19, 2017, the applicant forwarded clinical notes stating that the two subjects ((b) (6) and (b) (6)) had incorrectly entered dates of CVS use in their diaries, and the dating ultrasound report confirming date of conception occurred 8-14 days after last CVS use in subject (b) (6).

One additional subject, (b) (6), was excluded from the efficacy analysis. This 29-year-old subject's last clinic visit was in (b) (6). She did not complete any diary cards. In (b) (6), she contacted the site via telephone to report she was pregnant but did not return for confirmation. She was lost to follow up after that call. In (b) (6), the CVS and some diary cards were delivered to the clinic. Because the diary entries were never reviewed with the subject and the pregnancy was unconfirmed, this subject was not included in the efficacy analysis.

**Comment:** We agree with excluding this subject from the efficacy analysis since her pregnancy was never confirmed.

**Table 13. Adjudicated Pregnancies (300A)**

Subject	Start drug	Last CVS use	LMP	Pregnancy confirm	Estimated date of Conception	Applicant	Medical Officer Determination	
(b) (6)	(b) (6)	per crf (b) (6)	(b) (6)	narrative: neg UPT	(b) (6)	false serum hcg and excluded	On Chemical pregnancies count in contraceptive trials	
		per diary (b) (6)		(b) (6) βhCG 70 (b) (6) BHCG 20.				
		(b) (6)		date of GA confirmation (b) (6) (NOT (b) (6)) with US dating 23 wks.		8-14 days after CVS use		8-14 days after CVS use
		(b) (6)		(b) (6) βhCG 3917. US (b) (6) GA 6w6d		8-14 days after CVS use		8-14 days after CVS use (discount diary)
(b) (6)	(b) (6)	per diary: (b) (6)	(b) (6)	βhCG 579 US (b) (6) 4w6d	15+ days after CVS use	15+ days after CVS use (discount diary)		

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

		(b) (6)	(b) (6)	(b) (6)	(b) (6)	8-14 days after CVS use	On Incorrect use doesn't exclude pregnancy
		per diary: (b) (6)	per crf: (b) (6)	BhCG 388 US (b) (6) 5w5d			
			per diary: spotting (b) (6)				

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, p 205/1147, Response to IR Submitted 1/16/2018

For the analysis of PI in studies 300A, 300B and the integrated analysis of effectiveness, the FDA clinical team and the statistical team agreed to follow the statistical methodology specified in the statistical analysis plan of both studies 300A and 300B. The Pearl Index was based on the evaluable for efficacy population and cycles in which no adjunctive contraceptives were used. If a subject had more than 13 cycles during the study, her first 13 cycles were counted towards the evaluable cycles. The applicant submitted data file EFF.XPT, under sequence # 007, on December 5, 2017 was the source data for the FDA statistical reviewer's analyses.

**Table 14. Study 300 A: Pearl Index for subjects ≤ 35 years old using pregnancies from evaluable cycles within 7 days from CVS removal**

Efficacy Population				
Study	N	Number of Pregnancies	Number of evaluable cycles	PI using evaluable cycles (95% CI)
300A	1055	19	7970	3.10 (1.87, 4.84)

Source: Reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.  
 Note: 1. Include pregnancy from subject 11086. 2. Cycles beyond cycles 13 were not included in the calculation.  
 3. 95% CI was based on the Poisson distribution.

**Comments:** The PI and 95% CI for the CVS in this study are consistent with those of two recently approved CHCs: Quartette [approved in 2013 with PI 3.19 (2.49, 4.03)] and Lo Loestrin Fe [approved in 2010 with PI 2.92 (1.94, 4.21)]. All the studies calculated the PI similarly, with a 7-day on treatment pregnancy window and removing cycles where back up contraception was used.

The Division also requested analyses of the PI and 95% CI for pregnancies that occurred within 14 days after last CVS use. The applicant initially assigned four pregnancies conceived 8-14 days after CVS use. One of these (Subject (b) (6)) was recategorized to on-treatment. The Division agreed that the other three pregnancies occurred 8-14 days post CVS use.

**Table 15. Study 300 A: Pearl Index for subjects ≤ 35 years old using pregnancies from evaluable cycles within 14 days from CVS removal**

Efficacy Population				
Study	N	Number of Pregnancies	Number of evaluable cycles	PI using evaluable cycles (95% CI)
300A	1055	22	7970	3.59 (2.25, 5.43)

Source: Reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.  
 Note: 1. Include pregnancy from subject (b) (6) 2. Cycles beyond cycles 13 were not included in the calculation.  
 3. 95% CI was based on the Poisson distribution.

**Comment:** *The PI increases further when on-treatment pregnancy is defined as up to 14 days after CVS use. This demonstrates the need for prompt reinsertion of the CVS seven days after removal.*

### Efficacy Results – Supportive endpoints

Life table analyses of cumulative pregnancy rates were a supportive endpoint to CVS efficacy. The applicant's cumulative pregnancy rates for subjects ≤ 35 years old with pregnancies within seven days of last CVS use utilizing all cycles<sup>10</sup> are very similar to the cumulative pregnancy rate calculated by the FDA, as shown in Table 16 below.

**Table 16. Study 300A: Kaplan-Meier Analysis of Pregnancy Among Subjects ≤ 35 Years Old Using All Cycles**

Cycle	Subjects at Risk	Number of Pregnancies (with 7 days)	Cumulative Probability of Pregnancy (95% CI)
0	1055	2	0
1	1055	2	0.0019 (0.0005, 0.0076)
2	977	4	0.0060 (0.0027, 0.0133)
3	927	3	0.0092 (0.0048, 0.0176)
4	864	2	0.0115 (0.0064, 0.0207)
5	824	0	0.0115 (0.0064, 0.0207)
6	775	2	0.0140 (0.0082, 0.0241)
7	705	0	0.0140 (0.0082, 0.0241)
8	664	2	0.0170 (0.0102, 0.0282)
9	596	1	0.0187 (0.0114, 0.0305)
10	532	1	0.0205 (0.0127, 0.0331)
11	476	0	0.0205 (0.0127, 0.0331)
12	428	2	0.0251 (0.0157, 0.0399)
13	398	0	0.0251 (0.0157, 0.0399)

Source: Reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.  
 Note: 1. Include pregnancy from subject (b) (6) 2. Cycles beyond cycles 13 were not included in the calculation.

<sup>10</sup> NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.2.2.1, p 425/1147

**Comment:** The cumulative pregnancy rate of 2.5% (95% CI: 1.57, 3.99%) at one year is comparable to the PI of 3.10 (95% CI: 1.87, 4.84).

**Efficacy Results - Secondary endpoints**

Cycle control:

Overall, greater than 95% of subjects had some bleeding or spotting each cycle. The mean number of days was 5.0 and did not decrease with subsequent cycles. Between 2.5 and 4.4% of subjects had amenorrhea for any given cycle with an overall amenorrhea rate of 0.7%. Scheduled and unscheduled bleeding and spotting is presented in the table below.

**Table 17. Scheduled and Unscheduled Bleeding and Spotting (Study 300A)**

Cycle	N	none	% with no bleeding/spotting	Mean	SD	Min	Median	Max
1	988	43	4.4	6.2	3.62	0	5.0	24
2	901	29	3.2	5.3	2.85	0	5.0	24
3	783	23	2.9	5.3	2.61	0	5.0	28
4	752	21	2.8	5.2	2.77	0	5.0	31
5	755	23	3.0	5.2	2.42	0	5.0	28
6	649	16	2.5	5.2	2.45	0	5.0	27
7	633	20	3.2	5.4	2.78	0	5.0	25
8	620	23	3.7	5.3	2.64	0	5.0	25
9	529	16	3.0	5.4	2.67	0	5.0	25
10	476	13	2.7	5.5	2.71	0	5.0	23
11	439	13	3.0	5.6	2.92	0	5.0	24
12	397	11	2.8	5.7	3.24	0	5.0	26
13	340	13	3.8	5.3	2.87	0	5.0	19
Overall	1010	7	0.7	5.5	2.01	0	5.2	21

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.2.3.1 page 431/1147

The number of women with scheduled bleeding and/or spotting (withdrawal bleed at appropriate time) was greater than 91% for each cycle with the average of five days of bleeding and/or spotting. The longest withdrawal bleeding and/or spotting was 11 days and this did not decrease with subsequent cycles.

**Table 18. Scheduled Bleeding and Spotting (Study 300A)**

Cycle	N	n none	% no scheduled bleeding/spotting	Mean	SD	Min	Median	Max
1	991	61	6.2	4.9	1.96	0	5.0	11
2	907	69	7.6	4.5	1.92	0	5.0	11

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

3	788	54	6.9	4.6	1.90	0	5.0	11
4	761	55	7.2	4.6	1.98	0	5.0	11
5	756	63	8.3	4.4	1.97	0	5.0	11
6	653	46	7.0	4.5	1.88	0	5.0	11
7	637	54	8.5	4.5	1.94	0	5.0	11
8	621	55	8.9	4.4	1.96	0	5.0	11
9	530	42	7.9	4.5	1.95	0	5.0	11
10	477	37	7.8	4.5	2.00	0	5.0	9
11	440	36	8.2	4.5	1.94	0	5.0	10
12	398	31	7.8	4.5	1.94	0	5.0	11
13	341	27	7.9	4.3	1.88	0	4.0	11
Overall	1101	22	2.2	4.5	1.46	0	4.6	8

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.2.3.1 p 429/1147

Approximately 25% of subjects had unscheduled bleeding and/or spotting (day 1-21) for each cycle. The length of unscheduled bleeding and/or spotting averaged 0.8 to 1.3 days each cycle. The unscheduled bleeding and/or spotting did not decrease with subsequent cycles.

**Table 19. Unscheduled Bleeding and Spotting (300A)**

Cycle	N	n none	% no unscheduled bleeding/spotting	Mean	SD	Min	Median	Max
1	995	747	75.1	1.3	2.91	0	0.0	14
2	905	735	81.2	0.8	2.29	0	0.0	17
3	791	640	80.9	0.7	1.94	0	0.0	19
4	761	644	84.6	0.7	2.16	0	0.0	20
5	760	623	82.0	0.7	1.97	0	0.0	17
6	659	521	79.1	0.7	1.91	0	0.0	16
7	638	505	79.2	1.0	2.38	0	0.0	16
8	625	482	77.1	0.9	2.13	0	0.0	17
9	533	415	77.9	0.9	2.20	0	0.0	18
10	481	366	76.1	1.0	2.37	0	0.0	16
11	442	343	77.6	1.1	2.57	0	0.0	17
12	399	302	75.7	1.2	2.76	0	0.0	21
13	366	272	74.3	1.1	2.46	0	0.3	15
Overall	1016	364	35.8	1.0	1.66	0	0.3	14

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.2.3.1 p 430/1147

Most subjects provided data for cycle control with CVS use. Over 91% of subjects had an appropriately timed withdrawal bleed with the average duration of five days. Eighty-seven (87%) to 93% of subjects had no unscheduled bleeding any given cycle. Seventy-four (74%) to

85% of subjects had no unscheduled bleeding and/or spotting any given cycle; conversely 15% to 26% of subjects had unscheduled bleeding and/or spotting in any given cycle. When unscheduled bleeding and/or spotting occurred, the average length was one day. The maximum length of time for all bleeding and/or spotting (scheduled and unscheduled) ranged from 19-31 days/cycle. The number of days of bleeding or spotting did not decrease with subsequent cycles. The unscheduled bleeding incidence for this CVS (15-26%) is higher than the incidence of unscheduled bleeding and/or spotting for other products (i.e. 7-12% for NuvaRing and 6-18% for Ortho Evra). Compared to COCs, this CVS's unscheduled bleeding and/or spotting incidence is somewhat higher than that of a low dose COC (e.g. 6-12% for Yasmin), but not as high as that of Lo Loestrin FE (36-86%), which contains 10 µg of EE.

This CVS has a similar amenorrhea incidence as other non-oral CHCs (0.3-3.8%). Approximately 3% of subjects experienced amenorrhea for any given cycle with an overall amenorrhea rate of 0.7%.

*Comment: The bleeding profile from subject diaries will be noted in the label.*

## **8.2. Study 300B: A Multicenter, open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 mcg of Nesterone®\* and 15 mcg of ethinyl estradiol (\*segesterone acetate)**

### **8.2.1. Study Design**

Study 300B was conducted in eight countries including the US. The objectives, study design, and study endpoints of Study 300B were the same as Study 300A, except there were no routine laboratory tests at 6 months.

There was one additional procedure in 300B that was not included in 300A—an acceptability questionnaire. This questionnaire assessed the following CVS features:

- Ease of use
- Effects on sexual activity, including subjects' partners' perceptions of its impact on their sexual activity
- Satisfaction with the CVS, aspects of the CVS that subjects like or did not like, comparison with other contraceptive methods, and perception regarding using CVS for delivery of other therapies.

The acceptability questionnaire information was obtained by an interview administered by study site personnel or via audio computer assisted self-interviewing method (ACASI) during Cycle 3 (V2) and Cycle 13 or early termination (V5). Responses to the questionnaire were summarized using descriptive statistics.

There were no sub-studies in 300B. There was an extension study to 300B, called 300EX which allowed subjects to continue using the CVS after one year (a new CVS was dispensed) but this study was discontinued after 12 subjects had enrolled because the additional exposure after one year could not be used to meet the 20,000 cycles of exposure required for approval.

### **Statistical Analysis Plan**

The primary endpoint was the Pearl Index for women  $\leq 35$  years of age (at enrollment) derived from all cycles in which no back-up contraception was used. Detailed statistical methodologies for this endpoint are described in the Study Endpoints section.

The applicant followed FDA recommendations for a phase 3 trial of a new contraceptive containing a new chemical entity, stipulating that participants be exposed to the drug for approximately 20,000 cycles with at least 400 women completing one year of use. Considering the premature drop-outs during the study, about 1000 subjects were planned for study 300 B.

The following subject populations were used in the study:

- Enrolled: all subjects who were enrolled into the study.
- Evaluable for Safety: all enrolled subjects who inserted the ring.
- Evaluable for Efficacy: all subjects Evaluable for Safety who used the study drug for at least one day, provided diary card data, and were not pregnant at the start of Cycle 1. If no diary data was available, then the enrolled subject needed to have the date of last ring use recorded in their CRFs along with the other criteria to be included this population.

### **Protocol Amendments:**

The applicant submitted Amendment 7 on July 29, 2007 with the following protocol changes:

- Exclusion criteria for weight changed from  $>95$  kg to  $\text{BMI} \geq 35$   $\text{kg/m}^2$ , with exclusion of subjects with  $\text{BMI} >29$   $\text{kg/m}^2$  who were  $<35$  years old and had a risk factor for VTE.
- Two US study sites were added
- Changed requirement for two subsequent menses postpartum to one for post-abortal subjects and none for postpartum subjects.
- Changed upper limit of BP to  $>135/>85$  from  $\geq 135/\geq 85$ .
- Added randomization scheme to assign subjects to different methods of completing the acceptability interview.

The applicant submitted Amendment 8 on September 25, 2007, with the following protocol changes:

- Exclusion criteria weight changed to  $\text{BMI} >29$   $\text{kg/m}^2$  per the study DSMB recommendation due to review of VTEs. See section 10.5.1, Analysis of VTE, for detailed discussion.

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

- Postpartum women must have history of regular menses and have resumed at least 1 cycle postpartum with cycle length consistent with past cycles

The applicant submitted Amendment 9 on November 28, 2007, with the following protocol changes:

- Amended 1 year duration use to less than 1 year if enrolled after January 2008. Specified all subjects must discontinue from trial December 31, 2008 because batches of CVS were expiring and modified ICF for shorted treatment period.
- Physical and gynecological exams at visit 3 removed for subjects who started CVS in 2007 only.

The applicant submitted Amendment 9EX on November 28, 2007, with the following protocol changes:

- Added extension phase to Study 300B allowing subjects to enroll for up to 1 year of additional CVS use.

The applicant advised the Division of discontinuation of enrollment into EX study on February 7, 2008:

- Extension study terminated because the applicant could not use cycle exposure data for FDA efficacy data.

### **8.2.2. Study Results**

#### **Compliance with Good Clinical Practices**

The study report states that Study 300B was conducted according to guidelines of Good Clinical Practices (GCP) and the International Conference on Harmonization (ICH) in compliance with the regulations of the Declaration of Helsinki regarding the ethical use of human subjects in clinical trials. Institutional Review Boards (IRB) for each study site reviewed and approved the study protocol and subsequent amendments. In addition, an autonomous DSMB was established and conducted regular reviews of pregnancies and safety data. Population Council's SERC convened quarterly to review data in relation to study objectives.

#### **Data Quality and Integrity**

Each site underwent a study initiation visit to review study conduct and procedures. During the study, regular monitoring visits were made to each site to assess compliance. Data management review was conducted on CRF data and queries were sent to the sites to address any discrepancies or missing data.

During review of this study, the major concern regarding data quality and integrity was inconsistency in data between the patient diaries and CRFs. This included:

- Reconciliation of the inconsistencies occurred years after data were originally entered; therefore, any clarification of inconsistencies was not possible at this later date
- Many of the inconsistencies occurred at one site (Site 3, Santo Domingo, DR). Because this site had a large number of pregnancies, an analysis of PI with exclusion of the site was performed. By excluding site 3, the overall PI for study 300B was lower. Therefore, the site was not excluded for any of the PI calculations in this review. In addition, OSI selected this clinical site for inspection, and after their review classified the site as no deviation from regulation (NAI).

During review of study forms, there were instances of inconsistent documentation of subject information in the appropriate documents. An example of this was subject (b) (6), whose pregnancy was documented as a spontaneous abortion in the narratives for pregnancies occurring >7 days post CVS use AND as an ectopic pregnancy during CVS use in the narratives for SAEs.

**Comments:** *The lack of cross referencing data in real time and obtaining clarifying documentation decreased the quality of some information available in this study report. In addition, the inability to obtain information during the review process because the studies were conducted 10 years ago decreased the ability to evaluate data quality. However, the OSI inspection provided support that overall, the data quality and integrity for this study were sufficiently acceptable to support the indication. We then worked with the applicant to clarify issues that arose when the subject diaries and records were discordant.*

### Patient Disposition

There were 1,537 subjects screened of which 1,135 were randomized (73.8%). The efficacy and safety populations included 1,135 subjects.

**Table 20. Disposition of Study 300B Subjects**

Disposition	Study 300B (N=1135) n (%)
Completed the Study	721 (63.5)
Discontinued Study	414 (36.5)
Reason for Discontinuation	
Lost to follow-up	76 (6.7)
Adverse Event	146 (12.9)
Withdrew consent	64 (5.6)
Eligibility BMI>29 kg/m <sup>2</sup>	50 (4.4)
Compliance	19 (1.7)

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Pregnancy	29 (2.6)
Expulsions	24 (2.1)
Eligibility other	6 (0.5)
Other	0

Source: NDA 209627, Module 5.3.5.2, 300B Study Report, Figure 1 p 62/626

One hundred and fifty-eight subjects (158) or 13.9% enrolled in the 6-month follow up for return to fertility data.

The overall discontinuation rate for this global trial was 37%, which is lower than the US-only population trial (48%). This finding has been noted in other contraceptive trials such as NuvaRing with a 41% discontinuation rate in the US trial compared with a 30% discontinuation rate in the European trials. AEs accounted for 13% of discontinuations, with loss-to-follow up and withdrew consent accounting for 7% and 5% of the subjects. The majority of withdrew consent was due to other personal problems (24 subjects) and relocation (21 subjects). This is comparable to the Ortho Evra US/European trial with discontinuations occurring in 13%, 7%, and 5% of subjects for AEs, withdraw consent, and lost to follow up respectively.

#### Protocol Violations/Deviations

There were 40 eligibility criteria violations. Of these, 32 involved exclusions criteria violations: 12 abnormal serum chemistry, 8 abnormal blood pressure, 5 abnormal Pap smear, 4 smoking and  $\geq 35$  years old. There were six inclusion criteria deviations for healthy women aged 18 to 40 years of age at enrollment who wished to use CHC.

There were 548 deviations during the study recorded in a separate database by study monitors. The applicant does not provide totals for categories of deviations, i.e. visits out of time window, CVS not returned, deviations in laboratory tests, blood pressure, etc. Instead the largest number of deviations (20) noted by the applicant occurred for incorrectly measured height at site 9.

There were 1,135 CVSs distributed to 12 sites. Eighty-eight percent (88.5%) or 1,004 CVSs were returned.

**Comment:** *The number of eligibility criteria violations is surprising since all results were to be reviewed prior to enrollment of subjects and all the eligibility criteria were clearly delineated in the inclusion criteria. The finding that there were incorrect height measurements by study staff leads to concerns for possible inaccurate BMI data. Overall, based on detailed review, we conclude that the protocol violations and deviations did not affect the efficacy outcome of the study to any significant degree and actually may have allowed a more representative population of patients to be enrolled.*

**Demographic Characteristics**

The safety and efficacy populations are the same. The applicant’s table of summary demographics and baseline characteristics is shown in Table 21.

**Table 21. Demographics 300B**

<b>Characteristic</b>	<b>Study 300B (N=1135) n (%)</b>
<b>Race (Multiple Races Allowed per Subject)</b>	
Asian	35 (3.1)
Black or African American	150 (13.2)
American Indian or Native Alaskan	13 (1.1)
Native Hawaiian or Pacific Islander	3 (0.3)
White	985 (86.8)
Other/Unknown	42 (3.7)
<b>Ethnicity</b>	
Hispanic or Latina	502 (44.2)
Not Hispanic or Latina	633 (55.8)
<b>Marital Status</b>	
Never married	776 (68.4)
Married	303 (26.7)
Divorced	33 (2.9)
Separated	22 (1.9)
Widowed	1 (0.1)
<b>Age (years)</b>	
18 – 19	84 (7.4)
20 – 24	405 (35.7)
25 – 29	368 (32.4)
30 – 35	199 (17.5)
36 +	79 (7.0)
<b>Education: Highest Level Attained</b>	
College degree or higher	411 (36.2)
Some college	298 (26.3)
High school diploma/equivalent	304 (26.8)
Less than high school	122 (10.7)
<b>Subject Desires to Have Children After the Study</b>	
Yes	611 (53.8)
No	316 (27.8)
Unsure	208 (18.3)
<b>Body Mass Index (kg/m2)</b>	

Characteristic	Study 300B (N=1135) n (%)
value < 20	117 (10.3)
20 ≤ value < 25	642 (56.6)
25 ≤ value < 27	168 (14.8)
27 ≤ value ≤ 29	128 (11.3)
29 > value	80 (7.0)
<b>Smoking</b>	
Never smoked	825 (72.7)
Former smoker	122 (10.7)
Current smoker	188 (16.6)
Unknown	0
<b>Alcohol Use History</b>	
Never drank	394 (34.7)
Former drinker	19 (1.7)
Current drinker	722 (63.6)

Source: NDA 209627, Module 5.3.5.2, Study Report 300B, p 67/626

The mean age was 26.7 ±5.2 years and the mean BMI was 23.8 ±3.5 kg/m<sup>2</sup>. Most subjects were White, never married, educated, nonsmokers, with desire for future fertility. Five hundred and seventy-five (575) or 50.7% of subjects were nulliparous.

**Comment:** Overall, the subjects in this study have characteristics that are generalizable to the US population that use hormonal contraceptive products.

Menstrual characteristics showed 70.0% of subjects had moderate menstrual flow and 97.1% of subjects had menstrual flow ≤ 7 days. Typical symptoms associated with menstruation in this study population were 64% with cramps, 40% with mood changes, and 31.7% with bloating.

The majority of subjects used condoms or hormonal contraception in the 6 months prior to enrollment into the study. Some subjects used more than one type of contraceptive during this 6 month time period. The breakdown of contraception used is shown in the table below.

**Table 22. Contraceptive Use Within 6 Month of Enrollment (Study 300B)**

Type of contraceptive	Study 300B (N=1135) n (%)
Condoms	384 (33.8)
non-hormonal IUD	26 (2.3)
Withdrawal	36 (3.2)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

hormonal contraceptives	638 (56.2)
vaginal rings	198 (17.4)
COC	410 (36.1)
transdermal patch	11 (1.0)

Source: NDA 209627, Module 5.3.5.2, Study Report 300B, p 265/626

Twenty-three percent (23.6%) of subjects used hormonal contraception for systemic use within 30 days prior to CVS use: 148 (13.0%) of subjects used a vaginal ring and 193 (17.0%) used other CHCs. Almost a quarter of subjects could be considered continuous users of contraception and over 56% were prior users.

The table below lists selected active medical history by preferred term.

**Table 23. Selected Active Medical History of Subjects (Study 300B)**

Preferred Term	Study 300B (N=1135) n (%)
Headache	216 (19.0)
Dysmenorrhea	106 (9.3)
Drug Hypersensitivity	99 (8.7)
UTI	61 (5.4)
Acne	30 (2.6)
Depression	29 (2.5)

Source: NDA 209627, Module 5.3.5.2, Study Report 300B, p 258/626

**Concomitant Medications and Treatment Compliance**

946 (83.3%) subjects used at least one concomitant medication. A table of concomitant medication used in >10% of subjects (not including vitamins) is shown below.

**Table 24. Concomitant Medication Use in Subjects (Study 300B)**

Level 2 Therapeutic Class	Study 300B (N=1135) n (%)
Anti-inflammatory (including NSAIDs*)	512 (45.1)
Analgesics (majority acetaminophen)	498 (43.9)
Antibacterial for system use	303 (26.7)
Antihistamines for systemic use	202 (17.8)
Antimycotic for systemic use***	134 (11.8)

\*does not include gynecological anti-infective and antiseptics (clotrimazole, miconazole, clindamycin, nystatin and combinations = 77 subjects).

Source: NDA 209627, Module 5.3.5.2, Study Report 300B, Table 14.1.9.3 p 272/626

Compliance was determined by the subjects' diary cards. Only subjects who provided diary cards that confirmed insertion of CVS on day 1 for the given cycle were included in the compliance data. A subject was considered in compliance if the CVS was inserted on day 1 and had continuous use for the first 21 days of the cycles with no more than 2 hours interruption per day followed by 7 days of nonuse. The perfect compliance is >83.8% as defined above.

**Efficacy Results – Primary Endpoint**

Efficacy was based on the PI using all “on-treatment” pregnancies. On-treatment pregnancies were defined as those pregnancies for which conception occurred on or after the date of the first insertion of CVS and extended through seven days following removal of the CVS. The PI was derived from the population of women ages 18-35 years at the time of entry with exclusion of cycles where back-up contraception was used.

The applicant identified 22 on-treatment pregnancies. One pregnancy was in a 38 year old; therefore, there were 21 on-treatment pregnancies contributing to the PI for Study 300B. After detailed review and interaction with the applicant via Information Requests and responses, there was agreement between the Division and the applicant regarding these 21 on-treatment pregnancies (see detailed discussion below).

An IR, sent December 19, 2017, inquired about five additional pregnancies, four of which occurred in subjects whose diary data was crossed out and replaced with different dates added for last CVS use. The applicant provided source data obtained by the clinic staff which supports the assertion that these subjects filled out their diaries in advance of the actual dates of CVS usage. The fifth pregnancy occurred in Subject (b) (6), who had a βhCG level of 20 mIU/ml, and per laboratory report was categorized as inconclusive for pregnancy, with a follow up negative UPT.

**Table 25. Adjudicated Pregnancies (Study 300B)**

Subject	Start Drug	Last CVS Use	LMP	Pregnancy Confirm	Estimated date of Conception	Applicant	Medical Officer Determination
(b) (6)	(b) (6)	(b) (6)  per crf (b) (6) (crossed out)  per diary ring out (b) (6) Ring back in (b) (6) (all crossed out)	(b) (6)  per crf (b) (6) (crossed out)	positive UPT (b) (6)  US (b) (6) 5w3d  pregnancy notification	(b) (6)	15+	off (discount diary)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

				dates crossed out and changed.			
(b) (6)	(b) (6)	(b) (6)  per narrative subject "admitted" she d/c ring use (b) (6) but completed diary per schedule.  diary shows use through (b) (6) (crossed out)	(b) (6)  per crf (b) (6) (crossed out)	positive UPT (b) (6)  US (b) (6) 9wk3d  negative UPT (b) (6)	(b) (6)	15+	off (discount diary)
(b) (6)	(b) (6)	(b) (6)  per narrative subject "admitted: to d/c ring (b) (6) but completed her diary per schedule.  per crf last use (b) (6) (crossed out and (b) (6) placed)  per diary CVS out (b) (6) and in (b) (6) and out (b) (6) and in (b) (6) and out (b) (6) (Most of (b) (6) (b) (6) crossed out and written over)	(b) (6)  per diary bleeding (b) (6)  and bleeding (b) (6)	BhCG 3,729 mIU/ml on (b) (6)  per CRF, spontaneo us abortion in progress  US no evidence of IUP	(b) (6)  based on Imp	off	off (discount diary)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

(b) (6)	(b) (6)	<p>(b) (6) after questioning by study staff “admitted” to filling out diary according to what should have been her schedule</p> <p>per crf (b) (6) (crossed out and (b) (6) placed)</p> <p>per diary CVS out (b) (6) with nothing checked until (b) (6) when CVS back in until (b) (6), out (b) (6) and in (b) (6) (most crossed out)</p>	(b) (6)	<p>Positive UPT (b) (6)</p> <p>US (b) (6)</p> <p>6 wk GA</p>	(b) (6)	8-14 day	8-14 day (discount diary)
(b) (6)	(b) (6)	<p>“unsure” per narrative</p> <p>per crf (b) (6)</p> <p>per diary (b) (6)</p>	(b) (6)	<p>per preg notificat ion diary</p> <p>BhCG 20 mIU/ml and negative UPT on (b) (6)</p> <p>negative UPT (b) (6)</p>		<p>excluded from analyses</p> <p>“only document ation preg test is equivocal. We are unclear if she was ever pregnant”</p> <p>Applicate states possible “chemical pregnancy ” and has excluded subject from efficacy</p>	<p>BhCG inconclusive per lab test therefore agree with excluding this subject from efficacy analysis</p>

						analyses p 191 narrative.	
--	--	--	--	--	--	---------------------------------	--

Source: NDA 209627, Module 5.3.5.2, 300B Study Report, Response to IR Submitted 1/16/2018

**Comment:** *Three of the four subjects with diary data crossed out were enrolled at the same study site—Site 3. A sensitivity analysis was done for PIs, calculating PIs with and without subjects from Clinic 3 which showed a lower PI if Site 3 was excluded. In addition, this site was selected for inspection by OSI, and classified as NAI.*

There was one additional pregnancy in Subject (b) (6) which was identified as an ectopic pregnancy in a patient whose last date of CVS use was after she had a laparoscopic salpingectomy. The applicant provided chart documentation showing the date of conception occurred 15+ days after last use of the CVS. The subject subsequently restarted the CVS after her laparoscopic surgery. This same pregnancy was also reported as an off-treatment pregnancy ending in spontaneous abortion. The narrative describing this pregnancy as a spontaneous abortion was based on evidence of sequential decreasing  $\beta$ hCG levels and was classified as such prior to the diagnosis of the ectopic pregnancy.

The FDA statistical reviewer’s analysis of the PI (primary endpoint) is shown in the table below.

**Table 26. Study 300 B: Pearl Index for subjects  $\leq$  35 years old using pregnancies from evaluable cycles within 7 days from CVS removal**

Efficacy Population				
Study	N	Number of Pregnancies	Number of evaluable cycles	PI using evaluable cycles (95% CI)
300B	1056	21	9457	2.89 (1.79, 4.41)

Source: Reviewer’s analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.

Note: 1. Cycles beyond cycles 13 were not included in the calculation. 2. 95% CI was based on the Poisson distribution.

**Comment:** *The PI and 95% CI for the CVS in this one study are consistent with two recently approved CHCs: Quartette in 2013 with PI 3.19 (2.49, 4.03) and Lo Loestrin FE in 2010 with PI 2.92 (1.94, 4.21). All of the studies calculated the PI similarly, with a 7-day on treatment pregnancy window and removing cycles where back up contraception was used. The findings in Study 300B are similar to the findings in Study 300A.*

The Division also requested analysis of the PI for pregnancies that occurred within 14 days after last CVS use. The applicant and Division agreed on two additional pregnancies conceived 8-14 days after CVS, providing a total of 23 pregnancies. The PI for pregnancies occurring within 14 days after last CVS use in women  $\leq 35$  years with back up cycles removed was calculated by the applicant to be 2.99 (2.16, 4.00)<sup>11</sup>. The FDA statistical reviewer’s analysis is presented in the table below.

**Table 27. Study 300B: Pearl Index for subjects  $\leq 35$  years old using pregnancies from evaluable cycles within 14 days from CVS removal**

Efficacy Population				
Study	N	Number of Pregnancies	Number of evaluable cycles	PI using evaluable cycles (95% CI)
300B	1056	23	9457	3.16 (2.00, 4.74)

Source: Reviewer’s analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.  
 Note: 1. Cycles beyond cycles 13 were not included in the calculation. 2. 95% CI was based on the Poisson distribution.

**Comment:** *The PI increases further when on-treatment pregnancy is defined as up to 14 days after CVS use. This demonstrates the need for prompt use of the CVS after seven days with no use.*

#### Efficacy Results – Supportive endpoints

Life table methods of cumulative pregnancy rates were a supportive endpoint for CVS efficacy. The applicant’s cumulative pregnancy rates for subjects  $\leq 35$  years old with pregnancies occurring within seven days of last CVS use utilizing all cycles<sup>12</sup> are very similar to the cumulative pregnancy rate calculated by the FDA shown in the table below.

**Table 28. Study 300B: Kaplan-Meier Analysis of Pregnancy Among Subjects  $\leq 35$  Years Old Using All Cycles**

Cycle	Subjects at Risk	Number of Pregnancies (with 7 days)	Cumulative Probability of Pregnancy (95% CI)
1	1056	0	0
2	1002	3	0.0030 (0.0010, 0.0093)
3	957	2	0.0051 (0.0021, 0.0122)
4	902	0	0.0051 (0.0021, 0.0122)
5	869	4	0.0097 (0.0050, 0.0185)
6	848	0	0.0097 (0.0050, 0.0185)
7	805	0	0.0097 (0.0050, 0.0185)
8	772	2	0.0122 (0.0068, 0.0220)
9	708	2	0.0150 (0.0087, 0.0258)
10	648	3	0.0196 (0.0120, 0.0319)

<sup>11</sup> <\\cdsesub1\evsprod\nda209627\0007\m5\53-clin-stud-rep\535-rep-ffic-safety-stud\contraception\5353-rep-analys-data-more-one-stud\ise\day-74-requests.pdf>

<sup>12</sup> NDA 209627, Module 5.3.5.2, 300B Study Report, Table 14.2.2.1 p 343/626

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Cycle	Subjects at Risk	Number of Pregnancies (with 7 days)	Cumulative Probability of Pregnancy (95% CI)
11	585	3	0.0246 (0.0156, 0.0386)
12	533	1	0.0264 (0.0170, 0.0410)
13	499	1	0.0284 (0.0184, 0.0436)

Source: Table 14.2.2.1 in Study 300B CSR and reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.

**Comment:** The cumulative pregnancy rate of 2.84% at one year is comparable to the PI of 2.89 with a 95% CI between 1.79 and 4.41.

### Efficacy Results – Secondary endpoints

#### Cycle Control

Based on subject diary data, greater than 93% of subjects had some bleeding and/or spotting each cycle. The mean number of days of bleeding and/or spotting was between 4.8-5.8 days each cycle. The number of days of bleeding and/or spotting did not decrease with subsequent cycles. Between 2.5 and 6.2% of subjects had amenorrhea for any given cycle with an overall amenorrhea rate of 1.1%.

**Table 29. Scheduled and Unscheduled Bleeding and Spotting (Study 300B)**

Cycle	N	no bleeding or spotting		bleeding or spotting number of days				
		n	%	Mean	SD	Min	Median	Max
1	1020	26	2.5	5.8	3.26	0	5	25
2	831	34	4.1	4.9	2.38	0	5	28
3	716	21	2.9	5	2.12	0	5	19
4	693	22	3.2	5	2.31	0	5	26
5	649	23	3.5	5	2.34	0	5	22
6	603	28	4.6	5	2.41	0	5	22
7	573	15	2.6	5.1	2.52	0	5	27
8	550	26	4.7	5	2.57	0	5	20
9	490	23	4.7	5.2	2.58	0	5	17
10	455	19	4.2	5.2	2.62	0	5	21
11	410	11	2.7	5.4	2.62	0	5	19
12	381	9	2.4	5.2	2.47	0	5	18
13	307	19	6.2	4.8	2.6	0	5	20
Overall	1042	11	1.1	5.2	2.04	0	5	25

Source: NDA 209627, Module 5.3.5.2, 300B Study Report, Table 14.2.3.1 p 349/626

The number of women with scheduled bleeding and/or spotting (withdrawal bleed at appropriate time) was greater than 92% for each cycle with the average of 5 days of bleeding and/or spotting. The longest withdrawal bleeding and/or spotting was 11 days and this did not decrease with subsequent cycles.

**Table 30. Scheduled Bleeding and/or Spotting (Study 300B)**

Cycle	N	none	% with no bleeding/spotting	Mean	SD	Min	Median	Max
1	1029	51	5.0	4.8	1.83	0	5.0	11
2	837	50	6.0	4.5	1.82	0	5.0	11
3	721	32	4.4	4.7	1.71	0	5.0	11
4	695	29	4.2	4.7	1.67	0	5.0	9
5	650	31	4.8	4.6	1.74	0	5.0	11
6	606	36	5.9	4.6	1.83	0	5.0	11
7	577	22	3.8	4.6	1.71	0	5.0	11
8	553	34	6.1	4.5	1.82	0	5.0	10
9	492	33	6.7	4.6	1.90	0	5.0	11
10	455	23	5.1	4.6	1.88	0	5.0	10
11	410	16	3.9	4.7	1.80	0	5.0	11
12	382	13	3.4	4.7	1.78	0	5.0	10
13	308	25	8.1	4.2	1.98	0	4.0	9
Overall	1044	22	2.1	4.5	1.44	0	4.6	11

Source: NDA 209627, Module 5.3.5.2, 300B Study Report, Table 14.2.3.1 p 347/626

Approximately 10-18% of subjects had unscheduled bleeding and/or spotting (day 1-21) for each cycle. The length of unscheduled bleeding and/or spotting averaged less than one day and did not decrease with subsequent cycles.

**Table 31. Unscheduled Bleeding and/or Spotting (Study 300B)**

Cycle	N	none	% with no bleeding/spotting	Mean	SD	Min	Median	Max
1	1034	844	81.6	0.9	2.66	0	0.0	14
2	849	743	87.5	0.4	1.57	0	0.0	17
3	729	632	86.7	0.4	1.35	0	0.0	17
4	699	624	89.3	0.3	1.44	0	0.0	17
5	657	577	87.8	0.4	1.56	0	0.0	15
6	608	516	84.9	0.5	1.51	0	0.0	16
7	576	503	87.3	0.5	1.67	0	0.0	16
8	553	480	86.8	0.5	1.66	0	0.0	14

Cycle	N	none	% with no bleeding/spotting	Mean	SD	Min	Median	Max
9	494	419	84.8	0.6	1.82	0	0.0	12
10	458	390	85.2	0.6	1.86	0	0.0	13
11	414	341	82.4	0.7	1.98	0	0.0	17
12	384	320	83.3	0.6	1.74	0	0.0	12
13	347	286	82.4	0.7	1.92	0	0.0	13
Overall	1052	539	51.2	0.7	1.46	0	0.0	14

Source: NDA 209627, Module 5.3.5.2, 300B Study Report, Table 14.2.3.1 p 348/626

Most subjects provided data for cycle control with CVS use that was usable for analysis. Over 93% of subjects had a withdrawal bleed the four week of each cycle with the average duration of five days. Ninety-two to 97% of subjects had no unscheduled bleeding any given cycles. Eighty-two (82%) to 89% of subjects had no unscheduled bleeding and/or spotting any given cycles, with the remaining 11-18% of subjects with unscheduled bleeding and/or spotting in any given cycle. When unscheduled bleeding and/or spotting occurred, the average length was less than one day. The maximum length of time for all bleeding and/or spotting ranged from 17-28 days/cycle. The number of days of spotting or bleeding did not decrease with subsequent cycles. For comparison, in the non-US trial of NuvaRing, unscheduled bleeding and/or spotting occurred in 3-9% of the subjects during cycles 1-13 and the European trials for Ortho Evra had 14% of subjects with unscheduled bleeding and/or spotting at cycle 3 decreasing to 9% at cycle 6.

Approximately 4% of subjects experienced amenorrhea for any given cycle with an overall amenorrhea rate of 1.1%. Amenorrhea in the non-US NuvaRing trial was up to 2%.

***Comment:** Overall, the CVS has a somewhat higher incidence of unscheduled bleeding and/or spotting and a comparable incidence of amenorrhea compared with other non-oral CHCs. The label will address the above bleeding/spotting patterns so that users are aware of these issues.*

### 8.3. Integrated Summary of Effectiveness (ISE)

The ISE analysis for PI, life table estimates, and cycle control and how the four studies contributed to the different analysis sets is shown below (Table 35).

**Table 32. Pooled ISE Analysis Sets**

	Total		300A		300B		300 B-Ex		300 PK	
Analysis set	N	%	n	%	n	%	n	%	n	%
Total	2317		1143		1135		12		39	

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

All cycle	2303	99.4	1129	98.8	1135	100	12	100	39	100
Life table	2264	97.7	1129	98.8	1135	100	0		0	
Pearl Index	2062	89	997	87.2	1065	93.8	0		0	
Primary subgroup*	1923	83	931	81.5	992	87.4	0		0	
All cycle control	2108	91	1016	88.9	1054	92.9	5	41.7	38	97.4
Pivotal	2070	89.3	1016	88.9	1054	92.9	0		0	

\*primary ISE

Source: NDA 209627, Module 5.3.5.3, ISE Table 8-1, p42/433

The Analysis sets excluded 17 subject numbers from Study 300A involving nine subjects. One subject never used the CVS, five subjects enrolled at two concurrent sites (accounting for a total of 10 subject numbers), and three subjects enrolled at two sites sequentially. One subject (b) (6) was added when her pregnancy was determined to be on-treatment.

The ISE PI was derived from the Primary subgroup of the Pearl Index Analysis set, that is subjects ≤35 years of age at enrollment into studies 300A and 300B, and based on cycles excluding the ones where adjunctive contraception was used. The Life table analysis set included all subjects from 300A and 300B and included all cycles. The secondary efficacy endpoint (cycle control) was evaluated using the All cycle control and pivotal cycle control analysis sets which differed by the 43 subjects from 300B-Ex and 300PK.

**Comment:** During the review cycle, the Division also requested removal of cycles when heterosexual intercourse did not occur from the “at-risk” cycles when calculating the PI, as this information was collected on the diary cards. However, late in the cycle the applicant noted that data on occurrence of intercourse was not reliable, i.e. this data was not confirmed at clinic visits. Further, the applicant noted that two pregnancies occurred in cycles where the diary noted no intercourse had occurred. Because of the above information, and because the SAP did not specify removal of cycles where intercourse did not occur, the Division withdrew the request to remove these cycles for this application.

### Demographics

Selective demographic parameters of the Primary subgroup Pearl Index (used for PI), Life table (used for cumulative pregnancy), and the All cycle control analysis set (one of two analysis sets used to describe bleeding patterns) are shown in the table below.

**Table 33. Selected Demographics for Three ISE Analysis Sets**

Characteristic	Primary subgroup of Pearl Index N=1923	Life table N=2264	All cycle control N=2108
Mean age (SD)	25.9 (4.2)	26.7 (5.1)	26.7 (5.1)
BMI (SD)	23.9 (3.6)	24.2 (3.7)	24.0 (3.7)

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Caucasian race	%	78.1	76.8	77.6
Non-Hispanic ethnicity	%	70.3	71.3	70.1
Never married	%	72.0	70.7	68.4
College degree or higher	%	42.2	41.9	42.2
Never smoked	%	71.5	71.4	70.1

Source: NDA 209627, Module 5.3.5.3, ISE Table 1.3.1 p 83/433, Table 1.3.2 p90/433

The majority of subjects in the All cycle analysis set [1,531 out of 2303 (66.5%)] were from the US.

Medical and gynecologic history were similar between the ISE analysis sets.

### Disposition

Subject dispositions in the ISE analysis sets were very similar. The three analysis sets differed in proportion of subjects completing the study and early termination due to loss-to-follow up. The All cycle control set and the Primary subgroup of PI compared with the Life table analysis set had a higher completion (62% vs 58%) and a lower loss-to-follow-up proportion (6.4% vs 9.5%).

Disposition of the primary ISE and comparison to the two pivotal trials is shown below in the applicant's table.

**Table 34. Subject Disposition, Pooled Studies 300A and 300B**

Disposition	Study 300A (N=1129) n (%)	Study 300B (N=1135) n (%)
Completed the Study	582 (51.6)	721 (63.5)
Discontinued Study	547 (48.4)	414 (36.5)
Reason for Discontinuation		
Lost to follow-up	138 (12.2)	76 (6.7)
Adverse Event	130 (11.5)	146 (12.9)
Withdrew consent	129 (11.4)	64 (5.6)
Eligibility BMI>29 kg/m <sup>2</sup>	88 (7.8)	50 (4.4)
Compliance	26 (2.3)	19 (1.7)
Pregnancy	24 (2.1)	29 (2.6)
Expulsions	9 (0.8)	24 (2.1)
Eligibility other	2 (0.2)	6 (0.5)
Other	1 (0.1)	0

Source: NDA 209627, Module 5.3.5.3, ISE, p 50/433

**Comment:** Comparing subject disposition between the two pivotal studies shows the US only study had a higher overall discontinuation rate with withdrew consent and lost to follow-up being higher than the global study. For the global population, AEs were the most frequent reason for discontinuation, and this proportion was higher than the US only population. Having a BMI >29 kg/m<sup>2</sup> was the overwhelming reason for discontinuation due to eligibility and this was higher in the US study. The overall disposition of subjects in the two studies are similar with the differences being noted in other US and global contraceptive studies. Overall, the clinical reviewer concluded that there were sufficient numbers of cycles in women in the US to adequately assess efficacy of the product in the indicated population.

## 9. Integrated Review of Effectiveness

### 9.1. Assessment of Efficacy Across Trials

#### 9.1.1. Primary Endpoints

The primary endpoints are the PI derived from studies 300A and 300B separately and combined, using pregnancies occurring in women ≤35 years old at time of study entry whose date of conception was within seven days of last CVS use. Cycles in which adjunctive (or back-up) contraception was used were excluded.

The PI (95% CI) for the CVS based on the primary efficacy endpoints are shown in Table 35.

**Table 35. Studies 300A and 300B: Pearl Index for subjects ≤ 35 years old using pregnancies from evaluable cycles within 7 days from CVS removal**

Efficacy Population				
Study	N	Number of Pregnancies	Number of evaluable cycles	PI using evaluable cycles (95% CI)
300A	1055	19	7970	3.10 (1.87, 4.84)
300B	1056	21	9457	2.89 (1.79, 4.41)
Pooled	2111	40	17427	2.98 (2.13, 4.06)

Source: Reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.

Notes: 1. Include pregnancy from subject (b) (6). 2. Cycles beyond cycles 13 were not included in the calculation. 3. 95% CI was based on the Poisson distribution.

**Comments:** The pooled PI of 2.98 with an upper bound of the 95% CI of 4.06 is in line with two recently approved CHCs: Quartette 3.19 (upper bound of the 95% CI of 4.03) and Lo Loestrin 2.92 (upper bound of the 95% CI of 4.21). The pooled PI utilizes 17,000 cycles and provides a narrower 95% CI than either trial alone; the pooled PI and 95% CI is the primary efficacy endpoint included in the labeling of this product.

The key supportive endpoints for efficacy of the CVS presented in this review are:

- PI for subjects  $\leq 35$  y/o using at cycles with no back-up contraception for pregnancies within 14 days
- Life table analysis for cumulative pregnancy rate for  $\leq 35$  y/o using all cycles for pregnancies within 7 days
- Life table analysis for cumulative pregnancy rate for all subjects using all cycles for pregnancies within 7 days

Extending the on-treatment pregnancy window to within 14 days after CVS use increased the PI for both studies as shown below.

**Table 36. Studies 300A and 300B: Pearl Index for subjects  $\leq 35$  years old using pregnancies from evaluable cycles within 14 days from CVS removal**

Efficacy Population				
Study	N	Number of Pregnancies	Number of evaluable cycles	PI using evaluable cycles (95% CI)
300A	1055	22	7970	3.59 (2.25, 5.43)
300B	1056	23	9457	3.16 (2.00, 4.74)
Pooled	2111	45	17427	3.36 (2.45, 4.49)

Source: Reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.

Notes: 1. Include pregnancy from subject (b) (6) 2. Cycles beyond cycles 13 were not included in the calculation.

3. 95% CI was based on the Poisson distribution.

The Life table analysis for cumulative probably of pregnancy occurring within seven days of last CVS use provided by the applicant<sup>13</sup> is similar to the analysis performed by the FDA statistician in the table below.

**Table 37. Kaplan-Meier Analysis of Pregnancy Among Subjects  $\leq 35$  Years Old Using All Cycles**

Cycle	Subjects at Risk	Number of Pregnancies (with 7 days)	Cumulative Probability of Pregnancy (95% CI)
0	2111	2	0
1	2111	2	0.0009 (0.0002, 0.0038)
2	1979	7	0.0045 (0.0023, 0.0086)
3	1884	5	0.0071 (0.0042, 0.0120)
4	1766	2	0.0082 (0.0051, 0.0134)
5	1693	4	0.0106 (0.0068, 0.0164)
6	1623	2	0.0118 (0.0078, 0.0179)
7	1510	0	0.0118 (0.0078, 0.0179)
8	1436	4	0.0146 (0.0099, 0.0214)
9	1304	3	0.0168 (0.0117, 0.0242)

<sup>13</sup> [Application 209627 - Sequence 0018 - Integrated Summary of Efficacy - Table 2.3.1 Kaplan-Meier Life Tables of Pregnancy \(Revised\)](#)

Cycle	Subjects at Risk	Number of Pregnancies (with 7 days)	Cumulative Probability of Pregnancy (95% CI)
10	1180	4	0.0202 (0.0143, 0.0284)
11	1061	3	0.0229 (0.0165, 0.0319)
12	961	3	0.0260 (0.0189, 0.0358)
13	897	1	0.0271 (0.0197, 0.0371)

Source: Reviewer's analysis. Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.

The Life table analysis for cumulative probably of pregnancy for all subjects in the pivotal trials, irrespective of age, occurring within seven days of last CVS use was 0.0251 (95% CI 0.0346, 0.0182)<sup>14</sup>.

**Comment:** *The cumulative probably of pregnancy in women ≤ 35 years for the CVS at one year (2.71% [95% CI:1.97, 3.71]) is comparable to the pooled primary efficacy PI of 2.98 with a 95% CI between 2.13 and 4.06. Because life-table analysis is a secondary and supportive analysis, these results will not be included in labeling.*

### 9.1.2. Secondary Endpoints

We consider Cycle Control to be an important secondary efficacy endpoint because it often leads to method discontinuation. Cycle control was evaluated using two analysis sets, the All-Cycle Control Analysis Set and the Pivotal Cycle Control Analysis Set. The All-Cycle Control analysis set contained data from all 4 studies (300A, 300B, 300 PK, 300 Ex) while the Pivotal Cycle Control analysis set contained data from studies 300A and 300B only. To be included, the subject had to have diary entries on bleeding for at least 15 of 21 days during ring-in period and at least 3 of 7 days during the ring-out period. The subjects recorded spotting (no sanitary protections used), normal and heavy bleeding (sanitary protection used) with normal and heavy bleeding combined into one category "bleeding." Bleeding/spotting that occurred during the ring free interval and continuing through Day 1-4 was not considered unscheduled. Bleeding/spotting during Days 1-7 of the first cycle was not considered unscheduled.

In the pivotal cycle control analysis set, scheduled bleeding and/or spotting occurred in over 92% of users each cycle with the median number of 5 days with 1 year use, shown in Table 38. The number of days of scheduled bleeding did not decrease with use. Amenorrhea occurred in 3-5% of users each cycle over 1 year use and 0.9% overall (data not shown<sup>15</sup>).

**Table 38. Pivotal Cycle Control, Scheduled Bleeding and/or Spotting**

Cycle	N	n bleeding and/or spotting	mean days of bleeding and/or spotting	SD	maximum days of bleeding

<sup>14</sup> NDA 209627, Module 5.3.5.3, ISE p 8/433

<sup>15</sup> NDA 209627, Module 5.3.5.3, ISE, Table 2.4.1 p 391/433

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

		(%)			and/or spotting
1	2020	1908 (94.5)	4.9	1.89	11
2	1744	1625 (93.2)	4.5	1.87	11
3	1509	1423 (94.3)	4.6	1.81	11
4	1456	1372 (94.2)	4.6	1.84	11
5	1406	1312 (93.3)	4.5	1.87	11
6	1259	1177 (93.5)	4.5	1.85	11
7	1214	1138 (93.7)	4.5	1.83	11
8	1174	1085	4.5	1.90	11
9	1022	947	4.5	1.93	11
10	932	872	4.5	1.94	10
11	850	798	4.6	1.88	11
12	780	736	4.6	1.86	11
13	649	597	4.2	1.93	11
Overall	2055	2011	4.5	1.45	11

Source NDA 209627, Module 5.3.5.3, ISE, Table 2.4.1 p 389/433

Over 78% of subjects had no unscheduled bleeding and/or spotting in any given cycle. Of the 13-21% of subjects with unscheduled bleeding and/or spotting, the mean number of days was less than one.

**Table 39. Pivotal Cycle Control, Unscheduled Bleeding and/or Spotting**

Cycle	N	None* n (%)	Any* n (%)	mean days	SD Days	max days
1	2029	1591 (78.4)	438 (21.6)	1.1	2.79	14
2	1754	1478 (84.3)	276 (15.7)	0.6	1.98	17
3	1520	1272 (83.7)	248 (16.3)	0.6	1.69	19
4	1460	1268 (86.8)	192 (13.2)	0.5	1.85	20
5	1417	1200 (84.7)	217 (15.3)	0.6	1.80	17
6	1267	1037 (81.8)	230 (18.2)	0.6	1.73	16
7	1214	1008 (83.0)	206 (17.0)	0.7	2.09	16
8	1178	962 (81.7)	216 (18.3)	0.7	1.93	17
9	1027	834 (81.2)	193 (18.8)	0.8	2.03	18
10	939	756 (80.5)	183 (19.5)	0.8	2.15	16
11	856	684 (79.9)	172 (20.1)	0.9	2.31	17
12	783	622 (79.4)	161 (20.6)	0.9	2.33	21
13	713	558 (78.3)	155 (21.7)	0.9	2.22	15
Overall	2068	903 (43.7)	1165 (56.3)	0.8	1.57	14

\*unscheduled bleeding and/or spotting

Source NDA 209627, Module 5.3.5.3, ISE, Table 2.4.1. p 390/433

**Comment:** *The label will reflect that over 92% of users have withdrawal bleeding, up to 5% of subjects have amenorrhea, and 5-10% have unscheduled bleeding. The CVS bleeding profile has a higher incidence of unscheduled bleeding and/or spotting (up to 22%) compared with most other CHCs, and an amenorrheic rate similar to other non-oral CHCs. This information is important for providers and patients when considering use of this product.*

### 9.1.3. Subpopulations

The applicant provided subgroup analyses of the PI utilizing the All Cycle Population for the following subgroups:

- Race group (only Black, only White, Other/unknown)
- Ethnicity (Hispanic, Non-Hispanic)
- BMI ( $\leq 29 \text{ kg/m}^2$  vs.  $> 29 \text{ kg/m}^2$ )
- Geographic region (US vs. non-US, Europe vs non-Europe)
- Parity (0 vs.  $\geq 1$ )
- Age ( $\leq 35$  vs.  $> 36$ )
- Age quartiles
- Age of ring (post-hoc analysis)

The Division requested geographic subgroups for US/non-US. Subjects from the US made up 66-67% of the All-cycle and primary ISE analysis sets. Based on FDA analysis, US subjects contributed 62.7% of the 18,745 evaluable cycles (all ages).

**Table 40. US/Non-US Subjects and Cycles Used for PI**

Study	Country	# subjects in the safety and efficacy populations	# all cycles based on efficacy population	# evaluable cycles based on efficacy population*	# pregnancies within 7 days of
300A	US	1130	9880	8572	19
300 B	US	389	3433	3194	7
	Non-US	746	7509	6979	15
<b>Total</b>	<b>US</b>	1519	13313	11766	<b>26</b>

Source: electronic communication 4/10/18 from W. Zhang, PhD, FDA Statistician

\* Evaluable cycles are the cycles excluding adjunctive contraception.

\* This table included all subjects 18-40 years of age in the study.

The applicant presents subgroup analyses using the All Cycle population prior to adjudication of pregnancies and defining on treatment pregnancy within 7 days of last CVS use. The PIs with 95% CI submitted by the applicant<sup>16</sup> are similar to the PIs using all cycles of the primary ISE as calculated by FDA’s statistician shown in the table below.

<sup>16</sup> [Application 209627 - Sequence 0001 - Integrated Summary of Efficacy](#), Table 10-4 p 58/433

**Table 41. Pearl Index for subjects ≤ 35 years old by subgroup**

Efficacy Population						
Subgroup	N	Number of pregnancies	Number of evaluable cycles	Pear Index using evaluable cycles (95% CI)	Number of all cycles	Pear Index using all cycles (95% CI)
Race - White only	1511	18	13036	1.80 (1.06, 2.84)	14352	1.63 (0.97, 2.58)
- Black only	296	12	1867	8.36 (4.32, 14.60)	2279	6.85 (3.54, 11.96)
- Other races*	304	10	2524	5.15 (2.47, 9.47)	2774	4.69 (2.25, 8.62)
Ethnicity – Hispanic	618	27	5494	6.39 (4.21, 9.30)	5921	5.93 (3.91, 8.63)
- Non-Hispanic	1493	13	11933	1.42 (0.75, 2.42)	13484	1.25 (0.67, 2.14)
BMI ≤ 29	1935	38	16604	2.98 (2.11, 4.08)	18455	2.68 (1.89, 3.67)
> 29	176	2	823	3.16 (0.38, 11.41)	950	2.74 (0.33, 9.89)
Site – USA	1423	26	11015	3.07 (2.00, 4.50)	12499	2.70 (1.77, 3.96)
- Non-USA	688	14	6412	2.84 (1.55, 4.76)	6906	2.64 (1.44, 4.42)
Site – Europe	278	1	2477	0.52 (0.01, 2.92)	2692	0.48 (0.01, 2.69)
- Non-Europe	1833	39	14950	3.39 (2.41, 4.64)	16713	3.03 (2.16, 4.15)
Parity = 0	1441	14	12031	1.51 (0.83, 2.54)	13531	1.35 (0.74, 2.26)
> 0	670	26	5396	6.26 (4.09, 9.18)	5874	5.75 (3.76, 8.43)

Source: NDA209627\0017\m1\us\111-info-amend\mult-mod-info-amend.pdf and reviewer's analysis.

Data: \NDA209627\0007\m5\datasets\ise\analysis\legacy\datasets\eff.xpt.

Note: Using evaluable cycles and pregnancies with 7 days. \* include Asian, American Indian / Alaska Native, Native Hawaiian / Pacific Islander, or multi-races.

There are large differences in the PIs based on race, ethnicity, European vs non-European population, and parity. The studies were not statistically powered to detect differences in any of the above subgroups. Each subgroup is skewed in numbers of subjects producing PIs with wide 95% CIs. Because of this, meaningful comparisons are not possible. Physiologically, the CVS should be effective regardless of race or ethnicity. In general, PIs in European populations are consistently lower in CHC trials as compared to those that use US populations, a finding thought to be due to factors other than the CHC being studied, such as more adherent users and/or lower body mass index in the European clinical trial populations. Women of parity have proven fertility and may indeed be a different population than nulliparous women, but definitive conclusions cannot be drawn from the small number of parous subjects. For this application, we determined that although there are significant differences across the regions under study, there was sufficient cycle information from women in the US to allowing labeling for the indicated population.

**Comment:** Interestingly, the one subgroup that might be expected to show a difference, subjects with higher BMIs, had a PI similar to that of the general study population. The applicant's reasoning for this unexpected finding is discussed in Section 10.11 Integrated Assessment of Safety.

Analysis of PIs in the All Cycle analysis set based on age of CVS was performed post-hoc by the

applicant.

**Table 42. Pearl Index by Age of CVS at Insertion**

Analysis Set	Age of Ring	Pregnancies	N	Cycles	Pearl Index	95% CI
All Cycle	2 years or greater	13	745	5261	2.47	( 1.93, 3.16)
	1.69 years thru 1.99 years	16	777	6598	2.96	( 2.42, 3.61)
	Less than 1.69 years	12	781	6199	2.31	( 1.82, 2.92)
	Age of Ring Tertiles (Ratio)	.	.	.	1.04	( 0.88, 1.22)

Source: NDA 209627, Module 5.3.5.3, ISE Table 2.5.1 p 405/433

**Comment:** Age of CVS at time of insertion does not appear to affect efficacy of the CVS; therefore, no labeling on this is necessary.

#### 9.1.4. Considerations on Benefit in the Postmarket Setting

#### 9.1.5. Other Relevant Benefits

### 9.2. Statistical Issues

It was noted during the review that five subjects with 10 unique subject IDs who were enrolled in two centers at the same time were excluded from the efficacy and safety analyses. Three subjects with six unique subject IDs were enrolled in two centers sequentially and only clinical data from the first site was included in the efficacy and safety datasets. These issues were addressed in Study 300A's CSR and the ISE. An information request was sent on April 17, 2018 for further clarification. In the response submitted on April 26, 2018, the applicant confirmed that the five subjects were enrolled and received CVSs from two centers, attended visits at two centers, and four of them completed an end of study visit at both centers. Three of the sixteen CVSs dispensed to these eight subjects were not returned. Considering the feasibility of separating the cycles from the two sites for a subject and to be conservative to estimate the Pearl Index, we accepted the applicant's approach to exclude 7 subjects from the efficacy analysis while including one subject (Subject ID: (b) (6)) who was identified as pregnant by the clinical reviewer during the study.

We agreed that the impact of the data from these menstrual cycles on the Pearl Index calculation is minimal and did not affect the overall conclusion.

### 9.3. Integrated Assessment of Effectiveness

The fundamental goal of a contraceptive is to effectively prevent pregnancy. Contraceptive efficacy was based on the PI derived from the two pivotal trials (300A and 300B). Subjects ≤ 35 years at the time of entry into the trial were exposed to the risk of pregnancy using only the CVS for contraception for 17,427 28-day cycles. Over 800 subjects completed at least 13 cycles. There were 40 on-treatment pregnancies as determined by adjudication between the applicant and us. An on-treatment pregnancy was defined as a pregnancy with date of conception occurring within 7 days of CVS use.

**Table 43. Primary Efficacy of CVS (Primary ISE)**

	N subjects	number of on-treatment pregnancies (7 days)	number of evaluable cycles	PI using evaluable cycles (95%CI)
Pooled	2111	40	17427	2.98 (2.13, 4.06)

Source: Statistical reviewer’s analysis

For CHCs, a minimum of 10,000 28-day cycles with at least 200 subjects completing 13 cycles and at least 50% of subjects from the North American population are usually required for efficacy review. For the CVS, the Division had initially requested 20,000 cycles but agreed to fewer cycles for efficacy evaluation as long as there were 20,000 cycles from pooled data for CVS safety evaluation. There were 21,590 cycles for safety; therefore, the Division deemed the >15,000 28-day cycles adequate to evaluate the CVS for efficacy. US subjects contributed 9,006 or 62.7% of the evaluable cycles—close to the 10,000 cycles requested.

The PI of 2.98 with an upper bound of the 95% CI of 4.06 from all evaluable cycles is consistent with the PIs from two recently approved CHCs, both COCs. These PIs are shown in the table below along with the PI for the other approved vaginal contraceptive ring, NuvaRing.

**Table 44. PI (95% CI) for Selected CHCs**

CHC	Year Approved	PI (95% CI)
Quartette	2013	3.19 (2.49, 4.03)
Lo Loestrin FE	2010	2.92 (1.94, 4.21)
NuvaRing	2001	2.02 (1.1, 3.4)

Source: FDA approved USPI labels

**Comment:** *The CVS pivotal trials checked urine pregnancy tests (UPTs) every three months, which is consistent with other recent contraceptive trials. The applicant presented pregnancies as user or method failure, with 68% of the pregnancies due to*

*method failure. However, in recent contraceptive trials, pregnancies that occur, even with incorrect use, are counted because this represents actual use of the contraceptive ("real world use"). Labeling for this product will therefore include all evaluable cycles for efficacy, as this would best represent how the product is likely to perform in the intended US population.*

*Overall, the CVS is effective in preventing pregnancy in females of reproductive potential. The efficacy conclusions for the CVS are:*

- *The total number of 28-day cycles of exposure used to calculate the PI in the pivotal trials was adequate (17,427 cycles) for efficacy determination*
- *The PI of 2.98 with upper bound of 95% CI of 4.06 is acceptable for approval for contraceptive efficacy*
- *The cumulative probability of pregnancy of 2.71% over 13 cycles supports the efficacy of the CVS*

The bleeding profile of the CVS was studied in a secondary efficacy analysis. The findings were summarized descriptively.

The conclusions for the bleeding profile of CVS are:

- Over 92% of users had a monthly withdrawal bleed
- The average withdrawal bleed duration was 5 days
- Amenorrhea occurred in up to 5% of users any given cycle
- 5-10% of users experienced unscheduled bleeding per cycle
- The average unscheduled bleeding or spotting duration was less than one day

***Comment:*** *The bleeding profile of the CVS will be included in labeling to alert prescribers to this important information to discuss with women when initiating use of this product, because unscheduled bleeding can lead to method discontinuation.*

## 10. Review of Safety

---

### 10.1. Safety Review Approach

In women using combined hormonal contraceptive products, including the proposed CVS, the predominant safety concern is the risk of thromboembolism. The development program for the SA/EE CVS involved two manufacturers: SA-only CVSs and SA/EE CVSs with different combined doses. The safety analysis sets were separated by manufacturer and dosage with the All NES\*/EE CVS analysis set including all combined SA/EE CVSs. The primary ISS (All QPharma NES\*/EE CVS) contains the to-be-marketed CVSs. The application uses the abbreviation NES for

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

nestorone, which is the Population Council's proprietary name for segesterone acetate. (\*NES = SA)

The applicant provided the following table listing studies included in each safety analysis set.

**Table 45. Studies Contributing Safety Data and Pooled Analysis Sets in the ISS**

Protocol No. Number of Study Centers and Location	Number of Subjects in Pooled Analyses	Product	Dose(s) µg/d	Treatment Period; Duration of Study	Pooled Analysis Set			
					All QPharma NES*/EE CVS (N=2308)	All NES*/EE CVS (N=2843)	All NES*/EE 150/15 CVS (N=2569)	NES*-Only CVS (N=209)
300A 15 sites (US)	1134	QPharma NES/EE CVS	150/15	Thirteen 28 day (21/7) cycles; approximately 1 year	X	X	X	
300B 12 sites; US (5), Europe (3), Latin America (3), and Australia (1)	1135 <sub>b</sub> **	QPharma NES/EE CVS	150/15	Thirteen 28 day (21/7) cycles; approximately 1 year	X	X	X	
300PK 3 sites; Latin America (2) and US (1)	39	QPharma NES/EE CVS	150/15	Thirteen 28 day (21/7) cycles; approximately 1 year	X	X	X	
180 5 sites; US (2), Latin America (2) and Europe (1)	150	Population Council NES/EE CVS	150/15 150/20 200/15	Thirteen 28 day (21/7) cycles; approximately 1 year		X	X	
181 4 sites; US (1), Latin America (1), Europe (1) and Australia (1)	101	Population Council NES/EE CVS	150/15	Six 28 day (21/7) or 30 day cycles (26/4); approximately 6 months		X	X	

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

204R/2040L 5 sites; Latin America (2), US (1), Europe (1) and Australia (1)	250	Population Council NES/EE CVS	50/10 50/20 150/15	Menstrually signaled regimen; approximately 6 months		X	X	
323 1 site (Europe)	23	Population Council NES/EE CVS	150/15	Three 28 day (21/7) cycles; approximately 6 months		X	X	
174 3 sites; US (1), Latin America (1) and Europe (1)	179	Population Council NES CVS	50 75 100	Six 28-day continuous use cycles; approximately 6 months				X
175 1 site (Australia)	30	Population Council NES CVS	100	Six 28-day continuous use cycles; approximately 6 months				X

\*NES = SA

\*\*b includes 12 subjects enrolled in Study 300BEx. These subjects are only counted once

Source: NDA 209627, Module 2.7.4 Summary of Clinical Safety, Table 1 p 12/134

This safety review includes analysis of:

- Study 300A
- Study 300B
- Primary ISS (All QPharma SA/EE CVS)
- Secondary ISS SA/EE 150/15 CVS
- Secondary ISS All SA/EE CVS
- SA only CVS analysis set
- Safety Reports from 8 INDs for SA-only formulations (implant, CVS, IUS) and SA/EE CVSs not in analysis sets listed

The primary ISS analysis will inform the clinical trial safety sections of labeling since these studies utilized the to-be-marketed CVS.

The secondary ISS SA/EE 150/15 CVS data set was also reviewed, but is not described in detail in this review because the results are very similar to the secondary ISS All SA/EE CVS. The number of cycles that are contributed by CVSs other than 150/15 in the All SA/EE CVS analysis set is 2,233 cycles or 8.7% of the total number of safety cycles. Therefore, most of the findings reflect the 150/15 CVSs. Analyses of the All SA/EE CVS ISS and the SA-only CVS data set are utilized to capture any safety signals.

Other major adverse events of interest that were evaluated in the trials included hereditary angioedema, hypersensitivity/rash, liver disease, gallbladder disease, hypertension, adverse carbohydrate and lipid metabolic effects, headache, bleeding irregularities, and depression. With vaginal systems, findings related to expulsion, vaginal irritation, vaginal discharge, and infections including toxic shock syndrome were of particular interest and there was no indication that this differed across any subgroup, such as race or age.

## 10.2. Review of the Safety Database

### 10.2.1. Overall Exposure

**Table 46. ISS Subject Totals and Cycles of Therapy by Pooled Safety Analysis Set**

Population / Analysis Set	Total Subjects	Total Cycles	Subjects Completing at Least 13 Cycles
All NES*/EE CVS	2843	25,532	11090
All NES*/EE 150/15 CVS	2569	23,299	10343
All QPharma NES/EE CVS	2308	21,590	999
Subgroup w/ BMI $\leq 29.0$ kg/m <sup>2</sup>	2099	20,366	963
Subgroup w/ BMI $> 29.0$ kg/m <sup>2</sup>	209	1254	36
Subgroup w/ Age $< 36$ years	2146	20,031	924
Subgroup w/ Age $\geq 36$ years	162	1559	75
NES*-only CVS	209	1262	NA <sup>a</sup>

\*NES=SA

Source: NDA 209627, Module 5.3.5.3 ISS Table 1.1.6 p 53/3781

<sup>a</sup> NES\*-only CVS studies were 6 cycles in total duration

The All QPharma CVS is the primary ISS and included 300A, 300B, 300BEX, 300 PK where usage of CVS was confirmed by subjects' diary data. Study 300 PK added 39 subjects with a maximum of 13 cycles of exposure per subject. 300BEX included 12 subjects who used a second ring after completing 13 cycles for a total additional exposure of 3,267 days.

Although the All SA/EE CVS analysis set included studies that used different doses of SA and EE in the CVS, the majority (>91%) of cycles were derived from the to-be-marketed formulation, SA/EE 150/15 CVSs.

The NES\*-only analysis set contained studies which used varying doses of SA-only CVSs, all with less than 150µg SA.

Study 300A had a total of 1,129 subjects who used the CVS for at least 1 day and provided 9,874 cycles of CVS use. Of the 834 subjects who were eligible to complete 13 full cycles, 426 subjects (51.1%) completed one full year of treatment, contributing 5,538 cycles (56.1% of total exposure). An additional 295 subjects who were enrolled for less than one year contributed 2,233 cycles. Sixteen subjects used the same CVS for more than 13 cycles (against protocol) and were included in the overall number of cycle exposure.

Study 300B had 1,135 subjects who used the CVS for a total of 10,979 cycles. Of the 860 subjects eligible to complete 13 full cycles, 62.1% or 534 subjects completed one full year of treatment, contributing 5,538 cycles (50.4% total exposure). An additional 275 subjects who were not eligible for a full 13 cycles of use completed 2,273 cycles. Fifty-three subjects completed 14 cycles and 5 subjects completed 15 cycles against protocol but are included in exposure.

### **10.2.2. Relevant characteristics of the safety population:**

#### ***300A***

The study population in 300A was from the US with subjects between ages 18 and 40.0 years. Seventy-five subjects or 6.6% of the study population were between 35 and 40 years old. Sixty-six percent (66%) of subjects were White, 23% were Black, and 13% were Hispanic. Due to change in weight exclusion criteria only 2 subjects with a BMI > 29 kg/m<sup>2</sup> completed 13 cycles of CVS. Overall, the 88 subjects with a BMI > 29 kg/m<sup>2</sup> contributed to 413 cycles used for the efficacy data base.

#### ***300B***

The study population in 300B included subjects from US, Europe (Finland, Hungary, Sweden), South America, and Australia clinics between the ages of 18 and 40.8 years. Seventy-nine subjects or 7.0% of the study population were > 35 years old. Eighty-seven percent (87%) of subjects were White, 13% were Black, and 44% were Hispanic. Due to the change in weight exclusion criteria only seven subjects with a BMI >29 kg/m<sup>2</sup> completed 13 cycles of CVS. Overall, the 57 subjects with a BMI > 29 kg/m<sup>2</sup> contributed 345 cycles used for the efficacy data base.

#### ***ISS***

In the primary ISS, the majority of subjects were White (71%), non-Hispanic (70%), nulliparous (64%) with a mean age of 26.7 years and mean BMI of 24.1 kg/m<sup>2</sup>. The majority (67%) of the subjects were from the US.

Demographics of the primary ISS population categorized by BMI subgroup are shown in Table 47. Subjects with a BMI >29 kg/m<sup>2</sup> tended to be older (median age 27.9 years), parous (38% were nulliparous), from the US (81%), and Black (32% with BMI >29 kg/m<sup>2</sup> vs 12% with BMI ≤29 kg/m<sup>2</sup>).

**Table 47 Demographics and Baseline Characteristics of the Primary ISS with BMI Subgroups**

Characteristic	Primary ISS (N=2308) n(%)	Primary ISS ≤ 29.0 kg/m <sup>2</sup> (N=2099) n(%)	Primary ISS > 29.0 kg/m <sup>2</sup> (N=209) n(%)
<b>Age (years)</b>			
Mean	26.7	26.6	28.3
Median	25.9	25.7	27.9
Min-Max	18.1-40.8	18.1-40.8	18.1-40.0
<b>Race</b>			
Asian	82 (4)	81 (4)	1 (<1)
Black or African American	328 (14)	261 (12)	67 (32)
Caucasian	1628 (71)	1526 (73)	112 (54)
Other	248 (11)	220 (10)	28 (13)
Unknown	12 (<1)	11 (<1)	1 (<1)
<b>Ethnicity</b>			
Hispanic or Latina	690 (30)	619 (29)	71 (34)
Non-Hispanic or Latina	1618 (70)	1480 (71)	138 (66)
<b>USA geographic</b>			
USA	1536 (67)	1367 (65)	169 (81)
Non-USA	772 (33)	732 (35)	40 (19)
<b>Parity</b>			
0	1478 (64)	1398 (67)	80 (38)
≥ 1	830 (36)	701 (33)	129 (62)

Source: NDA 209627, Module 5.3.5.3 ISS, Table 7-1 p 63,64/3781

**Comment:** *There was a larger number of Hispanics (30%) in the ISS than in the 2010 US census population overall (16%). In the BMI >29 kg/m<sup>2</sup> category Blacks were over-represented and Asians were under-represented.*

*Important populations that are likely to use hormonal contraception that were not sufficiently represented in the pivotal trials are women >40 years old and women with BMI >29 kg/m<sup>2</sup>. The lack of data on these groups will be noted in the label.*

The secondary ISS analysis sets (the All SA/EE and 150/15 CVS sets) were similar to the primary ISS while the SA-only CVS set had some differences. The 209 subjects that made up the SA-only CVS analysis set were older (average age 28.2 years; 15% ≥36 years old), parous (57%), from non-US countries (71%), and 15% had a BMI >29 kg/m<sup>2</sup>. Race and ethnicity were not reported.

### **10.2.3. Adequacy of the safety database:**

For contraceptive trials containing a NME, the Division requests a total of 20,000 cycles with at least 200 subjects completing one year of use. The primary ISS population had over 21,000 cycles of exposure with over 900 subjects completing one year. Most of these cycles (19,726 cycles) and subjects were from the two pivotal trials (300A and 300B).

The study populations for 300A and 300B were limited for weight, initially excluding subjects >95 kg or >209 pounds, then excluding subjects with BMI >29 kg/m<sup>2</sup>, and for age, excluding subjects 40 years of age or older. Because of these limitations, the safety database does not adequately reflect women with a BMI >29 kg/m<sup>2</sup> or women over 40 years old.

## **10.3. Adequacy of Applicant's Clinical Safety Assessments**

### **10.3.1. Issues Regarding Data Integrity and Submission Quality**

The quality and integrity of the NDA acceptable for review. The NDA was organized with appropriately identified headings and subheadings that facilitated access to pertinent information for this clinical review.

The safety data sets included appropriate studies as requested by the Division. The grouping of the studies in the different ISSs limited our ability to analyze studies other than the pivotal trials because the secondary ISSs were composed predominantly of subjects and cycles from the pivotal trials, so the results overwhelmingly reflected the data from the primary ISS rather than the additional subjects' safety data.

Most of the studies were conducted over 10 years ago, therefore, the applicant's ability to obtain additional information was limited. Some narratives recorded the final diagnosis based on the subjects' telephone contact without further confirmation from medical records. The applicant worked with us to resolve outstanding questions so that there was sufficient information to allow analysis of individual adverse events.

AEs were reported for up to 14 days after last CVS use, and although the investigator was to note whether the AE was ongoing or resolved by the 14-day window, no further follow up was required. Therefore, in some cases, documentation of a TEAE or reason for early discontinuation of the CVS were missing. This is illustrated by Subject (b) (6) who discontinued the CVS due to vaginal discharge and irritation. At her termination visit, vaginal candidiasis and a UTI were diagnosed and treated but because the visit was >14 days after her last CVS use, neither of these diagnoses were documented as a TEAE or reason for early discontinuation of the CVS. There were also subjects with abnormal laboratories at the time of discontinuation that had no follow up laboratory values documented in the case report forms.

In narratives for VTE, the applicant did not follow protocol and use the BMI at the baseline visit (V1), but used either the screening (V0) or baseline (V1) value, whichever was greater. For example, in the description of VTE for Subject (b) (6) in Study 300A, the applicant used her screening BMI (V0) of 29.1 kg/m<sup>2</sup> rather than the per-protocol baseline BMI (V1) of 28.5 kg/m<sup>2</sup>. Further, the applicant notes in the narrative the subject's hospital BMI of 30.2 kg/m<sup>2</sup>, but does not note the baseline BMI of 28.5 kg/m<sup>2</sup> nor the BMI of 28 kg/m<sup>2</sup> at the subject's clinic visit 5 days after VTE hospitalization. This documentation classified Subject (b) (6) as having a BMI >29 kg/m<sup>2</sup> and resulted in her being one of the two subjects on which the DSMB based their decision to exclude further enrollment of subjects >29 kg/m<sup>2</sup> from the clinical studies.

**Comment:** *The applicant's assertion that there was a markedly increased risk of VTE for women with a BMI > 29 kg/m<sup>2</sup> is not adequately substantiated by the data. The clinical review found that multiple BMIs were reported for individual subjects with VTEs over the course of the trial, and therefore the data does not support use of a single BMI cutoff to assess VTE risk. Furthermore, the applicant's suggested BMI cutoff of > 29 kg/m<sup>2</sup> does not correspond to any clinically utilized BMI category. Our assessment is that there is insufficient power from the database to draw conclusions about actual VTE risk. This VTE risk will be prominently included in the warnings section of labeling. The definitive risk of VTE across all BMI categories for this product needs to be further evaluated in a large required postmarketing study.*

### 10.3.2. Categorization of Adverse Events

The applicant defined an AE as any untoward medical occurrence in a subject who was administered the investigational product, regardless of causality assessment. An AE could include an abnormal laboratory finding and worsening of a pre-existing condition.

In the study, any event occurring after the clinical trial subject signed the study Informed Consent Form (ICF) and up to 14 days following last use of the CVS was recorded and reported as an AE. Treatment-emergent adverse events (TEAEs) were defined as AEs (including worsening of preexisting conditions) that began on or after first use of the CVS and up to 14 days after final CVS use.

The AEs from studies 300A, 300B, 300BEX, 300 PK, and 330 were coded by System Organ Class (SOC) and preferred term by using Medical Dictionary for Regulatory Activities (MedDRA) Version 9.1. MedDRA Version 14.1 was used for studies 180, 181, 204, 323, 174, and 175. Verbatim AEs were reviewed for consistency before pooled for the ISS using MedDRA 9.1 as the standard.

The TEAEs were summarized by SOC, preferred term and the percentage of subjects reporting at least 1 TEAE within each SOC for all subjects. Subjects reporting the same event more than once within each SOC and preferred term were only counted once.

The severity of the AEs was graded as mild, moderate, or severe based on whether routine

activities were unaffected, compromised, or interrupted, respectively. The Investigator documented AE relationship to the CVS based on temporal sequence, dechallenge response, and other factors (concomitant therapy, subject's clinical state) and categorized as not related, unlikely, possible, probable, and definite/highly probable. The Investigator also documented resolution or outcome of AE, and action taken with respect to continuation in the study.

Serious adverse events (SAEs) were defined as an AE that resulted in death, was life-threatening, required in-patient hospitalization, resulted in persistent or significant disability, or was a congenital anomaly/birth defect in the offspring of the subject. In addition, spontaneous abortion, cancer, and drug overdose were classified as an SAE. The SAE reporting time period was after signed ICF through 30 days after last CVS use. SAEs were followed to resolution or stabilization of the condition.

### 10.3.3. Routine Clinical Tests

Urine pregnancy tests (UPTs) were performed at each clinic visit. Clinical laboratory testing was performed, at a minimum, at the beginning and end of the one-year studies, and included hematology, clinical chemistry, Pap smears, Chlamydia and gonorrhea testing, and urinalysis. Physical and gynecologic examinations were also performed at the beginning and end of the one-year studies.

### 10.3.4. ISS Disposition

The primary ISS subjects' disposition is shown in Table 48.

**Table 48. Disposition of Subjects in Primary ISS**

Disposition	Primary ISS(N=2308)	Primary ISS BMI Subgroups	
		≤29.0 kg/m <sup>2</sup> (N=2099)	>29.0 kg/m <sup>2</sup> (N=209)
Completed the Study, n (%)	1332 (58)	1296 (62)	36 (17)
Discontinued Prematurely, n (%) <sup>a</sup>	976 (42)	803 (38)	173 (83)
Adverse Event	281 (12)	267 (13)	14 (7)
Lost to Follow-up	214 (9)	191 (9)	23 (11)
Withdrew Consent	197 (9)	184 (9)	13 (6)
Eligibility	147 (6)	31 (1)	116 (56)
Pregnancy	54 (2)	50 (2)	4 (2)
Compliance	49 (2)	47 (2)	2 (<1)
Expulsions	33 (1)	32 (2)	1 (<1)

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Other	1 (<1)	1 (<1)	0
-------	--------	--------	---

Source: ISS Table 1.1.1 and ISS Table 1.1.5

NOTE: Adverse events as a reason for discontinuation were mapped following a manual review of all reasons for discontinuation and include 3 cases that were not initially considered adverse events leading to discontinuation in the AE database.

<sup>a</sup> Reasons for discontinuation were coded to the following categories based on the verbatim reasons given in the individual studies:

Adverse Event = verbatim AE; Lost to Follow-up = lost to follow-up; Withdrew Consent = not sexually active, other medical problems, other mood change, other pelvic problems, other personal problems, planning pregnancy, relocation, or widowed, divorced, separated; Eligibility = eligibility criteria changed or other medical problems; Pregnancy = ectopic pregnancy or intrauterine pregnancy; Compliance = CVR remained out too long, difficulty following schedule, lost CVR, other user compliance problem, or used other contraceptives; Expulsions = repeated expulsions; Other = erroneous diagnosis of pregnancy

Source: NDA 209627, Module 5.3.5.3, ISS, Table 7-3, p 69/3781

Disposition of subjects in the secondary ISSs is shown in Table 49.

**Table 49. Disposition of Subjects in Secondary ISSs**

<b>Disposition</b>	<b>All SA/EE CVR (N=2843)</b>	<b>All SA/EE 150/15 CVR (N=2569)</b>	<b>SA-Only CVR (N=209)</b>
<b>Completed the Study, n (%)</b>	<b>1761 ( 62)</b>	<b>1546 ( 60)</b>	<b>155 ( 74)</b>
<b>Discontinued Prematurely, n (%)<sup>a</sup></b>	<b>1082 ( 38)</b>	<b>1023 ( 40)</b>	<b>54 ( 26)</b>
Adverse Event	328 ( 12)	296 ( 12)	31 ( 15)
Withdrew Consent	228 ( 8)	214 ( 8)	9 ( 4)
Lost to Follow-up	220 ( 8)	218 ( 8)	2 (<1)
Eligibility	147 ( 5)	147 ( 6)	0
Pregnancy	63 ( 2)	56 ( 2)	3 ( 1)
Compliance	62 ( 2)	58 ( 2)	9 ( 4)
Expulsions	33 ( 1)	33 ( 1)	0
Other	3 (<1)	1 (<1)	0

Source: ISS Table 1.1.1 and ISS Table 1.1.3

NOTE: Adverse events as a reason for discontinuation were mapped following a manual review of all reasons for discontinuation and include 3 cases that were not initially considered adverse events leading to discontinuation in the AE database.

<sup>a</sup> Reasons for discontinuation were coded to the following categories based on the verbatim reasons given in the individual studies. Adverse Event = verbatim AE; Lost to Follow-up = lost to follow-up; Withdrew Consent = not sexually active, other medical problems, other mood change, other pelvic problems, other personal problems, planning pregnancy, relocation, or widowed, divorced, separated; Eligibility = eligibility criteria changed or other medical problems; Pregnancy = ectopic pregnancy or intrauterine pregnancy; Compliance = CVR remained out too long, difficulty following schedule, lost CVR, other user compliance problem, or used other contraceptives; Expulsions = repeated expulsions; Other = erroneous diagnosis of pregnancy.

Source: NDA 209627, Module 5.3.5.3, ISS, Table 7-4, p 70/3781

**Comment:** Because the primary ISS made up the majority of the secondary ISSs with SA/EE CVS, there were no substantive differences in subject disposition between the primary and secondary ISSs.

## 10.4. Safety Results

### 10.4.1. Deaths

There were no deaths reported in any studies.

### 10.4.2. Serious Adverse Events

In the primary ISS of 2308 subjects, 43 subjects (1.9%) experienced 47 SAEs. The SAEs experienced in the ISS all occurred in the two pivotal studies (300A and 300B) as shown in Table 50.

**Table 50. SAEs in Pivotal Trials and Primary ISS**

SOC Preferred Term	300A n subjects (N=1129)	300B n subjects (N=1135)	ISS n subjects (N=2308)
Subjects with any SAE, n(%)	21 (1.9)	22 (1.9)	43 (1.9)
Blood and Lymphatic System Disorders n(%)	1 (0.1)	1 (0.1)	2 (0.1)
Lymphadenitis	1	1	2
Ear and Labyrinth Disorders n(%)	1 (0.1)	0	1 (0.0)
Vertigo	1		1
Gastrointestinal Disorders n(%)	3 (0.3)	1 (0.1)	4 (0.2)
Abdominal Pain	2		2
Diarrhea/Nausea/Vomiting	1		1
Food Poisoning		1	1
General Disorders and Administration Site Conditions n(%)	0	1 (0.1)	1 (0.0)
Infusion Site Phlebitis		1	1
Hepatobiliary Disorders n(%)	0	1 (0.1)	1 (0.0)
Cholelithiasis		1	1
Immune System Disorders n(%)	3 (0.3)	0	3 (0.1)
Drug Hypersensitivity	1		1
Food Allergy	1		1
Hypersensitivity	1		1
Infections and Infestations n(%)	3 (0.3)	7 (0.6)	10 (0.4)
Amoebiasis		1	1
Appendicitis		2	2
Cellulitis		1	1
Dengue Fever		1	1

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

<b>SOC Preferred Term</b>	<b>300A n subjects (N=1129)</b>	<b>300B n subjects (N=1135)</b>	<b>ISS n subjects (N=2308)</b>
Influenza		1	1
Mastitis		1	1
Pneumonia	2		2
Pyelonephritis	1		1
Injury, Poisoning and Procedural Complications n(%)	0	3 (0.3)	3 (0.1)
Animal Bite		1	1
Back Injury		1	1
Ligament Injury		1	1
Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) n(%)	3 (0.3)	0	3 (0.1)
Malignant Melanoma	1		1
Salivary Gland Adenoma	1		1
Uterine Leiomyoma	1		1
Nervous System Disorders n(%)	1 (0.1)	2 (0.2)	3 (0.1)
Cerebral Venous Thrombosis		1	1
Headache	1		1
Multiple Sclerosis		1	1
Pregnancy, Puerperium and Perinatal Conditions n(%)	0	3 (0.3)	3 (0.1)
Abortion Incomplete		1	1
Abortion Spontaneous		1	1
Ectopic Pregnancy		1	1
Psychiatric Disorders n(%)	2 (0.2)	2 (0.2)	4 (0.2)
Bipolar Disorder	1		1
Bipolar I Disorder	1		1
Mania		1	1
Suicide Attempt		1	1
Reproductive System and Breast Disorders n(%)	1 (0.1)	0	1 (0.0)
Uterine Spasm	1		1
Respiratory, Thoracic and Mediastinal Disorders n(%)	2 (0.2)	0	2 (0.1)
Pleural Effusion	1		1
Pulmonary Embolism	1		1
Skin and Subcutaneous Tissue Disorders n(%)	0	1 (0.1)	1 (0.0)
Urticaria		1	1
Social Circumstances n(%)	1 (0.1)	0	1 (0.0)
Drug Abuser	1		1
Vascular Disorders n(%)	2 (0.2)	0	2 (0.1)
Deep Vein Thrombosis	2		2

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Source: NDA 208627, Module 5.3.5.2, 300A Study Report, Table 19 p 103/1147, 300B Study Report, Table 19 p 97/626; Module 5.3.5.3 ISS Table 2.5.5 p 2135/3781

In April 2018, the applicant submitted an updated SAE list which contained 10 additional SAEs that occurred more than 14 days after last drug use and had initially been considered nonemergent. Eight of the SAEs were pregnancies that ended in spontaneous abortion diagnosed after 14 days from last CVS use. One SAE was a pregnancy complicated by HELLP syndrome. These nine pregnancies were captured in the pregnancy data during efficacy review. The tenth SAE was pyelonephritis.

The SAEs included four VTEs (2 DVTs, 1 PE, 1 cerebral venous thrombosis) and two drug hypersensitivity reactions. These cases are described in detail in Section 10.5 Analysis of Submission-Specific Safety Issues.

The remaining SAEs of interest are discussed in detail below:

- one subject with vertigo but a history more consistent with transient ischemic attack (TIA)
- one subject with headache, nausea, vomiting, and diarrhea that resolved with discontinuation of the CVS
- one subject with vaginal bleeding and a fibroid
- two subjects with bipolar disorder that had worsening of symptoms
- one subject with a manic episode
- one subject with a suicide attempt

**300A - Subject (b) (6): Vertigo/possible Transient Ischemic Attack (TIA)**

A 25-year-old with Marfan syndrome used the CVS (b) (6) through (b) (6) removing the CVS on (b) (6) per protocol. On (b) (6), the subject had two episodes of vertigo, ataxia, weakness. She also had language problems and transient dizziness. On (b) (6), she presented to the emergency department where most of the symptoms resolved except for residual difficulty with balance. Physical examination showed trace intention tremor on the right and subjective feeling of unsteady gait. She was admitted to the hospital due to a concern for posterior circulatory TIA and vertebral artery dissection. TSH was elevated at 9.95 IU/ml. CT and MRI imaging of the head showed no abnormalities. EKG was normal. Echocardiography showed mitral prolapse with trace regurgitation. The subject was treated with SQ enoxapin, PO atorvastatin, aspirin, lansoprazole. Lab tests for protein C activity, protein S activity, Factor V Leiden and Prothrombin 2021GA Variant were within normal ranges. A neurologist determined the subject might have an inner ear imbalance. The subject was discharged from the hospital with no medication and was discharged from the study. The investigator ranked this treatment-emergent SAE as unlikely related to the CVS.

**Comment:** *The narrative describes a subject with acute neurologic deficit that is not expected with an inner ear imbalance and was treated with VTE prophylaxis upon admission to the hospital. The event resolved and the subject was discharged from the*

hospital after 3 days with no medication. The subject continued to use the CVS for another 11 days until she was discontinued from the study. Marfan syndrome (MFS), an autosomal dominant disorder of the connective tissue, carries a significant risk of aortic dissection, especially with increasing aortic root dilatation in pregnancy among women with the disorder. The USMEC does not separately address MFS. An interdisciplinary working group on pregnancy and contraception for women with cardiac disease rates MFS without aortic root dilatation as a risk category 2.<sup>17</sup> This TEAE as possibly related to the CVS, due to the documented neurologic deficits and their transient nature, which is suggestive of a TIA.

**300A - Subject (b) (6): Headache, Nausea, Vomiting, and Diarrhea**

A 32-year-old with a history of hyperlipidemia and seasonal allergies started the CVS on (b) (6). On day 2 through day 4 after CVS insertion the subject experienced headache (with pain level reported as 7 out of 10), nausea, vomiting, and diarrhea. She discontinued the CVS permanently on day 6 with “relief of headache, nausea, and vomiting” in a few hours. By day 7 all symptoms had resolved. The investigator ranked these symptoms as possibly due to CVS use.

**Comment:** *The timing of the symptoms suggests a possible relationship and headache, nausea, and vomiting are AEs that are associated with CHCs. The resolution of symptoms after CVS removal also supports an association between the CVS and the subject’s AEs.*

**300A - Subject (b) (6): Worsening Submucosal Fibroid (menorrhagia)**

A 28-year-old with known fibroids, including one submucosal fibroid, started the CVS on (b) (6). On (b) (6), the subject experienced continuous severe vaginal bleeding that was treated with progestin 5 mg twice daily from (b) (6) through (b) (6). Her hemoglobin was 8.3 g/dL on (b) (6). On (b) (6), she underwent a hysteroscopic resection of the submucosal fibroid. CVS use was interrupted (b) (6) and restarted (b) (6) until the end of the study, (b) (6). The investigator ranked the event as possibly related to the CVS.

**Comment:** *We agree with the applicant that the submucous fibroid becoming symptomatic might be related to the CVS. It is reassuring to note that after resection, the subject was able to continue use of the CVS for 7 more cycles.*

**Bipolar Disorder/Depression**

**300A - Subject # (b) (6): Bipolar Affective Disorder, Mixed**

A 25-year-old with a history of anxiety, anorexia nervosa, depression with suicidal thoughts, polysubstance dependence, irritable bowel syndrome and frequent urinary tract infections used the CVS (b) (6) through (b) (6). On (b) (6), the subject

<sup>17</sup> Contraception for the Medically Challenging Patient. Editors Rebecca Allen and Carrie Cwiak. Springer, Sep 3, 2014. Doi 10.1007/978-1-4939-1233-9

experienced symptoms of bipolar affective disorder. On [REDACTED] (b) (6), she was admitted to the hospital after purposefully cutting her leg and arm. History at admission included a prior episode of cutting one month previously, with gabapentin started [REDACTED] (b) (6); both occurring presumably on treatment. The subject also complained of racing thoughts, severe insomnia and mood swings with no onset date given. Escitalopram had been started [REDACTED] (b) (6) (prior to CVS use) for depression and anxiety. She was treated with Neurontin, buspirone, valproate, and paroxetine at the time of discharge from the hospital [REDACTED] (b) (6). She discontinued the CVS [REDACTED] (b) (6) and was discontinued from the study. The investigator considered the event to be unrelated to the study medication.

### 300A - Subject # [REDACTED] (b) (6) Bipolar Crisis

A 28-year-old with history of bipolar disorder, anxiety disorder, and depression with 3 previous inpatient psychiatric hospitalizations started the CVS [REDACTED] (b) (6). On [REDACTED] (b) (6), the subject was admitted for acute symptoms of bipolar illness and manic phase. She was paranoid, disorganized, hypomanic with pressured speech and racing thoughts. The subject had stopped taking her Abilify [REDACTED] (b) (6). Her laboratory testing was normal except for positive cannabinoids on toxicology. The subject was started on Abilify and Vistaril and was discharged 5 days later. The narrative does not provide a stop date for the study drug. The investigator considered the event to be unlikely related to the study medication.

### 300 B - Subject # [REDACTED] (b) (6) Mood Disorder, Bipolar I with Manic Episode and Psychotic Symptoms

A 24-year-old with history of mood disorder (Bipolar I with manic episode), used the CVS from [REDACTED] (b) (6) through [REDACTED] (b) (6). She discontinued the CVS due to her husband's objection. On [REDACTED] (b) (6) the subject was admitted to the hospital with a manic episode with psychotic symptoms similar to an episode experienced in [REDACTED] (b) (6). She underwent electroconvulsive therapy and was discharged [REDACTED] (b) (6) on therapy with trihexyphenidyl, risperidone, lithium, and chlorpromazine. The investigator considered the event unlikely related to the study medication.

### 300 B - Subject # [REDACTED] (b) (6) Suicide Attempt due to Worsening Depression

A 35-year-old with history of depression (on escitalopram), herniated disc, cystic ovaries and seasonal allergies started the CVS on [REDACTED] (b) (6). On [REDACTED] (b) (6), the subject attempted suicide by swallowing a bottle of cyclobenzaprine after she was physically attacked at work and then not supported by her superiors. During this time, her brother was having legal problems while serving in Iraq. The subject called her mother after she swallowed the pills and the subject was hospitalized. She was discharged from the hospital nine days later on Depakote and Invega. She continued the CVS. The investigator considered the event unlikely related to the study medication.

*Comment: All four subjects had underlying mental illness. In Study 300A, Subject # [REDACTED] (b) (6) had a history of inpatient psychiatric care and discontinued her bipolar medication two months prior to her acute bipolar episode which probably contributed to her acute*

episode. Subject # (b) (6) had an acute episode of bipolar affective disorder which temporally may have been related to CVS use, although with her extensive psychiatric history, the bipolar affective disorder may have been pre-existing. Subjects # (b) (6) and (b) (6) make up 0.2% of the study population in 300A, which had a 6.4% incidence of depression. In 300 B, Subject # (b) (6) continued using the CVS after in-hospital care and medication changes. Subjects # (b) (6) and (b) (6) make up 0.2% of the study population in 300B, in which 2.6% of subjects had a medical history of depression. Ortho Evra had three depressive SAEs including one suicide attempt for an incidence of 0.1% of the study population. Quartette had seven depressive SAEs including 5 suicide attempts for an incidence of 0.2% of the study population. Therefore, the findings in the CVS pivotal trials are comparable to that of other CHCs. Regardless, the risk of mood disorders and exacerbations of such disorders is adequately addressed in class labeling for CHCs and will be included in the label for the CVS.

There were an additional 10 SAEs in the secondary ISS; 8 with a SA/EE CVS and 2 with a SA-only CVS. Thirty (30) more SAEs occurred in 28 subjects under 8 SA INDs which were not pooled in the ISS. These SAEs were also reviewed.

**Comment:** From a clinical perspective, none of the SAE narratives indicate a new safety signal involving the various CVSs.

#### 10.4.3. Dropouts and/or Discontinuations Due to Adverse Effects

Early discontinuation due to AEs occurred in 11-12% of subjects in the two pivotal trials, the primary ISS, and the secondary ISS. The Reproductive System and Breast Disorders and Psychiatric Disorders SOCs contain the most frequent AEs leading to subject discontinuation.

**Table 51. TEAEs Leading to >1% Subject Early Discontinuation by SOC**

SOC1	300A n subjects (%) N=1129	300B n subjects (%) N=1135	Primary ISS n subjects (%) N=2308	All SA/EE ISS n subjects (%) N=2843
Total AEs Leading to Subject Discontinuation	127 (11.2)	144 (12.7)	275 (11.9)	323 (11.4)
Reproductive System and Breast Disorders	33 (2.9)	52 (4.6)	86 (3.7)	107 (3.8)
Psychiatric Disorders	29 (2.6)	24 (2.1)	54 (2.3)	63 (2.2)
Gastrointestinal Disorders	17 (1.5)	21 (1.9)	38 (1.6)	45 (1.6)
Nervous System Disorders	17 (1.5)	14 (1.2)	32 (1.4)	39 (1.4)
Infections and Infestations	8 (0.7)	13 (1.1)	21 (0.9)	27 (0.9)
Investigations	8 (0.7)	7 (0.6)	15 (0.6)	18 (0.6)

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.3.2.3.1 p 574/1147, 300B Study Report, Table 14.3.2.3.1 p 485/626, Module 5.3.5.2, ISS Analysis Dataset Legacy, Medical Officer's analysis of the AE data set using JMP, and ISS Table 8-13 p 97/3781

The PTs for subjects' early discontinuation are shown in Table below. The results between analysis sets are consistent because 81% of the All SA/EE ISS is from the Primary ISS, and 98% of the Primary ISS is made up of subjects from 300A and 300B.

**Table 52. AEs Leading to Early Discontinuation Occuring in  $\geq 2$  Subjects**

Preferred Term	300A n subjects (%) N=1129	300B n subjects (%) N=1135	Primary ISS n subjects (%) N=2308	All SA/EE ISS n subjects (%) N=2843
Subjects with AE leading to Early Discontinuation	127 (11.2)	144 (12.7)	275 (11.9)	323 (11.4)
Metrorrhagia, Menstrual Irregular	12 (1.1)	15 (1.3)	27 (1.2)	31 (1.1)
Vaginal Discharge	1 (0.1)	14 (1.2)	15 (0.6)	21 (0.7)
Headache	11 (1.0)	6 (0.5)	18 (0.8)	24 (0.8)
Mood Swings, Mood Altered, Affect Lability	10 (0.9)	5 (0.4)	15 (0.6)	19 (0.7)
Nausea	8 (0.7)	11 (1.0)	19 (0.8)	24 (0.8)
Depression, Depressive Symptoms Or Mood	7 (0.6)	3 (0.3)	10 (0.4)	14 (0.5)
Vomiting	7 (0.6)	2 (0.2)	9 (0.4)	12 (0.4)
Libido Decreased	5 (0.4)	10 (0.9)	15 (0.6)	15 (0.5)
Vulvovaginal Mycotic Infection/Vaginal Candidiasis	5 (0.4)	9 (0.8)	14 (0.6)	14 (0.5)
Menorrhagia*, Vaginal Hemorrhage	4 (0.4)	10 (0.9)	14 (0.6)	15 (0.5)
Anxiety	4 (0.4)	3 (0.3)	8 (0.3)	8 (0.3)
Migraine	4 (0.4)	7 (0.6)	11 (0.5)	11 (0.4)
Weight Increased	4 (0.4)	6 (0.5)	10 (0.4)	10 (0.4)
Abdominal Pain	3 (0.3)	5 (0.4)	8 (0.3)	8 (0.3)
Acne	3 (0.3)	2 (0.3)	5 (0.2)	6 (0.2)
Genital Pruritus Female	3 (0.3)	3 (0.2)	7 (0.3)	7 (0.2)
Blood Cholesterol Increased	2 (0.2)	0	2 (0.1)	2 (0.1)
Blood Triglycerides Increased	2 (0.2)	0	2 (0.1)	2 (0.1)
Deep Vein Thrombosis	2 (0.2)	0	2 (0.1)	2 (0.1)
Dysmenorrhea**	2 (0.2)	0	2 (0.1)	2 (0.1)
Fatigue	2 (0.2)	0	2 (0.1)	2 (0.1)
Insomnia	2 (0.2)	0	2 (0.1)	2 (0.1)
Premenstrual Syndrome	2 (0.2)	0	2 (0.1)	2 (0.1)
Urticaria	2 (0.2)	2 (0.2)	4 (0.2)	4 (0.1)
Vaginal Pain	2 (0.2)	1 (0.1)	2 (0.1)	3 (0.1)
Vulvovaginal Discomfort	1 (0.1)	3 (0.3)	4 (0.2)	4 (0.1)
Contraceptive/Medical Device Complication	1 (0.1)	2 (0.2)	3 (0.1)	3 (0.1)
Dyspareunia	1 (0.1)	2 (0.2)	3 (0.1)	6 (0.2)

Preferred Term	300A n subjects (%) N=1129	300B n subjects (%) N=1135	Primary ISS n subjects (%) N=2308	All SA/EE ISS n subjects (%) N=2843
Pain in Extremity	1 (0.1)	2 (0.2)	3 (0.1)	3 (0.1)
Urinary Tract Infection	1 (0.1)	2 (0.2)	3 (0.1)	3 (0.1)
Vulvovaginal Dryness	0	2 (0.2)	3 (0.1)	4 (0.1)
Back Pain	0	1 (0.1)	3 (0.1)	3 (0.1)

Terms used by applicant were \*withdrawal bleed and \*\*uterine spasm

Menstrual disorders make up the largest portion of AEs leading to CVS discontinuation. Metrorrhagia includes the verbatim terms of irregular bleeding, irregular spotting, breakthrough bleeding, breakthrough spotting, spotting, frequent spotting, and prolonged spotting. The preferred term “withdrawal bleed” includes the verbatim terms of heavy bleeding with menses, bleeding very much, prolonged bleeding with menses, and frequent bleeding with menses. However, review of data on AEs leading to early discontinuation shows all types of bleeding are categorized under metrorrhagia including 6 subjects with prolonged bleeding and prolonged menses.

**Comment:** Labeling of AEs leading to early discontinuation will group these terms together under menstrual disorders. This is also in concurrence with the draft guidance for Labeling for Combined Hormonal Contraceptives<sup>18</sup>

The primary ISS combines both pivotal trials and gives an overview of AEs leading to early discontinuation in the primary study population. Overall 11.9% of subjects had early discontinuation due to an AE. The most frequent AEs were:

- Menstrual disorders 1.7%
- Nausea/Vomiting 1.2%
- Headache, including Migraine 1.3%
- Vaginal discharge, vulvovaginal mycotic infection, vaginal candidiasis 1.3%.

CVS expulsions as the reason for early discontinuation was not treated as a AE, but 33 subjects (1.4%) in the primary ISS population had early discontinuation due to expulsions (see Section 10.4.13 CVS Expulsions/Issues).

In comparison, the NuvaRing<sup>19</sup> clinical trial experience showed 13% of subjects had early discontinuation due to an AE with the most common being device-related events (2.7%), mood changes (1.7%), headache including migraine (1.5%), and vaginal symptoms (1.2%). Other CHC trials have noted subject discontinuation due to menstrual irregularities rates of 1.1% (Ortho Evra) to 4.9% (Quartette).

<sup>18</sup> Labeling for Combined Hormonal Contraceptives, Guidance for Industry. DRAFT GUIDANCE December 2017

<sup>19</sup> NuvaRing label 8/2017

**Comment:** We conclude that rates of AEs leading to early discontinuation, and reasons for discontinuation, are sufficiently similar from a clinical perspective between the CVS and other CHCs that no specific safety concerns or trends were identified.

Review of the SA-only CVS ISS showed similar patterns of AEs leading to early discontinuation with no unexpected AEs.

#### 10.4.4. Significant Adverse Events

Significant adverse events considered to be submission-specific are described in Section 10.5 Analysis of Submission-Specific Safety Issues.

#### 10.4.5. Adverse Events and Treatment Emergent Adverse Events and Adverse Reactions

Most subjects (87%) reported at least one AE. In the primary ISS, 69% of the AEs were considered by the Investigator to be related to CVS use and 15% were categorized as severe. The most frequent AEs occurred in the SOCs of Infections and Infestations and Reproductive System and Breast Disorders as shown in the table below.

**Table 53. AEs by SOC Occuring in  $\geq 10\%$  of Subjects**

SOC	300A n subjects (%) N=1129	300B n subjects (%) N=1135	Primary ISS n subjects (%) N=2308	All SA/EE ISS n subjects (%) N=2843
Total AEs	1003 (88.8)	972 (85.6)	2016 (87.3)	2466 (86.7)
Infections and Infestations	671 (59.1)	601 (53.0)	1302 (56.4)	1495 (52.6)
Reproductive System and Breast Disorders	480 (42.5)	549 (48.4)	1052 (45.6)	1415 (49.8)
Gastrointestinal Disorders	519 (46.0)	456 (40.2)	998 (43.2)	1137 (40.0)
Nervous System Disorders	565 (50.0)	370 (32.6)	962 (41.7)	1160 (40.8)
Musculoskeletal and Connective Tissue Disorders	295 (26.1)	145 (12.8)	448 (19.4)	483 (17.0)
Psychiatric Disorders	203 (18.0)	178 (15.7)	388 (16.8)	441 (15.5)
Respiratory, Thoracic and Mediastinal Disorders	188 (16.7)	75 (6.6)	267 (11.6)	282 (9.9)
Skin and Subcutaneous Tissue Disorders	122 (10.8)	132 (11.6)	257 (11.1)	291 (10.2)
Injury, Poisoning and Procedural Complications	170 (15.1)	79 (7.0)	256 (11.1)	265 (9.3)
General Disorders and Administration Site Conditions	167 (14.8)	73 (6.4)	244 (10.6)	279 (9.8)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

NDA 209627, Module 5.3.5.2, 300A Study Report, Table 16 p 97/1147, 300B Study Report, Table 16 p 91/626, Module 5.3.5.3, ISS Table 8-3 p 74/3781, Table 8-5 p 79/3781

**Comment:** Overall, 87% of subjects experienced a AE. This is similar to Ortho Evra with 80% of subjects experiencing at least one AE and higher than NuvaRing with 38% of subjects experiencing at least one AE.

The number of subjects with AEs by PT is shown in the table below. Overall, the proportion of subjects with AEs decreased over time with the nadir of AEs occurring at Cycle 10.

**Table 54. AEs by PT Occuring in  $\geq$ 2% of Subjects**

Preferred Term	300A n subjects (%) N=1129	300B n subjects (%) N=1135	Primary ISS n subjects (%) N=2308	All SA/EE ISS n subjects (%) N=2843
Headache	494 (43.8)	312 (27.5)	829 (35.9)	1016 (35.7)
Nausea	244 (21.6)	257 (22.6)	514 (22.3)	572 (20.1)
Nasopharyngitis	212 (18.8)	242 (21.3)	475 (20.6)	494 (17.4)
Uterine Spasm~			281 (12.2)	307(10.8)
Dysmenorrhea	143 (12.7)	99 (8.7)	not reported	not reported
Vaginal Discharge	75 (6.6)	168 (14.8)	266 (11.5)	446 (15.7)
Upper Respiratory Tract Infection	204 (18.1)	41 (3.6)	247 (10.7)	249 (9)
Vulvovaginal Mycotic Infection*	142 (12.6)	84 (7.4)	232 (10.1)	259 (9)
Urinary Tract Infection*	97 (8.6)	109 (9.6)	211 (9.1)	229 (8)
Vomiting	117 (10.4)	60 (5.3)	182 (7.9)	201 (7.1)
Back Pain	114 (10.1)	63 (5.6)	181 (7.8)	197 (6.9)
Influenza	98 (8.7)	68 (6.0)	169 (7.3)	188 (6.6)
Diarrhoea	120 (10.6)	40 (3.5)	165 (7.1)	174 (6.1)
Metrorrhagia*	58 (5.1)	95 (8.4)	165 (7.1)	308 (10.8)
Breast Tenderness	69 (6.1)	72 (6.3)	142 (6.2)	153 (5.4)
Abdominal Pain Upper*	92 (8.1)	45 (4.0)	140 (6.1)	153 (5.4)
Pharyngolaryngeal Pain	95 (8.4)	41 (3.6)	138 (6.0)	138 (4.9)
Genital Pruritus Female	60 (5.3)	62 (5.5)	126 (5.5)	126 (4.4)
Dizziness	55 (4.9)	48 (4.2)	107 (4.6)	130 (4.6)
Migraine	58 (5.1)	38 (3.3)	104 (4.5)	112 (3.9)
Myalgia	82 (7.3)	18 (1.6)	101 (4.4)	105 (3.7)
Sinusitis	71 (6.3)	29 (2.6)	100 (4.3)	103 (3.6)
Insomnia	72 (6.4)	22 (1.9)	95 (4.1)	96 (3.4)
Abdominal Pain*	36 (3.2)	51 (4.5)	91 (3.9)	103 (3.6)
Abdominal Pain Lower*	30 (2.7)	55 (4.8)	89 (3.9)	145 (5.1)
Vaginal Candidiasis*	2 (0.2)	82 (7.2)	88 (3.8)	88 (3.1)
Pain in Extremity	55 (4.9)	28 (2.5)	84 (3.6)	86 (3.0)

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Preferred Term	300A n subjects (%) N=1129	300B n subjects (%) N=1135	Primary ISS n subjects (%) N=2308	All SA/EE ISS n subjects (%) N=2843
Seasonal Allergy	67 (5.9)	16 (1.4)	83 (3.6)	84(3.0)
Vaginitis Bacterial	45 (4.0)	29 (2.6)	82 (3.6)	86 (3.0)
Acne	24 (2.1)	57 (5.0)	80 (3.5)	101(3.6)
Libido Decreased	28 (2.5)	48 (4.2)	78 (3.4)	81 (2.8)
Dyspareunia	39 (3.5)	34 (3.0)	77 (3.3)	86 (3.0)
Fatigue	53 (4.7)	23 (2.0)	77 (3.3)	89 (3.1)
Toothache	46 (4.1)	28 (2.5)	75 (3.3)	80 (2.8)
Dyspepsia	65 (5.8)	10 (0.9)	75 (3.2)	77 (2.7)
Vulvovaginal Discomfort	42 (3.7)	32 (2.8)	74 (3.2)	81 (2.8)
Cervical Dysplasia	35 (3.1)	35 (3.1)	70 (3.1)	80(2.8)
Mood Swings*	38 (3.4)	29 (2.6)	67 (2.9)	78 (2.7)
Pyrexia	47 (4.2)	19 (1.7)	66 (2.9)	76 (2.7)
Menorrhagia§	24 (2.1)	40 (3.5)	65 (2.8)	80 (2.8)
Arthralgia	50 (4.4)	14 (1.2)	64 (2.8)	69 (2.4)
Cough	47 (4.2)	17 (1.5)	64 (2.8)	67 (2.4)
Stomach Discomfort	59 (5.2)	2 (0.2)	62 (2.7)	62 (2.2)
Constipation	35 (3.1)	25 (2.2)	60 (2.6)	61 (2.1)
Neck Pain	46 (4.1)	10 (0.9)	56 (2.4)	60 (2.1)
Breast Pain	14 (1.2)	39 (3.4)	55 (2.4)	94 (3.3)
Gastroenteritis Viral	43 (3.8)	12 (0.1)	55 (2.4)	--
Herpes Simplex	26 (2.3)	25 (2.2)	52 (2.3)	--
Anxiety	29 (2.6)	21 (1.9)	51 (2.2)	--
Abdominal Distension	32 (2.8)	17 (1.5)	50 (2.2)	59 (2.1)
Depression	23 (2.0)	26 (2.3)	50 (2.2)	59 (2.1)
Procedural Pain	40 (3.5)	7 (0.6)	50 (2.2)	--
Rash*	35 (3.1)	14 (1.2)	50 (2.2)	--
Gastroenteritis	9 (0.8)	36 (3.2)	47 (2.0)	--
Vulvovaginal Dryness	25 (2.2)	22 (1.9)	47 (2.0)	64 (2.3)

~ uterine spasm includes dysmenorrhea; §withdrawal bleed = heavy bleeding; \* see text in Reviewer's comment below. -- <2% incidence

Source: NDA 20627, Module 5.3.5.2, 300A Study Report, Table 17 p 99/1147, 300B Study Report, Table 17 p 93/626, Table 14.3.1.4.1 P 416/626, Module 5.3.5.3, ISS, Table 8-4 p 76/378, Table 8-16 ISS p 82/3781, and Medical Officer's analysis of ISS AE dataset using JMP

**Comment:** The CVS AEs listed are consistent with other CHC clinical trials with no unexpected safety signals. The CVS has a higher incidence in some of the AEs (e.g. headache, dysmenorrhea) as compared with AEs identified with other labeled CHCs.

*Since the rate does not confer causation by the CVS and the majority of AEs are mild, the CVS AE profile is acceptable for a CHC product.*

Analysis of AEs used MedDRA 9.1. The PT of uterine spasm included dysmenorrhea and the PT of withdrawal bleed was defined as heavy bleeding or menorrhagia. In addition, there were some conditions that were described using different terms. These terms include:

- vulvovaginal mycotic infection/vaginal candidiasis
- UTI/cystitis/genitourinary tract infection
- metrorrhagia/menstrual disorder
- mood swings/mood altered/affect lability
- depression/depressed mood/major depression/depressive symptom
- rash/papular/genital/generalized/macular/pruritic
- menorrhagia/withdrawal bleed

**Comment:** *We recommended that the applicant combine PTs that describe the same AE because it will give a more accurate picture of the given conditions. The Labeling for CHC Guidance<sup>3</sup> further recommends combining conditions that are found together (i.e. nausea and vomiting). The table below shows results of combining these PTs. Adverse events that occurred in ≥5% of subjects will be presented in Section 6.1 of the label.*

**Table 55. Medical Officer's Analysis of ISS Combining Related Preferred Terms**

<b>Combined Terms</b>	<b>n subjects</b>	<b>% (N=2308)</b>
<i>headache/migraine</i>	933	40.4
<i>nausea/vomiting</i>	696	30.2
<i>vulvovaginal mycotic infection/vaginal candidiasis</i>	321	13.9
<i>abdominal pain/lower/upper</i>	321	13.9
<i>UTI/cystitis/genitourinary tract infection</i>	228	9.9
<i>breast pain/tenderness/discomfort</i>	220	9.5
<i>metrorrhagia/menstrual disorder</i>	167	7.2
<i>mood swings/mood altered/affect lability</i>	105	4.5
<i>depression/depressed mood/major depression/depressive symptom</i>	68	2.9
<i>rash/papular/genital/generalized/macular/pruritic</i>	67	2.9
<i>menorrhagia/withdrawal bleed</i>	66	2.9

*Source: NDA 209627, Module 5.3.5.3, ISS, Medical Officer's analysis of the AE data set using JMP*

Within the primary ISS, the applicant presented the incidence of AEs based on BMI of ≤ 29 kg/m<sup>2</sup> and > 29 kg/m<sup>2</sup>. The incidences of AEs were lower for the group with BMI >29 kg/m<sup>2</sup> than the group with lower BMIs.

The SA-only CVS ISS had 180 subjects with AEs. There were no new AEs identified with use of the SA-only CVS. Two of the AEs had a higher incidence than found in the SA/EE CVS; metrorrhagia (58%) and vaginal discharge (32%).

#### 10.4.6. Laboratory Findings

Because this product contained a novel progestin, laboratory findings were evaluated to determine if there were any novel safety signals or trends in the data.

Hematology and serum chemistry laboratory parameters were evaluated at baseline, cycle 6 (Study 300A only), and cycle 13. Most subjects' laboratory parameters were within normal limits.

The largest hematology laboratory shifts involved <5% of subjects with a normal hemoglobin and hematocrit (H/H) at baseline who had a low H/H at final evaluation. Approximately 3% of subjects with a low H/H at baseline had a normal H/H at final evaluation. Shifts in leukocyte and platelet counts were not clinically significant. The highest platelet count occurred at baseline.

**Comment:** *Although there was irregular bleeding and spotting identified in the patient diaries and adverse events, the CVS does not appear to alter H/H to a clinically significant degree.*

The chemistry parameters of cholesterol, HDL, LDL, and triglycerides shifted from normal to high in >3% of subjects, with up to 11% of subjects having high cholesterol and HDL at the final evaluation.

There were four subjects who discontinued CVS use early due to elevated cholesterol and/or triglyceride levels. The table below shows the laboratory value at time of discontinuation.

**Table 56. Discontinued Subjects due to Elevated Cholesterol/Triglyceride Laboratory Values**

Subject ID	Cycle discontinued	Laboratory parameter	Laboratory value	Investigators relationship to CVS	Outcome
(b) (6)	6	cholesterol	248 mg/dL	possibly	ongoing
(b) (6)	7	triglyceride	471 mg/dL	not likely	ongoing
(b) (6)	6	triglyceride	415 mg/dL	possibly	ongoing
(b) (6)	6	triglyceride, cholesterol	140 mg/dL 300 mg/dL	possibly	ongoing

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Medical Officer's analysis of the disposition and laboratory data sets using JMP

In addition, there was one extreme outlier, a triglyceride value of 1,243 mg/dL (Subject (b) (6))

which was not flagged as an AE. This subject discontinued the study due to vaginal soreness and no follow-up labs are noted in the submission. Her narrative does not mention her elevated triglycerides or cholesterol levels at her termination visit. In response to an IR, the applicant noted the triglyceride value of 1,243 was obtained at the subject's termination visit which was 6 weeks after last CVS use and at the time the subject was taking a COC. No further information was provided.

**Comment:** *Mild elevations of cholesterol, HDL, LDL, and triglycerides occurred with the CVS. Adverse lipid and carbohydrate changes are a known effect of CHCs and these changes will be labeled.*

In Study 300A over 5% of subjects had a creatinine shift from normal to high. This finding did not occur in Study 300B. The applicant noted that the abnormal creatinine flag for 300A was particularly low at 80 µmol/L (0.91 mg/dL). The value of 107 µmol/L equals 1.22 mg/dl. A total of 87 creatinine values were >80 and 4 subjects had creatinine values between 100 and 107. The applicant notes an elevation of creatinine is not found with the other CVS studies because the other CVS studies had higher normal creatinine values.

**Comment:** *A creatinine of 0.6-1.2 mg/dl is considered normal by most laboratories and we agree with the applicant that the creatinine elevations are an artifact of the low normal range in the study.*

*Mild adverse lipid changes are a known effect of CHCs and these changes will be labeled. As for the outlier with elevated triglyceride levels six weeks after completing CVS use, it is known that pancreatitis and gallbladder disease can be initiated and/or exacerbated by CHCs. There is no indication that the CVS will have a different risk of these events from other CHC products. Therefore, the warnings on these events will be included in CVS labeling.*

There were eight subjects with an ALT and/or AST ≥ 2x normal; 0.3% of the ISS population. One of these subjects discontinued CVS use due to the laboratory abnormality. There were no BILLI values >2x normal. The eight subjects' laboratory values are summarized in the table below.

**Table 57. Subjects with ALT/AST >2 Times Upper Limit of Normal**

Subject ID	Visit	Lab Parameter	Result U/L	Subject Disposition
(b) (6)	Visit 5	AST	100	completion of study
(b) (6)	Visit 5	AST	215	completion of study
(b) (6)	Visit 5	ALT	106	completion of study

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

(b) (6)	Visit 3	ALT	147	termination due to abnormal labs
		AST	90	
	Visit 5	ALT	127	
		AST	117	
(b) (6)	Visit 5	ALT	97	termination due to planning pregnancy
(b) (6)	Visit 5	ALT	110	completion of study
		AST	85	
(b) (6)	Visit 5	ALT	97	completion of study
		AST	95	
(b) (6)	Visit 5	ALT	87	completion of study
	Visit 6	ALT	115	

\*confirmation that laboratory values returned to normal

Source: NDA 209627, Sequence 0019 Module 1.11.4, Response to Request for Information submitted 17 April 2018

**Comment:** *The liver enzyme abnormalities are mild and consistent with other CHCs. There do not appear to be any new safety concerns regarding liver toxicity and no labeling regarding these rare elevations are warranted.*

#### 10.4.7. Vital Signs/Physical Examination

##### 300A

##### Vital Signs

Systolic and diastolic blood pressures and pulse were assessed at baseline and at each clinical visit. The mean systolic pressures ranged from 107.5 to 108.5 mmHg and the mean percent change from baseline to final evaluation was 1.63% for all subjects. The mean diastolic pressures ranged from 68.8 to 69.8 mmHg and the mean percent change from baseline to final evaluation was 1.86% for all subjects. Mean pulse rate ranged from 74.0 to 76.6 beats/minute and the mean percent change from baseline to final evaluation was 4.7% for all subjects. There were 7 TEAEs due to elevated blood pressure.

**Comment:** *The vital sign data does not reveal any unexpected safety concerns compared with CHC users in general.*

##### Physical Examinations

Physical examinations were performed at baseline, Cycle 6, and Cycle 13. Abnormalities that were considered clinically significant by the investigator and that occurred after first use of the CVS were reported as AEs. Physical examination abnormalities occurring in >1% of subjects after initiation of the CVS were Skin, Breast, Vaginal Wall, and Vulva. Other than TEAEs, findings at the Cycle 6 and Cycle 13 visits were reviewed. There were 35 skin abnormalities noted during the treatment visits that were primarily due to acne, bruising, and increased

pigmentation. The 40 abnormal breast findings were predominantly breast masses consistent with fibrocystic changes and breast implants. Out of 83 vaginal abnormalities, 56 involved discharge. Seven subjects had vaginal erythema without discharge and 4 subjects had excoriations and/or abrasions. Seventy-seven subjects had 94 vulvar abnormalities with the majority (48 events) being vulvar erythema. Other abnormalities included herpetic lesions, fissures, folliculitis, excoriations.

**Comment:** *None of the findings in physical examinations are unexpected. The vaginal and vulvar findings reflect the TEAE findings of vaginal infections and discharge and vulvar irritation which are expected with ring insertion and removal and will be labeled.*

#### Urinalysis, Pap Smear, and STI Results

Urinalysis tests were performed at baseline with 15.8% having abnormal results and 3.8% clinically significant overall. Clinically significant abnormal findings on urinalysis after first use of the CVS were reported as a TEAE.

Abnormal Pap smear results were lower at baseline (31 subjects, 2.8%) than at final evaluation (67 subjects, 9.1%).

Positive Chlamydia tests were lower at baseline (5 subjects, 0.4%) than at final evaluation (14 subjects, 1.6%). Positive Gonorrhea tests were 0.1% at baseline and final evaluation.

**Comment:** *The increased proportion of abnormal Pap smear results has been noted with other CHCs. It is still unclear if this relationship is causal because of associated HPV exposure<sup>20</sup>. Increased STIs are likely due to sexually activity without barrier protection and patients are reminded of this in labeling. In addition, participation in clinical studies provides regular screening for cervical cancer and STIs and this may increase the diagnosis of both entities. Labeling will include that the CVS does not protect against STDs.*

#### Weight and BMI

Height was measured once at baseline and weight was recorded at each clinic visit. Most subjects (63.7%) experienced a weight change of between -2.27 to +2.27 kg during the study. The mean change from baseline to final evaluation for all subjects was +0.26 kg. Approximately halfway through the study, 88 subjects with a BMI >29 kg/m<sup>2</sup> were discontinued and no further recruiting of subjects >29 kg/m<sup>2</sup> occurred. The majority for this subgroup (75.7%) had a weight change was -2.27 to +2.27 at Cycle 3, however, over the course of the

---

<sup>20</sup> UpToDate. [https://www.uptodate.com/contents/risks-and-side-effects-associated-with-estrogen-progestin-contraceptives?search=vte%20and%20contraception&source=search\\_result&selectedTitle=2~150&usage\\_type=default&display\\_rank=2](https://www.uptodate.com/contents/risks-and-side-effects-associated-with-estrogen-progestin-contraceptives?search=vte%20and%20contraception&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2)

Accessed April 13, 2018.

study, 69% of these subjects experienced weight change of between -4.54 to +4.54 kg. The mean change from baseline to final evaluation for all subjects who were discontinued early due to BMI > 29 kg/m<sup>2</sup> was +0.27 kg.

**Comment:** *The mean change of weight from baseline to final evaluation in all subjects of +0.26 kg is consistent with a weight gain of ≤ 0.5 kg noted in other studies<sup>10</sup>. In the subpopulation of subjects with BMI > 29 kg/m<sup>2</sup> the overall weight change was similar at +0.27 kg. This weight change may be due to the length of the study or other factors, but does not appear to represent a concerning safety trend.*

### **300B**

#### Vital Signs

Systolic and diastolic blood pressures and pulse were assessed at baseline and at each clinical visit. The mean systolic pressures ranged from 109.2 to 110.2 mmHg and the mean percent change from baseline to final evaluation was 0.9% for all subjects. The mean diastolic pressures ranged from 68.7 to 69.6 mmHg and the mean percent change from baseline to final evaluation was 1.6% for all subjects. Mean pulse rate ranged from 73.9 to 75.9 beats/minute and the mean percent change from baseline to final evaluation was 2.8% for all subjects. There were 5 TEAEs due to elevated blood pressure, one of which led to early discontinuation.

**Comment:** *The vital sign data do not reveal any unexpected safety concerns compared with CHC users in general.*

#### Physical Examinations

Physical examinations were performed at baseline and Cycle 13. Abnormalities that were considered clinically significant by the investigator and that occurred after first use of the CVS were reported as AEs. Physical examination abnormalities occurring in >1% of subjects after initiation of the CVS were Extremities, Skin, Breast, Cervix, Uterus, Vaginal wall, and Vulva. Most TEAEs in Skin SOC were acne with 56 subjects (4.9%), rash with 14 subjects (1.2%), and allergic dermatitis and urticaria with 7 subjects (0.6%) each. Abnormal findings in the data sets were also reviewed. The 23 subjects with abnormal extremity findings included scars, scratches, and bruises. Thirty-five (35) subjects had breast abnormalities, the majority were fibrocystic breast. Cervical findings in 45 subjects were mainly ectropion and “bleeds easily.” Almost all of the 18 subjects with abnormal uterine findings had enlarged uterine size. All but four of the 99 subjects with abnormal vaginal wall findings had discharge or erythema. Most of the 78 subjects with abnormal vulvar findings had vulvitis and hyperemia.

**Comment:** *None of the findings in physical examinations are unexpected from a gynecologic perspective. The vaginal and vulvar findings reflect the TEAE findings of vaginal infections and discharge and vulvar irritation and may result from repeated ring insertion and removal.*

#### Urinalysis, Pap Smear, and STI Results

Urinalysis tests were performed at baseline with 17.6% having abnormal results with 3.7% being clinically significant. Clinically significant abnormal findings on urinalysis after first use of the CVS were reported as a TEAE.

Abnormal Pap smear results were lower at baseline (40 subjects, 3.5%) than at final evaluation (77 subjects, 9.4%).

Positive Chlamydia tests were higher at baseline (48 subjects, 4.3%) than at final evaluation (3 subjects, 3.3%). There were 0.1% positive Gonorrhea tests at baseline and zero at the final evaluation.

**Comment:** *The increase proportion of abnormal Pap smear results has been noted with other CHCs<sup>10</sup> and it is unclear if this is a causal relationship or related to HPV exposure. In addition, participation in clinical studies provides regular screening for cervical cancer and STIs and this may increase the diagnosis of both entities.*

#### Weight and BMI

Height was measured once at baseline and weight was recorded at each clinic visit. Most subjects (63.3%) experienced a weight change of between -2.27 to +2.27 kg during the study. The mean change from baseline to final evaluation for all subjects was +0.42 kg. Approximately halfway through the study, 52 subjects with a BMI >29 kg/m<sup>2</sup> were discontinued and no further recruiting of subjects >29 kg/m<sup>2</sup> occurred. Over 50% of this subgroup had a weight change between -2.27 to +2.27 at Cycle 3 and Cycle 6. The mean change from baseline to final evaluation for all subjects who discontinued early due to BMI>29 kg/m<sup>2</sup> was -0.77%.

**Comment:** *The mean weight change from baseline to final evaluation in all subjects of +0.42 kg is consistent with a weight gain of  $\leq 0.5$  kg noted in other studies<sup>10</sup>. In the subpopulation of subjects with BMI > 29 kg/m<sup>2</sup>, the average overall weight change in kg was not given, but 75% of the 48 subjects had < + 2.27 kg change with the mean change reported at -0.77%.*

#### **ISS**

Combined data on vital signs, physical (and gynecological) examinations, weight and BMI, and urinalysis, pap smear, and STI laboratory results reported in the ISS were evaluated.

**Comment:** *There were no new safety signals or trends noted in either of the two clinical studies or in the pooled ISS data for vital signs, weight/BMI or serum laboratory results. Vaginal infections and discharge were noted in both studies and these findings will be addressed in labeling.*

#### **10.4.8. Electrocardiograms (ECGs)**

ECGs were not done as part of the pivotal studies but were performed during QT evaluation studies discussed below.

#### 10.4.9. QT

A thorough QT study (TQT; Study POP-648) was performed to evaluate the potential for QTc prolongation with use of this product. Study POP-648 was a single-center, double-blind, three-period, randomized, crossover study to evaluate the effect of suprathreshold doses of intravenous (IV) SA on the QT/QTc interval in 44 healthy pre-menopausal female subjects. Subjects were randomized to either suprathreshold dose IV SA or open-label moxifloxacin 400mg in each period. Thirty-nine subjects completed the study per-protocol. The study results demonstrated that the largest upper bound of the 90% CI for the mean difference SA administered by IV bolus and placebo were below 10ms, the threshold for regulatory concern as described in the ICH E14 guidelines. The Interdisciplinary Review Team for QT (IRT QT) studies was consulted and reviewed the TQT study results. In a review dated February 5, 2018 the IRT QT concluded: "no significant QTc prolongation effect of Nesterone [i.e. SA] was detected in this TQT study."<sup>21</sup> The IRT QT consult also provided suggested labeling language for Section 12.2 of the label (Pharmacodynamics), which will be incorporated into the final label.

#### 10.4.10. Immunogenicity

See Section 10.5.2 Angioedema/Drug Allergy

#### 10.4.11. Pregnancy Outcomes

There were a total of 86 pregnancies in the Primary ISS. Of the 61 pregnancies that occurred during the study, there were 30 livebirths (49%), 10 spontaneous abortions (16%), 15 induced terminations (25%), 1 ectopic pregnancy (2%), and 5 unknown outcomes (8%). Of the 25 pregnancies that occurred in the 6-month follow up, there were 3 livebirths (12%), 5 spontaneous abortions (20%), and 17 unknown outcomes (68%). No congenital abnormalities were reported. See Clinical Appendices, 22.6.1 Pregnancies, for the complete listing of pregnancies and outcomes.

**Comment:** *We did not identify any pregnancy outcomes of concern during or after CVS use. See Section 10.4.12 Return to Fertility for comments.*

#### 10.4.12. Return to Fertility

Subjects who wished to become pregnant or use non-hormonal contraceptives could enter a 6-month follow up to assess return to fertility after CVS use. Two hundred and ninety (290) subjects qualified for inclusion and provided data on return to fertility defined by menses or pregnancy. All subjects (100%) had return to fertility based on this definition. Twenty four subjects (8.2%) became pregnant within 6 months' post-treatment and the remaining 266 subjects reported menses occurring.

---

<sup>21</sup>

[https://darrts.fda.gov/darrts/faces/ViewDocument?documentId=090140af8047e456&\\_afRedirect=1178869194318017](https://darrts.fda.gov/darrts/faces/ViewDocument?documentId=090140af8047e456&_afRedirect=1178869194318017)

**Comment:** *The return to fertility data with the CVS show no safety concerns that women will require an extended timeframe if they decide that they wish to become pregnant or use another contraceptive method.*

#### 10.4.13 CVS Expulsions/Issues

Expulsions of the CVS were self-reported by subjects on their diary cards. To be evaluable at least 15 of the first 21 days had to have a response (none, partial or complete) recorded. Of the 2096 subjects with evaluable diary cards, one completed expulsion occurred in 24.6% of subjects and in 7.0% of all treatment cycles. Expulsions occurred with the greatest frequency in the initial treatment cycles. Thirty-three (33) subjects or 1.4% discontinued the study due to CVS expulsions. There were seven subjects with device-related AEs which included vaginal discomfort (4 subjects), vaginal pain (1 subject), and urinary pressure (1 subject). By comparison, the NuvaRing label<sup>4</sup> reports the incidence of “device-related events” AEs of 6.3%. Device-related events include expulsion, discomfort, and foreign body feeling.

A summary of complete expulsions by cycle in the primary ISS is shown below.

**Table 58. CVS Complete Expulsions occurring in the Primary ISS**

Cycle	N <sup>a</sup>	Complete Expulsions <sup>b</sup> n (%)
1	2050	190 (9.3)
2	1994	120 (6.0)
3	1808	105 (5.8)
4	1751	90 (5.1)
5	1694	85 (5.0)
6	1561	66 (4.2)
7	1490	70 (4.7)
8	1445	61 (4.2)
9	1283	44 (3.4)
10	1185	42 (3.5)
11	1064	40 (3.8)
12	984	35 (3.6)
13	902	29 (3.2)
All Cycles <sup>c</sup>	21482	1509 (7.0)
All Subjects <sup>d</sup>	2096	515 (24.6)

Source: ISS Table 2.14

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

A cycle was deemed eligible for analysis of expulsions if the diary cards for that cycle had a proper response ('None', 'Partial', or 'Complete') recorded for at least 15 of the first 21 days.

- <sup>a</sup> Count of eligible subjects or cycles. Because each subject could only have one of each numbered cycle, by-cycle counts also corresponded to subject counts.
- <sup>b</sup> Count of eligible subjects/cycles during which at least 1 date on the diary card recorded an expulsion.
- <sup>c</sup> All eligible cycles in the All QPharma NES/EE CVR Analysis Set, including cycles after Cycle 13.
- <sup>d</sup> Subjects with at least one eligible cycle during the first 13 cycles. Data after Cycle 13 was excluded from this row.

Source: NDA 209627, Module 5.3.5.3, ISS, Table 6-5 ISS p 61/3781

**Comment:** *Although expulsions were not considered an AE, they are important information for prescribers and patients. The label will note that 25% of subjects reported at least one complete expulsion and 1.4% of subjects discontinued CVS use due to expulsions.*

## 10.5. Analysis of Submission-Specific Safety Issues

### 10.5.1. Venous Thromboembolism (VTE)

VTE is an AE of significant interest with CHC use. There were three VTEs in Study 300A and 1 VTE in Study 300B which are presented here. The VTEs occurred during cycles 2, 3, 6, and 7 of CVS use. All four subjects were past users of CHCs.

While Study 300A was ongoing, the Data Safety Monitoring Board (DSMB) met (August 22, 2007). At that time, two of the three VTEs (PE, DVT) had occurred and were reviewed. The meeting minutes are summarized below<sup>33</sup>:

At the DSMB meeting two serious adverse events (SAEs), one pulmonary embolism (PE) in one subject and one deep venous thrombosis (DVT) in one subject; both with a BMI 29.3 kg/m<sup>2</sup> were reviewed. These two SAEs represented a larger rate of thrombosis than expected and were considered “not likely to be attributable to chance”. The DSMB felt possible explanations of the thrombotic events were:

- increased risk of thrombosis with increased BMI
- higher than expected serum EE levels with the study ring during initial cycles

(b) (4)

The DSMB noted that the EE levels for the study CVS are higher than NuvaRing EE levels in the initial and third cycle, although less than daily serum levels for the OrthoEvra patch by cycle 4.

The DSMB recommended against further enrollment of new subjects with a BMI >29 kg/m<sup>2</sup>. For subjects of BMI >29 kg/m<sup>2</sup> and less than 35 y/o already in the study, the DSMB noted the greatest risk for elevated estrogen levels had passed and it was acceptable for these subjects to continue but that the study consents should be

reviewed to confirm there was adequate disclosure of possibly increased thrombosis risk.

After the recommendations, the applicant in agreement with DSMB decided to withdraw all subjects currently enrolled whose BMI was  $>29 \text{ kg/m}^2$  <sup>22</sup>.

In the context of VTE and BMI, the applicant (b) (4)

**Study 300A Subject #** (b) (6) DVT, right calf

A 26-year-old nonsmoker with a screening BMI of 30.8 who had previously used COCs and a vaginal contraceptive ring, started the CVS (b) (6). Concomitant medications included Valtrex, taken (b) (6) through (b) (6). She experienced right leg pain and swelling on (b) (6) (Cycle 6 Day 3). On (b) (6), the subject went to the ER and had a lower extremity venous duplex performed showing acute deep vein thrombosis of the right popliteal and posterior tibial veins. Vital signs were normal. The subject was started on enoxaparin and warfarin, and was sent home with instructions to discontinue the CVS. The last day she used the ring was (b) (6). Follow-up laboratory testing after anticoagulant therapy was stopped was negative for lupus anticoagulant, Factor V Leiden and Factor II DNA mutation and showed normal activity in Antithrombin III, Protein C Activity, Activated Protein C Resistance, Protein S-Functional, Factor II activity and D-Dimer. This subject had a confounding factor of driving for five hours one week prior to the VTE event. The Investigator classified this AE as probably related to CVS use. The DVT resolved with treatment.

**Comment:** Subject (b) (6) experienced a DVT while exposed to three risk factors for VTE. COC use increases risk of VTE 2-4 times compared to nonusers, obesity ( $>30 \text{ kg/m}^2$ ) further increases VTE risk in COC users 2.3-4.6 fold over non-obese COC users, and travel increases the relative risk of VTE by 2.8 compared to non-travelers<sup>23</sup>. We agree that all of these factors may have contributed to the VTE, however, we believe the emphasis on this subject's BMI is overstated. First, obesity is defined by  $>30 \text{ kg/m}^2$  and the use of BMI  $> 29 \text{ kg/m}^2$  is arbitrary and determined based on the VTEs experienced in the clinical study. Second, review of clinic data shows the subject's weight decreased during her use of the CVS. The day after her DVT was diagnosed (b) (6), she was seen in the clinic and her BMI was  $29.3 \text{ kg/m}^2$ . At her previous visit in (b) (6), her BMI was  $30.1 \text{ kg/m}^2$ . Clearly, subject (b) (6) hovered at the overweight/obese cut off and the five pound difference between her April visit and July VTE event doesn't, physiologically speaking, seem a

<sup>22</sup> [Application 209627 - Sequence 0007 - Report of DSMB Meeting Minutes for Protocols CCN006 \(300A & 300B\) - 22 Aug 2007](#)

<sup>23</sup> [https://www.uptodate.com/contents/risks-and-side-effects-associated-with-estrogen-progestin-contraceptives?sectionName=VENOUS%20THROMBOEMBOLIC%20DISEASE&topicRef=1361&anchor=H11&source=see\\_link#H11](https://www.uptodate.com/contents/risks-and-side-effects-associated-with-estrogen-progestin-contraceptives?sectionName=VENOUS%20THROMBOEMBOLIC%20DISEASE&topicRef=1361&anchor=H11&source=see_link#H11) UptoDate Risk and side effects associated with estrogen-progestin contraceptives. Accessed 6/13/18.

*compelling factor of her VTE.*

**Study 300A Subject #** (b) (6) **Pulmonary Embolism**

A 23-year-old with a screening BMI of 29.1, who had previously used COCs and transdermal contraception, started the CVS (b) (6). On (b) (6), the subject experienced numbness and tingling in the toes of both feet for a short time, but denied leg pain. On (b) (6) (Cycle 2) the subject experienced back and chest pain with difficulty breathing. On (b) (6), she was admitted to the hospital and computed tomography and pulmonary angiogram showed filling defects in the lingular segmental pulmonary artery, a subsegment of the posterior basal pulmonary artery in the right lower lobe, and the apical segmental pulmonary artery to the right upper lobe just past the bifurcation of the truncus anterior, giving a diagnosis of PE. Laboratory test results on admission were within normal range; tests for thrombophilia and for hemostatic factors were negative. She was treated with anticoagulants and discharged from the hospital on (b) (6). Her last CVS use was (b) (6). The applicant noted her screening BMI was 29.1. Her BMI at hospitalization was 30.2. The Investigator classified this AE as definite/highly probable in relation to CVS use. The PE resolved with treatment.

**Comment:** Subject (b) (6) experienced an unprovoked PE with a negative hypercoagulability workup during her second cycle of CVS use. The applicant notes her only risk factor was her BMI of > 29 kg/m<sup>2</sup>. We do believe that the patient's BMI alone precipitated her PE since her BMI was > 29 kg/m<sup>2</sup> at baseline and she had no prior history of DVT/PE despite her previous exposure of COCs. Review of BMI measurements shows the following:

<b>Visit</b>	<b>Date</b>	<b>BMI</b>	<b>Day of CVS Use</b>
V0	(b) (6)	29.1	screening
V1	(b) (6)	28.5	baseline day 1
Hospital/PE	(b) (6)	30.2	day 42
V5	(b) (6)	28.0	day 47
V6	(b) (6)	27.8	day 54

*The applicant suggests that a BMI over 29 kg/m<sup>2</sup> incurs a tenfold higher risk for VTE. Indeed, PE risk goes up as BMI increases beyond 22.5 kg/m<sup>2</sup> and the risk increases almost six fold at ≥35 kg/m<sup>2</sup> compared to those with BMI<22.5 kg/m<sup>2</sup> (Kabrhel et al 2012).<sup>24</sup> From the subject's BMI measurements, her BMI was >28 kg/m<sup>2</sup> before initiation of CVS and her BMI change on CVS was not remarkable; therefore, a temporal association between exposure to CVS and the occurrence of PE cannot be excluded.*

<sup>24</sup> Kabrhel C, Varraso R, Goldhaber S, Rimm EB, Camargo CA. Prospective study of BMI and risk of pulmonary embolism in women. *Obesity*. 2009;17:2040-2046

**Study 300A Subject #** (b) (6) DVT, Factor V heterozygous mutation

A 39-year-old with a baseline BMI of 24.7, history of hypothyroidism treated with Synthroid, and previous use of COC for 6 years (last use (b) (6) ago), and one pregnancy 15 years prior, started the CVS (b) (6). On (b) (6) (Cycle 3) she experienced left leg pain and swelling. On (b) (6) an “ultrasound scan” of leg was negative. The subject had increasing pain and difficulty walking and a second “ultrasound scan” was performed on (b) (6) with the diagnosis of acute DVT in left lower extremity involving the popliteal, peroneal and gastrocnemius veins at which time she discontinued the CVS. The subject was started on enoxaparin and warfarin and the CVS was discontinued. This subject was in the sub-study for hepatic factors and at baseline visit, (b) (6), her labs were normal. (b) (6) laboratory tests showed that she was positive for one copy Factor V mutation (heterozygous); the rest of thrombophilia labs were normal or negative. The Investigator classified this AE as possibly related to CVS. The DVT resolved with treatment.

**Comment:** Subject (b) (6) experienced a DVT and was found to have a Factor V Leiden mutation on subsequent thrombophilia laboratory testing. Presence of this mutation in women using OCs increases the risk of VTE 4-8 fold over women using OCs without the mutation. Screening for Factor V Leiden mutation prior to OC use is not recommended due to the prevalence (5% of women) and the low incidence of venous thrombosis-related mortality<sup>33</sup>.

**Study 300B Subject** (b) (6) Cerebral Venous Thrombosis

28-year-old former smoker (quit in (b) (6) with a history of depression and use of COC five weeks prior to study entry, started the CVS (b) (6) with a BMI of 25.0 kg/m<sup>2</sup>. On (b) (6) (Cycle 7 day 24) during the ring-out period, the subject experienced a localized headache that progressed during the night and was accompanied with nausea and vomiting. The next day the pain returned and worsened. On (b) (6), a magnetic resonance angiography of the head “showed near total occlusive thrombosis of the left transverse sinus and no evidence of intracranial arterial aneurysm, occlusion or flow limiting stenosis”. The subject was admitted to the hospital and treated with heparin. Laboratory tests on admission were within normal ranges. The subject was discharged from the hospital one week later on coumadin. Attempts to contact the subject by the study site were unsuccessful. The subject’s physician verbally stated that the subject’s coagulation profile laboratory tests were all normal. The Investigator classified this AE as possibly related to CVS use.

**Comment:** Subject (b) (6) experienced an apparent unprovoked cerebral venous thrombosis. The applicant was not able to obtain hospital records or follow up with the subject because the subject did not return calls nor had she given permission for medical records release. Her primary care physician verbally stated that “the subject was doing well and that her coagulation profile laboratory tests were all normal” to the Principal Investigator.

The applicant acknowledges the observed rate of VTE in this program, four (4) VTEs in the primary ISS (All QPharma) was higher than other CHC programs. The applicant states this increased rate was due to the disproportionate rate of VTE in obese women (b) (4). By removing this population and two of the four VTEs, the applicant is able to calculate a VTE risk consistent with other CHC programs (Table 59).

**Table 59. Summary of VTE risk by Analysis Sets and BMI**

<b>Rates by BMI Subgroup</b>					
<b>Baseline BMI (kg/m<sup>2</sup>)</b>	<b>N</b>	<b>VTEs Observed (n)</b>	<b>Exposure (cycles)</b>	<b>Cumulative Incidence Rate<sup>a</sup></b>	<b>95% Confidence Interval</b>
<b>All NES*/EE CVS (N=2843)</b>					
≤29.0	2536	2	24190.9	10.78	(8.90, 13.07)
>29.0	307	2	2083.7	125.21	(103.34, 151.71)
Ratio (>29.0 vs. ≤29.0)				11.61	(8.85, 15.23)
<b>All NES*/EE 150/15 CVS (N=2569)</b>					
≤29.0	2312	2	21709	11.98	(9.82, 14.61)
>29.0	257	2	1590	163.52	(134.03, 199.50)
Ratio (>29.0 vs. ≤29.0)				13.65	(10.31, 18.09)
<b>All QPharma NES*/EE CVS (N=2308)</b>					
≤29.0	2099	2	20336	12.79	(10.39, 15.73)
>29.0	209	2	1254	207.34	(168.51, 255.11)
Ratio (>29.0 vs. ≤29.0)				16.22	(12.10, 21.74)
Source: ISS Table 1.1.6; ISS Table 2.7.14; ISS Table 2.7.15					

<sup>a</sup> incidence rate per 10,000 women-years

\*NES=SA

Source: NDA 209627, Module 5.3.5.3, ISS, Table 8-15, p 108/3781

**Comment:** We do not agree with the applicant's proposed (b) (4)

(b) (4)

<sup>25</sup> Report of DSMB Meeting Minutes for Protocol CCN006 (300A & 300B) 22 Aug 2007. Submitted NDA 209627 Modules 1.6.3 Correspondence Regarding Meetings.

*Based on clinical review, the CVS VTE risk should be evaluated including all subjects and cycles in the primary ISS, (b) (4) Based on the primary ISS of 2308 women contributing 21,590 cycles with 4 VTEs, the cumulative incidence rate is 24.1 per 10,000 women-years (95%CI 6.6, 61.7). Although this is a somewhat higher incidence than noted in other recent CHC trials, the increased rate is due to one additional VTE event occurring in the trials. Further, these clinical studies were not powered to provide a precise estimate of the incidence of uncommon events such as VTEs, which is reflected in the wide confidence interval that speaks to the considerable uncertainty associated with the VTE incidence rate estimate of 24.1 per 10,000 women-years estimate.*

There have been numerous studies on VTE risk in CHCs, especially in relation to type of progestin. FDA labels show the likelihood of developing a VTE for a CHC-user of 3-12/10,000 women-years. The American College of Obstetrician and Gynecologists Committee Opinion 540 (reaffirmed 2016) provides the risk of VTE among COC users as 3-9/10,000 women-years<sup>26</sup> while the EURAS Study<sup>27</sup> has 10.2/10,000 women-years for “other OCs” (other than LNG COCs and Yasmin).

In the past 10 years, approved CHCs with the highest VTE incidence per 10,000 women-years based on clinical trial data are 16.7 for Lo Loestrin Fe (EE/NETA) and 11.3 for Quartette (EE/LNG). The absolute numbers of VTEs were small with Quartette having 3 VTEs and the rest of the CHCs having 0-2 VTEs. NuvaRing clinical trials which excluded women with a BMI >29 kg/m<sup>2</sup> was approved in 2001 and had a VTE incidence of 5.3 per 10,000 women-years. The OrthoEvra patch clinical trials had 2 VTEs for a 11.7 VTE/10,000 women-years (approved 2001).

The applicant notes the mean BMI of 26.7 kg/m<sup>2</sup> for the CVS is higher than other CHCs, and this may have increased the number of VTEs in the pivotal trials. However, Quartette trial subjects had a mean BMI of 27.3 kg/m<sup>2</sup> and LoSeasonique trial subjects had a mean BMI of 26.8 kg/m<sup>2</sup>. LoSeasonique had no VTEs in the clinical trials. Therefore, BMI is not the reason the VTE estimate appears high in this submission.

---

<sup>26</sup> <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Risk-of-Venous-Thromboembolism>

<sup>27</sup> Dinger J, Heinemann L, Kühl-Habich D. 2007. The Safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception; 75(5): 344-354.

The applicant states that three of the four subjects with VTE had predisposing factors (driving for an extended time, positive Factor V, and BMI). While this is true, subject recruitment in this contraceptive study was consistent with other contraceptive studies. As in other contraceptive studies, in the studies for this application, subjects with known risks for VTE (i.e. family history or personal history of VTE, hypertension, migraines with focal symptoms, smokers over 35 years old) were excluded. These studies are designed to reflect how the contraceptive product will be used in practice, with the above exclusions listed as contraindications in the label. Since many women are not aware of their personal risk for VTE both in clinical studies and in clinical practice, this study design reflects real-world evidence. Of note, all 4 subjects had previously used CHCs and would be classified as “previous users” (4 weeks had elapsed since last use) and might be considered at lower risk than naïve subjects.

**Comment:** *After discussions with the applicant, the identified VTE risk will be labeled in Warnings and Precaution (W&P) as in all CHCs. Within the W & P section, obesity as a risk factor for VTE is listed. I recommend discussion of the four (4) VTEs in the Clinical Trials experience. Whether to include subject level data, i.e. BMI and other risk factors, will be determined. Because we cannot draw a definitive conclusion about the actual VTE risk for the CVS based on the available data or how it would compare to other CHC products, we will require a postmarketing study to evaluate VTE risk with an appropriately powered required study to gain a more accurate risk assessment.*

#### 10.5.2. Angioedema/Drug Allergy

Hereditary angioedema is a rare familial disorder that is associated with exogenous estrogens (i.e. CHCs) or high estrogen levels (as in pregnancy). Drug allergies with CHCs are more common and have diverse etiologies. Two SAEs in the Angioedema/Drug Allergy category occurred in the pivotal trials.

**Study 300A Subject #** (b) (6) Combination Drug Allergy, Angioedema  
A 37-year-old who in the previous year used NuvaRing, used the CVS (b) (6) through (b) (6) and on (b) (6) experience angioedema, with throat constriction, respiratory wheezing and hives. She self-treated with Benadryl but later went to the emergency room and was treated with solumedrol and prednisone. She returned to the emergency room for the next 3 days (b) (6), was treated symptomatically and never admitted. The subject had been suffering from a viral illness and was using aspirin products. She had an evaluation by an allergist (b) (6) and the allergist made the diagnosis of angioedema/urticaria. The allergist felt the viral illness and use of NSAIDs and opioid therapy were contributing factors but that the reaction can be related to hormone therapy. The subject discontinued the CVS and restarted NuvaRing on (b) (6) with complete recovery from the event on (b) (6). The investigator classified this AE as probably related.

**Comment:** *Angioedema is an uncommon but known event that occurs with the estrogen*

*component of CHCs. This subject's symptoms of angioedema occurred within one month of starting the CVS and continued despite daily treatment until the CVS was discontinued. The episode resolved after the CVS was discontinued but while the subject was using NuvaRing. This is an interesting case because the symptoms of angioedema resolved despite using Nuvaring which contains the same estrogen component; therefore, it is possible the subject's angioedema is due to other components of CVS that is not ethinyl estradiol.*

**Study 300B Subject #** (b) (6) Urticaria, Facial Edema, Asthmatic Attack

A 33-year-old with a history of asthma and several allergies including nickel and penicillin and past use of CHCs, started the CVS (b) (6). On (b) (6), she "got a cold" and increased her asthma medication. Two day later she experienced urticaria mainly on her arms one hour after eating cashews. She had no history of allergy to cashew nuts. She was treated with cortisone and antihistaminic medication with the rash decreasing on (b) (6). However, on (b) (6) her urticaria increased and she experience facial edema. She removed the CVS on (b) (6). With continued treatment for asthma and allergic reaction, she recovered. There were no genital symptoms suggesting a local allergic reaction. The applicant felt the nuts were more likely the causal factor and that a slow recovery from the allergic reaction most likely explained the clinical resolution rather than allergic reaction to the CVS with a positive dechallenge test.

**Comment:** *Hypersensitivity to the CVS or any of its components will be listed in the Contraindications section of the label. Angioedema will be labeled in the Warnings section.*

## 10.6. Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability

There were no patient reported safety outcomes that required input from the clinical outcome assessment team regarding safety or tolerability.

## 10.7. Safety Analyses by Demographic Subgroups

The applicant presented MedDRA-based tables for their demographic subgroups of age, race, ethnicity and geographic region. There were no significant differences in the proportion or the types of TEAEs in any of the demographic subgroups.

Age was categorized by <36 years or ≥36 years. There were 1872 TEAEs in the <36 year group and 144 TEAEs in the ≥36 years group. Percentages for the different SOC and PT were similar between these groups.

Race was categorized by Caucasian, Black, and Other. There were 1429 TEAEs in the Caucasian, 261 TEAEs in the Black, and 287 TEAEs in the Other groups. Percentages for the different SOC and PT were similar for the three race categories.

The TEAEs between Hispanic and non-Hispanic, nulliparity and parity, US and non-US, and age of the CVS (<1.69 years, >1.69-1.99 years, ≥ 2 years) subgroups were similar.

## **10.8. Specific Safety Studies/Clinical Trials**

Nested within Study 300A, were three sub-studies to explore the effect of the CVS on vaginal microbiology, endometrial histology, and four estrogen-dependent hepatic proteins. The sub-studies procedures and results discussed in this section (10.8 Specific Safety Studies/Clinical Trials) relate to the specific safety parameters.

### **10.8.1. Microbiology sub-study**

The primary objective of the Microbiology sub-study was to evaluate changes in vaginal flora and risk of vaginal infection associated with use of the same CVS for 13 cycles.

The trial design was a single center sub-study of 300A where the subjects were also full participants in study 300A and included in the contraceptive efficacy and safety assessments in the main study. A separate and additional informed consent was obtained at enrollment into the microbiology sub-study.

In addition to the visits and procedures required for 300A, subjects in this sub-study had quantitative vaginal cultures, vaginal smear saline preparation, potassium hydroxide analysis, vaginal pH, Whiff test, gram stain, and temperature assessments at Screening (V0), cycle 6 (V3), and cycle 13 (V5). At Visit 5 (cycle 13) when the study ring was removed, quantitative culture of the vaginal ring was also performed. If subjects did not complete 13 cycles, they were to complete all of the cycle 13 assessments at their final study visit, regardless of when the final visit occurred. Visit 3 occurred on day 1-7 (in week 1 of CVS use) and Visit 5 occurred on day 21-27 (during last week of the last treatment cycle).

The endpoints for this sub-study were:

- the presence of bacterial vaginosis based on Amsels criteria and Nugent score

- presence of yeast based on KOH analysis
- presence and amount of WBCs
- presence or absence of trichomonads
- vaginal cultures presence of Lactobacillus, Gardnerella vaginalis, enterococcus, Staphylococcus aureus, E. coli, Candida albicans, other yeast, anaerobic gram-negative

Comparison between baseline (V0) and follow up visit (V6 and/or V13) was performed. Amsels and Nugent score were determined by the principal investigator. The criteria are presented in the Appendix (22.6.2 Microbiology Sub-study).

One hundred twenty (120) subjects were enrolled in the microbiology sub-study. One hundred and ten (110) subjects had a baseline and at least one follow-up visit and comprised the microbiology population. The disposition of the 120 subjects is shown in the table below.

**Table 60. Disposition of Microbiology Population**

Disposition	n subjects	% (N= 110)
Completed study	68	56.7
Discontinued study	52	43.3
Reason for Discontinuation		
Adverse event	18	15.0
Withdrew consent	17	14.2
Lost to follow up	6	5.0
BMI >29 kg/m <sup>2</sup>	6	5.0
Compliance	3	2.5
Expulsion	1	0.8
Pregnancy	1	0.8

Source: NDA 209627, Module 5.3.5.2, 300A Microbiology Sub-study Clinical Study Report, Figure 1 p 34/58

The 120 subjects' demographics in this single site study were predominantly White (82.5%), not Hispanic (94.2%), never married (86.7%), had some college or higher (93.4%), and desired children after completing the study (76.6%). Most subjects were nulliparous with 23.3% of the 120 having at least one pregnancy.

The mean age was 24.5 years with 85.0% of subjects between 20 and 29 years. The mean BMI was 23.1 with 66.7% of subjects between BMI of  $\geq 20$  and  $< 25$  kg/m<sup>2</sup>. Never smokers made up 62.5% of the population and 15.8% of subjects were current smokers.

Medical history for active conditions was present in 97.5% of the sub-study subjects. Compared with the general 300A study population, the sub-study population had a higher incidence of conditions in Nervous System Disorders (60.8% vs 35.3%) and Reproductive System and Breast Disorders (67.5% vs 20.0%). Infections and Infestations was similar between the sub-study and main study (14.1% vs 15.8%). In this sub-study, there were 19 subjects (15.8%) who used fluconazole concomitantly.

The results of quantitative tests given in the report are presented in Table 61. Results for remaining microorganisms (enterococcus, E. coli, Gardnerella vaginalis, Staph aureus, Candida albican, or other yeast) did not indicate any significant changes or trends. There were no differences in the culture results between vaginal aspiration and CVS ring except for anaerobic gram negative rods that were not preserved in transport during the CVS ring culture process.

**Table 61 Results of Microbiology Quantitative Tests**

ASSESSMENT	V0	V6	V13	SIGNIFICANCE
Bacterial vaginosis	N=120 (%)	N=110 (%)	N=61 (%)	
Amsel	3 (2.5)	3 (2.7)	1 (1.6)	NS
	N=119 (%)	N=110 (%)	N=61 (%)	
Nugents score $\geq 7$	15 (12.6)	12 (10.9)	5 (8.2)	NS
Yeast	N=120 (%)	N=110 (%)	N=61 (%)	
KOH	2 (1.7)	3 (2.7)	3 (4.9)	**
WBC	N=115 (%)	N=102 (%)	N=57 (%)	
moderate to many	6 (5.2)	4 (3.9)	0	NS
Vaginal culture	N=120 (%)	N=110 (%)	N=61 (%)	
Lactobacillus present	92(76.7)	91 (82.7%)	55 (90.2)	NS
Non H2O2 Lactobacillus	43 (35.8)	36 (32.7)	13 (21.3)	SS
Anaerobic gram negative rods (AGNR)	46 (38.3)	61 (55.5)	33 (54.1)	SS

NS=not significant, SS=statistically significant  $P < 0.05$ , \*\* applicant separated symptomatic from asymptomatic yeast infections and stated there was no significance for symptomatic yeast infections. There was no calculation for all yeast infections.

Source: NDA 208627, Module 5.3.5.2, 300A Microbiology Sub-study Clinical Study Report p 41-43/58

**Comment:** *The mean concentration of anaerobic gram negative rods (AGNR) increased with CVS use with the median concentrations remaining at a low level ( $\leq 10^2$ ) and no subjects with symptomatic infection suggesting that this increase is not clinically significant. The concentration of hydrogen peroxidase lactobacillus in vaginal flora cultures maintained high levels at all three assessments with no statistically significant changes based on shift tables. There was a decrease of non-hydrogen peroxidase lactobacillus between baseline and Cycle 13 that was statistically significant; this finding is not likely to be clinically significant since hydrogen peroxide-producing lactobacillus helps provide a normal vaginal ecosystem. The KOH results reported by the applicant separate the KOH results into symptomatic and asymptomatic, which I have combined in the above table. It is difficult to ascribe clinical significance to such small numbers; 2 vs 3 subjects.*

*Of concern is the concomitant use of fluconazole by 19 subjects during this study. It is unclear how this affects the results, especially for yeast. Also, the subjects of this sub-study, based on demographics, do not reflect the overall US population and it is*

*unknown if these results are generalizable to the US or global populations. In summary, none of the data obtained from this substudy shows a new trend or concern that would require specific labeling for vaginal infections.*

### 10.8.2. Endometrial Safety Sub-Study

The primary objective of the Endometrial safety sub-study was to demonstrate the safety of the CVS on the endometrium after 1 year of use.

The trial design was a multicenter (6 US centers) sub-study of 300A where the subjects were also full participants in study 300A and included in the contraceptive efficacy and safety assessments in the main study. A modified informed consent form with risks and benefits of the endometrial biopsies was signed prior to subjects' entry into the sub-study.

In addition to the visits and procedures required for 300A, subjects in this sub-study had two endometrial biopsies. All subjects in this sub-study (after a negative UPT) had an endometrial biopsy at Screening (V0). If the subject was not on CHCs, the biopsy was performed between days 7-14 of the subject's cycle. If the screening biopsy showed hyperplasia or carcinoma, the subject was to be excluded from enrolling in both this sub-study and the main study (300A). After CVS treatment started, the first 25 subjects to reach Cycle 6 (V3) were to have a second endometrial biopsy on Days 20-24 of Cycle 6. The remainder of the subjects were to have a second biopsy at Cycle 13 (V5) during Days 20-24 or at the time of early termination (provided the subject had been enrolled for at least 3 months).

Three pathologists with expertise in gynecology pathology read each of the processed endometrial tissue in a blinded fashion. The most severe diagnosis was recorded if there were differing diagnoses.

Endpoints included:

- Endometrial histology data summarized by visit and hormonal contraception history
- Changes in endometrial patterns from baseline

A total of 156 unique subjects had baseline endometrial biopsies and 83 subjects had a follow-up endometrial biopsy. Twenty seven (27) subjects had biopsies at Cycles 5 to 6, 25 subjects had biopsies at Cycles 7 to 11, and 31 subjects had biopsies at Cycles 12 to 13 and one subject had a biopsy performed 2 cycles after she finished using the CVS for 14 cycles. The disposition of the 156 subjects is shown in Table 62.

**Table 62. Disposition of Safety Population in the Endometrial Sub-Study**

Disposition	n subjects	% (N=156)
Completed study	77	49.4

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Discontinued study	79	50.6
Reason for Discontinuation		
Adverse event	23	14.7
Lost to follow up	22	14.1
Withdrew consent	17	10.9
Eligibility	15	9.6
Compliance	1	0.6
Pregnancy	1	0.6

Source: NDA 209627, Module 5.3.5.2, 300A Endometrial Safety Clinical Study Report, Figure 1 p 35/70

Six eligibility violations occurred; three due to abnormal baseline laboratory test results, two due to abnormal baseline Pap smears, and one due to the subject not having a history of regular menses.

The majority of the safety population’s demographic and baseline characteristics were White (66.7%), non-Hispanic (92.3%), never married (68.6%), and 48.7% had some college or higher education. The majority, 55.8%, had a history of at least one pregnancy.

The majority of subjects (71.2%) were between 20 and 29 years of age, with the mean age of 27.2 years. The mean BMI (SD) was 24.2 (±11.5). Never smokers made up 71.2% of the population and 12.2% of subjects were current smokers.

Compared to the general 300A study population, medical history in the sub-study was similar , except that more subjects in the sub-study had a history of reproductive and breast disorders (32.7% vs 20.0%).

There were two cases of endometrial hyperplasia, both at baseline. One subject was allowed to continue in the study (b) (6), the other subject was discontinued from the study. There were two subjects where one of the three pathologists diagnosed a polyp; one at Cycle 5-6, the other at Cycle 12-13.

The histology results of the endometrial biopsies are shown in the applicant’s table below.

**Table 63. Summary of Endometrial Biopsies in Endometrial Safety Sub-Study by Cycle Window and Prior Use of CHC**

	Safety Population <sup>a</sup>	Biopsy Population <sup>b</sup>			
		Baseline	Post-Baseline Biopsies		
	Baseline N=156 n (%)	Baseline N=83 n (%)	Cycle 6 N=24 n (%)	Cycles 12-13 N=30 n (%)	Other N=29 n (%)
Normal Results					

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Insufficient or No Tissue	14 (9.0)	4 (4.8)		3 (10.0)	1 (3.4)
Atrophic/Inactive	10 (6.4)	6 (7.2)	7 (29.2)	8 (26.7)	8 (27.6)
Proliferative	67 (42.9)	33 (39.8)	4 (16.7)	2 (6.7)	6 (20.7)
Secretory	43 (27.6)	25 (30.1)	7 (29.2)	11 (36.7)	1 (44.8)
Menstrual	2 (1.3)	2 (2.4)	1 (4.2)	2 (6.7)	
Mixed	13 (8.3)	9 (10.8)	4 (16.7)	3 (10.0)	1 (3.4)
<b>Abnormal Results</b>					
Hyperplasia <sup>c</sup>	2 (1.3)	1 (1.2)	0	0	0
<b>Other Abnormal Results<sup>d</sup></b>					
Other	5 (3.2)	3 (3.6)	1 (4.2)	1 (3.7)	0

Source: Table 14.8.3; Listings 16.6.1, 16.6.3.1, and 16.6.6.2.

<sup>a</sup> All subjects with endometrial biopsy data, excluding 3 subjects (Subjects (b) (6)) who were enrolled concurrently at two different sites.

<sup>b</sup> All subjects with both a baseline (Screening, Visit 0) and follow-up biopsy.

<sup>c</sup> At screening, 2 subjects were categorized as having a diagnosis of hyperplasia. One subject (Subject (b) (6)) was permitted to remain in the study based on the Investigator's clinical judgment. The other subject (Subject (b) (6)) was discontinued from the study due to the SAE of hyperplasia without a follow-up biopsy and was not included in the Endometrial Biopsy population.

<sup>d</sup> Includes one baseline reading of endometritis (Subject (b) (6)); all others were single pathologist readings of an endometrial polyp (Subjects (b) (6)).

Cycle windows: baseline (Screening, Visit 0): Days ≤ 1; Cycle 6: Days 141–168; Cycles 12-13: Days 309–364; Other: Days 2–140, 169–308, and ≥ 365. During each window, only the most recent, non-missing result per subject was summarized.

Source: NDA 209627, Module 5.3.5.2, 300A Endometrial Safety Clinical Study Report, Table 10 p 46/70

Subjects using CHC prior to enrollment had endometrial biopsies taken at any time during their cycle with the majority of biopsies showing secretory endometrium. Subjects not on hormonal contraception had biopsies taken day 7-14 of their cycle and the majority of biopsies showed proliferative endometrium. The endometrial biopsy changes over time showed no consistency in the shifts between benign endometrial types. The one subject with endometrial hyperplasia at baseline who remained in the study had secretory endometrium at Cycle 6.

**Comment:** *The difference in the baseline biopsy results is most likely due to cycle timing when biopsy was obtained. In this sub-study, there did not appear to be a shift towards atrophic/inactive endometrium with use of the CVS. Likewise, there was no evidence of premalignant/malignant changes of the endometrium with use of the CVS. Based on the findings, no additional labeling was required.*

### 10.8.3. Hepatic Factors Sub-Study

The primary objective of the hepatic factors sub-study was to evaluate the use of the CVS over 13 cycles on the effect of four (4) estrogen-dependent hepatic proteins: factor VIII, fibrinogen, Protein S, and sex hormone binding globulin (SHBG). Factor VIII, fibrinogen, and Protein S were selected due to their involvement in the coagulation system. The applicant notes that these

proteins may be associated with risk of thromboembolism although there is no biological marker established as an acceptable predictor of VTE risk.

The trial design was a two-center (both US) sub-study of 300A where the subjects were also full participants in study 300A and included in the contraceptive efficacy and safety assessments in the main study.

In addition to the visits and procedures required for 300A, subjects in this sub-study had an additional blood drawn of 10 cc for the hepatic markers at Screening (V0), Cycle 6 (V3), and Cycle 13 (V5). If subjects did not complete 13 cycles, at their final visit all of the Cycle 13 assessments were obtained. Visit 3 occurred on day 1-7 (in week 1 of CVS use) and Visit 5 occurred on day 21-27 (during last week of the last treatment cycle).

The endpoints for this sub-study were:

- Changes in each hepatic protein over time
- Compare values between the group of women with previous CHC use and the group of women without previous CHC use

One hundred twenty-nine (129) subjects were enrolled in the hepatic factors sub-study. One hundred and six (106) subjects had a baseline value, 104 subjects had a Cycle 6 value, and 61 subjects at Cycle 13 (or final visit) value. The safety population included all subjects enrolled who inserted the CVS. The hepatic-evaluable population included all treated subjects with at least one follow-up laboratory results.

The disposition of the 129 subjects is shown in the table below.

**Table 64. Disposition of Safety Population in the Hepatic Factors Sub-Study**

<b>Disposition</b>	<b>n subjects</b>	<b>% (N=106)</b>
Completed study	68	52.7
Discontinued study	61	47.3
Reason for Discontinuation		
Lost to follow up	17	13.2
Withdrew consent	15	11.6
Adverse event	14	10.9
BMI > 29 kg/m <sup>2</sup>	7	5.4
Pregnancy	5	3.9
Compliance	2	1.6
Expulsions	1	0.8

Source: NDA 209627, Module 5.3.5.2, 300A Hepatic Factors Sub-study Study Report, Figure 1 p 31/57

A total of 12 protocol violations of eligibility in the study were allowed by physician's judgment. There were 8 subjects who were included despite abnormal baseline laboratory test results.

The majority of the safety population's demographic and baseline characteristics were White (69.0%), not Hispanic (93.8%), never married (63.6%), and had some college (46.5%).

The mean age was 26.5 years (range 18.2-39.5). The mean ( $\pm$ SD) BMI was 23.9 ( $\pm$ 3.9) kg/m<sup>2</sup>. Never smokers made up 62.8% of the population and 16.3% of subjects were current smokers

Active medical conditions for this sub-study subjects differed from the Study 300A population. The hepatic sub-study subjects had a higher incidence than the main population in Infections and Infestations (21.7% vs. 14.1%), Nervous System Disorders (72.9% vs. 35.3%), and Reproductive System and Breast Disorders (29.5% vs 20.0%).

Of the 129 subjects, 38 subjects had used CHCs within 30 days of enrollment.

The results of the mean value for each hepatic protein by cycle is shown in Table 65.

**Table 65. Hepatic Factors Results by Cycle and Change from Baseline**

Parameter	Screening mean (SD) N=106	Cycle 6 evaluation mean (SD) N=104	Final evaluation mean (SD) N=61	Normal range	Final Change from Baseline mean (SD)
Factor VIII (relative to RS~)	1.1 (0.4)	1.3 (0.6)	1.4 (0.6)	0.5-1.8	0.2 (0.5)*
Fibrinogen (g/L)	2.8 (0.7)	2.9 (0.6)	3.0 (0.6)	2.1-4.3	0.2 (0.7)*
Protein S (relative to RS)	0.85 (0.2)^	0.8 (0.2)^^	0.8 (0.2)	0.6-1.4	-0.08 (0.2)*
SHBG (nmol/L)	89.9 (62.3)^	172.8 (73.8)	171.6 (91.9)^^^	8-112	81.7 (94.3)*

Source: NDA 209627, Module 5.3.5.2, 300A Study Report, Table 14.5.2.1 p 897/1147

~ RS=reference standard. ^N=105, ^^N=103, ^^N=60

\*P<0.005

All four hepatic proteins showed a statistically significant change from mean baseline value to mean final evaluation value. SHBG was the only hepatic protein where the final mean value was above the normal range.

The 36 subjects who used CHC within 30 days of enrollment had higher baseline values of Factor VIII, fibrinogen, and SHBG and lower baseline values of Protein S than the subjects who did not use CHC within 30 days of enrollment. The mean laboratory values of these 36 subjects increased from baseline for Factor VIII, fibrinogen, and SHBG with only the SHBG value rising above normal range and Protein S not decreasing from baseline.

**Comment:** *The hepatic protein changes are consistent with known changes that occur with CHCs.*

The SAEs and AEs are reported in the 300A Study report as all the subjects in this sub-study were enrolled in 300A. Subject (b) (6) was discontinued by the applicant from Study 300A due to a low Protein S level of 0.49 at Cycle 6 from a normal baseline of 0.74. Two subjects (Subjects (b) (6) and (b) (6)) in this sub-study had VTEs. Their baseline hepatic laboratory results for Subjects (b) (6) and (b) (6) were normal.

#### 10.8.4. Colposcopy

Study 180, a 13-cycle, multicenter, randomized, dose finding and efficacy study performed vaginal/cervical colposcopy on subjects at 3 of the 5 sites. The colposcopic examinations were performed at pretreatment, cycle 3, and cycle 13. Evaluation of the vagina and cervix was for epithelial abnormalities (e.g. abrasion, ectropion, ulcer, acetowhite, punctuation, vascularity). No severe abnormality was found at any time. The only finding that occurred in >2% of the subjects on treatment was vaginal erythema in 6 subjects (4%) at Cycle 3 and cervical erythema in 5 subjects (3.3%). Findings suggestive of cervical intraepithelial abnormality were categorized as AEs and reported in the All SA/EE ISS.

**Comment:** *There does not appear to be any safety signal with the CVS use in regards to cervical and vaginal epithelial integrity.*

#### 10.8.5. Lactation Studies

There are no lactation studies conducted with the CVS. However, three lactation studies with SA implants have been performed and are summarized here.

An early study<sup>28</sup> on 6 healthy lactating women using an implant with 20 mg SA evaluated the relationship between serum and breast milk SA levels. The average plasma concentration was 62 pg/ml and the average breast milk concentration was 38 pg/ml. The mean milk/plasma ratio was 0.6 with a range from 0.25 to 0.91.

Coutinho<sup>14</sup> studied lactating women with SA implants (50 mg) and their nursing infants for one year. On Day 75 mean maternal serum levels of SA were 381 pmol/L, mean maternal breast milk levels of SA were 373 pmol/L, and the mean infant serum levels of SA were 19 pmol/L.

---

<sup>28</sup> Lahteenmaki PLA, Diaz S, Miranda P, et al. Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435. *Contraception* 1990;42:555-562

There were no safety signals in feeding, growth and development of the infants observed between the SA and control groups (who used a Copper T380 IUD)<sup>29</sup>.

Massai<sup>30</sup> in a controlled study using SA implants delivering 100 µg/day studied lactation and infant growth. Mean SA levels in maternal serum were 175 pmol/L in the first months decreasing to 60 pmol/L at the end of the first year. The mean SA levels in the breast milk were 135pmol/L decreasing to 54pmol/L. It was estimated that the infants received 50 ng/day of SA through breast feeding. The body weight of infants was similar between the control group (copper IUD) and the SA group over the 1 year study period.

***Comment:** Although these studies were with SA-only implants and contained lower doses of SA than the CVS, the results of SA in lactating women, breast milk, and nursing infants showed no safety signals in feeding, growth, and development between the segesterone acetate implant group and the control group. This information is included in labeling in addition to the general recommendation against breast feeding with use of contraceptives containing EE.*

## **10.9. Additional Safety Explorations**

### **10.9.1. Human Carcinogenicity or Tumor Development**

None reported in this CVS database.

### **10.9.2. Human Reproduction and Pregnancy**

There were 40 reported case of pregnancy during the CVS trials, all in the first trimester. Evaluation of these pregnancies is provided in Section 8 of this review.

### **10.9.3. Pediatrics and Assessment of Effects on Growth**

The applicant submitted an initial Pediatric Study Plan (iPSP) on May 13, 2015, which was reviewed by the Pediatric Review Committee (PeRC) and agreed upon by the Division. The iPSP requested a waiver for males of any pediatric age and premenarchal females and assessment of extrapolation of data from adult women to post menarchal females to age (b) (4).

On July 18, 2018 PeRC agreed with the waiver for males and assessment from adult women to adolescent females.

---

<sup>29</sup> Coutinho EM, Athayde C, Dantas C, et al. Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women. *Contraception* 1999;59:115-122

<sup>30</sup> Massai MR, Diaz S, Quinteros, E, et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. *Contraception* 2001;64:369-376

#### 10.9.4. Overdose, Drug Abuse Potential, Withdrawal, and Rebound

No cases of toxicity due to overdose have been reported. The CVS is not believed to have any abuse or dependent potential. In addition, there is no evidence of impairment of fertility that would indicate a withdrawal-type phenomenon (See Section 10.4.12).

#### 10.10. Safety in the Postmarket Setting



Based on this information, there is no data from postmarketing that will add to the safety profile from the applicant's data.

Safety Concerns Identified Through Postmarket Experience Based on our review: Although the estimate for the VTE incidence rate has considerable uncertainty, it is possible that there may be a different or increased risk of thromboembolic disease with use of this CVS compared with other recently approved CHCs. However, the VTE risk should be further minimized with appropriate labeling, which can help prescribers select patients based on their low risk for VTE. The required postmarketing study will be necessary to determine whether the VTE risk with use of the CVS offers a different safety profile from that of other CHCs. At this time, labeling will reflect that the risk is likely comparable to that of other approved CHCs since the 95% CI of the CVS VTE incidence rate (6.6, 61.7) has some overlap with the 3-12 per 10,000 woman-years likelihood of developing a VTE for other CHC users.

---

<sup>31</sup> NDA 290627, Sequence 0018, submitted 4.26.2018, Response to IR, Module 1.11.4 p 10/11

<sup>32</sup> Email communication from Cherice Holloway CDER/OSE/OCT through Miriam Chehab OMPT/CDER/OSE/OPE/DPVII May 4, 2018

**10.10.1. Expectations on Safety in the Postmarket Setting Based on the safety profile from subjects in the CVS trials, it appears that safety is expected to be similar to other approved CHC products. See Section 16.**

**10.11. Integrated Assessment of Safety**

The safety assessment based on all submitted data (3,052 subjects with 26,794 cycles) for subjects treated with the TBM CVS and other formulations of SA and SA/EE CVSs indicates that the CVS has an acceptable safety profile. There were no new safety signals noted with the CVS which contains SA, an NME progestin. A post-marketing requirement (PMR) study to better characterize the VTE risk with use of the CVS is recommended because the submitted clinical trials are not powered for evaluation of VTE risk.

The safety findings in the TBM CVS population (primary ISS) with 2308 subjects contributing 21,590 cycles are summarized.

Subjects in the ISS were mostly Caucasian (71%), non-Hispanic (70%), nulliparous (64%), from the US (67%) with a mean age of 26.7 years and a mean BMI of 24.1 kg/m<sup>2</sup>

No deaths occurred.

Forty-three subjects or 1.9% of the primary ISS experienced an SAE.

There were four VTEs. Two DVTs occurred in two subjects; one who had driven for 5 hours a week prior to diagnosis and the other in a subject subsequently found to be heterozygous for Factor V Leiden mutation. There was one PE in a subject with normal laboratory evaluation. Another subject experienced a cerebral venous thrombosis and had unconfirmed normal laboratory testing. All four subjects had histories of previous CHC use.

The four VTEs in the pivotal studies give a higher incidence of VTE than other contraceptive pivotal studies. However, this higher incidence is based on one additional VTE. Since the clinical trials were not powered to evaluate a relatively uncommon event (VTE), the risk estimate is imprecise. A PMR will be performed to provide a more accurate risk assessment.

VTE is a known risk of CHC use. Risk based on differences in COC formulations show VTE rates of 7.2-9.8 VTE/10,000 women-years with no statistically significant difference between types of progestin or days of use. The class labeling for VTE risk will be included in the CVS label. (b) (4)

The applicant's data on BMI and VTE risk (b) (4)

Two VTEs occurred in subjects with a BMI 28-31 kg/m<sup>2</sup> and two VTEs occurred in subjects with a BMI 24-26 kg/m<sup>2</sup>. Only one subject had a BMI >29 kg/m<sup>2</sup> at the time of VTE and

this BMI was 29.3 kg/m<sup>2</sup>. Physiologically speaking this small difference in BMI should not increase VTE risk by tenfold.

There were four psychiatric events in four subjects with psychiatric history. There was one attempted suicide in a subject with depression. The remaining three events involved exacerbation of bipolar disorder. From a clinical perspective, the information in these events did not generate a new safety signal or trend for this CVS that required labeling that deviated from class labeling for CHCs.

Other SAEs included two subjects with drug hypersensitivity reactions (neither involved anaphylaxis), one subject with menorrhagia due to a worsening submucous fibroid, and one subject with headache, nausea, vomiting, and diarrhea.

Adverse events leading to discontinuation occurred in 275 subjects (11.9%) of the ISS. The most frequent AEs were vaginal symptoms (including discharge and infection) - 2.1%, menstrual disorders - 1.7%, mood changes - 1.4%, headache with migraine - 1.3%, nausea and vomiting - 1.2%. CVS expulsion was not considered an AE but was the reason 1.4% of subjects discontinued.

Common AEs experienced by CVS users did not show any additional safety issues that are noted in other CHCs although the incidences of many AEs were higher in CVS users. The frequency of the AEs are summarized in the table below.

**Table 66. AEs Experienced by Subjects in Primary ISS**

<b>Preferred Terms</b>	<b>n subjects</b>	<b>% (N=2308)</b>
Headache including migraine	933	40.4
Nausea/vomiting	696	30.2
Vulvovaginal mycotic infection/vaginal candidiasis	321	13.9
Abdominal pain/lower/upper	321	13.9
Dysmenorrhea	281	12.2
Vaginal Discharge	266	11.5
UTI/cystitis/pyelonephritis/genitourinary tract infection	234	10.1
Breast pain/tenderness/discomfort	220	9.5
Metrorrhagia/menstrual disorder	167	7.2
Genital pruritus	126	5.5
Mood swings/mood altered/affect lability	105	4.5
Acne	81	3.5
Libido decreased	78	3.4
Dyspareunia	77	3.3

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Preferred Terms	n subjects	% (N=2308)
Vulvovaginal discomfort	74	3.2
Depression/depressed mood/major depression/depressive symptom	68	2.9
Rash/papular/genital/generalized/macular/pruritic	67	2.9
Menorrhagia/withdrawal bleed	66	2.9
Anxiety	51	2.2
Vulvovaginal dryness	47	2.0

Source: 10.4.5 ISS analysis of ARs

**Comment:** AEs experienced by  $\geq 5\%$  of subjects will be labeled.

At least one complete CVS expulsion was reported by 25% of subjects, however CVS expulsion was the reason for discontinuation of CVS use in only 1.4% of subjects..

Laboratory findings did not suggest any safety signals. There was no significant reduction or improvement of hemoglobin/hematocrit. There were elevations of cholesterol, HDL, LDL, triglycerides, and liver enzymes that were consistent with CHCs.

Physical examinations including vital signs did not show safety signals although findings of vaginal discharge and vaginal and vulvar erythema were noted.

There were no issues concerning pregnancy outcomes or return to fertility.

There were no differences in the safety profile of the CVS, based on TEAEs, within demographic subgroups of age, race, ethnicity, and geographic region. Safety profiles were similar between the ages of the CVS subgroups.

Specific safety studies were reviewed and did not show any new or unique concerns outside of those previously identified for CHCs.

- QT studies showed no significant QTc prolongation effect of SA
- Microbiology studies showed no increases in symptomatic bacterial vaginosis, yeast, or anaerobic gram-negative rods
- Endometrial biopsies did not find evidence of hyperplasia or malignancy
- Estrogen-dependent hepatic proteins showed the same trends as found in other CHCs
- Colposcopic evaluations did not find evidence of vaginal or cervical epithelial integrity abnormalities other than erythema in <5% of subjects

**Comment:** The safety data was sufficient to conclude that the profile for this product does not appear to be significantly different from other CHCs except for the potential for a difference in VTE risk. As previously stated, in order to better determine if this VTE risk is different from other CHC products, a large postmarketing required study will be

*necessary. The applicant understands this concern and has agreed to conduct this study using acceptable required milestones.*

## **10.12. SUMMARY AND CONCLUSIONS**

### **11. Conclusions and Recommendations**

---

The review teams have concluded that the benefits of ANNOVERA for the prevention of pregnancy in females of reproductive potential outweigh the risks when used according to labeling, and recommend approval. Refer to the benefit-risk section in Section 1 of this review for additional discussion.

### **12. Advisory Committee Meeting and Other External Consultations**

---

No Advisory Committee meeting was conducted for this application. No issues were identified during the review cycle that required expert input from an Advisory Committee.

### 13. Pediatrics

---

The applicant submitted an initial Pediatric Study Plan (iPSP) on May 13, 2015, which was reviewed by the Pediatric Review Committee (PeRC) and agreed upon by the Division. The iPSP requested a waiver for males of any pediatric age and premenarchal females and assessment of extrapolation of data from adult women to post menarchal females to age 18.

On July 18, 2018 PeRC agreed with the waiver for males and assessment from adult women to adolescent females.

### 14. Labeling Recommendations

---

#### 14.1. Prescription Drug Labeling

The applicant's proposed Prescribing Information, submitted on April 5, 2018, was reviewed. The following significant revisions were recommended:


Summary of Significant Labeling Changes (High level changes and not direct quotations)		
Section	Proposed Labeling	Approved Labeling
Indications and Usage (Section 1)	(b) (4) BMI; (b) (4) indicating that this population has not been adequately evaluated	Applicant agreed.
Adverse Events (Section 6)	Utilize the combined pivotal trial data only to inform the label. (Do not include data from non-TBM CVS)	Applicant agreed.
Clinical Studies (Section 14)	Utilize the combined pivotal trial data to inform the PI	Applicant agreed

OPDP provided a consult containing recommendations on the prescription drug labeling. These comments were accepted by the reviewers and included in labeling to the applicant.

#### 14.2 Carton and Container Labeling

The Division of Medication Error and Prevention has worked with the applicant on carton and container labeling. Agreement has been reached and there are no outstanding issues from the medication error perspective. Additional discussion with the applicant took place regarding labeling of the compact case used to store the CVS during the 7 days per cycle it is not in use. The applicant agreed to providing a label for the compact case containing information including

Multi-disciplinary Review and Evaluation NDA209627  
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

 (b) (4) during a teleconference on July 25, 2018. This agreement resolved DMEPA's outstanding concern regarding labeling.

Please refer to the DMEPA consult in DARRTS dated June 8, 2018 and to supplementary memos dated June 19, 2018 and August 6, 2018.

## 15. Risk Evaluation and Mitigation Strategies (REMS)

---

DRISK, DBRUP and the applicant are in agreement that the benefit of the CVS can be adequately managed with labeling alone and that a REMS is not necessary to ensure that the product's benefit outweighs the risk.

Please see the consult from DRISK in DARRTS dated July 18, 2018.

## 16. Postmarketing Requirements and Commitment

---

It is expected that the CVS will be used chronically and that users will have a risk of thromboembolic disease. The size of the clinical trial for the CVS did not allow determination of whether this risk was different from the risks seen with other CHCs. The review team and the Division of Epidemiology agreed that this risk needed to be further characterized through a large epidemiologic study and communicated this to the applicant. The details of this study are outlined below:

1. A controlled, non-interventional, long-term cohort study that follows a series of cohorts comprising new users of your product (segesterone acetate and ethinyl estradiol vaginal system), new users of other ring contraceptives, new users of any intrauterine system, and new users of combined oral contraceptives containing other progestins. The primary objective of the study is to assess the risk for venous thromboembolism (VTE) and arterial thromboembolism (ATE) of short-term and long-term use of your product in a study population representative of actual users of the product in the United States and other countries where your vaginal system is prescribed.
  - The study should be sufficiently powered to rule out a 1.5 to 2-fold risk for VTE

(b) (4)



Two drug interaction studies were recommended by the Clinical Pharmacology and Clinical reviewers. These required studies are outlined below:

2. A clinical drug-drug interaction study to evaluate the effects of strong CYP3A induction and inhibition on the pharmacokinetics of SA and EE from your SA/EE contraceptive vaginal system (CVS) (See Section 6.3.1 for the rationale of this study request).
3. An [REDACTED] (b) (4) study to evaluate the effects of tampons on the [REDACTED] (b) (4) of SA and EE from your SA/EE CVS.

### Postmarketing Commitments

The CMC review team determined that the Applicant had not fully characterized the in vivo release rate of the CVS based on residual drug collected at one time point at the end of 13 cycles. Therefore, to accurately determine the strength of the product for labeling, the “true” in vivo release rate should be calculated using data collected throughout the period of use. Under a PMC, [REDACTED] (b) (4)

## 17. Appendices

### 17.1. Financial Disclosure

**Table 67. Covered Clinical Study (Name and/or Number): 300B, 300PK, 330, 331, 323, 427, 571, 648, 300A (CCN006)**

Was a list of clinical investigators provided:	Yes <input checked="" type="checkbox"/>	No <input type="checkbox"/> (Request list from Applicant)
Total number of investigators identified: <u>132</u>		
Number of investigators who are Sponsor employees (including both full-time and part-time employees): <u>0</u>		
Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): <u>9</u>		
If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)):		
Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: _____		
Significant payments of other sorts: <u>X</u>		
Proprietary interest in the product tested held by investigator: _____		

Significant equity interest held by investigator in S Sponsor of covered study: _____		
Is an attachment provided with details of the disclosable financial interests/arrangements:	Yes <input checked="" type="checkbox"/>	No <input type="checkbox"/> (Request details from Applicant)
Is a description of the steps taken to minimize potential bias provided:	Yes <input checked="" type="checkbox"/>	No <input type="checkbox"/> (Request information from Applicant)
Number of investigators with certification of due diligence (Form FDA 3454, box 3) 0_____		
Is an attachment provided with the reason:	Yes <input type="checkbox"/>	No <input type="checkbox"/> (Request explanation from Applicant)

**17.2. Nonclinical Pharmacology/Toxicology**

None.

**17.3. OCP Appendices (Technical documents supporting OCP recommendations)**

Refer to the clinical pharmacology review in DARRTS.

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

**17.4. Additional Clinical Outcome Assessment Analyses**

None.

**17.5. Clinical Appendices**

**17.5.1. Pregnancies**

**Table 68. Table of Pregnancies**

Protocol	Subject ID	Age	Treatment End	Conception Date	Outcome	Initial Determination per Applicant
300A on treatment pregnancies N=19						
300A	(b) (6)	26	(b) (6)	(b) (6)	Live Birth	During CVR use
300A	(b) (6)	22	(b) (6)	(b) (6)	Induced Termination	During CVR use
300A	(b) (6)	30	(b) (6)	(b) (6)	Induced Termination	During CVR use
300A	(b) (6)	26	(b) (6)	(b) (6)	Induced Termination	During CVR use
300A	(b) (6)	23	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300A	(b) (6)	28	(b) (6)	(b) (6)	Unknown	During CVR use
300A	(b) (6)	30	(b) (6)	(b) (6)	Live Birth	During CVR use
300A	(b) (6)	26	(b) (6)	(b) (6)	Induced Termination	During CVR use
300A	(b) (6)	23	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300A	(b) (6)	22	(b) (6)	(b) (6)	Unknown	During CVR use
300A	(b) (6)	22	(b) (6)	(b) (6)	Unknown	During CVR use
300A	(b) (6)	26	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300A	(b) (6)	18	(b) (6)	(b) (6)	Live Birth	During CVR use
300A	(b) (6)	30	(b) (6)	(b) (6)	Live Birth	During CVR use
300A	(b) (6)	24	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300A	(b) (6)	23	(b) (6)	(b) (6)	Induced Termination	During CVR use

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

Protocol	Subject ID	Age	Treatment End	Conception Date	Outcome	Initial Determination per Applicant
300A	(b) (6)	22	(b) (6)	(b) (6)	Unknown	During CVR use
300A	(b) (6)	23	(b) (6)	(b) (6)	Live Birth	1-7 days after CVR use
300A	(b) (6)	21	(b) (6)	(b) (6)	Live Birth	8-14 days after CVR use
<b>300A 8-14 days after last CVS use N=3</b>						
300A	(b) (6)	26	(b) (6)	(b) (6)	Live Birth	8-14 days after CVR use
300A	(b) (6)	23	(b) (6)	(b) (6)	Live Birth	8-14 days after CVR use
300A	(b) (6)	23	(b) (6)	(b) (6)	Induced Termination	8-14 days after CVR use
<b>300A 15+ days after last CVS use N=3</b>						
300A	(b) (6)	31	(b) (6)	(b) (6)	Induced Termination	15+ days after CVR use
300A	(b) (6)	29	(b) (6)	(b) (6)	Live Birth	15+ days after CVR use
300A	(b) (6)	31	(b) (6)	(b) (6)	Induced Termination	15+ days after CVR use
<b>300B on treatment pregnancies N=22</b>						
300B	(b) (6)	21	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	31	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300B	(b) (6)	25	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300B	(b) (6)	20	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	21	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	23	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	24	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	19	(b) (6)	(b) (6)	Induced Termination	During CVR use
300B	(b) (6)	19	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	21	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	19	(b) (6)	(b) (6)	Induced Termination	During CVR use
300B	(b) (6)	23	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300B	(b) (6)	19	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	23	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	25	(b) (6)	(b) (6)	Live Birth	During CVR use

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesteron acetate and ethinyl estradiol vaginal system)

Protocol	Subject ID	Age	Treatment End	Conception Date	Outcome	Initial Determination per Applicant
300B	(b) (6)	18	(b) (6)	(b) (6)	Induced Termination	During CVR use
300B	(b) (6)	27	(b) (6)	(b) (6)	Live Birth	During CVR use
300B	(b) (6)	38	(b) (6)	(b) (6)	Spontaneous Termination	During CVR use
300B	(b) (6)	24	(b) (6)	(b) (6)	Live Birth	1-7 days after CVR use
300B	(b) (6)	21	(b) (6)	(b) (6)	Unknown	1-7 days after CVR use
300B	(b) (6)	29	(b) (6)	(b) (6)	Live Birth	1-7 days after CVR use
300B	(b) (6)	24	(b) (6)	(b) (6)	Live Birth	1-7 days after CVR use
<b>300B 8-14 days after CVS use N=2</b>						
300B	(b) (6)	22	(b) (6)	(b) (6)	Spontaneous Termination	8-14 days after CVR use
300B	(b) (6)	29	(b) (6)	(b) (6)	Induced Termination	8-14 days after CVR use
<b>300B 15+ days after CVS use N=10</b>						
300B	(b) (6)	27	(b) (6)	(b) (6)	Live Birth	15+ days after CVR use
300B	(b) (6)	23	(b) (6)	(b) (6)	Live Birth	15+ days after CVR use
300B	(b) (6)	33	(b) (6)	(b) (6)	Live Birth	15+ days after CVR use
300B	(b) (6)	24	(b) (6)	(b) (6)	Live Birth	15+ days after CVR use
300B	(b) (6)	18	(b) (6)	(b) (6)	Spontaneous Termination	15+ days after CVR use
300B	(b) (6)	25	(b) (6)	(b) (6)	Induced Termination	15+ days after CVR use
300B	(b) (6)	29	(b) (6)	(b) (6)	Induced Termination	15+ days after CVR use
300B	(b) (6)	28	(b) (6)	(b) (6)	Induced Termination	15+ days after CVR use
300B	(b) (6)	31	(b) (6)	(b) (6)	Ectopic	15+ days after CVR use
300B	(b) (6)	29	(b) (6)	(b) (6)	Live Birth	15+ days after CVR use
<b>Other protocol on-treatment pregnancies N=2</b>						
300Ex	(b) (6)	21	(b) (6)	(b) (6)	Live Birth	During CVR use
300PK	(b) (6)	29	(b) (6)	(b) (6)	Live Birth	During CVR use
<b>300A Return to Fertility N=12</b>						
300A	(b) (6)	25	(b) (6)	(b) (6)	Spontaneous Termination	Return to fertility
300A	(b) (6)	27	(b) (6)	(b) (6)	Live Birth	Return to fertility

Multi-disciplinary Review and Evaluation NDA209627  
 ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Protocol	Subject ID	Age	Treatment End	Conception Date	Outcome	Initial Determination per Applicant
300A	(b) (6)	28	(b) (6)	(b) (6)		Return to fertility
300A		24				Return to fertility
300A		21			Spontaneous Termination	Return to fertility
300A		26				Return to fertility
300A		35				Return to fertility
300A		31				Return to fertility
300A		28				Return to fertility
300A		38			Spontaneous Termination	Return to fertility
300A		24			Spontaneous Termination	Return to fertility
300A		28				Return to fertility
<b>300B Return to Fertility N=12</b>						
300B	(b) (6)	26	(b) (6)	(b) (6)		Return to fertility
300B		20				Return to fertility
300B		25				Return to fertility
300B		26			Spontaneous Termination	Return to fertility
300B		23				Return to fertility
300B		35				Return to fertility
300B		26				Return to fertility
300B		28				Return to fertility
300B		22			Live Birth	Return to fertility
300B		31				Return to fertility
300B		33				Return to fertility
300B		23				Return to fertility
<b>Other protocol Return to Fertility N=1</b>						
300PK	(b) (6)	25	(b) (6)	(b) (6)	Live Birth	Return to fertility

\*subject excluded from efficacy population by applicant

### 17.5.2. Microbiology Sub-study

1. The diagnosis of bacterial vaginosis was determined by the Investigator utilizing the Amsel criteria. The presence of three of the following four criteria gave the diagnosis:
  - a homogenous excessive vaginal discharge
  - an alkaline vaginal pH (> 4.5)
  - a positive whiff test
  - the presence of 20% or more clue cells
  - [bacterial vaginosis was also categorized as symptomatic or asymptomatic]
2. The Investigator also determined the diagnosis of bacterial vaginosis utilizing the Nugent score. A score > 7 indicates bacterial vaginosis. The scores were categorized as:
  - Normal flora (Lactobacillus - predominant) - scores 0 to 3
  - Intermediate flora - scores 4 to 6
  - Bacterial vaginosis - scores 7 to 10

Source Microbiology Sub-study Clinical Study Report P6

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

MICHELLE CAREY  
08/09/2018

AUDREY L GASSMAN  
08/09/2018

VICTOR CRENTSIL  
08/09/2018

## Office of Clinical Pharmacology Review- Appendices

<b>NDA or BLA Number</b>	209627
<b>Link to EDR</b>	\\CDSESUB1\evsprod\NDA209627\209627.enx
<b>Submission Date</b>	August 17, 2017 (SDN001); December 20, 2017 (SDN008); January 19, 2018 (SDN010); March 14, 2018 (SDN014); May 11, 2018 (SDN020); June 12, 2018 (SDN024)
<b>Submission Type</b>	Standard
<b>Brand Name</b>	Annovera
<b>Generic Name</b>	Ethinyl Estradiol (EE) and Segesterone Acetate (SA)
<b>Dosage Form and Strength</b>	Vaginal system (ring) delivering on average 13 µg of EE and 150 µg of SA per day
<b>Route of Administration</b>	Vaginal administration
<b>Proposed Indication</b>	Prevention of Pregnancy
<b>Applicant</b>	The Population Council Inc.
<b>Associated IND</b>	IND 049980
<b>OCP Review Team</b>	Li Li, PhD; Doanh Tran, PhD; Nan Zheng, PhD; Yuching Yang, PhD
<b>OCP Final Signatory</b>	Gil Burckart, PharmD Associate Director Office of Clinical Pharmacology

## Table of Contents

---

APPENDICES.....	3
1. Summary of Bioanalytical Method Validation and Performance .....	3
2. Clinical BA/BE Assessments .....	4
2.1.Study 300PK (Pivotal PK/PD Study).....	4
2.2.Study 330 (Relative Bioavailability Study).....	10
3. Clinical Drug Interaction Assessments.....	15
3.1.Study 571 (DDI Study).....	15
3.2.Study XPD-17-301 (PBPK Modeling).....	20
4. Clinical PK/PD Assessment .....	24
4.1.Study 124 (Pilot Dose-Finding Study) .....	24
4.2.Study 174 (Pilot Dose-finding Study) .....	27
4.3.Study 180 (Pivotal Dose-finding Study) .....	30
4.4.Study 181 (Dosing Regimen-finding Study).....	34
5. Mechanistic Safety Assessment.....	36
5.1.Study POP-648 (QT) .....	36
6. Combined Review for In vitro Studies .....	38
6.1.Plasma Protein Binding .....	38
6.2.In Vitro Metabolism .....	38
6.3.Induction/Inhibition of Drug-Metabolizing Enzymes .....	39
7. Literature Review of SA Lactation Studies.....	41
7.1.Article 1: Contraceptive efficacy and clinical performance of SA implants in postpartum women.....	41
7.2.Article 2: Use of a Single Implant of Elcometrine (ST-1435), a Nonorally Active Progestin, as a Long Acting Contraceptive for Postpartum Nursing Women .....	42

**Note: This document contains the appendices to the Clinical Pharmacology review.**

## APPENDICES

### 1. Summary of Bioanalytical Method Validation and Performance

#### Gas Chromatography and Tandem Mass Spectrometry (GC-MS/MS)

Serum concentrations of SA and EE in Study 300PK, Study 330, Study 571 and Study POP-648 were measured using a validated assay GC-MS/MS method developed by (b) (4). The lower limit of quantification (LLOQ) for SA and EE were 50 pg/mL and 10 pg/mL, respectively. The detailed method and validation parameters are described in **Table 1**.

**Table 1. Summary of Validation Results for GC-MS/MS (Method 3857.042806)**

Analyte(s) of interest	SA	EE
Methodology	GC-MS/MS, negative ion mode	
Biological matrix	Serum	
Extraction method	Liquid-liquid	
Calibration curve range	50.0 -5000 pg/mL	10.0 -1000 pg/mL
Validation Report No.	3857.042806	
Standards:		
Inter-run Precision:	≤14.2%	≤4.35%
Inter-run Accuracy:	-8.00% to 4.00%	-2.00% to 2.00%
QCs:		
Within-run Precision:	≤12.3%	≤5.00%
Within-run Accuracy:	-6.40% to 9.33%	-0.333% to 12.0%
LLOQ:		
Precision:	4.96%	2.10%
Accuracy:	-1.60%	0.00%
Long-term stability	405 days at -20°C	2056 days at -20°C
Analyte Recovery	98.9%	90.7%
Freeze-thaw stability	Demonstrated for 4 cycles for at ≤ -20°C	Demonstrated for 4 cycles for at ≤ -20°C

#### Radioimmunoassay (RIA)

For earlier studies including Study 124, 174, 180 and 181, serum concentrations of SA were determined using a validated RIA technique developed at the University of Helsinki, Finland<sup>1</sup>. Briefly, this was a conventional RIA where serum samples were first extracted with petroleum ether. After processing, samples were incubated with an antibody to SA and a radiolabeled SA, free steroid was separated from bound steroid using dextran-charcoal, and the amount of radioactivity remaining in the supernatant fluids was determined. The LLOQ for SA was 13 pmol/L (4.8 pg/mL). Serum concentrations of EE were determined using RIA method developed by the USC Medical Center, Los Angeles, CA<sup>2</sup>. The LLOQ for EE was 10 pg/mL. The detailed method and validation parameters are described in **Table 2**.

<sup>1</sup> Lähteenmäki P, Weiner E, Lähteenmäki P, et al. Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435. *Contraception*. 1981; 23(1):63- 75.

<sup>2</sup> Brenner PF, Goebelsmann U, Stanczyk FZ, et al. Serum levels of ethinylestradiol following its ingestion alone or in oral contraceptive formulations. *Contraception*. 1980; 22(1):85-95.

**Table 2. Summary of Validation Results for RIA Method**

Analyte(s) of interest	SA	EE
Methodology	RIA	
Biological matrix	Serum	
Calibration curve range	5.3 -1350 pmol/L	10.0 - 2500 pg/mL
Standards:		
Intra-assay Precision:	5% to 14%	3.1% to 6.9%
Inter-assay Precision:	10% to 17%	7.2% to 11.0%
Long-term stability	4 years	2056 days at -20°C
Analyte Recovery	100% to 111%	Not available
Freeze-thaw stability	4 cycles	Demonstrated for 4 cycles for at $\leq$ -20°C

## 2. Clinical BA/BE Assessments

---

### 2.1. Study 300PK (Pivotal PK/PD Study)

---

**Title:** A multicenter, open-label study to evaluate the PK, PD, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 µg of SA and 15 µg of EE (150/15 SA/EE CVS)

**Objectives:**

- To evaluate the effects of a new SA/EE CVS on ovulation suppression
- To assess the PK of SA and EE during Cycles 1, 3 and 13 of CVS use.


**Study Design:** This was an open-label, non-randomized PK/ PD study of SA/EE CVS on a 21/7 day usage cycles in 39 healthy female subjects. Subjects were allowed to remove the CVS for short periods of time (up to 2 hours) for washing or sexual intercourse. The total duration of treatment is thirteen 28-day cycles (approximately 1 year).

Blood samples for PK analysis were collected before CVS insertion and after insertion on Day 1 (at 1, 2, 4 and 8 hours post-dose), Days 2, 3, 4, 5, 8, 15 and 22 of Cycles 1, 3, and 13. Additional blood samples were collected on Days 23, 24, 25, and 28/29 in Cycle 1 to determine the PK of SA and EE after CVS was removed. The primary PD assessment in this study was serum progesterone (P) concentration, a marker for suppression of ovulation. Estradiol (E2) concentrations were also measured to provide additional information on luteal activity. Ovulation was considered to have occurred when two consecutive P measurements, not including the first one done at pre-ring insertion, were  $\geq$  10 nmol/L. Blood samples for PD analysis were collected on Days 1, 4, 8, 12, 15, 18, 22, 25 and 29 of Cycles 1, 3, and 13.

Serum concentrations of SA and EE were measured using a validated GC-MS/MS assay developed by (b) (4). Details of the assay can be found in Bioanalytical Report No. 3836.083107.

**PK Results:** The study subjects were healthy, mostly Hispanic women with a mean age of 29.1 ( $\pm 6.4$  SD) years and a mean BMI of 26.18 (range: 16.89 - 37.46) kg/m<sup>2</sup>. Thirty (30) out of 39 subjects completed the study. The serum concentration-time profiles of SA and EE are shown in **Figure 1** with PK parameters summarized in **Table 3**. Following vaginal administration, SA and EE were absorbed into systemic circulation with median  $T_{max}$  around 2 hours in Cycles 1, 3, and 13. Concentrations of both components declined after  $T_{max}$  and became more constant after 96 hours postdose. Mean (SD) maximum SA concentration ( $C_{max}$ ) in Cycle 1 was 1147 (315) pg/mL and decreased over subsequent cycles of use. Specifically,  $C_{max}$  of SA were 363 (133) pg/mL in Cycle 3 and 294 (116) pg/mL in Cycle 13. Similar trend was observed with EE. Mean (SD)  $C_{max}$  of EE was 129 (39) pg/mL in Cycle 1. The mean EE  $C_{max}$  in Cycles 3 and 13 were approximately one-half and one-third, respectively, of the mean value reported in Cycle 1. Observed  $C_{max}$  values in Cycle 1, Cycle 3 and Cycle 13 suggested that <sup>(b) (4)</sup> release of SA and EE from this CVS was most significant upon initial use and became less prominent in subsequent cycles.

**Figure 1. Mean (SD) SA and EE Serum Concentrations-Time Profiles Delivered by SA/EE CVS (Study 300PK)**



**Table 3. PK Parameters for SA and EE Following the Administration of SA/EE CVS (Study 300PK)**


	Parameters	Statistic	Cycle 1	Cycle 3	Cycle 13
SA	AUC <sub>0-24</sub> (pg•h/mL)	n	39	36	27
		Mean (SD)	14983 (3208)	4953 (1621)	3912 (1396)
		n	39	36	27

	AUC <sub>0-96</sub> (pg•h/mL)	Mean (SD)	35296 (6935)	14551 (3215)	11248 (2765)
	AUC <sub>0-504</sub> (pg•h/mL)	n	39	36	26
		Mean (SD)	96243 (16881)	65933 (14805)	47162 (10148)
	C <sub>max</sub> (pg/mL)	n	39	36	27
		Mean (SD)	1147 (315)	363 (133)	294 (116)
	<b>EE</b>	AUC <sub>0-24</sub> (pg•h/mL)	n	39	36
		Mean (SD)	2095 (686)	937 (390)	667 (261)
	AUC <sub>0-96</sub> (pg•h/mL)	n	39	36	26
		Mean (SD)	6393 (2619)	3055 (1073)	2176 (841)
	AUC <sub>0-504</sub> (pg•h/mL)	n	39	36	26
		Mean (SD)	22158 (9795)	14716 (4744)	9568 (4059)
	C <sub>max</sub> (pg/mL)	n	39	36	23
		Mean (SD)	129 (39)	60 (33)	39 (16)

Note: Subject (b) (6), Subject (b) (6) and Subject (b) (6) are excluded from analysis due to noncompliance as indicated by undetectable Segesterone and EE during Cycle 13.

After SA/EE CVS was removed on Day 22 in Cycle 1, SA serum concentrations were below LLOQ (50 pg/mL) in 20% of subjects after 1 hour and 55% after 2 hours. The determined median half-life values using all available SA concentrations were 3.7 hours for SA and 16.5 hours for EE. The mean  $\pm$  SD half-life was  $4.5 \pm 3.4$  hours for SA and  $15.1 \pm 7.5$  hours for EE. Individual serum concentrations of SA and EE over time after CVS removal are shown in **Figure 2** with PK parameters summarized in **Table 4**.

**Figure 2. SA and EE Serum Concentrations Over Time After CVS Removal**



**Table 4. SA and EE Serum Concentrations after CVS Removal in Cycle 1**


Time (hour)	SA (pg/mL)		EE (pg/mL)	
	Mean (SD)	N	Mean (SD)	N
Time Post-dose (Time after removal)				
504 (0)	132.4 (32.9)	38	33.5 (13.9)	38
505 (1)	84.3 (18.6)	30	31.3 (15.9)	38
506 (2)	78 (45.1)	17	30.6 (13.7)	37

508 (4)	62.1 (12.0)	5	25.7 (13.7)	35
512 (8)	57.7 (6.5)	8	21.7 (10.0)	35

**Reviewer's Comment:** Similar PK profiles of SA after CVS removal were observed when plotting using all available PK data versus using data from 5 subjects with detectable SA concentrations through all the time points. Therefore, the determined half-life of 3.7 hours is acceptable.

**PD Results:** Figure 3 are plots of individual P and E2 levels observed in Cycle 1, Cycle 3 and Cycle 13. Three subjects were excluded from the analysis based on undetectable SA concentrations in the tested cycles (see note below). The mean (SD) P concentrations were 1.59 (1.88) nmol/L for Cycle 1, 1.24 (0.70) nmol/L for Cycle 3, and 1.60 nmol/L (3.64) for Cycle 13. No study subjects had luteal activity as defined as two consecutive P measurements of more than 10 nmol/L. One subjects had serum P concentrations < 10 nmol/L in Cycle 13. Serum E2 concentrations were also suppressed during the 21-day period of the cycle when the CVS was in place. Overall, these data suggest that when the SA/EE CVS was used as directed, serum progesterone concentrations remained adequately suppressed.

**Figure 3. P and E2 Serum Concentrations for Cycle 1 (N=39), Cycle 3 (N=35), and Cycle 13 (N=27)**



**Safety Results:** Thirty-nine (39) subjects were included for the safety analysis. The treatment-emergent adverse events (TEAEs) reported by the highest percentages of subjects were nasopharyngitis (51%), headache (49%), and nausea (33%). The majority (67%) of subjects reported TEAEs considered by the Investigator to be mild or moderate. Twelve (31%) of 39 subjects reported TEAEs considered severe. The most commonly reported severe TEAEs were migraine (15%) and headache (13%). No clinically significant changes were noted for vital signs, ECGs, or clinical laboratory test results.


Pregnancy:


During this study, 1 subject (Subject (b) (6)) became pregnant in Cycle 10. This subject had no luteal activity on Cycle 1 and Cycle 3. Unfortunately, the pregnancy occurred during a cycle in which PK analysis of NES/EE serum concentrations were not conducted.

**Reviewer's Comments:**

- *SA/EE CVS in obese subjects: About 50% of study subjects were overweight ( $30 \text{ kg/m}^2 \geq \text{BMI} \geq 25 \text{ kg/m}^2$ ) or obese ( $\text{BMI} \geq 30 \text{ kg/m}^2$ ). As shown in **Figure 4**, increased body weight associated with decreased concentrations of SA and EE.*


**Figure 4. Box-plot Comparison of SA and EE Systemic Exposure Grouped by BMI (Study 300PK)**






- *Bioanalytical Analysis: All study samples were analyzed within the established stability of 999 days for EE (maximum interval was 338 days). For SA, all samples were analyzed within the established stability of 405 days, except for one sample (463 days) from Subject (b) (6) in cycle 1, treatment day 1 before CVS insertion (Time 0). Considering the expected concentrations for EE and SA is zero for this timepoint, this reviewer considers the long-term stability data support the duration of sample storage.*
- *As shown in **Figure 5**, PK profiles of SA and EE using data only from 27 subjects who completed all three cycles are similar to the PK profiles including all available data.*

**Figure 5. Mean (SD) SA and EE Serum Concentrations-Time Profiles Delivered by SA/EE CVS (N=27)**





## 2.2. Study 330 (Relative Bioavailability Study)

**Title:** Phase 1 Cross-over Study to Evaluate the Kinetics of EE and SA Delivered Vaginally From a Silicone Rubber Ring as Compared With Oral Administration of EE and Levonorgestrel in an Oral Contraceptive Pill (Nordette21®)

**Objective:** To compare a vaginal ring developed to deliver daily doses of SA 150 µg and EE 15 µg with a second-generation oral contraceptive (OC) delivering EE 30 µg and levonorgestrel (LNG) (Nordette21®) 150 µg per day

**Study Design:**

(b) (4)

(b) (4)

**Reviewer's Comments:**

- *The objective of Study 330 was to compare EE exposure from SA/EE CVS to an approved COC and the purpose of the comparison was to provide support for the safety of SA /EE CVS with respect to venous thromboembolic events (VTE) risk. However, this study is not considered as applicable to the current NDA based on the following concerns: 1) Different CVS Formulations: Study 330 was not conducted with the to-be-marketed (TBM) formulation. However, the in-vitro in-vivo correlation (IVIVC) method proposed by the applicant is not considered adequate to bridge the two formulations (See Biopharmaceutics review). Based on Cross-study comparison provided in the NDA Section 2.7.1, the geometric mean EE AUC<sub>0-24h</sub> and AUC<sub>0-504h</sub> from Study 330 were (b) (4)% and (b) (4)%, respectively, (b) (4) As of today, the applicant did not provide evidence to adequately bridge the two formulations. Therefore, results from Study 330 may not be reliable to support relative bioavailability (BA) of the TBM CVS to an OC. 2) Small sample size: (b) (4)*



Time (h)

*Bioanalytical Issues with the Study: Study 330 was completed in 2004 and serum samples of SA and EE from Study 330 were analyzed using GS/MS/MS method in 2007 and 2010 after long term sample storage (b) (4). On January 19<sup>th</sup> 2018, the applicant submitted new sample storage stability data to support that serum level data for EE from study 330 is reliable. The reviewer agrees with the applicant that “results for EE from analyses (b) (4) (b) (4) are stable (b) (4). The report also showed SA was not stable in storage (b) (4) and thus PK Results for SA in Study 330 was not considered as reliable and not reported in the current review (b) (4).*



### 3. Clinical Drug Interaction Assessments

---

#### 3.1. Study 571 (DDI Study)

---

**Title:** An open-label study to evaluate the effects of concurrent administration of vaginal antimycotic medication (miconazole nitrate) on the PK of SA and EE delivered by a vaginal ring releasing a daily dose of 150 µg of SA and 15 µg of EE (150/15 SA /EE CVS) in normal ovulating women

**Objectives:**

- To evaluate the PK of EE and SA released from CVS in the presence of a single-dose and multiple-dose of antimycotic co-medication (miconazole nitrate suppository or cream)
- To evaluate the safety and tolerability of the CVS during two cycles of use in the presence or absence of antimycotic co-medication

**Study Design:** This was an open-label, randomized, crossover, DDI study in 45 healthy female subjects. This study had both single and three-day repeat dose cohorts (**Figure 9**).

Subjects in the cohorts were enrolled sequentially, beginning with the single-dose suppository, followed by the multiple-dose suppository and ending with the multiple-dose cream. Subjects in Cohort 1 were administered 1200 mg miconazole nitrate delivered as a vaginal suppository once on Day 8 of the treatment cycle. Subjects in Cohort 2 were administered 200 mg miconazole nitrate delivered as a once daily suppository for three consecutive days. Subjects in Cohort 3 were administered 200 mg miconazole nitrate delivered as a once daily cream for three consecutive days. Cohorts 2 and 3 were administered miconazole nitrate on Days 8, 9, and 10 during their respective treatment periods. During the study, sex hormones, other forms of hormonal contraception, vaginal lubricants containing mineral oil, silicone based lubricants, tampons and and medications, such as isotretinoin, requiring the use of concomitant effective contraception, were prohibited. Water-based vaginal lubricants, such as K-Y Jelly and Replens, were permitted.

Serum concentrations of SA and EE were measured using a validated GC-MS/MS assay developed by [REDACTED] (b) (4) Details of the assay can be found in Bioanalytical Report No. 8493.101514.

## Figure 9. Schematic Overview of the Study Design



### PK sampling time points:

- Cohort 1: A total of 19 blood samples (10 mL/sample) were collected in Cohort 1. On Day 8, serial blood samples were collected before and at 2, 4, 8, 12, 16, 24, 36 and 48 hours after miconazole treatment. Single blood samples collected on days 1 (before CVS insertion), 2, 12, 14, 15, 16, 18, 20, 21 and 22 (day of CVS removal).
- Cohort 2 and Cohort 3: A total of 23 blood samples (10 mL/sample) were collected in Cohort 2 and Cohort 3. On Day 8 and Day 9, serial blood samples were collected before (0 hour) and at 8 and 16 hours after miconazole treatment. On Day 10, blood samples were collected before and at 2, 4, 8, 12, 16 and 24 hours after miconazole treatment. Single blood samples collected on days 1 (before CVS insertion), 2, 12, 14, 15, 16, 18, 20, 21 and 22 (day of CVS removal).


**PK Results:** Twenty nine (29) subjects completed the study. Demographics and baseline characteristics were comparable for all three cohorts.

### Cohort 1: Effect of a Single-Dose of Miconazole Nitrate Suppository on the PK of SA and EE from CVS

PK profiles of SA and EE from CVS with and without a single-dose of vaginal miconazole suppository on Day 8 are shown in **Figure 10** with PK parameters summarized in **Table 8**. Vaginal administration of a single-dose of 1200 mg miconazole suppository increased serum concentrations of EE. Specifically,  $AUC_{Day8-10}$  and  $AUC_{Day8-21}$  were increased by approximately 18% and 67%, respectively. However,  $AUC_{Day8-9}$ , results representing the extent of absorption on the day of miconazole suppository administration, were similar between the control cycle and

the interaction cycle. Following a single-dose of vaginal administration of 1200 mg miconazole suppository, SA  $AUC_{Day8-9}$ ,  $AUC_{Day8-10}$  and  $AUC_{Day8-21}$  were increased by approximately 30%, 32% and 19%, respectively.

**Figure 10. Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with a Single-Dose of Miconazole Nitrate Suppository (Treatment B1) in Healthy Female Subjects in Cohort 1**



**Table 8. Statistical Comparisons of EE and SA PK Parameters after Administration of CVS Alone or CVS with a Single-Dose of Miconazole Nitrate Suppository in Healthy Female Subjects in Cohort 1**


	Treatment A (CVS Alone)	Treatment B1 (CVS + 1 Day Suppository)	Ratio of Treatment B1/ A (90% CI)
<b>EE</b>			
$AUC_{Day8-9}$ (h·pg/mL)	662	722	1.04 (0.91, 1.19)
$AUC_{Day8-10}$ (h·pg/mL)	1300	1650	1.18 (1.04, 1.35)
$AUC_{Day8-21}$ (h·pg/mL)	7910	14600	1.67 (1.51, 1.86)
<b>SA</b>			
$AUC_{Day8-9}$ (h·pg/mL)	3890	5070	1.30 (1.19, 1.41)
$AUC_{Day8-10}$ (h·pg/mL)	7940	10400	1.32 (1.19, 1.47)
$AUC_{Day8-21}$ (h·pg/mL)	45700	53300	1.19 (1.04, 1.36)

Note: AUC values are as Geometric Mean.

**Cohort 2: Effect of a Three-Day Regimen of Miconazole Nitrate Suppository on the PK of SA and EE from CVS**

When 200 mg miconazole vaginal suppository were administered on Day 8, Day 9 and Day 10 of CVS use, EE  $AUC_{Day10}$ ,  $AUC_{Day8-11}$ ,  $AUC_{Day8-15}$  and  $AUC_{Day8-21}$  were increased by 8%, 9%, 28% and 42%, respectively. SA  $AUC_{Day10}$ ,  $AUC_{Day8-11}$ ,  $AUC_{Day8-15}$  and  $AUC_{Day8-21}$  were increased by 6%, 28%, 26% and 27%, respectively (**Figure 11** and **Table 9**).

**Figure 11. Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with Three-Day Regimen of Miconazole Nitrate Suppository (Treatment B2) in Healthy Female Subjects in Cohort 2**




**Table 9. Statistical Comparisons of EE and SA PK Parameters after Administration of CVS Alone or CVS with Three-Day Regimen of Miconazole Nitrate Suppository in Healthy Female Subjects in Cohort 2**

	Treatment A (CVS Alone)	Treatment B2 (CVS+ 3-Day Suppository)	Ratio of Treatment B2/ A (90% CI)
<b>EE</b>			
AUC <sub>Day10</sub> (h·pg/mL)	659	712	1.08 (0.99, 1.18)
AUC <sub>Day 8-11</sub> (h·pg/mL)	2110	2290	1.09 (0.84, 1.40)
AUC <sub>Day 8-15</sub> (h·pg/mL)	4670	5990	1.28 (1.08, 1.53)
AUC <sub>Day 8-21</sub> (h·pg/mL)	8370	11900	1.42 (1.21, 1.66)
<b>SA</b>			
AUC <sub>Day10</sub> (h·pg/mL)	3220	3400	1.06 (0.93, 1.20)
AUC <sub>Day 8-11</sub> (h·pg/mL)	10300	13100	1.28 (1.03, 1.58)
AUC <sub>Day 8-15</sub> (h·pg/mL)	23300	29300	1.26 (1.10, 1.43)
AUC <sub>Day 8-21</sub> (h·pg/mL)	43000	54700	1.27 (1.15, 1.40)

**Cohort 3: Effect of a Three-Day Regimen of Miconazole Nitrate Cream on the PK of SA and EE from CVS**

EE and SA exposure (AUC<sub>Day10</sub>, AUC<sub>Day 8-11</sub>, AUC<sub>Day 8-15</sub>, and AUC<sub>Day8-21</sub>) was bioequivalent with and without 3-Day treatment of vaginal miconazole cream, indicating no PK interaction between SA/EE CVS and miconazole vaginal cream (**Figure 12** and **Table 10**).

**Figure 12. Mean SA and EE Serum Concentration-Time Profiles Following Administration of CVS Alone (Treatment A) or CVS with Three-Day Regimen of Miconazole Nitrate Cream (Treatment B3) in Healthy Female Subjects in Cohort 3**



**Table 10. Statistical Comparisons of EE and SA PK Parameters after Administration of CVS Alone or CVS with Three-Day Regimen of Miconazole Nitrate Cream in Healthy Female Subjects in Cohort 3**

	Treatment A (CVS Alone)	Treatment B3 (CVS+ 3-Day Cream)	Ratio of Treatment B3/A (90% CI)
<b>EE</b>			
AUC <sub>Day10</sub> (h·pg/mL)	770	778	1.01 (0.85, 1.20)
AUC <sub>Day 8-11</sub> (h·pg/mL)	2250	2140	0.98 (0.81, 1.11)
AUC <sub>Day 8-15</sub> (h·pg/mL)	5330	5970	1.12 (1.01, 1.25)
AUC <sub>Day8-21</sub> (h·pg/mL)	9740	11100	1.14 (1.07, 1.21)
<b>SA</b>			
AUC <sub>Day10</sub> (h·pg/mL)	3190	3610	1.13 (1.08, 1.18)
AUC <sub>Day 8-11</sub> (h·pg/mL)	9860	11700	1.19 (1.15, 1.22)
AUC <sub>Day 8-15</sub> (h·pg/mL)	22000	24500	1.11 (1.09, 1.14)
AUC <sub>Day8-21</sub> (h·pg/mL)	37100	40400	1.09 (1.04, 1.14)

**Safety Results:** Similar profiles were found in the frequency and intensity of AEs for the CVS only and the miconazole co-medication treatment groups.

**Conclusions:**

- Systemic exposure of SA and EE increased when a single or multiple doses of miconazole nitrate suppository were co-administered with the CVS, with up to a maximum EE geometric mean ratio (GMR) AUC<sub>Day8-21</sub> of 1.67 (1.51 - 1.86) for the single dose suppository and 1.42 (1.21-1.66) for the multiple dose suppository.
- By contrast, systemic exposure of SA and EE was bioequivalent with and without miconazole nitrate cream (all GMRs and confidence intervals within 0.80 to 1.25).

**Reviewer's Comments:**

- *Mechanism of Interaction*

The data suggest that lipophilic oil-based miconazole vaginal suppositories enhanced the release of lipophilic steroids such as SA and EE from the CVS, whereas a water-based vaginal cream did not. These findings suggest that the active ingredient, miconazole does not affect the release of SA and EE from the CVS; but the inactive ingredients in the suppository formulation have an effect on the release of SA and EE from the CVS.

- **Long-term Effect on CVS's performance**  
The effect on EE release seems to last beyond the duration of co-administration. For example, when a single dose of vaginal suppository was co-administered with CVS on Day 8, there was only 18% increase in  $AUC_{Day8-10}$  compared to the control cycle, whereas there was a 67% increase in  $AUC_{Day8-21}$ . This may indicate a change in the release mechanism of EE from CVS and it is not known whether the effect will persist through the following cycles.
- **Labeling Recommendation**  
Considering the potential long-term effect on the ring's performance, the review team recommends that concurrent use of oil-based vaginal products should not occur with SA/EE CVS use. If there is a need to treat a vaginal condition, water-based vaginal cream or oral therapy may be used concurrently with the ring.

### 3.2. Study XPD-17-301 (PBPK modeling)

---

**Title:** Physiologically-based PK (PBPK) modeling of the impact of CYP3A inhibition and induction on systemic exposure to parenterally administered segestronone (alone or with EE)

**Objective:** To predict the impact of CYP3A inhibitors and inducers on systemic exposure to parenterally administered nestorone (b) (4)

**Background:** SA is a progestin under development as a potential contraceptive agent, either alone or in combination with EE. The intended route of administration is parenteral, including (b) (4), contraceptive vaginal ring, (b) (4). Mass balance study in rat suggested that metabolism is the primary determinant of the systemic elimination of parenterally administered nestorone. Physicochemical properties of SA (e.g. low molecular weight [370 g/mol], high logP [3.64], low topological polar surface area [60 Å<sup>2</sup>], a lack of ionizable groups in pH 1-8) and structural similarity to many other steroids predicted high passive diffusion and metabolism by reductive enzymes in liver cytosol and by oxidative, reductive and/or hydrolytic enzymes in liver microsomes. The Applicant did not conduct a mass balance study or dedicated drug-drug interaction (DDI) studies in human.

The Applicant used a custom-built PK model and in-vitro datasets to predict the impact of CYP3A inhibitors and inducers on SA PK. This review evaluates adequacy of the Applicant's approach in the prediction of DDI between SA and CYP3A inhibitor/inducer.

**Methods:**

(b) (4)



**Reviewer's Comments:**

1. *The applicant's model is not adequate to support* [redacted] (b) (4)

[redacted]  
[redacted]  
[redacted]  
[redacted]  
[redacted]

2. *According to FDA Guidance for Industry - In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies, the contribution of a specific metabolizing enzyme to an investigational drug's clearance is considered significant if the enzyme is responsible for >25% of the drug's elimination based on in vitro phenotyping studies and human PK data.*

[redacted] (b) (4)

[redacted] *The applicant should conduct clinical DDI studies using strong index inhibitors and/or inducers of the enzyme.*

## 4. Clinical PK/PD Assessment

---

### 4.1. Study 124 (Pilot Dose-Finding Study)

---

**Title:** *ST-1435 (SA) Implant Dose-Finding Study*<sup>8</sup>

**Objectives:**

- To determine which of the 2 doses of ST-1435 (SA) delivered by the implant regimens was better for contraceptive purposes
- To determine the plasma levels of SA produced by both implants and the association of these levels with ovulation inhibition and with cervical mucus effects

**Study Design:** This was a parallel group, open-label, multi-sites, dose-finding study in 120 healthy women with regular menstrual periods. Study subjects were randomized to one of the two SA implant treatment groups:

- 100 µg/day dose (n = 60): Twenty (20) subjects at each of the 3 sites received one 4 cm SA implant (containing 80 mg of SA)
- 150 µg/day dose (n = 60): Twenty (20) subjects at each of the 3 sites received two 3 cm implants (containing a total of 120 mg of SA).

The implants were inserted by the fifth day of the menstrual period which occurred after the pretreatment cycle. Subjects participated in the study for 2 years.

Blood samples for P and E2 were taken twice a week for 6 weeks consecutively beginning at pre-specified time intervals (at months 1, 6, 12, 18, and 24 post-insertion). Vaginal ultrasound measurements were performed twice a week for 6 weeks in a subset of women (N=23/dose) to examine the effect of SA on endometrial thickness and ovarian follicles. Luteal activity was defined as at least 1 progesterone measurement above 10 nmol/L and/or ovulation documented by ultrasound. Other PD parameters such as Cervical Mucus, Endometrial Biopsy and Menstrual Diary Cards for Bleeding Patterns were also investigated in the study. SA serum concentrations were measured once a week in the same sampling periods as for P and E2.

Serum concentrations of SA were measured using a validated radioimmunoassay at the (b) (4) University of Helsinki in Finland. The assay used [125I] iodohistamine-CMO- NES as tracer. The antiserum was raised against NES-CMO- BSA in rabbits. The method gave linear results within the concentration range of 13-432 pmol/L. Recovery was between 100%-110%. The intra- and inter-assay CV were 5%-9% and 10%-17%, respectively.

**PD Results:** Table 14 shows the results of luteal activity based on a combination of P levels and vaginal ultrasound. No luteal activity was observed through the first 6 months of the study in either treatment group, and very little activity was observed at Month 12. However, at 18 months, the frequency of luteal activity in the low-dose group rose to 26.7% of cycles, as

---

<sup>8</sup> Brache, V.; Massai, R.; Mishell, D. R.; Moo-Young, A. J.; Alvarez, F.; Salvatierra, A. M.; Cochon, L.; Croxatto, H.; Robbins, A.; Faundes, A., Ovarian function during use of Nestorone(R) subdermal implants. *Contraception* 2000, 61 (3), 199-204

compared with only 2.4% of cycles in the high-dose group. A further increase to 34.9% vs 16.2%, respectively, was observed at 24 months.

**Table 14. Frequency of Cycles with Luteal Activity ( $P > 10$  nmol/L) and/or Ovulation by Ultrasound**

Period	NES 100 µg/day n (%)	NES 150 µg/day n (%)
Pretreatment Cycle	60/60 (100.0)	57/60 (95.0)
Month 1	0/60 (0.0)	0/60 (0.0)
Month 6	0/53 (0.0)	0/54 (0.0)
Month 12	3/50 (6.0)	2/52 (3.8)
Month 18	12/45 (26.7)	1/41 (2.4)
Month 24 <sup>a</sup>	15/43 (34.9)	6/37 (16.2)
Year 1 Total	3/163 (1.8)	2/166 (1.2)
Year 2 Total <sup>a</sup>	27/88 (30.7)	7/78 (9.0)

NES = SA. <sup>a</sup> Three subjects in the SA 100 µg/day and 5 subjects in the 150 µg/day treatment groups had not yet completed Year 2 of the study at the time of this analysis; therefore, Year 2 data for these 8 subjects were not included in the analysis.

Estrogen suppression, as shown by E2 concentrations constantly  $\leq 100$  pmol/L, was only observed during the first 6 months of use. The frequency with which subjects had E2 levels in the high range ( $> 1500$  pmol/L) increased from less than 10% in Month 1 to approximately 24% in the high-dose group and 35% in the low-dose group in Month 24. There were reduced mean cervical mucus maximum scores and decreased sperm penetration for subjects in both treatment groups at Months 18 and 24 compared to the Pretreatment Cycle.

Breakthrough bleeding and spotting episodes of 3 to 5 per 3-month period occurred in 50% or more of subjects in both treatment groups, and prolonged or irregular bleeding occurred in 20% or more of subjects in most 3-month periods in both treatment groups. Endometrial biopsy results showed no evidence of pathology in either treatment group.

**PK Results:** Serum levels of SA declined continuously with time, with a more pronounced drop during the first year of use (**Figure 13**). Mean serum concentrations of SA observed during the first month of use were near 110 and 160 pmol/L, declining to 60 and 85 pmol/L at 12 months for 100 µg/day and 150 µg/day SA treatment groups, respectively. The mean serum concentrations stabilized between 18 and 24 months of use at 50 and 70 pmol/L, for the low- and high-dose groups, respectively. The levels achieved with the lower dose were approximately two-thirds the levels provided by the higher dose.

When the mean serum SA concentrations in the sampling period were correlated with the frequency of luteal activity, a dose-relationship was observed. No luteal activity was observed in 244 sampling periods with serum SA levels  $> 80$  pmol/L. As serum SA levels decreased, the frequency of luteal activity increased.

**Figure 13. SA (Nesterone) serum concentrations among users of 100 µg/day (One 4 cm) and 150 µg/day (Two 3 cm) SA Implants**

o -

**Safety Results:** One subject in the 150 µg/day treatment group discontinued from the study and received a final diagnosis of encephalitis 3 months later from her neurologist. This event was not reported by the investigator as an SAE; however, it is considered to be an SAE by the applicant. No laboratory findings in the study were considered to be clinically significant for either treatment group.

**Pregnancy:** A single pregnancy occurred for a subject in the 100 µg/day treatment group at 24 months.

**Conclusions:**

- Serum concentrations of SA declined with time, with a more pronounced decrease during the first 18 months of implant use; thereafter, SA levels remained stable until the end of the study at 24 months.
- Luteal activity was very infrequent during the first year of use (<3%) but increased during the second year, occurring in 27% and 35% of the sampling periods in the 100 µg/day SA treatment group, and 2% and 16% of the sampling periods in the 150 µg/day SA treatment group, at months 18 and 24 of use, respectively.
- No luteal activity was observed with SA levels above 80 pmol/L.
- The SA-only implants in both treatment groups were well tolerated, based on the discontinuation data and clinical laboratory evaluations.

**Reviewer's Comments:**

*The study showed the exposure-response of SA on ovulation suppression. Per the applicant, the lowest effective SA concentration is around 80 pmol/L, as no luteal activity was observed with SA levels above this level.*

**Reviewer's Notes:**

*The reported SA doses of two implants are different between the study synopsis and the published article. The synopsis stated SA doses of 150 and 100 µg/day, whereas the publication reported doses of 75 and 50 µg/day. Based on SA serum concentrations, the study was most likely conducted using 75 and 50 µg/day SA doses.*

## 4.2. Study 174 (Pilot Dose-finding Study)<sup>9</sup>

---

**Title:** Phase 2 Study of SA Rings

**Objective:** To estimate the contraceptive efficacy and bleeding pattern of 3 doses of SA CVS.

**Study Design:** This was a parallel group, open-label, multi-site study in 180 healthy women at risk for pregnancy and with regular menstrual periods. It was a 6-month (7-cycle) continuous use dose-finding study in women using one of 3 different doses (50, 75, or 100 µg/day) of SA CVS as their only method of contraception.

Blood samples for progesterone and estradiol were taken twice a week for 5 weeks consecutively during a control cycle and during the 1st, 3rd, and 6th month of use. Sampling periods were classified as having luteal activity if P levels were  $\geq 10$  nmol/L in at least one sample. SA serum concentrations were also measured once a week in the same sampling periods as PD measurements.

Serum concentrations of SA were measured using a validated radioimmunoassay at the Steroid Research Laboratory of the University of Helsinki in Finland, according to the method of Lahteenmaki.

**PD Results:** Luteal activity was observed in 1.2 to 2.6% of the cycles studied with no detectable difference by dose. The lack of dose-response is likely due to the relatively high SA serum levels were achieved in all 3 SA doses (**Table 15**). Among 5 cycles with luteal activity, two cycles (one in the low dose group and one in the high dose group) had P levels  $< 20$  nmol/L (insufficient luteal function) and 3 cycles showed highest P values ranging from 23.5 to 29.6 nmol/L. The E2 levels during the sampling periods were inversely correlated with the dose of SA (**Figure 14**). Estradiol levels remained relatively constant in women using the 75 µg/day and 100 µg/day CVSs during the three sampling periods. Estradiol levels among users of the 50 µg/day CVS were significantly higher than with the other 2 treatment groups ( $p < 0.01$ ) and had a greater variability among subjects. Particularly, E2 mean concentrations ranged from 716 pmol/L at month 1 to 1,038 pmol/L at month 3 and 1,276 pmol/L at month 6, indicating greater follicular activity with anovulation. In contrast, the highest mean E2 level in the control cycle was between 800–900 pmol/L. The incidence, by cycle, of unscheduled bleeding or spotting over 6 continuous cycles of use, ranged from 63% to 76% in 50 µg/day CVS dose group, 53% to 63% in 75 µg CVS dose group, and 45% to 57% in 100 µg CVS dose group.

---

<sup>9</sup> Brache, V.; Mishell, D. R.; Lahteenmaki, P.; Alvarez, F.; Elomaa, K.; Jackanicz, T.; Faundes, A., Ovarian function during use of vaginal rings delivering three different doses of Nestorone. *Contraception* **2001**, *63* (5), 257-61.

**Table 15. Frequency of cycles with luteal activity ( $p \geq 10$  nmol/L) during use of CVS delivering three different doses of SA**

Month of use	50 $\mu\text{g/d}$	75 $\mu\text{g/d}$	100 $\mu\text{g/d}$
	n	n	n
1	0/29	1/28	0/30
3	2/26	1/26	1/27
6	0/25	0/23	0/24
Total	2/80 (2.5%)	2/77 (2.6%)	1/81 (1.2%)

**Figure 14. Mean highest E2 level (in 5-week sampling period) during use of 3 different CVS delivering 50, 75, and 100  $\mu\text{g/day}$  of SA**

o

**PK Results:** Mean serum SA concentrations were highest in Cycle 1 and decreased from Cycle 1 to Cycle 7. SA serum concentrations were dose related. Mean serum concentrations of SA from 50, 75 and 100  $\mu\text{g/day}$  CVS were all above 100 pmol/L at Cycle 7 (**Figure 15**)

**Figure 15. Mean SA Serum Concentrations during 6 Months Use of 3 Different CVS Delivering 50, 75, and 100  $\mu\text{g/day}$  of SA**

**Safety Results:** Of the 179 subjects in the safety population, 152 subjects (85%) experienced at least 1 AE. All 3 dose groups were comparable with respect to overall AE profiles and AEs leading to premature study discontinuation. There was no safety signal observed in any of the dose groups with regard to clinical chemistry, hematology, or gynecologic examinations.

**Pregnancy:** Two subjects reported a pregnancy during CVS use: one in 75 µg/day CVS dose group and one in 100 µg/day CVS dose group. Neither subjects had serum P measurements.

### **Reviewer's Comments**

The applicant plotted P vs. SA concentrations (b) (4)

(b) (4) (**Figure 16**). However, it is not clear whether this value can be applied to SA/EE 150/15 CVS due to the following concerns:

- (b) (4) the product in the current submission is a fixed-dose combination of SA and EE administered under a 21/7-day in/out regimen.
- Different bioanalytical techniques (i.e., RIA vs. GC-MS/MS) were used to determine SA serum concentrations and the values from one assay may not be interchangeable with another assay.

### **Figure 16 Progesterone vs. SA Concentrations**



### **Reviewer's Notes**

- The 6 months of study treatment (182 days) were analyzed as 28-day cycles. Therefore, the study is reported as a 7-cycle study with the understanding that subjects were expected to complete 6 full cycles and were not expected to complete the 7th cycle.
- APPEARS THIS WAY ON ORIGINAL
- **Figure 14** and **Figure 15** in the review are from the published article that is based on this clinical study.

### 4.3. Study 180 (Pivotal Dose-finding Study)<sup>10</sup>

---

**Title:** *Study of SA® Progestin/Ethinyl Estradiol Contraceptive Rings: Comparison of 200/15, 150/20, and 150/15 Doses*

**Objectives:** To determine if an increase in SA or EE dose would significantly improve ring performance compared to the SA/EE 150/15 CVS

**Study Design:** This was a 13-cycle, multicenter, randomized, parallel-group, dose-ranging study to compare the performance of SA/EE CVS in 3 different dose combinations. One hundred fifty (150) pre-menopausal women were randomized to one of the following treatment groups: SA/EE 150/15 CVS (N=50), SA/EE 150/20 CVS (N=50), or SA/EE 200/15 CVS (N=50). The CVS was to be used continuously for 21 days, removed for 7 days, and then inserted into the vagina to begin the next cycle. This pattern of use was to be replicated for 13 cycles. Subjects were instructed not to remove the CVS during the 21 days of ring use, but were permitted to remove the CVS for periods of no more than 2-hour intervals to allow for intercourse or washing of the CVS.

P levels were evaluated off-therapy at Pre-treatment and Post-treatment, and were also evaluated on-therapy during Weeks 1, 2, and 3 of Cycles 3, 6, 9, and 13. Luteal activity was deemed to have occurred in any cycle in which there was a progesterone measurement  $\geq 10$  nmol/L. At weeks 1, 2, and 3 of Cycles 3, 6, 9 and 13, a single weekly blood draw was scheduled to measure SA and EE concentrations.

#### Bioanalytical Method

Serum concentrations of SA were measured using a validated radioimmunoassay developed by (b) (4) Family Federation of Finland Helsinki, Finland. The validated quantitation range was 5.3 to 1350 pmol/L for SA. Serum concentrations of EE were measured by (b) (4) USC Medical Center, Department of OB/GYN (b) (4)

**PD Results:** The SA/EE 150/15 CVS treatment group had the greatest percent of cycles with luteal activity (10.7%) compared with 150/20 CVS treatment group (2.2%) and 200/15 CVS treatment group (4.3%). Increasing the dose of SA from 150 to 200  $\mu$ g further suppressed the luteal activity, but the difference was not statistically significant (**Table 16** and **Table 17**). Increasing the dose of EE from 15 to 20  $\mu$ g resulted in a significant decrease in luteal activity and a better bleeding control. However, subjects in this study group also reported more AEs related to the administration of EE (see safety results).

#### **Table 16. Summary of On-Therapy Luteal Activity by Subjects**

---

<sup>10</sup> Sivin, I.; Mishell, D. R., Jr.; Alvarez, F.; Brache, V.; Elomaa, K.; Lahteenmaki, P.; Massai, R.; Miranda, P.; Croxatto, H.; Dean, C.; Small, M.; Nash, H.; Jackanicz, T. M., Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. *Contraception* **2005**, *71* (2), 122-9


	SA/EE 150/15	SA/EE 150/20	SA/EE 200/15	Total
<b>Time point</b>	N (%)	N (%)	N (%)	N (%)
<b>Cycle 3</b>	1 (3.8)	0 (0)	0 (0)	1 (1.3)
<b>Cycle 6</b>	4 (16)	0 (0)	3 (13.6)	7 (9.5)
<b>Cycle 9</b>	4 (10.8)	2 (4.9)	2 (5.3)	8 (6.9)
<b>Cycle 13</b>	4 (11.8)	1 (2.9)	1 (3.0)	6 (5.9)

**Table 17. Summary of On-Therapy Luteal Activity by Cycles**


Period	SA/EE 150/15	SA/EE 150/20	SA/EE 200/15	Total
<b>Cycles Monitored</b>	122	134	117	373
<b>Cycles with Luteal Activity</b>	13	3	5	21
<b>Percent of Cycles with Luteal Activity</b>	10.7	2.2	4.3	5.6

**PK Results:** The higher dose SA and EE CVSs were associated with higher plasma levels of SA and EE through 13 cycles. Particularly, SA/EE 200/15 CVS group showed the highest SA concentrations compared to the other dose groups. Interestingly, SA concentrations from SA/EE 150/15 CVS group were lower at most of timepoints than those from SA/EE 150/20 CVS group (**Figure 17**). SA/EE 150/20 CVS group had higher EE concentrations than the 150/15 and 200/15 CVS groups which each had similar EE concentrations (**Figure 18**).

**Figure 17. Mean SA Serum Concentrations from SA/EE 150/15 CVS (Treatment A), SA/EE 150/20 CVS (Treatment B), SA/EE 200/15 CVS (Treatment C) for Weeks 1, 2, and 3 in Cycles 3, 6, 9, and 13**



**Figure 18. Mean EE Serum Concentrations from SA/EE 150/15 CVS (Treatment A), SA/EE 150/20 CVS (Treatment B), SA/EE 200/15 CVS (Treatment C) for Weeks 1, 2, and 3 in Cycles 3, 6, 9, and 13**



**Safety Results:** All 3 treatment groups were comparable with respect to AEs leading to premature study discontinuation; however, subjects in the SA/EE 150/20 CVS treatment group reported more nausea and vulvovaginal pruritus, and experienced 2 SAEs related to the administration of EE (cholecystitis and superficial thrombophlebitis). Colposcopic findings were comparable across treatment groups.

**Pregnancy:** During the study, no pregnancies occurred in users of the 150/15 and 150/20 rings, but there were two unintended pregnancies in the 200/15 dose group.

**Conclusions:** SA/EE 150/15 CVS treatment group had acceptable ovulation inhibition, an acceptable bleeding profile, and an acceptable AE profile compared to the higher dose treatment groups. Given the relatively lower systemic exposure of SA and EE compared to the other two studied dose groups, the SA/EE 150/15 dose was selected for further studies.


**Reviewer’s Comments**

*With the same SA and EE dose, the current study showed 10% of cycles with luteal activity as compared to 2% in Study 300PK. The reason for this discrepancy is not known.*


*This reviewer plotted the Progesterone vs. SA concentrations using data from the current study (Figure 19 and Figure 20).*

*[Redacted]* (b) (4)  
*[Redacted]*  
*[Redacted]*  
*[Redacted]* No clear exposure-response was observed from this study.

**Figure 19** *Observed P vs SA concentrations in Study 180*



**Figure 20** *SA Concentrations in Subjects with Luteal Activity*



Duration the late-cycle meeting with the applicant on May 30, 2018, the review team informed the applicant that data from Study 180 (b) (4) and requested a detailed analysis for this study. The applicant responded to this information request on June 12 2018. The applicant stated that (b) (4) for study 180 as had been noted in study 174 (NDA Amendment 0020). Plots of the data

by cycle and by dose also did not show a threshold effect for ovulation inhibition. When the data were plotted by site, it became apparent that all of the ovulations (progesterone levels > 10 nmol/L) in this study occurred at one site, the Los Angeles, California site. There were no ovulations at the sites in: Helsinki, Finland; Santiago, Chile; Santo Domingo, Dominican Republic; or St. Louis, Missouri.....Given the consistent ovulation inhibition for 5 of the 6 sites in study 180, and the evidence for ovulation inhibition with a dose effect in study 174, it is possible (and consistent with the findings) that the subjects at the Los Angeles site in study 180 did not adhere to the 21/7 regimen for CVR use but rather used the CVR for less than 21 days in some cycles. In 5 of the 6 sites in study 180, ovulation inhibition was observed that is consistent with the 21/7 use of a combined hormonal contraceptive, the result from the sixth site is an outlier.”

The review team acknowledges the importance of patient compliance in the efficacy of SA/EE CVS. However, adequate serum concentrations of SA (i.e., median SA concentration > 200 pmol/L) in women with luteal activity at the Los Angeles site in Study 180 does not seem to support the poor patient compliance as suggested by the applicant.

#### **4.4. Study 181 (Dosing Regimen-finding Study)**

---

**Title:** *Study of Ovulation Inhibition in Women Using SA Progestin/EE Contraceptive Rings: Comparison of Seven Days and Four Days Out*

**Objective:** To determine the effectiveness of SA 150 µg/day / EE 15 µg/day contraceptive vaginal ring (CVS) in preventing ovulation in subjects following either of 2 schedules: CVS 21 days in/7 days out or CVS 26 days in/4 days out

**Study Design:** This was a 6-cycle, randomized, multicenter, parallel-group, open-label study of the SA 150 µg/day / EE 15 µg/day CVS in 101 sexually-active women with regular menstrual periods. The eligible subjects were randomized to one of the following schedules:

- Schedule A - CVS 21 days in/7 days out (21/7). The CVS was inserted on Day 4 to 6 of Cycle 1, left in continuously for 21 days, and then removed for 7 days. This pattern of 3 weeks of use and 1 week of non-use was followed for 6 cycles using the same CVS.
- Schedule B - CVS 26 days in/4days out (26/4). The CVS was inserted on Day 4 or 5 of Cycle 1, used for 26 days, and then removed for 4 days. This pattern of 26 days of use followed by 4 days of non-use was followed for 6 cycles using the same CVS.

Progesterone and estradiol levels were evaluated off-therapy at Pre-treatment and Post-treatment, Cycle, and twice per week during Cycles 2, 4, and 6 of CVS use (8 collections per cycle). As some follicular development has been observed in the hormone-free interval, a blood sample was also collected on the day the CVS was removed in Cycles 1, 3, and 5. Samples were also collected twice per week in the Post-treatment Cycle. Serum levels of SA were determined from blood samples collected once per week (at the end of the week) during Cycles 2, 4, and 6 of CVS use.

**PD Results:** The mean values for progesterone during each month of the study were suppressed in relation to baseline for subjects in both treatment regimens, with the highest on-therapy maximums occurring in Month 1 (28.5 nmol/L) and Month 3 (37.2 nmol/L) for subjects in the 26/4-day regimen and in Month 6 (28.5 nmol/L) for subjects in the 21/7-day regimen (**Table 18**). The mean values for estradiol during each month of the study were suppressed in relation to baseline for subjects in both treatment regimens, but were higher for the subjects in the 21/7-day regimen compared with the 26/4-day regimen. The absence of unscheduled bleeding and/or spotting occurred at a similar frequency for subjects in the 2 treatment regimens: 56.3% of the subjects in the 21/7-day regimen and 50.0% of the subjects in the 26/4-day regimen had no unscheduled bleeding and/or spotting.

**Table 18. Concentrations of P and E2 by Month for Subjects Receiving the 21/7- or 26/4-Day Treatment Regimen**

-----  
\_\_\_\_\_  
N=number of subjects; SD=standard deviation.

Visit windows: Baseline: Days  $\leq$ 1; Month 1: Days 2-30; Month 2: Days 31-60; Month 3: Days 61-90; Month 4: Days 91-120; Month 5: Days 121-150; Month 6: Days 151-180.

**PK Results:** SA was assessed for the greatest number of subjects (64) during Month 2. At Month 2, the concentration of SA in the serum was approximately equal for subjects in the 2 regimens (**Table 19**).

## Table 19. Concentrations of SA by Month for Subjects Receiving the 21/7 or 26/4 Treatment Regimen

**Safety Results:** The safety profile of SA /EE 150/15 CVS was similar when used as either a 21/7-day in/out or a 26/4-day in/out regimen. Of the 101 subjects in the Safety population, 80 subjects (79.2%) experienced at least 1 AE. No deaths and 1 serious adverse event were reported during the study.

**Conclusion:** The 21/7-day regimen of SA /EE 150/15 µg dose was selected for further studies due to the lower SA dose compared to 24/4-day regimen.

## 5. Mechanistic Safety Assessment

---

### 5.1. Study POP-648 (QT)

---

**Title:** A Double-Blind, Placebo-Controlled, Randomized, Crossover Design Study with an Open-Label Active Control to Evaluate the Potential of SA® to Delay Cardiac Repolarization in Healthy Female Volunteers

In this study, 44 female healthy subjects were randomized to either a single i.v. bolus dosing of 200 µg (super-therapeutic dose) of SA, Placebo or open-label moxifloxacin 400 mg in each period using 2 Williams square schema, and 39 subjects completed the study. The Interdisciplinary Review Team for QT Studies (QT IRT) reviewed this study and concluded that no significant QTc prolongation effect of SA (200 µg i.v.) was detected in this TQT study (Table 20)<sup>11</sup>.

**Table 20. The Point Estimates and the 90% CIs Corresponding to the Largest Upper Bounds for SA (200 µg i.v.) and the Largest Lower Bound for Moxifloxacin 400 mg (QT IRT Analysis)**

---

<sup>11</sup> Interdisciplinary Review Team for QT Studies Consultation Report for IND 49980 by Dr. QianYu Dang et. al. dated 02/05/2014

Treatment	Time (hour)	$\Delta\Delta Q T_c F$ (ms)	90% CI (ms)
SA IV bolus	6	2.1	(-0.7, 4.8)
Moxifloxacin 400 mg*	4	12.8	(11.1, 14.6)

\* Multiple endpoint adjustment was not applied. The largest lower bound after Bonferroni adjustment for 3 timepoints (2, 3 and 4 hours) is 10.6 ms.

The PK and safety data were also reviewed by QT IRT and found acceptable. Thus, this study report is not assessed in current review. The supra-therapeutic dose (200  $\mu\text{g}$ ) produces a mean  $C_{\text{max}}$  value (6092 pg/mL) or ~5-fold the mean  $C_{\text{max}}$  at the therapeutic dose of 150  $\mu\text{g}/\text{day}$  from SA/EE CVS (1147 pg/mL). The PK data collected from Study POP-648 showed that volume of distribution of SA is 1176 L (~17 L/kg) (Figure 21 and Table 21).

Figure 21. Mean SA Serum Concentration-Time Profile (Study POP-648)




Table 21. Mean  $\pm$  SD PK Parameters of SA Following I.V. Administration of a Single Dose of 200  $\mu\text{g}$  SA

Parameter	Units	Geometric		Arithmetic Mean and Other Stats									
		n	Geom. Mean	n	Mean	SD	SE	CV (%)	Min	Q1	Median	Q3	Max
%AUC <sub>back</sub> extrap_obs	%	12	0.67	22	2.18	5.114	1.090	234.199	0.0	0.00	0.03	0.91	22.3
%AUC <sub>back</sub> extrap_pred	%	12	0.67	22	2.18	5.125	1.093	234.560	0.0	0.00	0.03	0.91	22.4
%AUC <sub>extrap_obs</sub>	%	22	11.91	22	13.51	6.865	1.464	50.800	3.7	8.25	10.95	19.05	28.9
%AUC <sub>extrap_pred</sub>	%	22	11.88	22	13.49	6.907	1.473	51.194	3.7	8.28	11.20	18.90	29.1
%AUMC <sub>extrap_obs</sub>	%	22	60.21	22	61.82	14.030	2.991	22.694	33.0	50.22	59.67	73.48	84.6
%AUMC <sub>extrap_pred</sub>	%	22	60.13	22	61.75	14.059	2.997	22.767	32.9	50.30	59.96	73.58	84.7
AUC <sub>24</sub>	h·pg/mL	38	3018.2	38	3081.5	634.65	102.95	20.60	2170	2543.9	3046.5	3566.3	4360
AUC <sub>0-24</sub>	h·pg/mL	22	3495.6	22	3601.2	889.03	189.54	24.69	2336	2810.6	3419.1	4429.2	5058
AUC <sub>0-24</sub> /D	h·pg/(mL· $\mu\text{g}$ )	22	17.478	22	18.006	4.4451	0.9477	24.6869	11.68	14.053	17.095	22.146	25.29
AUC <sub>0-24</sub> pred	h·pg/mL	22	3494.8	22	3600.3	888.64	189.46	24.68	2334	2794.8	3415.9	4468.5	5066
AUC <sub>0-24</sub> pred/D	h·pg/(mL· $\mu\text{g}$ )	22	17.474	22	18.002	4.4432	0.9473	24.6822	11.67	13.974	17.080	22.342	25.33
AUC <sub>all</sub>	h·pg/mL	38	3020.9	38	3084.4	636.23	103.21	20.63	2171	2544.3	3048.0	3567.4	4361
AUC <sub>last</sub>	h·pg/mL	38	3016.0	38	3079.7	636.12	103.19	20.66	2150	2544.3	3048.0	3567.4	4361
AUMC <sub>0-24</sub> obs	h <sup>2</sup> ·pg/mL	22	29158.5	22	36024.9	24663.90	5258.36	68.46	5961	17465.3	29439.3	44423.5	108065
AUMC <sub>0-24</sub> pred	h <sup>2</sup> ·pg/mL	22	29110.9	22	35995.1	24777.65	5282.61	68.84	5923	17355.4	29251.8	43883.0	108579
AUMC <sub>last</sub>	h <sup>2</sup> ·pg/mL	38	10900.2	38	11401.0	3244.88	526.39	28.46	3271	9031.5	10880.7	13224.1	18347
Cl <sub>obs</sub>	mL/h	22	57215.1	22	58961.4	14775.83	3150.22	25.06	39540	45155.2	58828.0	71158.3	85610
Cl <sub>pred</sub>	mL/h	22	57227.6	22	58971.6	14760.33	3146.91	25.03	39476	44758.1	58889.2	71562.4	85708
C <sub>0</sub>	pg/mL	22	1056.0	38	1863.5	4330.88	702.56	232.41	0	0.0	177.5	1960.0	23865
C <sub>last</sub>	pg/mL	38	22.77	38	24.08	8.077	1.310	33.542	11.8	16.00	23.70	30.10	45.5
C <sub>max</sub>	pg/mL	38	5150.2	38	6091.8	3941.40	639.38	64.70	2080	3290.0	4975.0	8000.0	21200
C <sub>max</sub> /D	pg/(mL· $\mu\text{g}$ )	38	25.75	38	30.46	19.707	3.197	64.700	10.4	16.45	24.88	40.00	106.0
MRT <sub>0-24</sub> obs	h	22	8.342	22	9.517	4.9410	1.0534	51.9176	2.55	5.904	7.967	12.699	21.36
MRT <sub>0-24</sub> pred	h	22	8.330	22	9.509	4.9573	1.0569	52.1313	2.54	5.969	8.028	12.634	21.43
MRT <sub>last</sub>	h	38	3.614	38	3.716	0.8317	0.1349	22.3777	1.52	3.327	3.656	4.255	5.53
R <sup>2</sup>		22	0.9786	22	0.9788	0.02003	0.00427	2.04679	0.927	0.9672	0.9833	0.9954	1.000
R <sup>2</sup> Adj.		22	0.9664	22	0.9668	0.02734	0.00583	2.82793	0.903	0.9515	0.9665	0.9908	1.000
T <sub>1/2</sub>	h	38	23.08	38	23.33	0.2747	0.446	11.771	9.0	24.03	24.04	24.05	24.1
T <sub>max</sub>	minutes	38	2.78037	38	3.28026	2.745356	0.445356	83.693165	1.1667	2.05000	2.57500	3.31667	17.4333
V <sub>ss</sub> obs	mL	22	477261.6	22	532740.7	247283.99	52721.12	46.42	195027	318352.7	505350.6	685181.1	1138227
V <sub>ss</sub> pred	mL	22	476691.7	22	532386.5	247899.07	52852.26	46.56	196592	316675.6	504751.4	701181.6	1139319
V <sub>z</sub> obs	mL	22	1100130.6	22	1176306.4	418861.28	89301.53	35.61	467877	872452.7	1172443.5	1497205.7	2089956
V <sub>z</sub> pred	mL	22	1100371.9	22	1176432.5	418775.27	89283.19	35.60	468409	873595.2	1175244.4	1485459.7	2088282
$\lambda_z$	h <sup>-1</sup>	22	0.05201	22	0.05770	0.032523	0.006934	56.368284	0.0260	0.03851	0.05427	0.06571	0.1830
$\lambda_z$ : Lower Limit	h	22	8.97	22	9.35	2.508	0.535	26.834	4.0	9.01	9.03	12.02	12.1
$\lambda_z$ : Number of Points		22	3.6	38	2.1	1.91	0.31	90.93	0	0.0	3.0	4.0	5
$\lambda_z$ : Upper Limit	h	22	22.40	22	22.82	3.554	0.758	15.574	9.0	24.03	24.04	24.06	24.1
t <sub>r</sub> (lit C)		0		22	-0.9893	0.01018	0.00217	-1.02941	-1.000	-0.9977	-0.9916	-0.9835	-0.963
t <sub>90</sub>	h	22	13.33	22	14.49	5.803	1.237	40.048	3.8	10.55	12.77	18.00	26.6

## 6. Combined Review for In vitro Studies

---

### 6.1. Plasma Protein Binding

---

#### **Study ADME2**

Title: Determination of Free SA Concentration In Rat, Mouse and Human Serum by Ultrafiltration

Method: Samples were incubated with  $^3\text{H}$ -SA and  $^{14}\text{C}$ -Glucose and were then subjected to centrifugal ultrafiltration. The percentage of free SA was estimated by dividing the ratio of  $^3\text{H}$ -SA and  $^{14}\text{C}$ -Glucose concentration in the ultrafiltrate by the ratio of the  $^3\text{H}$ -SA and  $^{14}\text{C}$ -Glucose in the retentate.

Result: About 4.42% (SE 0.368) of SA was free (not protein bound) in human serum.

#### **Study SA® General Pharmacology 1**

Title: Relative Binding Affinity of SA to Steroid Hormone Receptors and Sex Hormone Binding Globulin (SHBG)

Method: Third trimester pregnancy serum was used as the source of SHBG and  $^3\text{H}$ -testosterone was used as the radioactive ligand. Dextran-charcoal was used to separate bound and free radioactivity.

Result: Levonorgestrel and desogestrel bound to SHBG with significant binding affinity. The binding of SA and progesterone to SHBG was negligible.

### 6.2. In Vitro Metabolism

---

#### **Study XT174097**

Title: In vitro cytochrome P450 reaction phenotyping of SA in human liver microsomes and recombinant human CYP enzymes

Method: In vitro clearance of SA (based on loss of parent test drug) in incubations with a panel of recombinant human CYP enzymes (namely, CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, and 3A5), and with pooled human liver microsomes in the absence and presence of selective inhibitors of the aforementioned CYP enzymes.

Result: Incubations of SA (0.5  $\mu\text{M}$ ) in the presence of selective metabolism-dependent inhibitors for various CYP enzymes further supported CYP3A4-mediated metabolism of SA. SA clearance was significantly diminished in the presence of the metabolism-dependent CYP3A4/5 inhibitor troleanomycin (71.8% inhibition) and the selective CYP3A4 inhibitor CYP3cide (84.6% inhibition). The contributions of other CYP enzymes to the clearance of SA were less than 20%. The contribution of CYP3A4 to the microsomal clearance of SA based on the degree of

inhibition by CYP3cide (~85%) was comparable to that previously estimated from the degree of inhibition by the CYP3A4/5 inhibitor ketoconazole (87%).

Conclusion: CYP3A4 is the major contributor (~85%) to the metabolic clearance of SA by human liver microsomes.

### **6.3. Induction/Inhibition of Drug-Metabolizing Enzymes**

---

#### **Study XT103116**

Title: In Vitro Evaluation of SA as an Inducer of Cytochrome P450 Expression in Cultured Human Hepatocytes

Method: Three preparations of cultured human hepatocytes from three separate livers were treated once daily for three consecutive days with dimethyl sulfoxide (DMSO, 0.1% v/v, vehicle control), one of three concentrations of SA (10, 100 or 1000 nM) or one of three known human CYP inducers, namely, omeprazole, phenobarbital and rifampin. After treatment, the cells were incubated in situ with the appropriate marker substrates for the analysis of phenacetin O-dealkylation (marker for CYP1A2), bupropion hydroxylation (marker for CYP2B6), amodiaquine N-dealkylation (marker for CYP2C8), diclofenac 4'-hydroxylation (marker for CYP2C9), S-mephenytoin 4'-hydroxylation (marker for CYP2C19) and testosterone 6 $\beta$ -hydroxylation (marker for CYP3A4/5) by LC/MS/MS.

Result: Treatment of cultured human hepatocytes with up to 1000 nM SA final concentration, caused little or no change in CYP1A2, 2B6, 2C8, 2C9, 2C19 and 3A4/5 activity (<2.0-fold increase and less than 8% of the effect caused by the appropriate positive control)

Conclusion: At up to 1000 nM, SA did not induce CYP1A2, 2B6, 2C8, 2C9, 2C19 and 3A4/5.

#### **Study XT105121**

Title: In Vitro Evaluation of SA as an Inhibitor of Cytochrome P450 (CYP) Enzymes in Human Liver Microsomes

Method: Human liver microsomes from a pool of 16 individuals were incubated with marker substrates, at concentrations approximately equal to  $K_m$  or  $S_{50}$ , in the presence or absence of SA. To evaluate time- and metabolism-dependent inhibition, SA was preincubated with human liver microsomes in the absence and presence of an NADPH-generating system, respectively, for 30 minutes prior to incubation with the marker substrate. Known direct and metabolism-dependent inhibitors of CYP enzymes were included as positive controls.

Result: Under the experimental conditions examined, there was little or no evidence of direct or time-dependent inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 by SA. At the highest concentration tested (i.e., 1000 nM) and above, SA

may have the potential to cause metabolism-dependent inhibition of CYP3A4/5 (as measured by midazolam 1'-hydroxylation) as an increase in inhibition (26%) was observed upon preincubation in the presence of NADPH.

**Conclusion:** Considering the therapeutic exposure levels of SA/EE CVS are less than 5 nM at the most, SA is unlikely to affect the PK of other drugs via CYP inhibition.

## Study XT185010

**Title:** In Vitro Evaluation of Metabolites of SA as Inhibitors of Cytochrome P450 Enzymes in Human Liver Microsomes

**Method:** The ability of 5 $\alpha$ -dihydro-SA (M3) or 17 $\alpha$ -hydroxy-5 $\alpha$ -dihydro-SA (M6) to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 was investigated using a pool of 200 individual human liver microsomal samples. The inhibitory potency of M3 and M6 was determined in vitro by measuring the activity of each CYP enzyme in the presence and absence of test article. The concentration of inhibitor that causes 50% inhibition of marker substrate activity (IC<sub>50</sub> value) for direct and time- and metabolism-dependent inhibition of each human CYP enzyme were examined.

**Result:**

**Table 22. In vitro evaluation of M3 as an inhibitor of human CYP enzymes in human liver microsomes**

Enzyme	Substrate	Direct inhibition		Time-dependent inhibition		Metabolism-dependent inhibition <sup>c</sup>		Inhibition potential conclusion
		Zero-min preincubation		30-min preincubation without NADPH		30-min preincubation with NADPH		
		IC <sub>50</sub> $\pm$ SE ( $\mu$ M) <sup>a</sup>	Maximum inhibition (%) <sup>b</sup>	IC <sub>50</sub> $\pm$ SE ( $\mu$ M) <sup>a</sup>	Maximum inhibition (%) <sup>b</sup>	IC <sub>50</sub> $\pm$ SE ( $\mu$ M) <sup>a</sup>	Maximum inhibition (%) <sup>b</sup>	
CYP1A2	Phenacetin	> 30	5.4	> 30	0.3	> 30	0	None
CYP2B6	Efavirenz	> 30	14	> 30	14	> 30	14	None
CYP2C8	Amodiaquine	11 $\pm$ 2	68	13 $\pm$ 2	65	15 $\pm$ 1	61	Direct
CYP2C9	Diclofenac	> 30	37	> 30	30	> 30	38	Direct
CYP2C19	S-Mephenytoin	16 $\pm$ 2	67	16 $\pm$ 1	68	20 $\pm$ 1	58	Direct
CYP2D6	Dextromethorphan	> 30	16	> 30	13	> 30	6.9	None
CYP3A4/5	Midazolam	7.0 $\pm$ 1.1	72	9.5 $\pm$ 0.8	66	2.6 $\pm$ 0.2	82	Direct and MDI
CYP3A4/5	Testosterone	> 30	36	> 30	18	> 30	46	MDI

<sup>a</sup> Average data (i.e., percent of control activity) obtained from duplicate samples for each test article concentration were used to calculate IC<sub>50</sub> values.

<sup>b</sup> Inhibition observed (%) is calculated with the following formula for the concentration of inhibitor demonstrating the most inhibition (results are rounded to two significant figures): Inhibition observed (%) = 100% – Percent solvent control.

<sup>c</sup> Metabolism-dependent inhibition was determined by comparison of IC<sub>50</sub> values both with and without preincubation and with and without NADPH regenerating system present in the preincubation, by comparison of the observed inhibition (%) for all preincubation conditions and by visual inspection of the IC<sub>50</sub> plots.  
SE Standard error

**Table 23. Summary of results: In vitro evaluation of M6 as an inhibitor of human CYP enzymes in human liver microsomes**

Enzyme	Substrate	Direct inhibition		Time-dependent inhibition		Metabolism-dependent inhibition <sup>c</sup>		Inhibition potential conclusion
		Zero-min preincubation		30-min preincubation without NADPH		30-min preincubation with NADPH		
		IC <sub>50</sub> ± SE (µM) <sup>a</sup>	Maximum inhibition (%) <sup>b</sup>	IC <sub>50</sub> ± SE (µM) <sup>a</sup>	Maximum inhibition (%) <sup>b</sup>	IC <sub>50</sub> ± SE (µM) <sup>a</sup>	Maximum inhibition (%) <sup>b</sup>	
CYP1A2	Phenacetin	> 30	16	> 30	6.4	> 30	5.8	None
CYP2B6	Efavirenz	> 30	23	> 30	21	> 30	4.5	None
CYP2C8	Amodiaquine	> 30	28	> 30	20	> 30	29	Direct
CYP2C9	Diclofenac	> 30	8.0	> 30	6.0	> 30	13	None
CYP2C19	S-Mephenytoin	2.1 ± 0.1	91	2.5 ± 0.3	90	3.5 ± 0.2	88	Direct
CYP2D6	Dextromethorphan	> 30	4.7	> 30	0	> 30	6.4	None
CYP3A4/5	Midazolam	> 30	29	> 30	24	> 30	40	Direct
CYP3A4/5	Testosterone	> 30	29	> 30	34	> 30	31	Direct

**Conclusion:** Based on much low serum concentrations of M3 and M6 relative to determined IC50 values, M3 and M6 are unlikely to result in clinically relevant inhibition of CYP enzymes.

## 7. Literature Review of SA Lactation Studies

The SA/EE 150/15 CVS has not been evaluated in lactating women and CHCs are not recommended in this population. There are 4 publications that evaluated the effect of SA in lactation. Based on the relevance to the current submission, two studies of SA contraceptive implants in nursing women were reviewed below.

### 7.1. Article 1: Contraceptive efficacy and clinical performance of SA implants in postpartum women<sup>12</sup>


**Method:** blood and milk samples were obtained in a subset of 14 SA implant users who volunteered for this procedure. Blood samples (5 mL) were drawn from the contralateral arm to the implant site, once per week for the first month after insertion of the implant and once every other week thereafter, until weaning. Milk samples (10 mL) were collected by manual compression in the same subjects, immediately after blood samples were obtained. Concentrations of SA in serum and milk were measured by a validated radioimmunoassay.

#### **Result:**

SA levels rose in serum to mean concentrations of 175 pmol/liter during the first month after implant insertion (Figure 22). Later on, serum SA decreased progressively reaching mean levels of 60 pmol/liter at the end of the first year. SA concentrations in milk followed a similar pattern to those in serum, and the highest and lowest concentrations were 135 pmol/liter and 54 pmol/liter, respectively. With few exceptions, the milk/serum ratio was under 1. The estimated dose transferred to the infant, assuming a daily intake of 800 mL of milk, is around 50 ng/day in the first month after insertion decreasing thereafter to around 20 ng/day.

<sup>12</sup> Massai, M. R.; Diaz, S.; Quinteros, E.; Reyes, M. V.; Herreros, C.; Zepeda, A.; Croxatto, H. B.; Moo-Young, A. J., Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. *Contraception* **2001**, *64* (6), 369-76.

**Figure 22. SA levels in serum and milk of lactating women in the first year of use of a single SA implant and SA milk/serum ratio (open circle: plasma level, closed circle: milk levels)**




## 7.2. Article 2: Use of a Single Implant of Elcometrine (ST-1435), a Nonorally Active Progestin, as a Long Acting Contraceptive for Postpartum Nursing Women<sup>13</sup>

**Method:** Blood and milk samples were obtained from the mother before implant insertion as a control. After implant insertion, blood samples were drawn at 15 and 75 days of implant use. Breast milk was obtained at 75 days of implant use. A blood sample was drawn from the baby in the third month of the study, when the baby was 4 months old and the mother had been using the implant for 75 days. Concentrations of SA in serum and milk were measured by a validated radioimmunoassay.

### Result:

SA concentrations in the blood and milk of the lactating women indicated that SA passes freely from maternal blood into milk with a milk to serum ratio of approximately 1 (Figure 23). However, its concentration in the infants' blood (~19 pmol/L) was only about 5% of the mean levels measured in the mothers' blood, likely due to extensive first pass metabolism.

**Figure 23. Levels of SA (Elcometrine) in serum and breast milk of mothers and in serum of infants (mean ± SE, n = 25)**



<sup>13</sup> Coutinho, E. M.; Athayde, C.; Dantas, C.; Hirsch, C.; Barbosa, I., Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women. *Contraception* 1999, 59 (2), 115-22.

---

**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**

---

/s/  
-----

LI LI  
08/08/2018

NAN ZHENG  
08/08/2018

YUCHING N YANG  
08/08/2018

DOANH C TRAN  
08/08/2018

GILBERT J BURCKART  
08/08/2018

**PHARMACOLOGY/TOXICOLOGY  
SECONDARY REVIEW MEMO**

Date:	July 18, 2018
NDA #	209627
Sponsor:	The Population Council, Inc.
Drug:	Segesterone acetate/Ethinyl estradiol Contraceptive Vaginal System (SA/EE CVS)
Indication:	Contraception
Reviewer:	Kimberly Hatfield, PhD
Division:	Division of Bone, Reproductive and Urologic Products

**Background:**

The Population Council has submitted NDA 209627 for an intravaginal ring containing segesterone acetate and ethinyl estradiol for the indication of contraception. Segesterone acetate (SA) is a novel synthetic progestin, and a new chemical entity. Ethinyl estradiol (EE) is a known synthetic estrogen, and has been previously approved for use in several contraceptive and non-contraceptive products. The current application was submitted as a 505(b)(2) application, relying on published scientific literature to support the nonclinical safety of ethinyl estradiol. Nonclinical studies were only conducted to establish the nonclinical safety of segesterone acetate, and to establish the safety of the to-be-marketed device.

Intravaginal rings have recently been termed by the Agency as 'vaginal systems', and due to the clinical indication, this drug/device product is termed a contraceptive vaginal system (CVS). This CVS is designed for continuous daily release of SA (150 µg/day) and EE (15 µg/day) for a maximum of 13 menstrual cycles of 28 days each. The product is unique in that it is reusable; it is inserted at the beginning of each menstrual cycle, remaining in place for 21 days, removed and stored for a 7-day drug-free interval, and then re-inserted for the subsequent cycle.

A comprehensive nonclinical package was submitted to support the pharmacology and toxicology of SA at the proposed dose and duration. Relevant published literature was submitted to support the pharmacology and toxicology of EE at the proposed dose and duration. Toxicology studies to evaluate the SA/EE combination were not specifically conducted for this application. The chronic safety of SA and EE alone had already been evaluated via a 12-month monkey study using SA implants, and via literature reference, respectively. EE also has a long history of chronic use in approved drug products with vaginal administration. The local intravaginal safety of the proposed ring containing SA alone was evaluated in a 4-week monkey study, with only expected pharmacodynamic effects observed, and no local toxic effects. In addition, clinical studies informed the PK for the intravaginal use of the SA/EE CVS, eliminating the need for a nonclinical study of chronic duration with the combination. To assess the biocompatibility of the drug/device

combination, nonclinical studies were completed using extracts from the proposed SA/EE CVS to test the intravaginal safety of the to-be-marketed product. These studies were reviewed by CDRH, and were deemed sufficient to evaluate the local toxicity of the combined drug/device product.

**Summary of nonclinical data:**

**Pharmacology:** SA demonstrated high binding affinity for the progesterone receptor, with agonist effects. SA did not bind to the estrogen or androgen receptor, or sex hormone binding globulin. Following administration to female rabbits, SA transformed the uterine endothelium from a proliferative to a secretory state and also blocked fertilization. In female rats, SA blocked spontaneous ovulation and prevented pregnancy. SA did not induce any cardiovascular, central nervous system, or respiratory safety pharmacology effects.

EE binds the estrogen receptor to promote the proliferation and growth of the vaginal, uterine and mammary epithelium, among other effects.

**Toxicology:** Pivotal studies to evaluate the toxicity of SA were conducted in mice, rats, rabbits and monkeys, and used various routes of administration – vaginal gel, subdermal implant, and vaginal ring – and durations – 4 weeks, 3-months, and 12 months. These studies with SA primarily produced expected pharmacologic effects of a progestin (disruption of estrus cycle, vaginal morphology changes, inhibition of ovulation, mammary growth, decreased reproductive organ weights). One of the 3-month studies was also conducted in male rats, with SA subdermal implants causing decreased testosterone and luteinizing hormone levels, decreased reproductive organ weights and increased adrenal weights.

SA was not genotoxic following the standard battery of testing (Ames assay, chromosome aberration test in human peripheral blood lymphocytes, and micronucleus assay in mice).

2-year carcinogenicity studies were conducted in mice and rats. A dose of 30 mg/kg/day SA (vaginal gel formulation) in mice increased the incidence of adenocarcinoma and lobular hyperplasia in the breast. All doses of SA gel (3, 10, 30 mg/kg/d) increased the incidence of subchronic or chronic inflammation in the vagina. In rats, no evidence of a tumorigenic effect was observed at any dose of SA via administration by subdermal implant (40, 100, 200 µg/d; 267, 667, 1333 µg/kg/day). Only pharmacologic effects were observed. As such, SA was considered carcinogenic in female mice at 30 mg/kg/day, but not in rats. SA was also considered an irritant at all doses in mice. Due to use of subdermal implants, irritation was not evaluated in rats.

Female rats treated for 3 months with SA via subdermal implant demonstrated a return to fertility 7 weeks after implants were removed. Return of cyclicity, number of corpora lutea and number of implantations were then comparable to controls. An embryofetal development study in rats dosed with SA (GD6-15; up to 250 µg/kg/day) showed no maternal toxicity, embryotoxicity or teratogenicity. An embryofetal development study in rabbits dosed with SA (subcutaneous; up to 250 µg/kg/day) showed an increase in embryofetal death, increased resorptions, and increased vertebral and rib malformations at the high dose of 250 µg/kg/day. In rabbits, the maternal NOAEL was 250 µg/kg, while the fetal NOAEL was 50 µg/kg/day.

**Table 1: NOAELs and Safety Multiples for Segesterone Acetate across studies**

Species	Duration	SA Route	Dose	NOAEL (females)	Safety multiples	
					Based on AUC	Based on BSA
Mouse (F)	4-week	Gel	200, 600 1800 µg/d (10, 30, 90 mg/kg/d)	90 mg/kg	132	2926
Rat (M&F)	3-month	Subdermal implant	86 µg/d (175 µg/kg/d males 286 µg/kg/d females; live weight basis)	286 µg/kg	--	19
Rabbit (F)	3-month	Subdermal implant	24.6, 128.9, 551.4 µg/d (14, 72, 306 µg/kg/d)	72 µg/kg	--	9
Rat (F)	12-month	Subdermal implant	11.4, 15.1, 47.8 µg/d (76, 101, 319 µg/kg/d)	None*	--	5
Monkey (F)	12-month	Subdermal implant	30, 87, 395 µg/d (10, 29, 132 µg/kg/d)	132 µg/kg	--	17
Monkey (F)	4-week	Vaginal ring	80-100 µg/d (26-33 µg/kg/d)	33 µg/kg	--	5
Mouse (F)	6-month carcinog.	Gel	0.3, 1, 3% (3, 10, 30 mg/kg/d)	10 mg/kg	3	325
Rat (M&F)	2-year carcinog.	Subdermal implant	40, 100, 200 µg/d (267, 667, 1333 µg/kg/d)	1.33 mg/kg	--	86
Rat (F)	EFD	Subcutaneous	10, 50, 250 µg/kg/d	0.25 mg/kg (maternal & fetal)	--	16
Rabbit (F)	EFD	Subcutaneous	10, 50, 250 µg/kg/d	0.25 mg/kg (maternal) 0.05 mg/kg (fetal)	7.4 1.9	32 6
Rat (F)	PPND	Subcutaneous	Ph 1: 10, 50, 250 µg/kg/d Ph 2: 2 µg/kg/d	<2 µg/kg (maternal & fetal)	--	0.13

\* (7 unscheduled deaths including 3 at high dose; all presented with enlarged mammary and pituitary glands, but not the cause of death)

SA: Segesterone acetate; NOAEL: No observed adverse effect level; AUC: Area under the curve; BSA: body surface area; EFD: embryofetal development toxicity study; PPND: perinatal and postnatal development toxicity study

Multiples calculated based on a clinical daily dose of SA=150 µg/day; 0.0025 mg/kg/day; AUC=14.99 ng\*hr/mL

In a prenatal and postnatal development study in rats (subcutaneous SA up to 250 µg/kg/day; GD15-PND21), SA was found to prolong gestation and parturition. In dams that had not delivered or partially delivered by GD25, delivered pups were dead or stillborn, while excised uteri showed dead fetuses in animals that had partially delivered. Unscheduled deaths in the vehicle, mid and high dose were due to prolonged gestation and delivery complications. At the mid and high dose (50 and 250 µg/kg/day), there was significant maternal mortality during parturition, increased parturition, increased perinatal pup deaths, and only 2/25 high dose rats delivered live pups. The maternal and fetal NOEL was determined to be <2 µg/kg/day.

The toxicity of EE was provided in published literature reports. The acute toxic dose for EE in rodents is 0.5-5 g/kg (liver and kidney injury) and repeat dose studies primarily induce pharmacologic effects in female reproductive organs (uterine hypertrophy, vaginal keratinization, mammary gland development) with toxic effects observed in the liver and hematopoietic tissues at supra-physiological doses. EE is not mutagenic via the Ames assay, but is positive in mammalian cell chromosomal aberration assays. EE can act as a tumor promoter. At doses up to 4 mg/kg/day in rats for 2 years, EE did not increase the incidence of tumors or tumor development, but altered the incidence of tumor types, namely hepatocellular adenomas, uterine polyps, pituitary adenomas and mammary gland tumors. This is currently noted in class labeling for estrogens. In the reproductive system, EE prevents reproduction either alone or in combination with progestins.

**Label:** Final changes have not been negotiated in the physician's label with the sponsor. However, class labeling will be included for the EE component and PLLR labeling will be included in Section 8 for Pregnancy and Lactation.

**Outstanding Nonclinical Issues:** None.

**Conclusion:** I concur with the review and recommendations of the primary nonclinical reviewer. This NDA is approvable from a pharmacology/toxicology perspective.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

KIMBERLY P HATFIELD  
07/18/2018